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Abstract

Acetylcholine (ACh) is one of the main neuromodulators in the mammalian central
nervous system (CNS). This chemical messenger has been implicated in the underlying
physiology of many distinct cognitive functions. However, the exact role that ACh plays
in regulating information processing in the brain is still not fully understood. The
vesicular acetylcholine transporter (VAChT) is required for the storage of ACh into
synaptic vesicles, and therefore it presents a means to modulate release. Diminished
VAChT levels cause a decrease in cholinergic tone, whereas increased VAChT
expression has been shown to augment ACh release. Previously published data have
shown that elimination of VAChT in the basal forebrain in genetically-modified mice
impairs learning and memory.
For our studies we have used different mouse lines in which the expression of the
VAChT gene is changed, both increased and decreased. We are therefore able to study
the consequences of altered cholinergic tone in vivo. Our hypothesis is that changes in
cholinergic tone produce specific molecular signatures in target brain areas that underlie
alterations in cognitive function. Our studies aimed to elucidate the behavioural and
molecular consequences of cholinergic dysfunction. Behavioral testing included
classical learning and memory tests as well as sophisticated tasks using novel touch
screens chambers to measure attention, learning and memory as well as cognitive
flexibility. At the molecular level, the goal was to examine how long-term changes in
cholinergic tone impact mechanisms regulating synaptic plasticity and neuronal health.
Finally, by aging mouse models of cholinergic dysfunction we were able to elucidate the
role that cholinergic tone plays in the classical pathological hallmarks of
neurodegenerative disorders.
Ultimately, by establishing the molecular signature of increased and decreased
cholinergic tone in targeted brain regions (cortex and hippocampus) it may become
possible to find novel targets for therapeutic interventions to improve cognitive deficits
due to altered cholinergic tone.
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Chapter 1
1 Introduction
1.1 Central Cholinergic Tone
Acetylcholine (ACh) was the first neurotransmitter to be identified (Loewi 1921). Cells
which secrete, and thus signal via ACh, are deemed cholinergic cells. Cholinergic cells
are found throughout the mammalian body and they are both neuronal and nonneuronal cell types. Neuronal ACh acts both in the peripheral nervous system (PNS)
and in the central nervous system (CNS). In the PNS ACh is the neurotransmitter which
activates skeletal muscles, in the neuromuscular junction. Furthermore, ACh in the PNS
is the neurotransmitter of the autonomic nervous system which regulates a host of
involuntary and unconscious bodily functions. CNS ACh is a neuromodulator affecting
synaptic plasticity and regulating many behaviours including learning and memory,
attention, and reward (Hasselmo 1999, Picciotto, Higley et al. 2012).

1.1.1Regulation of ACh Release
Synthesis of ACh relies on the uptake of choline into the presynaptic cholinergic nerve
terminal. This process is mediated by the activity of the high affinity choline transporter
1 (CHT-1) (Yamamura and Snyder 1972) Kuhar and Murrin 1978). Choline in the
presynaptic cell is then combined with Acetyl-CoA and synthesized into ACh by the
choline acetyltransferase enzyme (ChAT) (Hersh 1982, Rylett and Schmidt 1993).
Newly synthesized molecules of ACh are then packaged into synaptic vesicles by the
vesicular acetylcholine transporter (VAChT) (Prado, Reis et al. 2002, Prado, Roy et al.
2013). VAChT represents the rate liming step in the release of ACh. Genetic elimination
of VAChT has demonstrated that VAChT is required for the storage and release of ACh
(Prado, Martins-Silva et al. 2006, de Castro, De Jaeger et al. 2009). Unlike monoamine
which have multiple and redundant transporters (Liu, Peter et al. 1992), VAChT is the
sole transporter for ACh. Following stimulation of the presynaptic cell, ACh containing
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synaptic vesicles fuse with the presynaptic membrane and ACh is released into the
synapse (Katz and Miledi 1965, Varoqui and Erickson 1996). In the synapse, ACh can
bind and act upon pre and post synaptic ACh receptors. These receptors fall into two
main classes, ionotropic nicotinic receptors, and metabotropic muscarinic receptors.
Upon dissociation from the receptors, synaptic ACh is broken down into its constituents
by the activity of the acetylcholinesterase enzyme (AChE) (Marnay and Nachmansohn
1937, Soreq and Seidman 2001). Schematic of ACh release is depicted in Figure 1.1.
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Figure 1.1 The Cholinergic Synapse. (A) Choline is taken up into the pre-synaptic
cholinergic neuron by the activity of the high affinity choline transporter, CHT-1. (B)
Choline and acetyl-CoA are combined to form acetylcholine by the choline
acetyltransferase enzyme. (C) The Vesicular Acetylcholine Transporter packages
acetylcholine into synaptic vesicles, exchanging one cytoplasmic molecule of
acetylcholine for two vesicular H+ ions. (D) Following excitation of the pre-synaptic
cholinergic neurons, acetylcholine containing synaptic vesicle fuses with the plasma
membrane and acetylcholine is released into the synapse. Acetylcholine can then bind
to either ionotropic nicotinic receptors or metabotropic muscarinic receptors. These
receptors can be expressed both pre- and post-synaptically. (E) Following dissociation
of acetylcholine from its receptors, the molecule is broken down by the
acetylcholinesterase enzyme into acetate and choline.
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1.1.2The Vesicular Acetylcholine Transporter
To speed up synaptic transmission, neurotransmitters are packaged into synaptic
vesicles, and released as a quantum (Katz and Thesleff 1957, Stevens 1993). This
quantal release mechanism allows for the local concentration of neurotransmitters
released into the synapse to be orders of magnitude larger than if neurotransmitters
were simply released uniformly across the nerve terminal. Release events of ACh from
neurons into the synapse have been well characterized as quantal events (Katz and
Thesleff 1957, Van der Kloot and Molgo 1994). It has been estimated that roughly
10,000 molecules of ACh are packaged into each vesicle (Linder, Pennefather et al.
1984). As ACh is a cation, it will not simply diffuse passively through membranes. A
transport mechanism is required for the packaging of ACh into vesicles for synaptic
release. VAChT is the protein responsible for the packaging of ACh into synaptic
vesicles (Alfonso, Grundahl et al. 1993). Evidence of how VAChT carries out this
transport has been elucidated from models of the proteins structure.
Although the structure of the protein has not been resolved by crystallography or other
methods, models of the protein structure have been proposed to explain the
biochemical activity of the transporter. It has been suggested, based on the knowledge
of other transporters in the same protein family, that VAChT would assume a 12
transmembrane domain structure (Vardy, Arkin et al. 2004). Following the proposed
model, the protein would be separated into two distinct large structural halves, allowing
for a central transport path to be formed between them (Khare, Ojeda et al. 2010).
VAChT is able to pump ACh into synaptic vesicles, by exchanging two intra-vesicular
protons, for one cytoplasmic molecule of ACh (Nguyen, Cox et al. 1998). Experimental
evidence suggests that this exchange occurs within the described central transport path
of the protein (Ojeda, Kolmakova et al. 2004).
In vitro studies have indicated that the activity of VAChT is highly regulated. VAChT will
concentrate ACh into vesicles at a rate 30 folds lower than predicted, based on the free
energy formed by the exchange of two protons (Parsons 2000). The pharmacological
agent vesamicol is a selective non-competitive VAChT inhibitor. Studies using
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vesamicol have shown that the compound is able to block ACh storage in vesicles, and
also block release of ACh into the synapse (Anderson, King et al. 1983, Collier, Welner
et al. 1986, Whitton, Marshall et al. 1986, Prado, Gomez et al. 1992, Van der Kloot
2003). Therefore, synaptic release of ACh is dependent on VAChT packaging the
neurotransmitter into vesicles. These findings have been confirmed in vivo, where mice
with targeted deletions of VAChT no longer release ACh upon KCl stimulation (Prado,
Martins-Silva et al. 2006, de Castro, De Jaeger et al. 2009, Lima Rde, Prado et al.
2010, Guzman, De Jaeger et al. 2011). Taken together, these results place VAChT as
the rate limiting step in the release of ACh into the synapse.
The majority of total VAChT protein is found within the synaptic vesicles of cholinergic
neurons. The VAChT protein however is not locally translated at the synapse (Park,
Gondre-Lewis et al. 2011). The intracellular trafficking of VAChT is therefore a key
cellular process within cholinergic neurons (Prado and Prado 2002). VAChT trafficking
to synaptic vesicles has been shown to be a clathrin-mediated process (Santos,
Barbosa et al. 2001, Barbosa, Ferreira et al. 2002, Ferreira, Santos et al. 2005).
Experiments using a yeast two hybrid system to investigate protein-protein interaction,
have shown that the C-terminal domain of VAChT interacts with the AP-2 adaptor
complex (Barbosa, Ferreira et al. 2002). AP-2 is a multimeric protein that is a master
regulator of chlatrin-mediated endocytosis (Pearse, Smith et al. 2000). A di-leucine motif
has been characterized within the C-terminus of the VAChT protein, and plays a critical
role in the clathrin-mediated endocytosis of the transporter (Tan, Waites et al. 1998).
Mutations in this di-leucine motif abolish the interaction between VAChT and the AP-2
complex (Barbosa, Ferreira et al. 2002). Likewise, the C-terminal segment of vesicular
monoamine transporters (VMATs) regulates their trafficking (Tan, Waites et al. 1998).
This is not surprising as there is a large degree of homology between VAChT and
VMATs (Liu and Edwards 1997). Interestingly, the intracellular trafficking of these
proteins is vastly different. In the brain, VMATs are trafficked to many different types of
secretory vesicles (Nirenberg, Liu et al. 1995, Nirenberg, Chan et al. 1996). Conversely,
VAChT is localized almost exclusively to synaptic vesicles (Gilmor, Nash et al. 1996,
Weihe, Tao-Cheng et al. 1996). It appears that the phosphorylation of this C-terminus is
important to the subcellular specificity of VAChT trafficking (Krantz, Waites et al. 2000,
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Ferreira, Santos et al. 2005). The kinase PKC has been shown to both modulate
VAChT phosphorylation as well as ACh release from hippocampal synaptosomes
(Tanaka, Fujiwara et al. 1986, Allgaier, Daschmann et al. 1988, Barbosa, Clarizia et al.
1997). VAChT phosphorylation can therefore be highly relevant to cholinergic signalling
in the brain (Van der Kloot and Molgo 1994).

1.1.3 Choline Acetyltransferase
Synthesis of ACh within neurons occurs within the cytoplasm of cholinergic nerve
terminals. ChAT is the enzyme responsible for the production of ACh within cells. As its
name suggests, choline acetyltransferase transfers an acetyl group from an acetyl-CoA
to a choline molecule to produce the neurotransmitter ACh (Nachmansohn and Berman
1946). Expression of the ChAT enzyme is extremely sparse, estimated to comprise less
than a ten thousandth of a percent of total brain proteins (Eckenstein and Thoenen
1982, Bruce, Wainer et al. 1985). Despite this low abundance, ChAT protein is found
within every cholinergic cell in the brain (Docherty, Bradford et al. 1985), its expression
pattern therefore follows the anatomical distribution of cholinergic neurons in the brain.

Interestingly, the genes for ChAT and VAChT are present in the same gene locus,
termed the cholinergic gene locus (Eiden 1998, Mallet, Houhou et al. 1998). Cloning of
the ChAT gene revealed a rather unique structure for the gene (Berrard, Brice et al.
1987, Strauss, Kemper et al. 1991). Upstream of the coding region for ChAT, within the
intron between the first and second exons, the VAChT 1590bp open reading frame was
discovered (Bejanin, Cervini et al. 1994, Erickson, Varoqui et al. 1994, Roghani,
Feldman et al. 1994). The VAChT gene is found in the same transcriptional orientation
as ChAT (Berrard, Varoqui et al. 1995). This unique gene organization is evolutionarily
conserved and can be found in C. elegans (Alfonso, Grundahl et al. 1994, Roghani,
Feldman et al. 1994), drosophila (Kitamoto, Wang et al. 1998), mice (Misawa, Ishii et al.
1992, Barbosa, Massensini et al. 1999), rats (Bejanin, Habert et al. 1992) and men
(Berrard, Brice et al. 1987). Although arising from the same gene locus, VAChT and
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ChAT are transcribed as separate transcripts (Alfonso, Grundahl et al. 1994, Erickson,
Varoqui et al. 1994).
ChAT is localized predominantly in the cytoplasm (Bruce, Wainer et al. 1985). However,
membrane-bound forms of the protein have been reported (Bruce and Hersh 1987). In
addition, a variant of the human form of the enzyme can localize to the nucleus, wherein
it plays a role in the regulation of gene expression and chromatin modeling (Gill,
Bhattacharya et al. 2003, Matsuo, Bellier et al. 2011). The ChAT enzyme is organized
as a globular, single strand, protein (Govindasamy, Pedersen et al. 2004). Site-directed
mutagenesis studies have shown that a number of critical amino acid residues regulate
the catalytic function of the protein (Carbini and Hersh 1993, Dobransky, Davis et al.
2000). This work showed that a histidine residue is the acid/base catalytic residue of the
enzyme, while a nearby arginine residue interacts with, and binds the CoA molecule.
Further structural biology experiments have confirmed these findings (Kim, Rylett et al.
2006).
Interestingly, there appears to be no correlation between the mRNA level of ChAT
within a cellular population, and the enzymatic activity of the cells (Berrard, Brice et al.
1987). This finding suggests that regulation of ChAT protein levels and activity occur at
the post-transcriptional level. Translation of the ChAT protein occurs within the soma of
neurons (Berrard, Brice et al. 1987) and the enzyme is then transported by an
undetermined mechanism to the synapse. The transport of the enzyme represents a
means by which cells can regulate their production of ACh. A critical post-translational
modification to the ChAT enzyme is its phosphorylation (Bruce and Hersh 1989,
Dobransky and Rylett 2003). A number of phosphorylation sites have been
demonstrated on the enzyme and it appears that these modifications play a role in
regulating the catalytic activity of the enzyme (Dobransky and Rylett 2003). A key
phosphatase involved in the regulation of ChAT enzymatic activity is PKC (Dobransky,
Doherty-Kirby et al. 2004). Importantly ChAT phosphorylation in synaptosomes is
sensitive to Ca2+ levels (Dobransky and Rylett 2005). The enzymatic activity of ChAT,
and consequently ACh synthesis, can therefore be regulated in response to neuronal
depolarization. Deletion of the chat gene from the mouse genome is post-embryonically
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lethal (Misgeld, Burgess et al. 2002). Studies of the embryos from these animals have
shown in the absence of ChAT there is dramatic restructuring of the PNS in these
animals (Brandon, Lin et al. 2003), indicating that ChAT, and therefore ACh, is essential
for proper developments of the nervous system.

1.1.4 The High Affinity Choline Transporter
Synthesis of ACh is dependent on the intracellular concentrations of choline. Neurons
are unable to synthesise enough of their own choline for cholinergic neurotransmission
(Yamamura and Snyder 1972, Collier and Katz 1974).Therefore, ACh releasing neurons
are dependent on the activity of a transporter to obtain their choline (Birks, Macintosh et
al. 1956, Birks and Macintosh 1957). The transporter responsible for the uptake of
choline into neurons is the CHT1 transporter. This transporter regulates choline levels
within a cell, by transporting choline into the cell in a Na+ dependant manner (Simon
and Kuhar 1975, Birks, Worsley et al. 1985). This protein is encoded by the SLC5A7
gene, which was first identified in C. elegans, and subsequently identified in the rat,
mouse and human (Apparsundaram, Ferguson et al. 2000, Okuda, Haga et al. 2000).
There is a very high degree of homology between the rat and human gene (Okuda and
Haga 2000) as well as between the rat and mouse gene (Apparsundaram, Ferguson et
al. 2001). Importantly, CHT1 is preferentially expressed in cholinergic neurons, and can
therefore be used as a specific marker for these cells (Misawa, Nakata et al. 2001).
CHT1 is not the sole choline transporter expressed in the mammalian brain. The
Torpedo-like choline transporter, CTL1 is highly expressed in oligodendrocytes, where it
provides choline for the synthesis of phospholipids (Traiffort, Ruat et al. 2005). CLT1
also differs from CHT1 in that its function is dependent on K + ions rather than Na+ ions
(Fujita, Shimada et al. 2006). The other choline transporter expressed in the
mammalian brain is the organic cation transporter 2 (OCT2). Unlike CTL1, OCT2 is also
expressed in cholinergic neurons, being found on synaptic vesicles within these
neurons (Nakanishi, Haruta et al. 2011, Nakata, Matsui et al. 2013). OCT2 however is
not selective for choline, but rather can transport all organic cations. Given that OCT2
and CHT1 share similar localization in cholinergic neurons, it has been hypothesized
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that these two transporters may collaborate to transport choline into cholinergic neurons
(Nakata, Matsui et al. 2013).
The CHT1 protein is 580 amino acids long and organized on plasma membranes in a
13 transmembrane domain structure (Apparsundaram, Ferguson et al. 2000, Okuda,
Haga et al. 2000, Torres, Gainetdinov et al. 2003). CHT1 has been shown to have
consensus PKA and PKC phosphorylation motifs, implicating these signalling pathways
in the regulation of this protein (Gates, Ferguson et al. 2004, Brock, Nickel et al. 2007).
Experimental inhibition of these signalling pathways has led to decreases in cell surface
levels of the transporter (Gates, Ferguson et al. 2004). Although CHT1 carries out its
physiological function at the plasma membrane, the vast majority of the protein is found
within intracellular vesicles, with only a small portion of the total protein pool found on
the plasma membrane (Ferguson, Savchenko et al. 2003, Ribeiro, Alves-Silva et al.
2003, Ribeiro, Black et al. 2005). Inclusion of CHT1 in the plasma membrane of
synapses is dependent on the activity of the neuron. Depolarization by action potential
of the neuron increases the levels of CHT1 at the plasma membrane in a calcium
dependant manner (Collier and Katz 1974, Simon and Kuhar 1975). The trafficking of
CHT1 to the plasma membrane is mediated by the clathrin endocytic pathway (Ribeiro,
Alves-Silva et al. 2003). Plasma membrane CHT1 then can be internalized in a clathrin
dependant manner to either be tagged for proteasome degradation, or to be trafficked
back to the plasma membrane (Ribeiro, Black et al. 2005).
Genetic elimination of CHT1 from the mouse genome results in post-natal lethality,
within an hour of birth, due to an inability of the animals to breathe (Ferguson,
Bazalakova et al. 2004). Mice with a heterozygous null mutation are however viable and
are able to maintain the same level of choline uptake as wild-type control animals
through posttranslational compensation of CHT1 function, by increased inclusion at the
plasma membrane (Ferguson, Bazalakova et al. 2004). Furthermore, in mice with a
heterozygous null deletion of the ChAT gene (and therefore a reduced capacity to
synthesize ACh), levels of the CHT1 protein were increased in compensation (Brandon,
Mellott et al. 2004). Analysis of the prefrontal cortex of rats performing attention based
cognitive tasks showed both an increase in choline uptake and in CHT1 protein levels
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(Apparsundaram, Martinez et al. 2005). These findings demonstrate that the trafficking
of CHT1 to the plasma membrane is a highly dynamic process which plays a role in
normal physiological functioning. Importantly polymorphisms in the CHT-1 gene have
been identified in patients with Attention Deficit Disorders, related to cholinergic deficits
in these patients (English, Hahn et al. 2009). The trafficking of CHT1 to the plasma
membrane is thus a critical determinant to the levels of choline within cholinergic cells
and a critical process for cognitive functioning.

1.1.5 Nicotinic Receptors
Nicotinic acetylcholine receptors (nAChRs) are ionotropic receptors which are selective
for ACh. nAChRs are expressed in both the peripheral and in the CNS. This class of
receptors are involved in neuronal excitability and regulation of neurotransmitter
release. There are nine different nicotinic receptor subunits that are expressed in the
CNS, they are either  subunits (2, 3, 4, 5, 6, 7) or  subunits (2, 3, 4) all encoded by
distinct genes (Le Novere and Changeux 1995, Dani and Bertrand 2007). These
subunits combine as either homomeric or heteromeric pentameric receptors. The most
prominent homomeric nicotinic receptor in the mammalian CNS is the 7 nicotinic
receptor (7nAChR). However the most prominently expressed nicotinic receptor in the
brain is the 42nAChR (Wada, Wada et al. 1989).
Regardless of their make-up, nicotinic receptors share the same general structure. They
are organised as a transmembrane receptor with a central ion channel, an extracellular
ligand binding domain with a ligand binding pocket (Karlin and Akabas 1995). Although
they share similar structures, 7nAChRs and 42nAChRs have drastically different
functional properties (Giniatullin, Nistri et al. 2005). 7nAChRs are quick to be activated
by ACh and are quickly desensitized (Pidoplichko, DeBiasi et al. 1997). These receptors
are permeable to Na+, and K+, but are highly permeable to Ca2+ (Seguela, Wadiche et
al. 1993). 42nAChRs on the other hand are slow to be activated by ACh and are also
slow to desensitize (Alkondon and Albuquerque 2005). These receptors are only
permeable to Na+ and K+ ions.
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In situ hybridization studies have demonstrated that the 4 and 2 nAChR subunits are
expressed ubiquitously across the mammalian brain (Wevers, Jeske et al. 1994).
Expression of these receptors is highest in the thalamus and cortex and relatively low in
the hippocampus (Alkondon, Reinhardt et al. 1994). 2 nAChRs is essential for nicotine
evoked release of GABA and dopamine from synaptosomes collected from a number of
brain regions (Turner 2004, McClure-Begley, King et al. 2009). Furthermore nicotine
evoked striatal release of dopamine is abolished in mice lacking the 2 subunit (King,
Caldarone et al. 2004). This regulation of dopamine release by 2nAChRs is
functionally relevant as mice lacking this receptor do not display place preference
conditioning to cocaine (Zachariou, Caldarone et al. 2001). Young mice lacking the 2
nAChR subunit do not display memory impairments, however as these mice age they
display cortical atrophy and cell loss in the hippocampus (Zoli, Picciotto et al. 1999).
The age dependant neurodegeneration in these animals is associated with learning and
memory impairments.
The 7nAChR like the 4 and 2 is expressed throughout the brain. However the
distribution pattern of the 7nAChR is antithetical to the pattern of the 4 and 2
subunits. 7nAChRs are most expressed in the hippocampus and cortex, but are
almost absent in the thalamus (Seguela, Wadiche et al. 1993). Although 7nAChRs are
highly involved in synaptic plasticity in the hippocampus, 7-subunit knockout mice did
not differ from wild-type controls in a host of memory assays including contextual and
cued fear-conditioning and on the Morris water maze (Paylor, Nguyen et al. 1998,
Fernandes, Hoyle et al. 2006). 7nAChRs are also expressed on non-neuronal cells in
both the brain and in the periphery, including astrocytes and microglia. 7nAChRs on
these non-neuronal cells play a critical role in inflammation (de Jonge and Ulloa 2007)
and in neuroprotection (Ren, Puig et al. 2005). On immune cells activation of 7
receptors regulates the production of inflammatory cytokines (Wang, Yu et al. 2003).

1.1.6 Muscarinic Acetylcholine Receptors
ACh can act upon a class of metabotropic receptors, the muscarinic acetylcholine
receptors (mAChRs). There have been 5 subtypes of mAChRs that have been
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identified, the M1, M2, M3, M4 and M5 receptors. All of these receptors function as
classical G-protein coupled receptors (Wess 1996). mAChRs can be subdivided into
two categories, the Gq coupled receptors which includes the M1, M3 and M5 receptors
(Berstein, Blank et al. 1992, Offermanns, Wieland et al. 1994, Qin, Dong et al. 2011),
and the Gi/o coupled M2 and M4 receptors (Winitz, Russell et al. 1993, Migeon and
Nathanson 1994). The Gq coupled receptors activate phospholipase C and increase
intracellular Ca2+ levels; these receptors are therefore deemed excitatory. The Gi/o
coupled receptors on the other hand act by decreasing cyclic nucleotide levels,
decreasing intracellular Ca2+ levels and promoting K+ efflux, thus inhibiting the neuron.
G proteins can also directly regulate K+ channels, which is a common mechanism for
M2 muscarinic receptors (Kunkel and Peralta 1995).

All five of the mAChR are expressed in the mammalian nervous system. These
receptors are found to be expressed on both neuronal and glial cell types in the nervous
system. The expression of the M1, M4 and M5 subtypes is enriched in the CNS,
whereas the M2 and M3 receptors are equally found in both the CNS and the PNS
(Levey 1993). mAChRs in the brain have been shown to play regulatory roles in many
cognitive processes. Each of the five muscarinic receptors are encoded by a unique
gene. This has allowed for the genetic manipulation of the individual receptor types and
from this their distinct physiological roles in the central nervous system have been
elucidated (Wess 2004).

M1 mAChRs are expressed throughout the mammalian forebrain, including cerebral
cortex, hippocampus, and in the striatum (Wolfe and Yasuda 1995). It is by its broad
level of expression that the receptor is thought to play a role in many cognitive
processes. Mice lacking the M1 mAChR have been shown to be hyperactive (Gerber,
Sotnikova et al. 2001) and have impaired working memory (Anagnostaras, Murphy et al.
2003) and consolidation (Gould, Dencker et al. 2015). These animals also present a
number of biochemical (Berkeley, Gomeza et al. 2001) and electrophysiological
(Anagnostaras, Murphy et al. 2003) abnormalities that underlie their impaired behaviour.
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M3 mAChRs are expressed throughout the brain but are most prominently expressed in
the hypothalamus (Wall, Yasuda et al. 1991). Hypothalamic M3 mAChRs regulate food
intake and appetite. These receptors are found on melanin-concentrating hormone
producing neurons of the hypothalamus, and their activations stimulates production of
the appetite regulating hormones (Yamada, Miyakawa et al. 2001). Mice lacking this
receptor are lean and have a pronounced reduction in bodyweight and food intake
compared to control animals (Yamada, Miyakawa et al. 2001). In the periphery these
receptors have been shown to regulate smooth muscle function (Matsui, Motomura et
al. 2002) and the salivary response (Bacman, Sterin-Borda et al. 1996).

M5 mAChRs have low levels of expression throughout the brain and are enriched in
limited cellular populations (Wei, Walton et al. 1994). M5 mAChRs are expressed on the
midbrain dopaminergic neurons, originating from the substantia nigra (Vilaro, Palacios
et al. 1990), and are therefore highly critical to the regulation of dopamine release in the
striatum. M5 mAChRs have been shown to directly regulate striatal dopamine release,
although other muscarinic subtypes can also modulate striatal dopamine by indirect
mechanisms (Zhang, Yamada et al. 2002). The ventral tegmental area of mice deficient
in the M5 mAChR do not respond to cholinergic stimulation demonstrating that these
receptors also regulate ventral tegmental area dopamine release (Yeomans, Forster et
al. 2001, Forster, Yeomans et al. 2002). Given the role of these receptors in regulating
dopamine signalling, mice lacking M5 mAChRs have altered responses to opioids and
cocaine (Basile, Fedorova et al. 2002, Thomsen, Woldbye et al. 2005).

The inhibitory M2 and M4 mAChRs function mainly as auto-receptors for ACh in the
brain (Starke, Gothert et al. 1989). These receptors are also both present on the
GABAergic medium spiny neurons in the striatum (Yan, Flores-Hernandez et al. 2001).
For the most part, these receptors are responsible for inhibiting release of ACh (Zhou,
Meyer et al. 2002). They are therefore predominantly presynaptic receptors found on
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cholinergic neurons (Levey, Edmunds et al. 1995). These receptors therefore play a
critical role in the regulation of the timing and release of ACh, processes which are
highly relevant to cognitive function (Sarter, Parikh et al. 2009). Mice lacking the M2
receptor show a broad range of hippocampal behavioural and electrophysiological
impairments (Seeger, Fedorova et al. 2004). Mice lacking the M4 receptor also present
with learning impairments and hyperactivity (Koshimizu, Leiter et al. 2012). Given that
these receptors regulate release of ACh; it is difficult to differentiate the specific roles of
these receptors to cognition, from general roles of cholinergic tone in the brain.

1.1.7 Basal Forebrain Cholinergic System
The basal forebrain is a collection of nuclei including the medial septum (MS), the
ventral pallidum (VP), the diagonal band nuclei, magnocellular preoptic nucleus, and the
nucleus basalis magnocellularis (nBm) (Zaborszky, Pang et al. 1999). The neurons
found within this brain region have been implicated in many cognitive functions including
learning and memory and executive function (Miyamoto, Shintani et al. 1985). The basal
forebrain is composed of a highly variable population of neurons. ACh releasing
neurons represent roughly 20% of the neurons in the basal forebrain (Semba 2004).
Other neurons in the basal forebrain release glutamate, GABA and neuropeptides
(Henny and Jones 2008).
The output of basal forebrain cholinergic neurons is dependent on the nuclei from which
these neurons are found (Figure 1.2A). Neurons originating in the MS and the diagonal
band nuclei provide the major cholinergic innervation to the hippocampus (Mesulam,
Mufson et al. 1983). Cholinergic neurons from the diagonal band and from the
magnocellular preoptic nucleus project to the olfactory bulb and to the enthorinal cortex
(Gaykema, Luiten et al. 1990), while the nBm cholinergic neurons project to both the
basolateral amygdala and the entire cortex (Boegman, Cockhill et al. 1992, Power, Thal
et al. 2002). Just as the basal forebrain is not a homogenous cell population, the
described projections are not purely cholinergic with both GABAergic and glutamatergic
projection neurons sharing the same projection tracks as the cholinergic cells (Huh,
Goutagny et al. 2010).
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Basal forebrain cholinergic neurons receive afferent input from midbrain and brainstem
as well as from the hypothalamus. Unlike the non-cholinergic neurons in the basal
forebrain, the cholinergic neurons in the basal forebrain do not appear to receive top
down input from the cortex (Zaborszky 1989, Zaborszky and Duque 2000).
Hypocretin/orexin positive neurons from the hypothalamus have been identified as the
main source of innervation to the basal forebrain (Henny and Jones 2006). These
neurons have been shown to synapse onto both cholinergic and non-cholinergic neuron
in the basal forebrain. These neurons are histaminergic and are important regulators of
arousal. Midbrain afferent connections to the basal forebrain originate from the
dopaminergic cells of the substantia nigra and from the ventral tegmental area (Fallon
and Moore 1978, Zahm and Trimble 2008). Brainstem structures which project to the
basal forebrain cholinergic cells are adrenergic in nature from the medulla and the locus
coeruleus and cholinergic from the pedunculopontine nucleus.
Basal forebrain cholinergic neurons role in regulating executive function and memory
has largely been investigated by immunotoxin lesioning of these cells (Baxter, Bucci et
al. 2013). The 192 IgG-saporin is a specific neurotoxin which, when delivered to the
basal forebrain, will selectively kill cholinergic neurons and spare the other cell types in
the region (Book, Wiley et al. 1992). An important caveat to the attribution of these
behaviours to cholinergic signalling is that these neurons may not be simply cholinergic.
In culture, these cholinergic neurons from the basal forebrain have been shown to be
able to release glutamate (Allen, Abogadie et al. 2006). Recent optogenetic
experiments have demonstrated that basal forebrain cholinergic which project to the
cortex co-release GABA from distinct pools of vesicles (Saunders, Granger et al. 2015).
The behavioural consequences of this co-transmission have yet to be investigated, but
suggest that GABA and/or glutamate co-released with ACh may influence behaviours
thought to be regulated by ACh signalling alone (Granger, Mulder et al. 2016).

1.1.8 Striatal Cholinergic System
Contrary to projection cholinergic neurons found in the basal forebrain and the
pedunculopontine tegmental nucleus, the cholinergic neurons in the striatum are local
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interneurons (Figure 1.2B). As such, they are characterized by shorter axons and form
circuits with nearby neuron within the same brain region (Zhou, Wilson et al. 2002). The
cholinergic interneurons of the striatum are the primary source of ACh in the striatum,
but only comprise less than 1% percent of all cells in the striatum (Bolam, Wainer et al.
1984). Cholinergic neurons in the striatum, relative to other cholinergic neurons, have
higher levels of the key cholinergic markers choline acetyltransferase (Hebb and Silver
1961) and acetylcholinesterase (Woolf and Butcher 1981). This enrichment in
cholinergic markers demonstrates the importance that these cells play in regulating
striatal function. 33 1.2 B.

A key role of the cholinergic interneurons in the striatum is to integrate information from
afferent inputs to the striatum. This is achieved by assimilating inputs of a large number
of neurons which release various different neurotransmitters, by expressing a large
number of different receptor classes for these neurotransmitters. These
neurotransmitters can either act in an excitatory manner, such as glutamate (Calabresi,
Centonze et al. 1998), serotonin (Bonsi, Cuomo et al. 2007), histamine (Bell,
Richardson et al. 2000) and substance P (Aosaki and Kawaguchi 1996).
Neurotransmitters can also inhibit cholinergic interneurons, such as GABA (DeBoer and
Westerink 1994), adenosine (Brown, James et al. 1990), and endogenous opioids
(Rada, Mark et al. 1991). Other neurotransmitters can be both excitatory and inhibitory,
depending on which class of receptors they activate such as with dopamine, excitatory
D1-like signalling (Aosaki, Kiuchi et al. 1998) and inhibitory D2-like (Chuhma, Mingote et
al. 2014). It is therefore the role of these cholinergic interneurons to integrate all of
these various signals.

Despite their relatively small cell number, striatal interneurons project throughout the
striatum and can therefore have broad physiological effects. GABA-ergic medium spiny
neurons (MSNs) are the primary output of the striatum (Chuhma, Tanaka et al. 2011).
These neurons are not thought to express nicotinic acetylcholine receptors (Luo,
Janssen et al. 2013), though nicotine can indirectly modulate their activity (Liu, Otsu et
al. 2007). Cholinergic signalling therefore directly modulates the activity of MSNs by

17
activation of muscarinic receptors. Activation of M1 muscarinic receptors on these cells
is thought to reduce KCNQ potassium inhibition (Shen, Hamilton et al. 2005) and Ca2+
entry (Perez-Garci, Bargas et al. 2003), increasing the excitation of MSNs. Nicotinic
receptors in the striatum are highly concentrated on both glutamatergic and
dopaminergic nerve terminals. Glutamatergic nerve terminals in the striatum are
enriched in 7 nicotinic receptors, and activation of these receptors leads to release of
glutamate (Campos, Alfonso et al. 2010). Release of dopamine in the striatum is also
highly dependent on cholinergic signalling. Unlike glutamate, the release of dopamine in
the striatum has been shown to be dependent on the synchrony of cholinergic
interneuron firing, and the activation of 2 nicotinic receptors on dopaminergic terminals
(Cachope, Mateo et al. 2012).

An important caveat for many of the studies of striatal cholinergic neurons, is that these
cells co-transmit glutamate. This co-transmission is achieved through synergism
between VAChT and the vesicular glutamate transporter-3 (VGLUT-3) (El Mestikawy,
Wallen-Mackenzie et al. 2011). VAChT and VGLUT-3 are found on the same vesicles in
these neurons and it has been shown that VGLUT-3 enables these vesicles to package
additional ACh (Gras, Amilhon et al. 2008). Studies using genetically modified mice
have shown that the glutamate and the ACh released from these neurons can have
separate and potentially opposite physiological roles in regulating striatal function and
behaviour (El Mestikawy, Wallen-Mackenzie et al. 2011, Guzman, De Jaeger et al.
2011, Sakae, Marti et al. 2015). Behavioural studies of mice with lesioned striatal
cholinergic interneurons were found to be hyperactive, have a heightened response to
cocaine and do not show haloperidol induced catalepsy (Hikida, Kaneko et al. 2001,
Kitabatake, Hikida et al. 2003). These behaviours were initially attributed to the
cholinergic properties of these cells. However mice lacking release of ACh from the
striatum were not hyperactive and did not display heightened responses to cocaine
(Guzman, De Jaeger et al. 2011). In fact, it was mice lacking the VGLUT-3 transporter
which recapitulated the phenotype of the lesioned animals (Gras, Amilhon et al. 2008).
The ACh released from these cells seems to be playing a critical role in regulating
release of dopamine. The animals lacking release of ACh from the striatum showed a
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functional increase in dopamine receptor expression and activity, assessed by
pharmacological MRI (Guzman, De Jaeger et al. 2011). VGLUT-3 and VAChT have
opposing roles in the regulation of dopamine release. Elimination of VAChT from striatal
interneurons decreases KCl stimulated dopamine release, whereas elimination of
VGLUT-3 from these neurons potentiates the dopamine response (Sakae, Marti et al.
2015). These results suggest that other physiological properties of striatal ACh may
potentially be attributable to the glutamate released from these cholinergic interneurons
or may be dependent on the combined action of both neurotransmitters.

1.1.9 The Pedunculopontine Tegmentum Cholinergic System
The pedunculopontine tegmentum (PPT) is a collection of nuclei found within the
brainstem behind the substantia nigra. The nuclei found within the PPT are a
heterogeneous population of neurons that differ by the neurotransmitters they release.
The three major neurons within the PPT are cholinergic, GABAergic and glutamatergic
(Martinez-Gonzalez, Wang et al. 2012). These three types of neurons are largely
segregated into separate regions of the PPT. The majority of cholinergic neurons within
the PPT are located in the PPT pars compacta (Pahapill and Lozano 2000).

Much of the work to characterize the projection of the cholinergic neurons from the PPT
has been done in non-human primates. These experiments have shown that these
cholinergic neurons project predominantly to structures within the basal ganglia (Figure
1.2 C). Both the substantia nigra (Futami, Takakusaki et al. 1995) and the ventral
tegmental area receive significant input from the cholinergic neurons of the PPT
(Charara, Smith et al. 1996). This anatomical data place these cholinergic cells as key
regulators of dopamine signalling in the brain. The primary output of the cholinergic
neurons from the PPT is the thalamus (Parent, Pare et al. 1988). Additionally the
striatum also receives direct input from the cholinergic neurons of the PPT (Dautan,
Huerta-Ocampo et al. 2014). The PPT is therefore an alternate source of cholinergic
tone in the striatum, besides the cholinergic interneurons. Finally an important target of
the cholinergic neurons in the PPT is the contralateral PPT (Benarroch 2013).
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Given the anatomical connectivity data, the cholinergic output from the PPT is placed to
be a key regulator of dopamine signalling in the brain. Experimental evidence for this
was first shown by studying the addictive properties of nicotine; by increasing dopamine
release acting specifically through 2 nicotinic acetylcholine receptors in the VTA
(Picciotto, Zoli et al. 1998). Further work has also demonstrated that M5-type
muscarinic receptors can also stimulate dopamine release from the VTA (Corrigall,
Coen et al. 2002). Since the cholinergic output from the PPT can robustly modulate
dopamine signaling, these neurons are important intermediaries of addiction and
reward. Not only do these neurons release more ACh into the VTA during cocaine
administration and cocaine seeking behaviours (You, Wang et al. 2008), but these
cholinergic neurons will also increase their firing rate in response to environmental cues
associated with reward (Goldberg and Reynolds 2011). Given these findings,
cholinergic PPT neurons have been proposed to be master regulators of dopamine
signalling in the brain (Maskos 2008).

The PPT cholinergic neurons also play a key role in regulating sleep and arousal. PPT
cholinergic neurons are completely inhibited during seizures, this inhibition is
accompanied by changes in EEG recordings (Motelow, Li et al. 2015). In line with these
findings, PPT cholinergic neurons play a critical role in increasing arousal states during
sleep. Recent optogenetic studies have found that activation of cholinergic neurons in
the PPT is an important modulator of REM sleep and plays a critical role in the initiation
of REM sleep (Van Dort, Zachs et al. 2015).
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Figure 1.2 The Central Cholinergic System in the Murine Brain. Sagittal 3D
reconstructions of the mouse brain. Image data detailing axonal projections labeled by
rAAV tracers injections into ChAT-IRES-Cre mice, and visualized using serial twophoton tomography. (A) Cholinergic projections from the basal forebrain. (B) Cholinergic
interneurons in the striatum (C) Cholinergic projections from the pedunculopontine
tegmental nucleus. Images generated from the Allen Brain Institute Mouse Connectivity
Atlas. © 2016 Allen Institute for Brain Science. Allen Mouse Brain Connectivity Atlas
[Internet]. Available from: http://connectivity.brain-map.org. Oh, S.W. et al. (2014) A
mesoscale connectome of the mouse brain, Nature 508: 207-214.
doi:10.1038/nature13186
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1.2 Cholinergic Regulation of Brain Functions
1.2.1 Cholinergic Regulation of Hippocampal Function
The hippocampus has been extensively studied for its role in regulating learning and
memory (Squire 1992). This brain region plays an important role in the formation and
maintenance of new memories. In Alzheimer’s disease (AD) the hippocampus is one of
the first brain regions to be affected by pathology (De Leon, George et al. 1997,
Padurariu, Ciobica et al. 2012). Hippocampal degeneration mediates some of the
learning and memory deficits in AD patients (Graham and Hodges 1997).

The finding in humans that drugs which block cholinergic receptors in brain impair
performance on task of learning and memory (Ghoneim and Mewaldt 1975, Atri,
Sherman et al. 2004), have placed this neurotransmitter as a central regulator of
memory. Functional MRI studies have shown that cholinergic modulation of the
hippocampus occurs during learning and memory tasks (Goekoop, Scheltens et al.
2006, Wink, Bernard et al. 2006). Much of the work delineating the mechanism of
cholinergic control of hippocampal function has been performed in rodents. In both
rodents and man, the cholinergic innervation to the hippocampus arises from the medial
septum nucleus within the basal forebrain cholinergic system (Lewis and Shute 1967).

The involvement of the basal forebrain cholinergic system in memory is supported by
several works employing various methods ranging from unspecific and specific lesion
methods (Wrenn, Lappi et al. 1999, Chudasama, Dalley et al. 2004), pharmacological
manipulations (Granon, Poucet et al. 1995) and more recently the use of genetic
manipulations (Fernandes, Hoyle et al. 2006, Martyn, De Jaeger et al. 2012, Al-Onaizi,
Parfitt et al. 2016). The observation of a transient increase of cholinergic activity during
and after a memory tasks can be observed in hippocampus (Durkin and Toumane 1992,
Durkin 1994). It is suggested that this increase in neurotransmitter release may support
synaptic plasticity in the hippocampus, a mechanism which is essential for learning and
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memory (Fadda, Melis et al. 1996, Hironaka, Tanaka et al. 2001).

Synaptic plasticity is a process whereby the nervous system changes the weight of
functional connectivity; it can help form, eliminate, potentiate and weaken connections
of neuronal circuits (Abbott and Nelson 2000). The mechanism of cholinergic regulation
of hippocampal plasticity has been well studied (Hasselmo and Bower 1993, McEwen
1999, Yakel and Shao 2004, Hasselmo 2006, Drever, Riedel et al. 2011, Yakel 2012).
The addition of low concentrations of carbachol, a cholinergic mimetic, onto cultured
slices induces LTP, an effect dependent of muscarinic receptors (Auerbach and Segal
1996). In vivo experiments have consistently demonstrated the role of cholinergic tone
in the modulation of LTP. Free walking mice showed reduced LTP in the hippocampus,
after cholinergic denervation in the medial septum or following administration of
muscarinic receptors antagonists (Leung, Shen et al. 2003, Doralp and Leung 2008).
Furthermore, deletion of VAChT from basal forebrain neurons also disrupts
hippocampal LTP ex vivo (Martyn, De Jaeger et al. 2012) and in vivo (Al-Onaizi, Parfitt
et al. 2016).

The mechanisms by which cholinergic neurons regulate synaptic plasticity are complex
and are likely to involve short-term changes in membrane conductance and also on
second messengers. Carbachol can induce another type of synaptic plasticity in the
hippocampus and the cortex, long-term depression (LTD), once again requiring
muscarinic activation (Jo, Son et al. 2010, Caruana, Warburton et al. 2011). LTD is
correlated with learning and information storage, furthermore, it has been related to
processes which require cognitive flexibility such as extinction and behavior flexibility
(Collingridge, Peineau et al. 2010).

Reports have proposed the notion that cholinergic modulation of synaptic plasticity is
highly dependent on time, and that nicotinic receptors serve as a switch between LTP
and LTD. Ge and Dani (2005), using a protocol to induce a short-term, transient,
potentiation (STP) observed that the STP became an LTP response when ACh was
administered multiple seconds prior to the stimulation, however when ACh was
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delivered less than a second prior the stimulation then the STD turned into a LTD
response. Similarly, cholinergic stimulation 120 ms prior to stimulation lead to an
α7nAChR dependent LTP. When the same cholinergic stimulation was administered 10
ms after electrical stimulation, a muscarinic dependant LTP was observed (Gu and
Yakel 2011).Thus depending on the timing of the activation, either induction of LTP or
LTD can occur and will depend on the activation of nicotinic or muscarinic receptors.
Cholinergic activity seems necessary to regulate neuronal synchrony (Metherate, Cox et
al. 1992). Neuronal synchrony is the simultaneous change in membrane potential
across multiple neurons. This process, in the hippocampus, is thought to underlie many
different types of cognitive processing, such as learning and memory (Benchenane,
Tiesinga et al. 2011). Furthermore, it has been suggested that disruption of neuronal
synchrony may underlie cognitive deficits in diseases such as Alzheimer’s and
Parkinson’s (Uhlhaas and Singer 2006).

1.2.2 Cholinergic Regulation of Attention
Release of ACh from the basal forebrain into the prefrontal cortex (PFC) is essential for
attentive processing. ACh signalling in the PFC is an important mechanism for
neuromodulation of cortical synaptic activity. The efflux of ACh into the PFC, occurs in
rapid transients that act on the millisecond time scale and tonicaly release ACh (Celesia
and Jasper 1966). These cholinergic transients are correlated with both cue detection
and attentional performance in rodents.
Both selective cholinergic lesions and non-selective lesions of the basal forebrain
produce robust deficits in attentional performance in rodents (Robbins, Everitt et al.
1989, Muir, Dunnett et al. 1992, Turchi and Sarter 1997, McGaughy and Sarter 1998).
Importantly, the attentional deficits produced by lesions to the basal forebrain
cholinergic system are permanent (McGaughy, Kaiser et al. 1996). In addition, these
deficits do not alter response times in lesioned animals. On a task where rodents are
rewarded for both detecting the presence of salient stimuli and their absence,
cholinergic lesions produced drastic deficits in detection of the salient cues, but the
rodents had no deficits on trials where they were required to detect the absence of the
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stimulus (McGaughy, Kaiser et al. 1996, McGaughy and Sarter 1998). These results
implicate basal forebrain cholinergic tone in mediating cue detection. The attention
deficits in basal forebrain cholinergic lesioned animals were insensitive to
pharmacological administration of nicotinic agonists, suggesting that specifically the
release of ACh is critical for cue detection in tasks of attention (McGaughy, Decker et al.
1999).
Microdialysis studies have shown that release of ACh into the PFC is increased when
rodents are performing attentional tasks (Passetti, Dalley et al. 2000). Efflux of ACh into
the PFC appears to vary based on the difficulty of the attentive task, where the harder
the task, the more ACh is released (Dalley, McGaughy et al. 2001). Experiments
recording cholinergic signalling in the PFC using enzyme coated microelectrodes
demonstrated that attentionally relevant cues correlated with rapid transient increases in
ACh levels in the PFC (Parikh, Kozak et al. 2007). These cholinergic transients
correlated with attentive behaviour in the animals and were absent when the cues were
missed by the animals. Optogenetic stimulation of basal forebrain cholinergic afferents,
to simulate cholinergic transients, during tasks of attention produced “false alarms”
where rodents behaved as if they had seen a rewarding cue, when no cue had been
presented (Gritton, Howe et al. 2016).
Evidence for nicotinic regulation of attention comes from a number of studies which
demonstrated the pro-attentive effects of nicotine (Wesnes and Warburton 1984,
Rusted and Warburton 1992). The two most prevalent nicotinic receptors in the PFC are
the 42nAChRs and the 7nAChRs. Evidences from animal models suggest that the
effects of nicotine on attention are mediated by 42nAChRs (Potter, Corwin et al.
1999, Howe, Ji et al. 2010). Administration of a 42nAChRs agonist had a greater
effect on attentive behaviour than nicotine (Howe, Ji et al. 2010). Mice lacking the
2nAChR subunit had impairments in attention as assessed by the 5-choice serial
reaction time task. These deficits were reversed by viral mediated expression of the 2
subunit specifically in the PFC, demonstrating the necessity and sufficiency of the
2nAChR subunit (Guillem, Bloem et al. 2011). The mechanism of 42nAChRs
signalling in attention has been thoroughly studied. Stimulation of 42nAChRs evoked
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release of glutamate into the PFC, lesions of the mediodorsal thalamic nucleus
eliminated the glutamate release (Parikh, Man et al. 2008). 42nAChRs thus recruit
thalamic glutamatergic inputs to regulate cue detection (Howe, Ji et al. 2010).
Histological studies have shown that the thalamic glutamatergic nerve terminals in the
PFC do indeed express 42nAChRs (Lambe, Picciotto et al. 2003).
The evidence for the involvement of 7nAChRs in attention is more contentious. Initial
studies suggest that mice null for the 7nAChR have deficits in sustained attention
(Hoyle, Genn et al. 2006, Young, Crawford et al. 2007). Others have however reported
no deficits in these same mice on the same tasks (Guillem, Bloem et al. 2011). It should
be noted that in the latter study the task was substantially easier. The attentional deficits
in mice null for the 7nAChR may therefore be dependent on the difficulty of the task
assessing attention. Pharmacological manipulations of 7nAChRs have also had mixed
results, with some showing improvements in attention and others showing no
behavioural effects (Grottick and Higgins 2000, Pichat, Bergis et al. 2007, Rezvani,
Kholdebarin et al. 2009, Wallace, Callahan et al. 2011).
The role of muscarinic receptors in attention has been investigated in human studies
using the muscarinic inhibitor scopolamine. Administration of scopolamine induces
cognitive impairments in healthy human subjects (Dunne and Hartley 1986). The effects
of muscarinic blockade on attention appear to involve the visual cortex along with the
PFC (Davidson and Marrocco 2000). mAChR blockade in the visual cortex prevents V1
neuronal adaptation to attentional stimuli. Stimulation of mAChRs in the PFC
potentiates release of ACh from basal forebrain cholinergic neurons. This top down
modulation of attention circuitry by mAChRs plays a role in ignoring distracting stimuli
(Sarter, Gehring et al. 2006, Broussard, Karelina et al. 2009). The predominant
hypothesis is that attentional performance is the result of synergy between nAChRs and
mAChRs. Nicotinic receptors would mediate cue detection and the saliency of the
attentionally relevant stimuli, and the muscarinic receptors regulate the top-down
processes and recruit the relevant circuitry for sustained attention (Greenwood, Lin et
al. 2009).
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1.2.3 Cholinergic Regulation of Executive function
Executive function is the umbrella term for the collection of cognitive processes that
includes attention, working memory, cognitive flexibility and planning. These cognitive
processes allow an organism to monitor their own behaviour and allow for the organism
to achieve goal directed behaviour. Impairments in executive function are associated
with a number of neurological and neuropsychiatric disorders (Tekin and Cummings
2002).
It is by modulating the activity of various cortical networks, that ACh is believed to
regulate executive functioning (Hasselmo and Sarter 2011). Of particular interest, ACh
in the PFC is thought to function in a signal-to-noise manner to mediate salient cue
detection in the environment (Sarter, Hasselmo et al. 2005). Cortical cholinergic tone
has been shown to modulate gamma oscillations (Buhl, Tamas et al. 1998); this effect
seems to be dependent of muscarinic activation, mainly by M1 muscarinic receptors
(Fisahn, Pike et al. 1998, Fisahn, Yamada et al. 2002). Activation of nicotinic receptors
in the PFC has been shown to increase post-synaptic activity (Couey, Meredith et al.
2007). Recently, two-photon imaging has been used to explore the role of nicotinic
receptors in the regulation of these effects. Poorthuis and colleagues (2013) have
demonstrated that cortical pyramidal neurons can be differentially modulated by 7 and
2 nAChRs depending on the layer of the cortex.
Of importance for executive function and attention, ACh in the PFC appears to regulate
both LTP and LTD (Bueno-Junior, Lopes-Aguiar et al. 2012). However, the effects of
cholinergic projections arising from the basal forebrain are highly important in synaptic
plasticity all throughout the cortex. It regulates both the function and the development of
the visual cortex (Hohmann and Berger-Sweeney 1998, Morishita, Miwa et al. 2010).
Finally, cortical cholinergic tone is thought to play a role in synchronizing activity in the
motor cortex and regulate responses to attentionaly relevant stimuli (Conner, Culberson
et al. 2003). The mechanisms underlying the role of cortical cholinergic tone to regulate
synaptic plasticity seem to be divergent from those in the hippocampus. For example, in
the hippocampus carbachol induction of LTD does not require PLC or PKC activity,
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whereas, in the mPFC carbachol-induced LTD requires the participation of PLC and
PKC signaling (Huang and Hsu 2010, Caruana, Warburton et al. 2011). Furthermore,
cortical cholinergic tone appears to function synergistically with noradrenaline to
modulate cortical plasticity (Bear and Singer 1986, Kirkwood, Rozas et al. 1999).

1.2.3.1 Cholinergic Regulation of Cognitive Flexibility
Cognitive flexibility is defined as the ability of higher organisms to adapt under varying
environmental conditions, which is essential for survival. In order to test cognitive
flexibility in rodents, tasks such as the pairwise visual discrimination are used (Clark,
Cools et al. 2004). All tasks which assess cognitive flexibility require the animal to learn
a given “rule”, usually a pairing of a stimulus with a reward, then to abandon this rule in
favour of a new one. Performance on such behavioural tasks are highly dependent on
the PFC. Specifically, the prelimbic subregion of the PFC, has been shown to be
important in regulating anxiety-related behaviours, and reversal learning in a visual
discrimination task (Heidbreder, Thompson et al. 1996). Direct lesions or temporary
inactivation of the prelimbic regions of the prefrontal cortex has no effect on the
acquisition of different stimuli, that is to say the initial “rule” but has a robust
consequence when a shift in using another strategy is needed in order to a adapt and
learn a new “rule” (de Bruin, Sanchez-Santed et al. 1994, Ragozzino, Detrick et al.
1999, Birrell and Brown 2000, Delatour and Gisquet-Verrier 2000, Dias and Aggleton
2000, Ragozzino, Kim et al. 2003). Previous studies have also shown that the striatum,
which receives input from the prelimbic region, plays an important role in cognitive
flexibility (Dunnett and Iversen 1981, Packard, Hirsh et al. 1989, Knowlton, Mangels et
al. 1996, Packard and Teather 1997).
Cholinergic tone in the striatum has been thought to play an important role in mediating
cognitive flexibility. Striatal ACh was demonstrated to be critical for regulating synaptic
plasticity that underlies forms of learning and memory (Calabresi, Centonze et al. 1998).
In addition to the role of ACh in memory functions, Aosaki et al (Aosaki, Tsubokawa et
al. 1994) reported that the activity of striatal tonic active neurons was correlated with the
presentation of rewards, providing insight on the role of striatal ACh in goal-oriented
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behaviors. However, the exact role of striatal ACh in cognitive flexibility is still under
investigation. Mice with striatal interneurons deficient for VAChT showed no deficits in a
water maze based reversal learning paradigm (Guzman, De Jaeger et al. 2011), a form
of cognitive flexibility.
Results from mice lacking forebrain VAChT indicate that cholinergic tone is not required
for the initial spatial learning phase in a Morris Water Maze task. However, when the
contingencies are changed, and the platform is moved to a different quadrant of the
pool, these mutant mice are completely unable to adapt and learn the new “rule”,
suggesting that forebrain cholinergic tone is required for such behaviour (Martyn et al.,
2012). Although there is a clear role of ACh in cognitive flexibility little is known of the
mechanisms by which ACh exerts its effect.
Administration of the M1 muscarinic antagonist scopolamine is one of the most robust
means by which impairments in behavioural flexibility can be induced (Ragozzino, Jih et
al. 2002, Klinkenberg and Blokland 2010). Furthermore administration of agonists and
positive allosteric modulators of M1 improve performance on measures of cognitive
flexibility (McCool, Patel et al. 2008, Shirey, Brady et al. 2009). Interestingly, visual
discrimination and reversal learning tested in mice deficient for the M1 muscarinic
receptor showed no significant differences from control mice on acquisition or reversal
(Bartko, Romberg et al. 2011), in contrast to the pharmacological data. Aging induced
impairments in cognitive flexibility has been correlated with decreased expression of the
M2 muscarinic receptor. Seeger et al (2004), investigated the role of M2 receptors,
using M2 knockout mice in behavioural tasks assessing working memory and
behavioural flexibility. They reported that M2 null mice had deficit in the acquisition
phase of the Barnes Maze by their inability to switch from a random strategy to a more
efficient strategy. Thereby, concluding that cognitive flexibility could be mediated
through M2 receptors.
The role of nicotinic receptors in cognitive flexibility has not been greatly explored.
Nicotinic ACh receptors, specifically the 7nAChR, have been shown to alter both
release of glutamate in the PFC (Marchi, Risso et al. 2002, Gomez-Varela and Berg
2013) and trafficking of glutamate receptors (Yang, Paspalas et al. 2013). As Glutamate
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signalling (Karlsson, Tanaka et al. 2009) and glutamate receptor trafficking (Brigman,
Feyder et al. 2008, Brigman, Daut et al. 2013) play important roles in cognitive flexibility,
it is possible that cholinergic modulation of glutamate signalling, via nicotinic receptor
activation, may contribute to one’s ability to reverse contingency rules and demonstrate
cognitive flexibility.

1.3 Alzheimer’s Disease
AD is a chronic neurodegenerative disease which is characterized by loss of neurons
and synapses in cortical and subcortical brain regions. This cell loss results in atrophy
of the effected brain regions. This neuropathology manifests itself symptomatically early
on as memory loss, but as the disease progresses the symptoms expand to include
long term memory loss, impairments in executive functioning and mood disorders. The
pathological hallmarks of the disease are extracellular amyloid plaques, and intracellular
neurofibrillary tangles. This pathology has been hypothesised to play a critical role in
disease development, however the etiology of the disease remains poorly understood.

1.3.1 Amyloid Pathology in AD
A pathological hallmark of AD, is the appearance of extracellular amyloid plaques. The
presence of these plaques are a required diagnostic criteria for AD and plaque burden
within the brain is used to determine the Braak staging of AD (Braak, Braak et al. 1986).
These amyloid plaques are composed of aggregated fragments of the amyloid
precursor protein (APP) (Weidemann, Konig et al. 1989).

APP is an integral membrane protein and within the brain its expression is highest at
synapses (Muller and Zheng 2012, Puig and Combs 2013). Mice deficient in the APP
gene present subtle cognitive deficits and electrophysiological changes but do not
recapitulate an “Alzheimer’s-like” phenotype (Zheng, Jiang et al. 1996, Mileusnic,
Lancashire et al. 2000, Wang, Yang et al. 2005). It is therefore understood that the
amyloid toxicity in the AD brain arises from a gain of function of the protein rather than a
loss of the protein normal functions. The normal cellular function of the amyloid
precursor protein remains unclear. The protein has been linked to many key neuronal
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functions including synaptic formation (Priller, Bauer et al. 2006), neuronal transport
(Torroja, Chu et al. 1999), iron export (Rogers, Bush et al. 2008) and hormonal
signalling (Bandyopadhyay, Goldstein et al. 2007).

APP under normal conditions undergoes a series of post-translational modifications,
most notably proteolytic cleavage of the protein. APP can undergo either an
amyloidogenic or a non-amyloidogeneic proteolytic cleavage, these cleavage pathways
are mediated by distinct proteolytic enzymes. The non-amyloidogeneic pathway begins
with APP cleavage by -secretase into a soluble APP fragment and a C83 fragment
(Esch, Keim et al. 1990, Sisodia, Koo et al. 1990). The C83 fragment is subsequently
cleaved by the -secretase enzyme to form the non-toxic P3 (Haass, Hung et al. 1993)
and the APP protein’s intracellular domain or AICD C-terminus fragments (Gu, Misonou
et al. 2001).
Amyloidogeneic proteolytic cleavage of APP is initiated by the -secretase (BACE1)
enzyme (Cai, Wang et al. 2001). Given its role in initiation of toxic APP processing,
BACE1 is the rate limiting step in A production (Stockley and O'Neill 2007). BACE1 will
cleave APP into soluble APP fragments and C99 fragments (Luo, Bolon et al. 2001). It
is these C99 fragments which can be cleaved at a number of sites by the -secretase
enzymatic complex to produce A species and AICD fragments (Citron, Westaway et al.
1997, Dovey, John et al. 2001). The cleavage pathway by which APP is catabolised is
determined by the relative abundance of the - and -secretases. However mutations in
both the APP gene (De Jonghe, Esselens et al. 2001) and in the secretase enzymes
can favour production of A(Yan, Bienkowski et al. 1999, Jankowsky, Fadale et al.
2004) Changes in the catabolism of APP to produce A-proteins is thought to trigger
the amyloid cascade in the AD brain and is the basis of the amyloid hypothesis of AD
(Hardy and Higgins 1992). There are three predominant forms of A peptides: A38,
A40 and A42 (Portelius, Tran et al. 2007). Additionally, an A43 peptide has been
described in presenilin-1 mutation knockin mice (Xia, Kelleher et al. 2016). There is
evidence that the more hydrophobic forms of these peptides, in particular the A42, are
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more related to severity of AD (Chui, Tanahashi et al. 1999). Specifically, the ratio of
A42 to A40 is most related to disease severity (Jarrett, Berger et al. 1993).
A key component therefore in Aproduction is the -secretase enzymatic complex. This
enzymatic complex is composed of four essential core proteins (Edbauer, Winkler et al.
2003): presenilin-1(Haass and Steiner 2002), nicastrin (Yu, Nishimura et al. 2000),
APH-1 (Goutte, Tsunozaki et al. 2002) and presenilin enchancer-2 (Francis, McGrath et
al. 2002). Mutations in these core proteins enhance production of A42 peptides
(Citron, Westaway et al. 1997, Yu, Nishimura et al. 2000). Inhibition of -secretase on
the other hand reduces beta-amyloid production in the brain (Dovey, John et al. 2001).
The individual core proteins have also been shown to play regulatory roles in APP
processing beyond their enzymatic activity. Presenilin-1 for example can modulate APP
processing by regulating the intracellular trafficking of the protein (Leem, Saura et al.
2002, Cai, Leem et al. 2003). Depictions of the amyloidogenic and non-amyloidogeneic
APP cleavage pathways are shown in Figure 1.3.
Given the highly neurotoxic nature of A-oligomers and potentially of Aplaques, many
therapeutic approaches have been developed to target the production of A, by
inhibiting BACE1(Vassar 2001) or the -secretase complex (Dovey, John et al. 2001).
Although targeting these enzymatic pathways may be promising therapeutic avenues,
concerns have been raised that interfering with these enzymes may be detrimental to
neuronal health (Hu, Hicks et al. 2006, Haapasalo and Kovacs 2011). The -secretase
enzymatic complex for instance, plays many other critical roles in the cell including
Notch processing (De Strooper, Annaert et al. 1999). Therefore, the general inhibition of
this complex has been shown not to be a good approach for therapeutic interventions
for AD (Haass and Selkoe 2007). Targeting the amyloidogenic activity of the complex
while leaving the Notch signalling unaffected can be achieved by modulating proteins
which activate the complex (Netzer, Dou et al. 2003, He, Luo et al. 2010).
Total A levels, particularly the A42 molecule, in the brain can either be elevated by
increase in production of the toxic species or by a reduction in their clearance (Selkoe
1993, De Felice and Ferreira 2002). This increase in A-proteins leads to the
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propensity to form A-oligomers in the brain (Lambert, Barlow et al. 1998, Walsh,
Klyubin et al. 2002, Gong, Chang et al. 2003). The oligomers disrupt synaptic function
(Wang, Pasternak et al. 2002, Lacor, Buniel et al. 2004, Lacor, Buniel et al. 2007).
Eventually the accumulation of these oligomers triggers amyloid plaque formation
(Ahmed, Davis et al. 2010) and elicits an inflammatory response (White, Manelli et al.
2005, Sondag, Dhawan et al. 2009). This accumulation of A-oligomers therefore leads
to progressive neuronal injury (Zhang, McLaughlin et al. 2002). A-oligomers have also
been shown to trigger tau hyperphosphorylation (Ma, Yang et al. 2009). These events
together have been suggested to underlie neuronal dysfunction and cognitive decline in
the AD brain (Cleary, Walsh et al. 2005, Tomic, Pensalfini et al. 2009).
A-oligomers can produce cytotoxicity by a number of mechanisms. A number of
transmembrane receptors have been identified that A-oligomers can bind to, including
the NMDA receptor (Texido, Martin-Satue et al. 2011), 7nAChR (Wang, Lee et al.
2000, Lilja, Porras et al. 2011), insulin(Zhao, De Felice et al. 2008) and the PrPc
(Lauren, Gimbel et al. 2009, Chen, Yadav et al. 2010). Binding to these membrane
proteins can trigger a number of cytotoxic signalling pathways, ultimately leading to cell
death (Haass and Selkoe 2007). A-oligomers have also been proposed to increase
membrane permeability and by doing so, disrupt the cationic homeostasis of the
affected cells (Lin, Bhatia et al. 2001, Demuro, Mina et al. 2005). A-oligomers can also
trigger cytotoxic cellular signalling when it accumulates within neurons. These
intracellular aggregates of A have been shown to impair proteasome function (Tseng,
Green et al. 2008), disrupt mitochondria (Manczak, Anekonda et al. 2006) and increase
production of toxic reactive oxygen species (Cenini, Cecchi et al. 2010).
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Figure 1.3 Processing of the Amyloid Precursor Protein. (A) Transmembrane APP
protein can be cleaved by either the α-secretase or the -secretase enzymes. Cleavage
by the -secretase enzyme leads to the amyloidogenic processing of the protein, while
cleavage by the -secretase leads to the non- amyloidogenic processing of the protein.
(B) The amyloidogenic processing of APP. Following cleavage by the -secretase
enzyme a  soluble APP fragment and a C99 fragment of the protein are formed. The
C99 fragment undergoes subsequent cleavage to form toxic A fragments and AICD
fragments. This cleavage is mediated by the -secretase complex. (C) The nonamyloidogenic processing of APP. Following cleavage by the α-secretase enzyme an 
soluble APP fragment and a C83 fragment of the protein are formed. The C83 fragment
undergoes subsequent cleavage to form inert P3 fragments and the AICD fragment.
This cleavage is mediated by the -secretase complex.
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1.3.2 Tau Pathology in Alzheimer’s Disease
Another key pathological hallmark of AD, is the appearance of intracellular
neurofibrillary tangles (NFTs). Inclusion of NFTs, along with amyloid plaques, are a
diagnostic criteria for AD and the severity of the NFT pathology are also important for
the Braak staging of AD (Braak, Braak et al. 1986). NFTs are composed of aberrantly
phosphorylated microtubule associated protein tau (Goedert, Wischik et al. 1988). The
exact relationship between tau pathology and neurodegeneration remains unclear.
Specifically, it is not fully understood if tau pathology arises from the loss of the protein
normal function, or if tau hyperphosphorylation leads to a toxic gain of function of the
protein.

The full length tau protein is 441 amino acid residues long and presents two
characteristic domains. Near the C-terminus of the protein, there are a number of
tubulin binding domains, and near the N-terminus there are two acidic domains. The
predominant function of the tau protein is to stabilize microtubules (Lee, Cowan et al.
1988). This function is mediated by the two characteristic structural domains of the
protein, with the tubulin binding domain binding -tubulin (Maccioni, Rivas et al. 1988),
and the acidic domains binding to the negatively charged regions of microtubules
(Ennulat, Liem et al. 1989). This interaction between tau and microtubules can be
regulated by phosphorylation of the tau protein. Phosphorylation of tau negatively
regulates its interaction with microtubules (Steiner, Mandelkow et al. 1990). Aberrant
phosphorylation of the tau protein can thus lead to microtubule instability, a potential
mechanism of tau neurotoxicity.

The effects of tau phosphorylation are dependent on which amino acid residues on the
protein are phosphorylated. Different phosphorylation sites can have different
physiological or pathological outcomes. Tau phosphorylation plays an important role in
regulating microtubule dynamics in neurons, however when deregulated this process
can become neurotoxic. The key inhibitory phosphorylation sites on tau are Ser262,
Thr231, and Ser235; tau phosphorylated at any of these amino acids will have inhibited
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microtubule binding capacities (Sengupta, Kabat et al. 1998). Furthermore,
phosphorylation at Ser199/Ser202/Thr205, Thr212, Thr231/Ser235, Ser262/Ser356,
and Ser422, will not only inhibit the function of the protein, but will cause tau to
sequester normal tau proteins away from microtubules and inhibit their function as well
(Alonso Adel, Mederlyova et al. 2004). Finally phosphorylation at Thr231, Ser396, and
Ser422 have also been shown to promote self-aggregation of the tau in vitro (Abraha,
Ghoshal et al. 2000).

Phosphorylation of tau is a dynamic process with a number of kinases and
phosphatases interacting with the protein. The kinases which have been identified to
phosphorylate tau are glycogen-synthase kinase-3β (GSK-3β) (Takashima, Noguchi et
al. 1993), cyclin-dependent protein kinase 5 (Baumann, Mandelkow et al. 1993), cAMPdependent protein kinase (Jicha, Weaver et al. 1999),and stress-activated protein
kinases (Ferrer, Gomez-Isla et al. 2005). These kinases preferentially phosphorylate tau
at different amino acid residues. GSK-3β in particular has been identified as promoting
toxic phosphorylation of tau. This kinase will preferentially phosphorylate at
Ser202/Thr205, Ser214/Thr212, Thr231 and Ser396 residues (Song and Yang 1995).
PP2A has been identified as the major phosphatase of tau (Goedert, Jakes et al. 1995).
Importantly, activity and expression of this phosphatase has been shown to be
decreased in the AD brain (Liu, Grundke-Iqbal et al. 2005).

Tau neurotoxicity is likely the result of both the gain and loss of functions resulting from
hyperphosphorylated tau. As described above, when tau is hyperphosphorylated it no
longer stabilizes microtubules. Hyperphosphorylation of the protein can therefore
destabilize microtubules and compromise axonal transport (Zhang, Maiti et al. 2005).
Furthermore, tau hyperphosphorylation causes the protein to bind to its unphosphorylated form and inhibits its own function. This again leads to microtubule
instability and compromised axonal transport (Zhang, Maiti et al. 2005). Microtubule
instability is highly toxic to neurons (Gornstein and Schwarz 2014), drugs that inhibit
microtubule stability are toxic to cultured neurons within hours and can cause
neurological impairments within a week in vivo (Pisano, Pratesi et al. 2003).
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1.3.3 Cholinergic Vulnerability in Alzheimer’s Disease
A central hypothesis in AD, is that the cognitive symptoms of the disease arise as a
result of the loss of basal forebrain cholinergic signalling. It was first reported in the
1970’s that anticholinergic drugs could impair cognitive function in humans (Deutsch
1971). Given these findings, it was hypothesized that this neurotransmitter system may
be dysfunctional in dementia. Post mortem analysis of AD brains has revealed
significant reductions in levels of the ChAT enzyme in the cortex (Bowen, Smith et al.
1976, Perry, Gibson et al. 1977). Furthermore, it has been shown that in the AD brain
there is a reduction in choline uptake (Rylett, Ball et al. 1983), ACh release (Nilsson,
Nordberg et al. 1986), VAChT (Efange, Garland et al. 1997, Chen, Reese et al. 2011,
Parent, Bedard et al. 2013) and an overall reduction in the number of cholinergic
neurons in the basal forebrain region (Davies and Maloney 1976, Whitehouse, Price et
al. 1982). This body of evidence lead to the cholinergic hypothesis of AD (Bartus, Dean
et al. 1982). This hypothesis is the basis for the use of cholinesterase inhibitors as
standard therapy for AD. These drugs have been shown to be effective in improving
behavioural symptoms of the disease and delaying the placement of the patients in
nursing homes (Cummings 2003).

One of the hypothesis of AD is that the neuronal dysfunction that occurs in the disease
precede the cognitive decline (Nestor, Scheltens et al. 2004). That is, the pathological
changes observed in the brain cause neuronal dysfunction and cell loss, leading to
cognitive decline. It is therefore important to detect AD prior to the clinical manifestation
of the disease. It was reported that there was no change in ChAT or AChE levels in the
cortex of individuals with mild-AD (Davis, Mohs et al. 1999). Furthermore, the activity of
the enzyme was reported as unaltered in the mild-AD brain and activity was increased
in the brain of patients with mild cognitive impairment (DeKosky, Ikonomovic et al.
2002). These findings led to criticisms of the validity of the cholinergic hypothesis of AD
(Morris 2002). A strong counterargument to these criticism, however is that neither total
levels nor activity of the ChAT or AChE enzymes represent accurate measures of ACh
release. Therefore the levels of these enzymes in the AD brain are not necessarily
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indicative of changes in cholinergic signalling (Terry and Buccafusco 2003). Further
evidence of cholinergic dysfunction (either for or against), in particular assessment of
ACh release, in early AD is therefore still needed.

The main risk factor for AD is aging (Lindsay, Laurin et al. 2002). Therefore, numerous
studies have examined the effect of aging on the cholinergic system. It was shown that
in mice, ACh synthesis is reduced by 75% when comparing young (3 months old) to
aged (30 months old) animals (Gibson, Peterson et al. 1981). Furthermore, as mice
age, their cholinergic neurons no longer release as much ACh as their younger
counterparts (Gibson and Peterson 1981). These findings were confirmed in rats as well
(Wu, Bertorelli et al. 1988). Numerous studies in animals have suggested that
cholinergic neurons function “normally” and that the aging process stresses these
neurons and decreases their function (Meyer, Crews et al. 1986, Gilad, Rabey et al.
1987, Moore, Stuckman et al. 1996). Accelerating the aging-induced deficits in
cholinergic signalling has been shown to have functional consequences in rat model of
sustained attention (Burk, Herzog et al. 2002).

Recent evidence has added a new dimension to the cholinergic hypothesis of AD.
Clinical findings report that there is an increased incidence of dementia in patients
following the cumulative use of anticholinergic drugs (Gray, Anderson et al. 2015,
Risacher, McDonald et al. 2016). It is well understood that the use of these compounds
can impair cognition while the patient is taking them. However, there is a growing body
of clinical evidence suggesting that anticholinergic medications can produce cognitive
impairments long after consumption of the medications has been cessed (Carriere,
Fourrier-Reglat et al. 2009, Jessen, Kaduszkiewicz et al. 2010). Furthermore, it has
been reported that prolonged use of these drugs, specifically anti-muscarinic agents,
increases Alzheimer’s pathology in the brains of these patients (Perry, Kilford et al.
2003). In vitro models, have confirmed that anti-muscarinic agents have the most potent
effect on neuronal and astrocytic cells (Woehrling, Parri et al. 2015). Mechanistic
insight, however, into how anticholinergic medications can increase risk of dementia are
still largely unknown.
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Cholinergic neurons also appear to be highly vulnerable to AD pathology. Post-mortem
analysis of AD brains has shown that basal forebrain cholinergic neurons present with
both amyloid (Baker-Nigh, Vahedi et al. 2015) and tau pathology (Vana, Kanaan et al.
2011, Ahmadian, Rezvanian et al. 2015). These cholinergic basal forebrain neurons
have been shown to be vulnerable to both of these AD related pathologies. This
selective vulnerability is mediated by the dependence of these basal forebrain
cholinergic neurons on trophic factors. Aspecies impair trophic signalling in these
neurons, resulting in impairment in their function and toxicity to the cells (Cuello and
Bruno 2007). Targeting these neurotrophic pathways in mouse models of AD can
improve cognitive outcomes in these mice, and at the same time reduce tau and A
related pathology (Nguyen, Shen et al. 2014). Furthermore, it has been shown that A
species promote tau hyperphosphorylation in basal forebrain cholinergic neurons
(Zheng, Bastianetto et al. 2002). Cholinergic neurons are therefore highly vulnerable to
AD pathology and this is thought to play a role in mediating cognitive dysfunction in the
disease. Also, the magnitude of the loss of these neurons correlates to cognitive deficits
in patients (Mufson, Ma et al. 2002). It should be noted that other factors have been
shown to correlate to cognitive dysfunction including A oligomers (Cleary, Walsh et al.
2005, Tomic, Pensalfini et al. 2009) and general synaptic dysfunction in the AD brain
(DeKosky and Scheff 1990, Selkoe 2002).

Aberrant cholinergic signalling can also impact the signalling pathways related to both
tau and amyloid pathology. Immunolesions of basal forebrain cholinergic neurons in the
3xTG mouse model of AD (which has both amyloid and tau pathology), significantly
enhanced pathology in these mice (Hartig, Saul et al. 2014). Furthermore administration
of an M1 muscarinic agonist to 3xTG mice significantly decreased the pathology and
hippocampal specific memory impairments in the animals (Caccamo, Oddo et al. 2006).
These effects were purported to be mediated by regulating GSK3 activity and BACE1
expression. Crossing Alzheimer’s model mice with mice lacking the M1 muscarinic
receptor significantly increased amyloidogenic processing of APP and accumulation of
toxic A species (Davis, Fritz et al. 2010). Further work in mice has shown that

39
impairing cholinergic signalling accelerates tau hyperphohsphorylation (Zhang, Chen et
al. 2014). These studies speak to the complexity of AD pathology and provide evidence
that cholinergic signalling, along with being highly vulnerable to AD pathology, may also
be important in regulating AD pathology.

1.3.4 RNA Metabolism Dysfunction in Alzheimer’s Disease
RNA metabolism refers to any events in the life cycle of an RNA molecule, including its
synthesis, modification, processing, translation and ultimately its degradation (Stamm,
Ben-Ari et al. 2005). Alternative splicing is the process by which the mRNA of a given
gene can be edited to form differential transcripts. This process involves the inclusion or
the exclusion of particular exons or introns in a transcript (Zahler, Neugebauer et al.
1993). Alternative splicing is a central aspect of neural physiology and is carried by RNA
binding proteins. The function of a number of RNA binding proteins is therefore
essential for both the development and function of neurons (Jensen, Dredge et al.
2000).
Alternative splicing of mRNAs prior to their translation is an essential regulatory process
in eukaryotic cells. It is by alternative splicing that a single gene composed of multiple
exons can be translated into proteins which have different structures and functions
(Padgett, Grabowski et al. 1986, Breitbart, Andreadis et al. 1987). Furthermore, the
alternative splicing of an mRNA plays a critical role in the final cellular localization of the
gene product. For example, if a nuclear localization signal of a given protein is added by
alternative splicing that protein will now translocate to the nucleus, as is the case with
CaM-Kinase (Srinivasan, Edman et al. 1994). Alternative splicing plays a critical role in
both the development and in the normal function of the mammalian nervous system (Li,
Lee et al. 2007, Raj and Blencowe 2015).
There are multiple patterns of alternative splicing that have been identified in eukaryotic
cells (Sammeth, Foissac et al. 2008). Schematic depictions of the different forms of
alternative splicing can be found in Figure 1.4. The most common alternative splicing
event is the cassette-exon event (Sammeth, Foissac et al. 2008); this is the inclusion or
exclusion of a single exonic sequence from the final mRNA transcript (Van der Ploeg,
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Liu et al. 1982). A mutually exclusive exon splicing event is when the inclusion of a
given exon in a transcript results in the exclusion of another (usually a proximal exon)
(Smith and Nadal-Ginard 1989). Alternative splicing can also occur within an exon.
Splicing of a sequence which changes the length of the exon at the 5’- end is an
alternative 5’ splicing event, and an event that does the same at the 3’ end of an exon is
a 3’ alternative splicing event (Fu, Mayeda et al. 1992). Intronic sequences are usually
spliced out of a final transcript, however alternative splicing of an mRNA can result in
the retention of intronic sequences (Galante, Sakabe et al. 2004). Alternative splicing
can also occur within the promoter region of a given transcript, when this event occurs it
results in a different first exon for the final transcript (Cramer, Caceres et al. 1999).
Alternative splicing also plays a significant role in the regulation of the 3’ UTR of a
transcript, as it can result in a completely different 3’-UTR (Grimm, Holinski-Feder et al.
1998). The length of the 3’UTR is also prone to alternative splicing, these events are
termed alternative polyadenylation events (Proudfoot, Furger et al. 2002). Alternative
polyadenylation of a transcript is an important determinant of which microRNA end up
binding to the transcript and therefore can effect translation and degradation of the
transcript (Sandberg, Neilson et al. 2008).
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Figure 1.4. Patterns of alternative splicing in eukaryotic cells. (A) Cassette-exon
splicing events are the inclusion or exclusion of a single exonic sequence from the final
mRNA transcript. (B) Mutually-exclusive splicing events occur when the inclusion of a
given exon in a transcript results in the exclusion of another. (C) Intronic retention, when
an intronic sequence is retained in the final mRNA transcript. (D) Alternative promoter
events are when alternative splicing changes the first exon of a given transcript. (E)
Alternative polyadenylation events occur when the length of the 3’-UTR of a transcript is
altered. (F) Alternative 3’-UTRs occur when the 3’UTR of a transcript is completely
alerted by alternative splicing. (G) 3’-Splicing event. When alternative splicing occurs
within the 3’ region of an exon. (H) 5’-Splicing event. When an alternative splicing event
occurs within the 5’ region of an exon.

All of these different patterns of alternative splicing occur concurrently on transcripts
within eukaryotic cells. These splicing events are regulated by hosts of RNA-binding
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proteins (RBPs) (Mount, Pettersson et al. 1983, Mayeda and Krainer 1992, Wu and
Maniatis 1993, Izaurralde, Lewis et al. 1994). RBPs all bind to RNA and either enhance
or repel spliceosome formation and ultimately the alternative splicing of specific
sequences (Blencowe 2000). Any given RBP can have different effects on a single
transcript based on where the RBP binds to the mRNA, post-translational modification
to the RBP and interactions with other RBPs (Tacke, Chen et al. 1997, Xiao and Manley
1997, Black 2003). In the mammalian nervous system, there is a significant amount of
overlap between the functions of the various RBPs. This creates a complex and finely
tuned regulatory network regulating RNA metabolism within each neuron in the brain
(Vuong, Black et al. 2016). The interactions between these RNA binding proteins in
neurons is complex and plays a vital role in neuronal function (McGlincy and Smith
2008) and are dysfunctional in AD (Bai, Hales et al. 2013).

Many familial mutations have been identified in key AD related genes that cause
alternative splicing of these transcripts. This includes the genes for the amyloid
precursor protein (Golde, Estus et al. 1990) and tau (Niblock and Gallo 2012).
Furthermore mutations in genes involved in RNA metabolism are central to many
familial forms of neurodegeneration, including AD (Lemmens, Moore et al. 2010). In
particular, dysfunction of RNA metabolism is an important factor in the etiology of
Amyotrophic Lateral Sclerosis (ALS). Many of the key processes in RNA metabolism
have been shown to be disrupted in ALS (Strong 2010). Microarray analysis has shown
that a large number of key transcripts are both up and down regulated in ALS,
suggesting impaired regulation of transcription in the disease (Ferraiuolo, Heath et al.
2007). Furthermore, there is evidence of altered alternative splicing(Rabin, Kim et al.
2010), mRNA transport deficits (Millecamps and Julien 2013) and impairment in RNA
translation in ALS (Ling, Polymenidou et al. 2013). Mutations in hnRNPA2/B1 and
hnRNPA1 (see below) have been associated with familial forms of ALS. Importantly,
these mutations result in the proteins aggregating in stress granules and forming
cytoplasmic inclusions (Kim, Kim et al. 2013).
The role of alternative splicing in sporadic AD however is not well defined. The
hippocampus was identified as a region vulnerable to changes in RNA metabolism in
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the sporadic AD brain. Importantly, these observed changes in RNA metabolism, were
uncorrelated to pathological hallmarks of AD (Doebler, Markesbery et al. 1987). Many
studies have demonstrated that transcriptome level changes in genes related to
neuronal function are a hallmark of AD (Miller, Oldham et al. 2008). Microarray studies
of the AD brain temporal lobe found that there was significant amounts of alternative
splicing, and that this was reflected by changes in RNA binding protein levels (Tollervey,
Wang et al. 2011). Further microarray analysis of post-mortem entorhinal cortices from
AD and non‐demented control brains, found global changes in alternative splicing in the
sporadic AD brain (Berson, Barbash et al. 2012). Importantly, these changes in
alternative splicing were linked to hnRNPA/B proteins.

1.3.4.1 hnRNPA/B Proteins
Heterogeneous nuclear ribonucleoproteins (hnRNP) are a large family of protein which
associate with and bind pre-mRNA into hnRNP particles. hnRNP particles are
complexes of mRNA and protein. A mRNA being in an hnRNP particle indicates to the
cell that the mRNA is not mature, and is not ready for translation (Konig, Zarnack et al.
2010). It is within this hnRNP particle that splicing of the mRNA occurs. A subfamily of
the hnRNP proteins is the A/B family. The hnRNPA/B family is comprised primarily of
the hnRNPA1 hnRNPA2/B1 proteins (Minoo, Martin et al. 1991), although hnRNPA0
(Myer and Steitz 1995) and hnRNPA3 (Matsui, Motomura et al. 2002) are also members
of the family. All hnRNPA/B proteins have two RNA-recognition motifs within a glycine
rich domain (Dreyfuss, Matunis et al. 1993). All proteins within the family have a
relatively high level of homology between these RNA-recognition motifs (Burd, Swanson
et al. 1989). hnRNPA/B proteins are the most abundant hnRNP proteins within cells.
hnRNPA2/B1 and A1 comprise roughly 60% of all hnRNP proteins within cells (Beyer,
Christensen et al. 1977). hnRNPA/B proteins are most abundant within the nucleus of
cells (Pinol-Roma, Swanson et al. 1989), however the shuttling of these proteins
between the nucleus and the cytoplasm is critical for many of their functions.
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The key function of hnRNPA/B proteins is their involvement is RNA-editing. hnRNPA/B
proteins are essential components of the spliceosome and are involved in alternative
and constitutive splicing events (Jurica, Licklider et al. 2002). hnRNPA/B proteins do not
directly splice mRNA, rather, they regulate alternative splicing by attracting or repulsing
serine/arginine-rich (SR) proteins (Martinez-Contreras, Cloutier et al. 2007). Therefore,
hnRNPA/B proteins can act as either splicing enhancers or repressors, depending on
their RNA-recognition motif and the element they bind on a given mRNA, and their
effect on SR proteins.
hnRNPA/B proteins can also play important roles in other aspects of RNA metabolism.
These proteins can play a role in gene transcription, by binding to promoter regions of
genomic DNA (Takimoto, Tomonaga et al. 1993, Campillos, Lamas et al. 2003). The
binding of these hnRNPA/B proteins can either promote or inhibit transcription of genes.
hnRNPA/B proteins also play a role in shuttling mRNA out of the nucleus. hnRNPA/Bs
interact with transportin 1 and 2 proteins (Rebane, Aab et al. 2004) and is then be
exported from the nucleus by nucleoporins (Bonifaci, Moroianu et al. 1997). hnRNPA/Bs
then shuttle mRNAs to polysomes for translation (Visa, Alzhanova-Ericsson et al. 1996).
In neurons this can involve transporting key transcripts, in an activity dependant
manner, from the nucleus to the synapse, such as BDNF mRNA (Leal, Afonso et al.
2014). hnRNPA2/B1 is also found to bind to, and interact with miRNAs. hnRNPA2/B1
will specifically bind miRNAs which have a recognition element for hnRNPA2/B1, the
protein controls the loading of miRNAs into exosomes (Villarroya-Beltri, GutierrezVazquez et al. 2013).

1.3.4.2 hnRNPA/B Proteins in AD
The selective loss of hnRNPA/B proteins in the AD brain was an important breakthrough
in understanding the mechanism which regulate alternative splicing (Berson, Barbash et
al. 2012). In mice, viral mediated knockdown of hnRNPA/B proteins recapitulated many
of the alternative splicing events observed in the AD brain (Berson, Barbash et al.
2012). Furthermore knocking down hnRNPA/B proteins produced memory and
electrophysiological impairments in the mice (Berson, Barbash et al. 2012). Taken
together, these results implicate broad changes in alternative splicing as a causal factor
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to cognitive impairments in AD. Importantly, this change in hnRNPA/B protein levels
was independent of Aβ and Tau toxicity in mouse models of AD. Rather, it was shown
that cholinergic signalling mediated hnRNPA/B protein levels (Berson, Barbash et al.
2012), and that manipulating cholinergic tone in mice could impair RNA metabolism.
An unbiased analysis of the human brain-insoluble proteome identified a number of
protein components of the U1-snRNP, both the U1-70K and the U1A proteins, as being
aggregated in the AD brain (Bai, Hales et al. 2013). This complex is a primary
component of the spliceosome and mediates spliceosome binding to RNA and the
initiation of splicing (Hodnett and Busch 1968, Seraphin and Rosbash 1989). In line with
the observation of aggregation of splicing factors in the AD brain, a number of genes
were shown to be alternatively spiced in the AD brain, including the BACE1 gene (Bai,
Hales et al. 2013). In vitro manipulations of U1-70K expression altered APP processing
in cultured neurons and induced production of A species (Bai, Hales et al. 2013).
Experimental evidence has shown that he aberrant aggregation of the U1-70K splicing
factor in the AD brain is the result of abnormal truncation of the protein in the AD brain
(Bai, Chen et al. 2014).

Taken together, these findings demonstrate multiple neurodegeneration-related
alterations in RNA processing which may play a role in AD pathogenesis and disease
progression. The mechanisms regulating these disease related changes in RNAmetabolism remain poorly understood, however cholinergic signalling has been
demonstrated as an important mediator of this process. Insight into the cellular
mechanisms regulating this interaction could provide crucial insight into the
pathogenesis of AD.

1.3.4.3 RNA Sequencing as a Tool to study RNA Metabolism
The study of entire transcriptome at once (the sum of all transcripts within a cell, or
group of cells) has proven to be an invaluable tool in neuroscience from basic science
(Okaty, Sugino et al. 2011), up to clinical research (Gould and Manji 2004). A number of
techniques have been developed in order to study the transcriptome. Sequencing based
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approaches is one of the powerful tools used to study of RNA metabolism. The
depection of the typical workflow of an RNA-Seq experiment can be found in Figure 1.5.
RNA-Seq can provide an in depth qualitative and quantitative analysis of the
transcriptome. The first step in RNA-Seq is the isolation of total RNA from the cell
population/tissue of interest. This total RNA is then converted into a library of cDNA and
fragmented. Adapter sequences are added to each fragment of cDNA. The adapter
sequences provide necessary elements for sequencing and also contain DNA barcodes
which allows for the determination of the 5’-3’ orientation of the sequence fragment. The
cDNA fragments are then sequenced in a high throughput manner, producing “reads” of
the fragments. After being sequenced, the resulting “reads” are then aligned using
assembly algorithms either with or without a reference genome (Mortazavi, Williams et
al. 2008). This mapping process provides the qualitative analysis of the transcriptome,
while the quantitative aspect of RNA-Seq comes from the count of the reads from same
transcript (Kanitz, Gypas et al. 2015, Conesa, Madrigal et al. 2016). This “reads count”
can be used to compare the level of transcripts across experimental conditions.
Given that RNA-Seq can provide quantitative and qualitative analysis of transcripts at
an extremely high level of resolution, the technique is an invaluable tool to the study of
alternative splicing and RNA processing. The resulting data from RNA-Seq experiments
can be analyzed in a number of ways to quantify alternative splicing. The most
conservative approach to this kind of analysis is to quantify the number of reads which
map to particular transcript isoform which have unique sequences, be they exons, intron
or splice junctions (Filichkin, Priest et al. 2010). The normalized count of these reads
provides an absolute quantification of the abundance of these transcript variants. This
approach however is limited to transcripts which have these unique sequences, or
which only have very minor (a couple of base pairs) differences between transcript
variants. An alternative approach is to quantify all the reads which map onto a specific
gene of interest, and normalizing the reads to the average for that gene. This approach
will thus provide the relative abundance of transcript variants, and has led to the
discovery of many novel alternative splicing events and splice junctions (Trapnell,
Pachter et al. 2009).
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Figure 1.5 Workflow of an RNA-Seq Experiment. (A) A tissue sample of interest is
isolated. (B) mRNA is isolated from the tissue sample. (C) The mRNA is converted into
cDNA and fragmented into short segments (reads). (D) The reads are sequenced. (E)
Sequenced reads are aligned to a reference genome. (F) Aligned sequences are then
counted (read counts) to allow for comparisons between samples.
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1.4 Rationale and Hypothesis
AD is a progressive neurodegenerative disease and is characterized by a number of
key pathological and molecular changes in the brain. These molecular and pathological
changes converge to perturb neuronal function, leading to cognitive decline, and
ultimately lead to loss of neurons in the brain. A key aspect of AD is the loss of basal
forebrain cholinergic neurons. ACh has been implicated in the underlying physiology of
many distinct cognitive functions; however the exact role that ACh plays in regulating
information processing in the brain is still not fully understood.

Therefore, the overall objective of thesis is to first characterize how altered cholinergic
signalling in mice can lead to cognitive dysfunction. Additional objectives include to
evaluate the molecular changes that follow long-term cholinergic dysfunction and how
they may be related to AD pathology. VAChT is required for the storage of ACh into
synaptic vesicles, and therefore it presents a means to modulate release. We can
leverage this knowledge to generate mice with brain region specific changes in
transporter level. Specifically, the aims of this thesis are:

1. To investigate the consequences of cholinergic dysfunction on distinct cognitive
domains in mice and attempt to dissect underlying receptor signalling pathways.
2. Determine the genome-wide transcriptome level changes in mice with long-term
cholinergic dysfunction and to determine the molecular mechanisms
underpinning these changes.
3. Examine the molecular alterations that contribute to molecular pathology in a
mouse model with deficient cholinergic signaling in the forebrain.
Several lines of research suggest that long-term cholinergic dysfunction may lead to
cognition dysfunction, suggesting a role for decreased ACh signaling on the broad
molecular and pathological changes in the demented brain. The hypothesis we tested is
that changes in cholinergic tone produce specific molecular signatures in target brain
areas that underlie alterations in cognitive function. We combined behavioural and
molecular techniques and unique mouse models to test this hypothesis and to define
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basic aspects of regulation of behaviour by cholinergic activity. Dysfunction of the
cholinergic system has been shown to play a role in a host of neurological and
neuropsychiatric disorders beyond just AD. Thus, understanding the basic physiological
aspects of this system may lead to the development of novel treatments for neurological
and psychiatric disorders.
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Chapter 2
ChAT–ChR2–EYFP mice have enhanced motor endurance but
show deficits in attention and several additional cognitive domains
2.1 Chapter Summary
Acetylcholine (ACh) is an important neuromodulator in the nervous system implicated in
many forms of cognitive and motor processing. Recent studies have used bacterial
artificial chromosome (BAC) transgenic mice expressing channelrhodopsin-2 (ChR2)
protein under the control of the choline acetyltransferase (ChAT) promoter (ChAT–
ChR2–EYFP) to dissect cholinergic circuit connectivity and function using optogenetic
approaches. We report that a mouse line used for this purpose also carries several
copies of the vesicular acetylcholine transporter gene (VAChT), which leads to
overexpression of functional VAChT and consequently increased cholinergic tone. We
demonstrate that these mice have marked improvement in motor endurance. However,
they also present severe cognitive deficits, including attention deficits and dysfunction in
working memory and spatial memory. These results suggest that increased VAChT
expression may disrupt critical steps in information processing. Our studies demonstrate
that ChAT–ChR2–EYFP mice show altered cholinergic tone that fundamentally
differentiates them from wild-type mice.
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2.2 Introduction
Acetylcholine (ACh) has multiple functions in the CNS, including modulation of attention
and memory encoding, consolidation, and retrieval (Prado et al., 2013). Understanding
the precise roles of ACh in distinct brain regions has remained a challenge because of
the myriad of cholinergic receptors that can modulate postsynaptic and presynaptic
cholinergic activities (Hasselmo and Sarter, 2011). Genetic approaches have been used
to determine the specific roles of ACh in different brain regions (Guzman et al., 2011;
Martyn et al., 2012; Patel et al., 2012), as well as to pinpoint precise functions of ACh
receptors (for review, see Wess et al., 2007; Changeux, 2010). More recently,
optogenetics has also been used to further dissect and understand cholinergic signaling
in the CNS (Witten et al., 2010; Nagode et al., 2011; Ren et al., 2011; Zhao et al., 2011;
Gu et al., 2012). One of the approaches to specifically activate cholinergic neurons
using optogenetics is in vivo injection of Cre-inducible viral vectors carrying the
channelrhodopsin-2 (ChR2) gene. Cholinergic specificity is ensured by using bacterial
artificial chromosome (BAC) transgenic mice expressing Cre recombinase under the
control of the choline acetyltransferase (ChAT) promoter (Gradinaru et al., 2007).
Alternatively, BAC transgenic mice expressing ChR2 protein under the control of the
ChAT promoter (ChAT–ChR2–EYFP) have also been used, for example, to examine
ACh/glutamate cotransmission in neurons thought to be strictly cholinergic (Ren et al.,
2011; Zhao et al., 2011). However, a unique characteristic of the ChAT locus, also
called cholinergic gene locus (Eiden, 1998), is that the entire open reading frame for the
vesicular acetylcholine transporter (VAChT) lies within the intron between the first and
second exons of the ChAT gene (Bejanin et al., 1994; Erickson et al., 1994; Roghani et
al., 1994; Cervini et al., 1995; Naciff et al., 1997). Thus, the BAC containing the ChAT
gene used to generate these mouse lines carries also the VAChT gene.
Importantly, increased expression of VAChT can alter ACh release. For example, in
vitro overexpression of the VAChT in Xenopus neurons results in increased amplitude
of miniature currents and in more synaptic vesicles containing ACh (Song et al., 1997).
Moreover, a recent report indicates that a mouse line containing four copies of the
ChAT–BAC driving the expression of GFP presents increased ACh release (Nagy and
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Aubert, 2012). However, the consequences of VAChT overexpression for cognitive
functions are not yet understood. Because ChAT–ChR2–EYFP mice have the potential
to become widely used by the neuroscience community as a tool to determine the
consequences of cholinergic activation for behavior manifestations, we determined the
extent by which VAChT is overexpressed in this mouse line and whether
overexpression of VAChT affects mouse behavior.
We report that ChAT–ChR2–EYFP mice have several extra copies of the VAChT gene
and express increased VAChT mRNA and protein levels. ACh release is increased
threefold in these mice. Importantly, we find that ChAT–ChR2–EYFP have increased
physical endurance, consistent with increased cholinergic tone. In contrast with the
improved motor function, cognitive tests demonstrated that increased expression of
VAChT interferes with multiple domains of cognitive function.

2.3 Material and Methods
2.3.1 Animals
All experiments were performed in compliance with the Canadian Council of Animal
Care guidelines for the care and use of animals. The protocol was approved by the
University of Western Ontario Institutional Animal Care and Use Committee (2008-127).
All efforts were made to minimize the suffering of animals. ChAT–ChR2–EYFP mice
[B6.Cg-Tg(Chat-COP4*H134R/EYFP)6Gfng/J; The Jackson Laboratory] and VGAT–
ChR2–EYFP mice [B6.Cg-Tg(Slc32a1-COP4*H134R/EYFP)8Gfng/J; The Jackson
Laboratory] were described previously (Zhao et al., 2011) and were maintained as
hemizygous. Control mice consisted of ChAT–ChR2–EYFP or VGAT–ChR2–EYFP
negative littermates. Only male mice were used in these studies. Animals were housed
in groups of two to four per cage in a temperature-controlled room with a 14/10
light/dark cycle. Food and water were provided ad libitum. Behavioral assessment
started with less demanding (locomotor activity) to more demanding (depression and
anxiety-like behavior, spatial memory in the Barnes maze, water maze, and then
attention) tasks. Treadmill experiments were done after the water maze and before
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attention measurements. There was an interval of 3–5 d between distinct behavioral
tasks. The experimenter was blind to the genotypes, and, in most behavioral tasks,
software-based analysis was used to score mouse performance. All behavioral
experiments were performed from 9:00 A.M. to 4:00 P.M. in the light cycle, except for
the light/dark transition (always performed after 7:00 P.M.) and locomotor activity tests
(performed from 5:00 P.M. to 9:00 P.M.; lights off at 7:00 P.M.).

2.3.2 Immunofluorescence microscopy
Mice were anesthetized using a ketamine (100 mg/kg)-xylene (20 mg/kg) solution and
then killed by transcardial perfusion with 4% paraformaldehyde (v/v) in 1× PBS. Brains
were harvested and placed in 4% paraformaldehyde in 1× PBS at 4°C for 4 h, and they
were kept at 4°C until being sliced using a vibratome. Brain sections (40 μm) were
prepared, and free-floating sections in 1× PBS (one per well in a 24-well plate) were
permeabilized with 0.4% Triton X-100 in 1× PBS for 1 h. Nonspecific epitopes were
blocked using a solution of 1× PBS/0.4% Triton X-100 containing 0.1% glycine (w/v),
0.1% lysine (w/v), 1% BSA (w/v), and 1% normal donkey serum (w/v). Primary antibody
(an FITC-conjugated goat polyclonal anti-GFP; catalog #ab6662; Abcam) was
incubated in blocking buffer overnight at 4°C. Sections were then washed five times in
1× PBS/0.4% Triton X-100 (10 min each). Sections were mounted on slides and
visualized using an Olympus IX81 laser-scanning microscope (FluoView) using an
argon laser with parameters set for GFP. Images were taken using a 10× objective
(numerical aperture 0.40) with the tile feature. Acquired images were then used to
reconstruct the entire brain using the Olympus software.

2.3.3 qPCR and Western blotting
To genotype mice and to measure gene copies of VAChT, genomic DNA was extracted
from tail-snip samples, and qPCR was used with the following primer pair: forward, 5′GAGAGTACTTTGCCTGGGAGGA-3′; and reverse, 5′GGCCACAGTAAGACCTCCCTTG-3′. The results were normalized to Sti1p1 using the
following primer pair: forward, 5′-ATGTATCTGAGCATGCCTCTG-3′; and reverse, 5′-
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ATTGCCCTTCTCCTTTAGCTC-3′. To measure VAChT mRNA expression, total RNA
was extracted using the Aurum Total RNA for fatty and fibrous tissue kit (Bio-Rad)
according to the kit manual. cDNA synthesis and qPCR analysis were performed as
described previously (Guzman et al., 2011). Immunoblotting was performed as
described previously (Martins-Silva et al., 2011). The antibodies used were anti-VAChT
(catalog #139103; Synaptic Systems), anti-ChAT (catalog #A144p; Millipore), antiSynaptophysin (catalog #S5768; Sigma-Aldrich), and anti-Actin (catalog #ab49900;
Abcam).

2.3.4 Acetylcholine Release
ACh release from hippocampal brain slices was done as described previously (Guzman
et al., 2011), by labeling slices with [3H] methyl-choline, before using KCl to stimulate
release of labeled ACh.

2.3.5 Metabolic assessments
Oxygen consumption, carbon dioxide production, respiratory exchange ratio (RER),
food and water intake, and physical activity were simultaneously measured for young
and adult mice by using the Comprehensive Lab Animal Monitoring System interfaced
with Oxymax software (Columbus Instruments) essentially as described previously
(Guzman et al., 2013). Mice were individually housed in the metabolic chambers
maintained at 24 ± 1°C and given ad libitum access to powdered standard rodent chow
and water. All the measurements were taken every 10 min for 24 h (12 h light/12 h dark)
after a 16 h habituation period in the individual metabolic chambers. Total activity,
ambulatory activity, and sleep (periods of inactivity) were obtained using the Opto-M3
Activity Monitor and Oxymax software algorithms (Columbus Instruments) as described
previously (Guzman et al., 2013).

2.3.6 Glucose tolerance test
Animals were fasted for 5 h and then received an intraperitoneal injection of 2 g/kg
glucose. Blood glucose levels were measured at 0 (baseline), 30, 60, 90, 120, and 150
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min after glucose injection. Glucose levels were determined in blood samples obtained
from a tail snip using ACCU-CHEK Advantage (Roche Diagnostics).

2.3.7 Grip force
Forelimb and hindlimb grip strength were assessed using a previously described
protocol (Prado et al., 2006).

2.3.8 Treadmill
To test motor endurance, a rodent treadmill (IITC Life Sciences), with a grid behind the
track that delivered a mild electric shock (15–20 V) when the mouse fell off, was used.
Before testing, mice were trained for 4 d (3 min/day). On the first day, inclination was
set to 5°. The inclination was increased by 5° on each subsequent training day. The
initial training speed was 8 m/min, and the treadmill was accelerated by 1 m/min, up to 9
m/min. In the second training session, the initial speed was 10 m/min and was
increased to 11 m/min, whereas on the third day and fourth days, the speed was
maintained at 12 m/min. On the test day, the initial speed was set to 12 m/min, and the
ramp angle was set to 20°. Speed was increased to 20 m/min over the course of the
first 15 min of testing, after which it remained constant, until the test was complete. The
test ended when 60 min had elapsed or the mouse had reached exhaustion (Lund et al.,
2010).

2.3.9 Elevated plus maze, forced swimming test, and tail
suspension test
Anxiety-like behavior was assessed using the elevated plus maze test, performed as
described previously (Martins-Silva et al., 2011). Sessions were recorded and the video
was analyzed using the ANY-Maze Software (Stoelting) to determine total time spent in
the open and closed arms. Depressive-like behavior was assessed using the forced
swim and tail suspension tests (Martyn et al., 2012). For the forced swim test, mice
were placed in a 2 L beaker containing 1.8 L of 25–27°C water, for 6 min. For the tail
suspension test, mice were suspended from their tails for 5 min, held in place by a strip
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of masking tape placed ∼1.5 inches from the base of the tail. Sessions were recorded
for both tests, and immobility time and episodes were assessed using the ANY-Maze
Software. For the forced swim test, only data obtained after the initial 2 min of the test
were used for the analysis.

2.3.10 Rotarod
The rotarod task was conducted as described previously to assess motor learning and
acrobatic motor skill (Prado et al., 2006; de Castro et al., 2009a).

2.3.11 Locomotor activity
Spontaneous locomotor activity in a new environment to determine exploratory behavior
was recorded using automated locomotor boxes essentially as described previously
(Guzman et al., 2013).

2.3.12 Spontaneous alternations Y-maze
The spontaneous alternations Y-maze task to investigate working memory was
performed using a symmetrical, three-armed Y-maze as described previously (de
Castro et al., 2009a). All sessions were recorded. Both the order and the number of arm
entries were recorded. A spontaneous alternation was counted when the mouse visited
all three arms in a row without revisiting a previous arm.

2.3.13 Barnes maze
Barnes maze testing to determine spatial memory was performed as described
previously (Patil et al., 2009; Martyn et al., 2012) using a white circular platform (92 cm
in diameter) with 20 equally spaced holes (5 cm in diameter; 7.5 cm between holes),
elevated 105 cm above the floor (San Diego Instruments), and spatial cues (posters,
streamers, and plastic props) were placed around the maze. Briefly, animals were given
four training trials a day for 4 d, with a 15 min intertrial interval (ITI). On the fifth day,
memory was assessed via a probe trial. The probe trial consisted of barring access to
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the target hole and assessing nose pokes to the holes within the target quadrant.
Sessions were recorded and analyzed using the ANY-Maze Software.

2.3.14 Morris water maze
The spatial version of the Morris water maze (MWM) was conducted as described
previously to investigate spatial memory (Vorhees and Williams, 2006; Martyn et al.,
2012). Briefly, animals were given four training trials a day (90 s each) for 4 d, with a 15
min ITI. If the mice did not find the platform after 90 s during the learning phase, they
were gently directed to the platform. On the fifth day, memory was assessed via a probe
trial (60 s), during which the platform is removed and time spent in the target quadrant is
measured. The task was performed in a 1.5-m-diameter pool with 25°C water. The
platform was submerged 1 cm below the surface of the water, and spatial cues (posters,
streamers, and plastic props) were distributed around the pool. Sessions were recorded
and analyzed using the ANY-Maze Software.
Both the two-trial and cued variations of the MWM were performed as described
previously (Vorhees and Williams, 2006). Briefly, for the two-trial variation, used to
assess working or trial-dependent learning and memory, mice were tested over the
course of 8 d. The mouse was first given a 90 s trial, and then after a 15 s ITI, the
mouse was given a second trial with identical platform location and starting point. This
was repeated with four unique starting location/platform location combinations a day. As
for the cued variation, used to assess goal-directed behavior, mice were tested for 2 d
using novel platform and starting location combinations. For this variation, the platform
was at water level and a cue was placed on it (a plastic block). Sessions were recorded
for both tests and were analyzed using the ANY-Maze Software.

2.3.15 Five-choice serial reaction time task
The five-choice serial reaction time (5-CSRT) task is used to determine attention in mice
(Robbins, 2002; Romberg et al., 2011). Mice were trained in the 5-CSRT in automated
Bussey-Saksida Mouse Touch Screen Systems model 81426 (Campden Instruments
Limited). Schedules were designed and data were collected using the ABET II Touch
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software v.2.15 (Lafayette Instruments). Before being trained on the 5-CSRT task, mice
were first put through a pretraining program. This consisted of first habituating the
mouse to the testing chamber with the lights off for 15 min. The next day, the mouse
was left in the chamber with the lights off for 20 min. At this time, the reward tray was
primed with strawberry milkshake (Saputo Dairy Products), and a tone was played when
the mouse entered the reward tray. Whenever the mouse returned to the reward tray, it
received a reward paired with the tone. This was repeated the next 2 d for 40 min
sessions (phase 1).
The next training phase (phase 2) involved pairing the reward with presentation of the
stimulus (flash of light in one of the five windows) on the touchscreen. The stimulus
appeared randomly, and, after 30 s, it was removed and a reward was given paired with
a tone. If the mouse touched the screen while stimulus was displayed, it immediately
received a reward. Once the mouse collected the reward, a new trial was initiated. This
phase was repeated until the mouse completed 30 trials within 60 min (phase 2).
To further shape behavior, phase 3 involved displaying the stimulus randomly in one of
the windows. The mouse had to touch the stimulus on the screen to receive a reward
paired with a tone. There was no response to the mouse touching anything but the
stimulus. Once again, this was repeated until the mouse completed 30 trials within 60
min. The next phase (phase 4) was identical to phase 3 except that the mouse had to
initiate each trial by nose poking the reward tray. Criterion was 30 correct trials within 60
min.
Finally, in the last pre-training phase (phase 5), the previous procedure was repeated,
but if the mouse touched an incorrect screen, it received a 5 s timeout, during which the
chamber light was turned on. The final phase had a stricter criterion, requiring the mice
to perform 30 trials in 60 min with 23 correct responses in 2 consecutive days.
For the 5-CSRT training phase, mice were trained to respond to brief flashes of light
pseudo randomly displayed in one of the five spatial locations on the touchscreen. Each
trial was initiated after the mouse poked the magazine. In this phase, the stimulus was
delivered after a variable 5–10 s delay (delay period), during which the animal was
required to attend to the screen. In case the mouse prematurely touched the screen
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during this delay, the response was recorded as premature and the mouse was
punished with a 10 s timeout. The stimulus duration was initially set to 4 s, followed by a
limited holding period of 5 s, during which the stimulus was absent but the mouse could
still respond to the location (holding period). Each session lasted 50 trials or 1 h.
Responses to the stimulus window during stimulus presence or the holding period were
recorded as correct, whereas responses to any other window were recorded as
incorrect. A correct choice was rewarded with a tone and food delivery. An incorrect
response was punished with a 10 s timeout. A failure to respond to any window either
during stimulus display or the holding period was recorded as an omission, and the
mouse was punished with a 10 s timeout. Perseverative responses to the screen after
premature, correct, and incorrect choices were also recorded. Our initial goal was to
have the performance of a mouse reaching criterion at 4 s stimulus duration (80%
accuracy, 20% omissions for 3 consecutive days) and reduce the stimulus duration to 2
s. However, ChAT–ChR2–EYFP BAC mice were not able to reach criterion at 4 s
stimulus duration. Therefore, we used another training procedure, that is, the same
cohort of mice was trained in a 16 s stimulus duration, and when they reached criterion,
the stimulus duration was reduced to 8 s. After reaching criterion with the 8 s stimulus,
the mice were tested 2 more days, and the mean measures of those additional 2 d were
used to assess baseline performance.
After finishing training at 8 s stimulus duration, mice were probed for attentional deficits
in the following probe trial schedule: each mouse was tested over two sessions at a
given stimulus duration (4 and 2 s). Between each different stimulus duration, the
mouse was returned to an 8 s stimulus duration for two baseline sessions. The order of
the probe trial sessions was semi randomized using a Latin square method.
On all 5-CSRT task sessions, accuracy was defined as the total number of correct
responses divided by the number of correct and incorrect responses (touches to a
wrong window while the correct stimulus was still displayed). Rate of omissions were
the proportion of omitted responses to total trials. Response latency was the time for the
mouse to touch the correct stimulus from its onset. Reward collection latency was the
time for the mouse to return to the reward tray once it had touched the correct stimulus.
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A premature response was counted when the mouse touched one of the windows
before stimulus onset. Finally, a perseverative response was any identical response that
occurred after a correct, incorrect, or premature response.

2.3.16 Statistical analyses
Data are expressed as mean ± SEM. SigmaStat 3.5 software was used for statistical
analysis. Comparison between two experimental groups was done by Student's t test or
Mann–Whitney rank-sum test when the data did not follow a normal distribution. When
several experimental groups or treatments were analyzed, two-way ANOVA or two-way
repeated-measures (RM) ANOVA were used as required. When appropriate, a Tukey's
HSD post hoc comparison test was used.

2.4 Results
2.4.1 Increased levels of VAChT in the ChAT–ChR2–EYFP BAC
mice
Immunofluorescence analysis confirmed previous findings that ChR2–EYFP is highly
expressed in different areas of the brain (Zhao et al., 2011), including the striatum and
basal forebrain (Fig. 2.1A), as well as interpeduncular nucleus and brainstem motor
nuclei (data not shown). qPCR assays showed that ChAT–ChR2–EYFP mice contain
∼56 copies of the VAChT gene and 54 copies of the YFP gene (Fig. 2.1B), suggesting
that close to 50 copies of the ChAT–BAC were inserted in the mouse genome. RTqPCR data indicate that these additional copies of the VAChT gene are functional
because VAChT mRNA was increased almost 20-fold in the striatum of ChAT–ChR2–
EYFP mice when compared with controls; importantly, expression of ChAT, as
expected, was not changed (Fig. 2.1C). This increased VAChT mRNA level is
consistent with the elevated copy number of ChAT–ChR2–EYFP BAC. Expression of
the VAChT protein is also increased (Fig. 2.1D) in this mouse line. In the hippocampus,
there is a 550% increase in VAChT protein levels, whereas in the brainstem, VAChT
levels are augmented by 350% when compared with control littermates (Fig. 2.1D).
Expression of the ChAT protein was unaltered in both brain regions (Fig. 2.1E).
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Importantly, increased expression of VAChT protein had functional consequences,
because ChAT–ChR2–EYFP BAC mice presented threefold to fourfold increase in the
release of newly synthesized [3H]ACh from hippocampal slices (Fig. 2.1F). Moreover,
BAC transgenic expression of VAChT was able to rescue postnatal lethality attributable
to VAChT elimination. We crossed ChAT–ChR2–EYFP with VAChTdel/wt
[heterozygous VAChT knock-out (de Castro et al., 2009b)] mice and then intercrossed
heterozygous littermates to obtain ChaT–ChR2–EYFP VAChTdel/del. Screening of the
offspring was done by qPCR of the VAChT del allele (de Castro et al., 2009b). Our data
show that ChAT–ChR2–EYFP VAChTdel/del mice are viable and survive to adulthood
(Table 1).
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Figure 2.1- Overexpression of VAChT in ChAT–ChR2–EYFP mice. A, YFP
expression in the CNS of ChAT–ChR2–EYFP mice (n = 3). B, VAChT and YFP gene
copy numbers determined by genomic qPCR (n = 5). C, VAChT and ChAT mRNA
expression in the striatum of wild-type and transgenic mice (n = 6 for both genotypes).
D, VAChT protein expression in the hippocampus and brainstem with representative
immunoblots (n = 3 for both genotypes). E, ChAT protein expression in the
hippocampus and brainstem with representative immunoblots (n = 3 for both
genotypes). F, Release of newly synthesized ACh in hippocampal slices (n = 4 for both
genotypes). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2.1- Overexpression of VAChT in ChAT–ChR2–EYFP mice.
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Table 2.1. Rescue of lethality in VAChTdel/del mice. ChAT–ChR2–EYFP mice were
crossed to VAChTdel/wt mice and offspring were then intercrossed. Genomic qPCR
using primers that amplify the VAChTdel allele was used to identify live VAChTdel/del
mice containing the ChaT BAC.

117
Table 2.1. Rescue of lethality in VAChTdel/del mice.

Genotype

Number of mice born

VAChTwt/wt

2

VAChTwt/del

7

ChAT–ChR2–EYFP VAChTwt/del 10
ChAT–ChR2–EYFP VAChTdel/del 4
ChAT–ChR2–EYFP VAChTwt/wt 6
Total

29

118

2.4.2 ChAT–ChR2–EYFP mice have improved motor endurance
To assess neuromuscular function in ChAT–ChR2–EYFP mice, both forelimb and
hindlimb grip strength were measured, but there was no statistical difference between
ChAT–ChR2–EYFP mice and control littermates (Fig. 2.2A). In contrast, ChAT–ChR2–
EYFP mice performed much better than wild-type controls in the treadmill. By using a
protocol designed to determine physical fitness, we observed that ChAT–ChR2–EYFP
mice were able to run almost twice as much compared with control mice (t(14) = 2.497,
p = 0.0256; Fig. 2.2B).
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Figure 2.2 ChAT–ChR2–EYFP mice have increased physical endurance. A, Grip
force in wild-type and transgenic mice. B, Treadmill analysis of physical endurance in
wild-type and transgenic mice (*p < 0.05, n = 8 for both genotypes).
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Figure 2.2 ChAT–ChR2–EYFP mice have increased physical endurance.
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2.4.3 ChAT–ChR2–EYFP mice do not present gross alterations in
metabolism
To investigate whether increased copy numbers of VAChT affects homeostasis,
transgenic ChAT–ChR2–EYFP mice were assessed in metabolic cages. Transgenic
mice had body weight statistically similar to controls (t(14) = 0.6920, p = 0.500; Fig. 2.3).
These mice presented similar metabolic profiles as controls, with no statistical
differences in RER, in the light (t(14) = 0.9898, p = 0.831) or the dark (t(14) = 0.5414, p
= 0.702) cycles (Fig. 2.3A). They did not consume more O2 during the light cycle (t(14)
= 0.1897, p = 0.8523) or dark cycle (t(14) = 1.402, p = 0.1828; Fig. 2.3B). Similar results
were obtained for CO2 release during the light (t(14) = 0.09952, p = 0.9221) or dark
(t(14) = 1.462, p = 0.1658) cycle (Fig. 2.3C). Likewise, locomotor activity, sleep time, or
blood glucose levels were not significantly altered in this transgenic mouse line (Fig.
2.3). Interestingly, ChAT–ChR2–EYFP mice consumed both more food and water
during the dark cycle than control mice (food consumption, t(14) = 2.212, p = 0.0441;
water consumption, t(14) = 2.878, p = 0.0122; Fig. 2.3D,E).
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Figure 2.3. Metabolic analysis in ChAT–ChR2–EYFP mice. A, Respiratory exchange
rate analysis. B, VCO2 consumption. C, VO2. D, Food consumption. E, Water
consumption. F, Sleep time. G, Home cage activity. H, Body weight at time of analysis.
I, Glucose tolerance test. *p < 0.05, n = 8 for both genotypes.
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Figure 2.3. Metabolic analysis in ChAT–ChR2–EYFP mice.
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2.4.4 ChAT–ChR2–EYFP mice do not present anxiety or
depression-like behavior
We tested ChAT–ChR2–EYFP mice for anxiety using the elevated plus maze paradigm.
These mice visited the open (t(14) = 0.2304, p = 0.8211) or closed (t(14) = 0.1365, p =
0.8934) arms at rates statistically comparable with those observed in controls (Fig.
2.4A). In addition, they did not spend more time than controls in the open (t(14) =
0.2304, p = 0.8211) or closed (t(14) = 0.1314, p = 0.8973) arms (Fig. 2.4B). ChAT–
ChR2–EYFP mice were also tested for depressive-like behavior using both the tail
suspension and forced swim tests and presented no statistical difference from wild-type
controls (swim test, t(14) = 0.4016, p = 0.6941; tail suspension, t(14) = 0.04468, p =
0.9650; Fig. 2.3C,D, respectively).
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Figure 2.4. Assessment of anxiety and depressive-like behavior in ChAT–ChR2–
EYFP mice. A, Number of arm entries in the elevated plus maze. B, Time spent in the
open and closed arms. C, Immobility time in the forced swimming test. D, Immobility
time in the tail suspension test (n = 8 for both genotypes).
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Figure 2.4. Assessment of anxiety and depressive-like behavior in ChAT–ChR2–
EYFP mice.
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2.4.5 ChAT–ChR2–EYFP mice show normal locomotion but have
impaired motor learning
We assessed locomotor activity in ChAT–ChR2–EYFP mice using an automated novel
open-field environment for 4 h: 2 h in the light and 2 h in the dark. No statistical
differences in locomotor activity were observed between genotypes (F(1,658) = 0.2468,
p = 0.6271; Fig. 2.5A). There was no interaction between time × genotype (F(47,658) =
0.4313, p = 0.9997), with both genotypes significantly reducing their locomotor activity
during the course of the test in the light phase (F(47,658) = 9.725, p < 0.0001).
Moreover, habituation in the open field was not affected in ChAT–ChR2–EYFP mice
[Fig. 2.5B; two-way RM-ANOVA shows a significant effect of day (F(2,42) = 15.07, p <
0.0001), no effect of genotype (F(1,42) = 2.653, p = 0.1108), and no interaction (F(2,42)
= 0.880, p = 0.4225)].
Knowing that transgenic mice have increased endurance and no overt deficits in
locomotor behavior, the accelerating rotarod task was used to assess motor learning.
Surprisingly, the ChAT–ChR2–EYFP mice failed to improve their performance in the
rotarod, whereas wild-type control mice improved the time spent on the rotarod as well
as distance traveled [Fig. 2.5C,D; two-way RM-ANOVA revealed main effect of
genotype (F(1,182) = 6.015, p = 0.0279) and trial (F(13,182) = 2.796, p = 0.0012)]. Post
hoc analysis confirmed that the ChAT–ChR2–EYFP mice did not significantly improve
their performance from their first trial.
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Figure 2.5. ChAT–ChR2–EYFP mice have normal locomotor activity but impaired
motor learning. A, Locomotor activity of wild-type or ChAT–ChR2–EYFP mice during
the light (2 h) and dark (2 h) activity periods in an open arm. The test was done from
5:00 P.M. to 9:00 P.M. B, Habituation in the open field. C, Acrobatic motor performance
and motor learning in the rotarod. Time spent on the rod. D, Distance traveled in the
rotarod (*p < 0.05, significant difference between genotypes; #p < 0.05, ##p < 0.01,
###p < 0.001, significant difference within genotype; n = 8 for both genotypes).
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Figure 2.5. ChAT–ChR2–EYFP mice have normal locomotor activity but impaired
motor learning.
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2.4.6 ChAT–ChR2–EYFP mice have impaired spatial memory
To assess other forms of learning, we tested spatial learning and memory in the ChAT–
ChR2–EYFP mice using the Barnes maze and MWM. During the acquisition phase of
the Barnes maze, there were no statistical differences for the performance between the
two genotypes. The two groups made a similar number of errors before reaching the
target hole (F(1,42) = 0.2685, p = 0.6124; Fig. 2.6A). In contrast, during the probe trial,
on day 5, ChAT–ChR2–EYFP mice visited the target hole location significantly less than
controls (t(14) = 3.360, p = 0.0047; Fig. 2.6B) and showed a significantly decreased
preference for the target hole, as defined by the target hole preference index [target
hole visits/mean visits per hole (Holmes et al., 2002), t(14) = 2.712, p = 0.0168; Fig.
2.6C]. Although both genotypes showed a significant effect of the hole location during
the probe trial (F(1,154) = 26.66, p = 0.001), there was a significant effect of genotype
(F(1,154) = 11.29, p = 0.047) and a significant genotype × hole location effect (F(1,154)
= 2.819, p = 0.022). Post hoc analysis revealed that wild-type mice preferred the target
hole, whereas ChAT–ChR2–EYFP mice did not (Fig. 2.6D,E). Representative traces of
two controls (Fig. 2.6F) and two ChAT–ChR2–EYFP mice (Fig. 2.6G) show the
performance of the two genotypes in this task.
To further determine the mechanisms involved with potential spatial memory deficits,
the MWM was used. Once again during the course of acquisition, the performance of
ChAT–ChR2–EYFP mice was indistinguishable from that of controls in terms of latency
to find the target (F(1,42) = 0.8933, p = 0.3606) and the distance traveled to the target
(F(1,42) = 2.783, p = 0.1175; Fig. 2.7A–C). Mutants learned the location of the platform
similar to control mice, confirming the observations using the Barnes maze. These
results indicate that the ChAT–ChR2–EYFP mice do not have any gross sensorimotor
deficits and were able to use the cues to learn the task. However, on the probe trial day,
ChAT–ChR2–EYFP mice showed no preference for the target quadrant of the pool (Fig.
2.7D). The occupancy plots in the MWM on the probe trial show that the controls clearly
remembered where the platform should be (Fig. 2.7E). In contrast, ChAT–ChR2–EYFP
mice did not seem to retrieve this information during the probe trial (Fig. 2.7F).
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Figure 2.6. ChAT–ChR2–EYFP mice have spatial memory deficits in the Barnes
maze. Mice were subject to the Barnes maze paradigm, and the average values of four
3-min trials per day are plotted. A, Number of errors before finding the target hole. B,
Visits to the target hole during the day 5, 90 s probe trial. C, Preference for the target
hole over other holes during the probe trial (target hole visits/average nontarget visits).
D, Nose pokes per hole were measured on day 5 in a 90 s probe trial for control mice.
T, Target hole. Numbers refer to the location of holes adjacent to the target hole. Op,
Opposite hole. E, ChAT–ChR2–EYFP mice. F, Representative path tracings for two
control mice during the probe trial (target quadrant highlighted; T). G, Same as in F but
for ChAT–ChR2–EYFP mice. *p < 0.05, **p < 0.01, ***p < 0.001, n = 8 for both
genotypes.
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Figure 2.6. ChAT–ChR2–EYFP mice have spatial memory deficits in the Barnes
maze.
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Figure 2.7. ChAT–ChR2–EYFP mice have spatial memory deficits in the MWM.
Mice were subject to the MWM paradigm, and the average values of four 90-s trials per
day are plotted. A, Latency to find the platform. B, Distance traveled to the platform. C,
Mouse speed. D, Percentage time spent per quadrant was measured on day 5 in a 60 s
probe trial with the platform removed. E, Representative occupancy plots for two control
mice. F, Representative occupancy plots for two ChAT–ChR2–EYFP mice during the
probe trial (T indicates the location of the target quadrant). ###p < 0.001, significant
difference within genotype, n = 8 for both genotypes. L, Left; O, opposite; R, right; T,
target.
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Figure 2.7. ChAT–ChR2–EYFP mice have spatial memory deficits in the MWM.
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2.4.7 ChAT–ChR2–EYFP mice have deficiencies in cue-directed
memory
To assess cue-driven learning in these mice, the cued version of the MWM was used
(Vorhees and Williams, 2006). There was a significant difference between genotypes
(F(1,14) = 5.262, p = 0.0378) and a significant effect of day (F(1,14) = 7.834, p =
0.0142) in terms of latency to find the target (Fig. 2.8A). Post hoc analysis confirmed
that control mice improved their performance from day 1 to day 2, whereas ChAT–
ChR2–EYFP mice did not (Fig. 2.8A). There was a trend for ChAT–ChR2–EYFP mice
to swim a greater distance to the target (Fig. 2.8B), but this failed to reach significance
(F(1,14) = 7.834, p = 0.0861). A closer examination of the path traces revealed that
ChAT–ChR2–EYFP mice do not seem to use the cue to find the target on the second
day (Fig. 2.8C,D).
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Figure 2.8. ChAT–ChR2–EYFP mice have deficits in cue memory. Mice were
subject to the cued version of the MWM in which they had to associate the platform with
a cue. A, Primary latency to find the platform. B, Distance traveled to the platform. C,
Representative path tracings to the target of two control mice. D, Representative path
tracings to the target of two ChAT–ChR2–EYFP mice. Traces are from the second trial
on the first and second days of the experiment, with T indicating the location of the
platform. The average of four 90-s trials per day is plotted. *p < 0.05, n = 8 for both
genotypes.
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Figure 2.8. ChAT–ChR2–EYFP mice have deficits in cue memory.
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2.4.8 ChAT–ChR2–EYFP have impaired working memory
The above experiments suggest that ChAT–ChR2–EYFP mice can learn the spatial
version of the MWM, but they have difficulty retrieving that memory trace. Moreover,
these transgenic mice show impaired motor learning and cued-driven learning. These
results suggest the possibility that chronically increased cholinergic tone disturbs
distinct forms of information processing. To evaluate working memory, we first used
spontaneous alternations in the Y-maze (de Castro et al., 2009a). In contrast to results
obtained with littermate control mice, ChAT–ChR2–EYFP mice revisited the arms of the
Y-maze more often, showing significantly less spontaneous alternations (t(14) = 2.448,
p = 0.0293; Fig. 2.9A). The number of arm entries was not affected (t(14) = 0.6031, p =
0.5568; Fig. 2.9B), nor was distance traveled (t(14) = 0.5620, p = 0.5837; data not
shown). However, performance of ChAT–ChR2–EYFP mice was above chance (>50%)
regarding alternations, suggesting that these mice had a partial dysfunction on their
working memory. To exclude the possibility that the cognitive deficits observed could be
related to the introduction of ChR2 or EYFP, we also tested VGAT–ChR2–EYFP and
their littermate controls in the Y-maze alternation. qPCR analysis showed that these
mice had ∼20 copies of EYFP and therefore 20 copies of the ChR2 gene. Distinct from
ChAT–ChR2–EYFP mice, VGAT–ChR2–EYFP mice did not differ statistically from their
littermate controls in terms of either spontaneous alternations (t(10) = 0.1914, p =
0.8520; Fig. 2.9C) or number of arm entries (t(10) = 1.562, p = 0.1494; Fig. 2.9D).
To further probe working memory in ChAT–ChR2–EYFP mice, the two-trial variation of
the MWM was used (Vorhees and Williams, 2006). In this variation of the task, mice
must first find a novel platform location by chance and then, after a 10 s ITI, find it
again. To analyze mouse performance on this task, we used the latency and distance
savings ratio to standardize data (Varvel and Lichtman, 2002). These ratios were
calculated by dividing the distance traveled, or latency on the first trial by that on the
sum of the first and second trials. Values >0.5 indicate improvement from the first to the
second trial. ChAT–ChR2–EYFP mice had significantly lower distance savings ratio
(t(14) = 2.501, p = 0.0254) and latency savings ratio (t(14) = 3.684, p = 0.0025; Fig.
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2.9E–H) than control mice. Together, these results indicate that ChAT–ChR2–EYFP
mice have impaired working memory.
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Figure 2.9. ChAT–ChR2–EYFP mice have deficits in working memory. A,
Spontaneous alternations in the Y-maze were used to assess working memory for
ChAT–ChR2–EYFP mice. B, Number of arms visited for ChAT–ChR2–EYFP mice (n =
8 for both genotypes). C, Spontaneous alternations in the Y-maze for VGAT–ChR2–
EYFP mice. D, Number of arms visited for VGAT–ChR2–EYFP mice. n = 6 for both
genotypes. E, ChAT–ChR2–EYFP mice were subject to the two-trial MWM paradigm to
further assess working memory. Savings ratios were calculated from the average of the
first and second 90 s trials across all 4 d of the experiment. The graph shows the mean
distance savings ratios. F, Latency saving ratio. G, Representative path tracings to the
target for two control mice. H, Representative path tracings to the target for two ChAT–
ChR2–EYFP mice. Traces are from the first and second trials during the third day of the
experiment. T indicates the location of the platform. *p < 0.05, **p < 0.01, n = 8 for both
genotypes.
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Figure 2.9. ChAT–ChR2–EYFP mice have deficits in working memory.
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2.4.9 ChAT–ChR2–EYFP mice have impaired attentional
processing
To determine whether ChAT–ChR2–EYFP mice may be affected in other cognitive
domains that are sensitive to cholinergic tone and could contribute to the deficits we
observed, we used the 5-CSRT task. During pretraining, transgenic mice did not differ
from controls in terms of trials needed to achieve criterion [two-way RM-ANOVA; no
effect of genotype (F(1,48) = 0.6766, p = 0.4268) and no effect of training phase
(F(4,48) = 2.306, p = 0.0717)]. It should be noted that one mouse of each genotype
never completed the pretraining and were not subjected to training in the 5-CSRT task.
Our initial goal was to train mice first using a 4 s stimulus duration and then proceed to
2 s as described previously (Romberg et al., 2011). However, after 12 training sessions
at 4 s stimulus duration, whereas all control mice reached criterion with an average of
10.28 ± 1.23 trials, all ChAT–ChR2–EYFP mice failed to acquire the task. Therefore, we
increased the stimulus duration time (decreased the attentional demand) to 16 s and
then 8 s to do the training. Probe trials were then performed with 4 and 2 s stimulus
durations.

Under less demanding attentional conditions, ChAT–ChR2–EYFP mice were able to
acquire the task, reaching criteria at both stimulus durations (16 and 8 s) in the same
number of sessions as controls [two-way RM-ANOVA; no effect of genotype (F(1,12) =
1.122, p = 0.3103) and no effect of stimulus duration (F(1,12) = 2.492, p = 0.1404)].
However, during probe trials, ChAT–ChR2–EYFP mice showed significant impairments
in choice accuracy [two-way RM-ANOVA; main effect of genotype (F(1,12) = 29.86, p =
0.0001) and no effect of stimulus duration (F(1,12) = 0.6894, p = 0.4226); Fig. 2.10A],
with post hoc analysis showing that the ChAT–ChR2–EYFP mice had impaired
accuracy at both stimulus durations. The rate of omissions for ChAT–ChR2–EYFP mice
was unaffected [two-way RM-ANOVA; no effect of genotype (F(1,12) = 1.928, p =
0.1902) and main effect of stimulus duration (F(1,12) = 13.79, p = 0.0030); Fig. 2.10B].
Additionally, ChAT–ChR2–EYFP mice showed a significant increase in premature
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responses [two-way RM-ANOVA; main effect of genotype (F(1,12) = 21.74, p = 0.0005)
and main effect of stimulus duration (F(1,12) = 7.657, p = 0.0171); Fig. 2.10C]. Post hoc
analysis revealed that the ChAT–ChR2–EYFP mice had more premature responses at
each stimulus duration. No change in perseverative responses was observed in ChAT–
ChR2–EYFP mice [two-way RM-ANOVA; no effect of genotype (F(1,12) = 0.05002, p =
0.8268) and no effect of stimulus duration (F(1,12) = 0.6894, p = 0.4226); Fig. 2.10D].
Importantly, there were no differences between genotypes in terms of response latency
[two-way RM-ANOVA; no effect of genotype (F(1,12) = 1.570, p = 0.2341) and no effect
of stimulus duration (F(1,12) = 2.112, p = 0.1718)] or reward collection latency [two-way
RM-ANOVA; no effect of genotype (F(1,12) = 1.082, p = 0.3189) and no effect of
stimulus duration (F(1,12) = 0.001394, p = 0.9708); Fig. 2.10E,F].
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Figure 2.10. ChAT–ChR2–EYFP mice have deficits in attention. The 5-CSRT task
was used to measure attention in the ChAT–ChR2–EYFP mice. A, Mean response
accuracy during probe trial sessions. B, Rate of omissions. To assess response
patterns, both premature (C) and perseverative (D) responses were monitored during
probe trials. E, Mean response latency. F, Mean reward collection latency. *p < 0.05,
***p < 0.001, n = 7 for both genotypes.
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Figure 10. ChAT–ChR2–EYFP mice have deficits in attention
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2.5 Discussion
Here we report an extensive characterization of the BAC transgenic ChAT–ChR2–EYFP
mouse line and reveal two major findings. First, there are several extra copies of the
VAChT gene in this mouse line, which led to increased levels of functional transporter,
increased release of ACh, and improvement of physical endurance. Second, it seems
that this chronic increase in cholinergic tone is deleterious in the CNS, disrupting
several distinct cognitive domains. Interestingly, increase in VAChT mRNA expression
was approximately fourfold higher than increase in protein expression. This result
suggests the existence of translational or posttranslational mechanisms limiting the
availability of the VAChT protein in cholinergic neurons.
Vesicular storage of ACh is a required step for ACh release (de Castro et al., 2009b),
and decreased VAChT expression leads to motor and cognitive dysfunctions (Prado et
al., 2006; Martyn et al., 2012). Specifically, reduction of VAChT levels affects grip
strength and fatigue; VAChT knockdown homozygous mice, with 70% reduction in
VAChT levels, are unable to run in a treadmill test (Prado et al., 2006). In agreement
with these early results, overexpression of the high-affinity choline transporter in
motoneurons improves the performance of transgenic mice in the treadmill (Lund et al.,
2010). The present results with ChAT–ChR2–EYFP mice further support the notion that
physical fitness is related to changes in cholinergic synaptic activity. Increased VAChT
levels allowed transgenic mice to run farther than control nontransgenic littermates on
the treadmill. However, it is unknown whether the increase in motor endurance results
only from increased VAChT levels in motoneurons because, in this mouse line, VAChT
is likely to be overexpressed in all cholinergic nerve endings. Decreased VAChT
expression in the periphery has been shown to affect cardiac activity by distinct
mechanisms (Lara et al., 2010; Rocha-Resende et al., 2012; Roy et al., 2012; Prado et
al., 2013). Thus, ChAT–ChR2–EYFP mice will be essential to determine whether
increased VAChT expression can improve cardiovascular function.
Although a number of studies indicate that ACh is involved in the regulation of metabolic
homeostasis (for review, see Picciotto et al., 2012), no significant difference between
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ChAT–ChR2–EYFP and wild-type littermates was observed when an extensive list of
metabolic parameters was analyzed, including RER, the volume of oxygen produced
(VO2), the volume of carbon dioxide produced (VCO2), body weight, sleeping time,
ambulatory movement, and serum glucose. However, our data show that ChAT–ChR2–
EYFP mice consume significantly more food and water during the dark period. It is
possible that the small increase in food and water intake observed in these transgenic
mice reflects the fact that, in the home-cage-like environment, they have a small
tendency to be more active than controls. Surprisingly, ChAT–ChR2–EYFP mice did not
show changes in locomotor activity in a novel environment, anxiety-like behavior, or
depression-like behavior. To note, increased cholinergic transmission has been
suggested to be pro-depressive (Janowsky et al., 1972; Overstreet et al., 1986;
Overstreet, 1993; Fagergren et al., 2005). Moreover, antagonists of nicotinic and
muscarinic receptors have antidepressant activity (Rabenstein et al., 2006; Andreasen
and Redrobe, 2009). Because chronic increase in cholinergic tone may affect the
expression of distinct receptors in specific brain regions, it is unlikely that all phenotypes
described previously attributable to cholinesterase inhibition or dysfunction may be
affected in ChAT-ChR2-EYFP mice.
Despite their increased motor endurance, ChAT–ChR2–EYFP mice were unable to
improve their performance in the rotarod, suggesting that increased cholinergic tone in
the CNS is deleterious for learning an acrobatic skill. Previous experiments with mice
presenting reduced levels of VAChT (40% VAChT knockdown heterozygous mice) had
indicated that motor learning depends on cholinergic tone (Prado et al., 2006; de Castro
et al., 2009b). Together, these results suggest that either too much or too little ACh in
the brain is detrimental for motor learning.
We have also detected diminished performance of ChAT–ChR2–EYFP mice in two
distinct tasks designed to measure spatial memory. In both the Barnes maze and MWM,
ChAT–ChR2–EYFP mice present a specific deficit in the retrieval of information. In both
tests, ChAT–ChR2–EYFP mice were able to learn the task (location of the platform or
the exit hole), as evidenced by their improved performance over the 4 d of training.
However, in probe trials, ChAT–ChR2–EYFP mice performed poorly compared with
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their littermate controls in both tests. This phenotype may not be related only to spatial
memory deficits, because these mice also presented impairments in the cued version of
the MWM. Because ChAT–ChR2–EYFP mice can improve their performance during the
4 d of training in the Barnes maze and MWM, it is unlikely that they present any gross
sensory motor deficits that would preclude visualization of cues. Conversely, deficits in
the cued version of the MWM suggest that increased cholinergic tone might interfere
with the mouse's ability to recognize that the platform is the goal (cue detection). It has
been reported that detection of signals depends on cholinergic neurotransmission
(Sarter et al., 2005; Parikh et al., 2007). Therefore, the chronic excess of cholinergic
tone may disrupt the transmission of salient information related to a cue, preventing
these animals from using such information to guide them to their goal.
Working memory is a prefrontal cortical process that is modulated by cholinergic
signaling (Croxson et al., 2011). There is strong evidence implicating cholinergic activity
in enhancing discrimination of signal-to-noise in the prefrontal cortex (for review, see
Hasselmo and Sarter, 2011), a role that is critical in regulating attention (Sarter et al.,
2006; Parikh et al., 2007; Hasselmo and Sarter, 2011). However, the focus in the
literature has been on hypocholinergic function (McGaughy et al., 2002; Dalley et al.,
2004; Harati et al., 2008; Parikh et al., 2013), and to date, there has not been an
evaluation of chronic cholinergic deregulation on attentive processing. Additionally, ACh
has been shown to be important for feature binding, the process by which the brain
processes specific features of an object and compile a unified picture of it (Botly and De
Rosa, 2009). Interestingly ChAT–ChR2–EYFP mice showed inattentive behavior related
to cholinergic dysregulation; however, they also showed increased premature
responses in the 5-CSRT task, a behavior that has been shown to be regulated by
serotonergic signaling (Fletcher et al., 2013; Humpston et al., 2013). ACh has been
proposed to help filter sensory information by increasing persistent spiking in cortical
neurons, compatible with its proposed role in facilitating cue detection (Hasselmo and
Stern, 2006). Such a mechanism depends on background tonic level of ACh but also on
the transient increase in cholinergic activity (Parikh et al., 2007). Whether tonic
cholinergic activity in the ChAT–ChR2–EYFP mice is so high that it precludes additional
transient increases in cholinergic tone remains to be determined. However, the

149
observation that ChAT–ChR2–EYFP mice have working memory and attention deficits
suggests the possibility that multiple forms of information encoding are affected in these
mice. Therefore, these experiments emphasize the importance of regulated ACh
release in cognitive function.
The precise mechanism by which excessive release of ACh in ChAT–ChR2–EYFP mice
affects memory is not yet clear. It is likely that cellular regulation of neuronal spiking
(Hasselmo and Sarter, 2011) may be affected by chronically increased levels of
extracellular ACh. Moreover, increased and sustained cholinergic tone may affect
forebrain circuitries by changing the expression of receptors and the regulation of other
neurochemical systems, leading to abnormal processing, encoding, or retrieval of
information. The overall memory deficits observed in ChAT–ChR2–EYFP mice suggest
the need for specific temporal and spatial control of synaptic ACh levels for optimal
cognitive performance.
In contrast with the worse performance of ChAT–ChR2–EYFP mice in cognitive tasks,
augmented cholinergic tone seems to improve physical fitness, suggesting that
increasing cholinergic tone may be beneficial in the periphery. Whether increased
cholinergic function will be beneficial in other parameters regulated by the autonomic
nervous system, as well as for improving the activity of the cholinergic anti-inflammatory
pathway, remains to be determined.
Given that we detect improvement physical endurance and decreased performance in a
series of behavioral tasks that have been previously related to cholinergic functions, we
have interpreted our results as a potential consequence of increased cholinergic tone. It
should be noted that we cannot eliminate the possibility that the large number of copies
of the BAC inserted in the mouse genome disrupted a specific gene locus that could
both improve physical endurance and disrupt cognition, although this seems unlikely.
Also, we cannot discard the possibility that the high copy number of ChR2 or YFP may
have unexpected consequences. We attempted to test this possibility by using another
mouse line with high copy number of ChR2 and YFP. The VGAT–ChR2–EYFP mice,
which have 20 copies of these genes, did not present impairments in working memory.
These results support the argument that the effects observed in ChAT–ChR2–EYFP
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mice are related to cholinergic hyperfunction. Importantly, these altered phenotypes
fundamentally differentiate ChAT–ChR2–EYFP from control mice.
In short, our experiments indicate that ChAT–ChR2–EYFP mice overexpress VAChT
and show important functional consequences, including unforeseen effects in cognitive
processing. Because most studies using optogenetic control of cholinergic neurons
have used mice expressing Cre or ChR2 that was inserted in the ChAT–BAC (Witten et
al., 2010; Bell et al., 2011; Gu and Yakel, 2011; Nagode et al., 2011; Cachope et al.,
2012; Kalmbach et al., 2012), it is important to be aware that VAChT overexpression
may contribute to behavioral or cellular outputs. Therefore, novel approaches to control
cholinergic neurons using optogenetics may be necessary. Inactivation of the VAChT
gene in the ChAT–BAC is a possible alternative. However, ChAT–ChR2–EYFP mice
will be valuable to test current theories of cholinergic function and the consequences of
overactive cholinergic signaling for information processing.
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Chapter 3
Forebrain deletion of the vesicular acetylcholine transporter
results in deficits in executive function, metabolic, and RNA
splicing abnormalities in the prefrontal cortex
3.1 Chapter Summary
One of the key brain regions in cognitive processing and executive function is the
prefrontal cortex (PFC), which receives cholinergic input from basal forebrain
cholinergic neurons. We evaluated the contribution of synaptically released
acetylcholine (ACh) to executive function by genetically targeting the vesicular
acetylcholine transporter (VAChT) in the mouse forebrain. Executive function was
assessed using a pairwise visual discrimination paradigm and the 5-choice serial
reaction time task (5-CSRT). In the pairwise test, VAChT-deficient mice were able to
learn, but were impaired in reversal learning, suggesting that these mice present
cognitive inflexibility. Interestingly, VAChT-targeted mice took longer to reach criteria in
the 5-CSRT. Although their performance was indistinguishable from that of control mice
during low attentional demand, increased attentional demand revealed striking deficits
in VAChT-deleted mice. Galantamine, a cholinesterase inhibitor used in Alzheimer's
disease, significantly improved the performance of control mice, but not of VAChTdeficient mice on the 5-CSRT. In vivo magnetic resonance spectroscopy showed
altered levels of two neurochemical markers of neuronal function, taurine and lactate,
suggesting altered PFC metabolism in VAChT-deficient mice. The PFC of these mice
displayed a drastic reduction in the splicing factor heterogeneous nuclear
ribonucleoprotein A2/B1 (hnRNPA2/B1), whose cholinergic-mediated reduction was
previously demonstrated in Alzheimer's disease. Consequently, several key
hnRNPA2/B1 target transcripts involved in neuronal function present changes in
alternative splicing in VAChT-deficient mice, including pyruvate kinase M, a key enzyme
involved in lactate metabolism. We propose that VAChT-targeted mice can be used to
model and to dissect the neurochemical basis of executive abnormalities.
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3.2 Introduction
The prefrontal cortex (PFC) is essential for the modulation of executive function, which
is loosely defined as a set of cognitive tools that allows hierarchical and timely control of
actions leading to specific behaviors (Alvarez and Emory, 2006; Robbins and Roberts,
2007; Chudasama, 2011). Disruption in executive function is a key symptom in
neurological and neuropsychiatric disorders, including Alzheimer's disease (AD; Perry
and Hodges, 1999; Traykov et al., 2007; McGuinness et al., 2010), schizophrenia
(Morice, 1990), autism (Hill, 2004; Sala et al., 2011), and drug addiction (Stalnaker et
al., 2009). The basic neurochemical underpinnings of executive function are, however,
still poorly understood.
Cholinergic deficits are a hallmark of AD (Perry et al., 1977; Whitehouse et al., 1981,
1982). Moreover, amyloid β (Aβ) oligomers, potential toxins in AD, disrupt cholinergic
synaptic transmission in the PFC (Chen et al., 2013). Cholinergic deficiency in AD can
have widespread effects, including global changes in alternative splicing of genes
involved in synaptic plasticity (Berson et al., 2012).
Acetylcholine (ACh) in the PFC has been implicated in controlling attention (Elliott,
2003; Jurado and Rosselli, 2007), one of the components of executive function. Cue
detection and top-down modulation of attentive behavior have both been shown to
activate PFC cholinergic activity and to be modulated by cholinergic signaling (Sarter et
al., 2001; Parikh et al., 2007). Cholinergic transients in the PFC have been linked to cue
detection, and both tonic and phasic PFC ACh release seem to regulate attentional
demand (Parikh et al., 2007; for review, see Hasselmo and Sarter, 2011), which may
depend mainly on nicotinic receptor signaling (McGaughy et al., 1999; Grottick and
Higgins, 2000; Parikh et al., 2010; Guillem et al., 2011).
Cognitive flexibility, the ability to alter strategy according to changing environmental
cues, is another key component of executive function (Elliott, 2003; Jurado and Rosselli,
2007). The neurochemical basis of cognitive flexibility is not fully understood, but
serotonin is thought to play critical roles (Schmitt et al., 2006; Evers et al., 2007;
Brigman et al., 2010).
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Release of ACh is a tightly regulated process, with the vesicular acetylcholine
transporter (VAChT) controlling a limiting key step (de Castro et al., 2009a; Kolisnyk et
al., 2013; for review, see Prado et al., 2013). Genetic elimination of VAChT from the
forebrain causes deficits in reversal learning assessed using the Morris Water Maze
(MWM) (Martyn et al., 2012). Deficits in reversal learning may be related to
hippocampal dysfunction, but could also reflect alterations in behavioral flexibility. To
examine if decreased levels of VAChT, a change observed in AD (Efange et al., 1997;
Chen et al., 2011), affects executive function we have used touchscreen tasks. We
report that elimination of forebrain VAChT caused severe deficits in cognitive flexibility
and in sustained attention. In addition, we found that these mutant mice have profound
changes in RNA processing in the PFC, which correlate with behavioral and metabolic
deficits. Our results suggest that elimination of forebrain cholinergic activity in mice
provides a model for understanding the neurochemical basis of executive function.

3.3 Material and Methods
3.3.1Animals
Generation of VAChTSix3-Cre-flox/flox mice was previously described (Martyn et al.,
2012). In short, VAChTSix3-Cre-flox/flox mice were generated by crossing
VAChTflox/flox (mixed C57BL/6J × 129/SvEv background, backcrossed to C57BL/6J for
five generations) with the Six3-Cre mouse line (NMRI background, backcrossed to
C57BL/6J for five generations). We then intercrossed VAChTSix3-Cre-flox/wt mice to
obtain VAChTSix3-Cre-flox/flox. For the galantamine experiments, the mice used were
wild-type C57BL/6J. Mice were housed in groups of three or four per cage without
environmental enrichment in a temperature-controlled room with 14/10 h light/dark
cycle, and water was provided ad libitum. Only male mice were used in these studies.
Mice were restricted to 85% of their free-feed weight and maintained on 85% of their
weight for the duration of the study. All procedures were conducted in accordance with
guidelines from the Canadian Council of Animal Care at the University of Western
Ontario with an approved institutional animal protocol (2008–127).
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3.3.2 Western Blotting
Mouse PFC was collected, protein was isolated, and immunoblotting was performed as
previously described (Martins-Silva et al., 2011). The antibodies used were anti-VAChT
(catalog #139103; Synaptic Systems) at a 1:3000 dilution, anti-Synaptophysin (catalog
#S5768; Sigma-Aldrich) at a 1:500 dilution, anti-hnRNP A2/B1 (catalog #sc-10035;
Santa Cruz Biotechnology) at a 1:500 dilution, and anti-β-Actin (catalog #ab49900;
Abcam), at a 1:15000 dilution. Band intensity was quantified using FluoroChemQ
software (Thermo Fisher Scientific).

3.3.3 Acetylcholine Release
ACh release from prefrontal cortical brain slices was quantified by labeling slices with
[3H] methyl-choline before using KCl to stimulate release of labeled ACh as previously
described (Guzman et al., 2011).

3.3.4 qPCR
To measure mRNA expression, total RNA was extracted from freshly dissected PFC
tissue, using the Aurum Total RNA for fatty and fibrous tissue kit (Bio-Rad) according to
the manufacturer's instructions. cDNA synthesis and qPCR analysis were performed as
previously described (Guzman et al., 2011). Primer sequences used to determine
alternative spliced transcripts are found in Table 3.1. β-Actin was used as a reference
transcript for all reactions. For alternative splicing experiments, the alternative exon
levels were normalized to a constitutively expressed exon from the same gene.
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Table 3.1. Primers for alternative splicing assay
Target

Forward primer(5′ → 3′)

Reverse primer (5′ → 3′)

CD55 exon 8

CCCAGCATGTACCTGTTACC

TCACATGCAAAACTGTCAAGG

CD55 exon 1

TGTCTCTGTTGCTGCTGTCC

TGCTCAGCAAACTTGGAGTG

DRAM2 exon 2

TGATTCAAGGTTCACACTCACA AAAACTGAGGCCTTGCTGAA

DRAM2 exon 4

TTCAGCAAGGCCTCAGTTTT

TCAGGAGGTATTGTCCCTGTG

SIPA1L1 intron 5

TCAGGCATGCAGTTCTTTTG

GAAAGCAGGCAGTACCTTCG

SIPA1L1 exon 4

TAGTGTGGACGCTGCTGTCT

GGCTCTGTGGTCACCAGAAT

DYSTONIN exon 41 ATGGCATTTCCCCCATTAG

GGAGGTTGGTTTTGCTTCAA

DYSTONIN exon 7

GAGCGGGACAAAGTTCAAAA

CCCGTCCCTCAGATCCTC

REELIN exon 3

ATCATGTCCGACCACCAGTT

ATCATGTCCGACCACCAGTT

REELIN exon 18

GCAGTGCCAGACTTTCCTCT

GCCTCCCATCTTTGTTGAAA

REELIN exon 1

GGCAACCCCACCTACTACG

GACTGGATGCTTGTCGAGGT

mENAH

CGGCAGTAAGTCACCTGTCA

C TTCAGCTTTGCCAGCTCTT

mENAH invasive

GATTCAAGACCATCAGGTTGTG CAATGTTGGCCCTAAATAGAA

PKM1

CATGCAGCACCTGATAGCTC

TTATAAGAGGCCTCCACGCTG

PKM2

GCAGTGGGGCCATTATCGT

GGGATTTCGAGTCACGGCAA
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3.3.5 Magnetic resonance imaging
Magnetic resonance spectroscopy of the prefrontal region was performed in four
VAChTSix3-Cre-flox/flox mice and four littermates (VAChTflox/flox). Spectroscopic
localization of a 24 μl voxel was achieved by adiabatic selective refocusing (DelaBarre
and Garwood, 1998) on a 9.4 tesla horizontal bore small animal Agilent magnetic
resonance imaging (MRI) scanner. Water-suppressed full spectra (TR/TE = 3250/20
ms, 128 acquisitions), water-suppressed macromolecule spectra (TR/TE = 5000/20 ms,
inversion time TI = 873 ms, 128 acquisitions), and water-unsuppressed spectra (TR/TE
= 3250/20 ms, 8 acquisitions) were acquired. All animals were anesthetized with 2%
isoflurane during the procedure and were maintained at 37° by blowing warm air into the
bore of the magnet using a Model 1025 Small Animal Monitoring and Gating System
(SA Instruments).

3.3.6 Metabolite analysis
Magnetic resonance spectra were analyzed using purpose-built software (fitMAN;
Bartha et al., 1999) to determine the contribution of each metabolite relative to total
creatine as previously described (Bartha, 2007, 2008). Briefly, spectra were lineshape
corrected (Bartha et al., 2000b) and the macromolecule and residual water contribution
was removed (Kassem and Bartha, 2003). Then, the spectrum was fitted in the time
domain to a basis set of 19 metabolite lineshapes (Pfeuffer et al., 1999; Bartha et al.,
2000a). Five metabolites (measured relative to creatine) were reliably measured and
included in group comparisons: N-acetylaspartate (NAA), myo-inositol (Myo), choline
(Cho), taurine (Tau), and lactate (Lac).

3.3.7 Touchscreen behavioral assessment
3.3.7.1 Apparatus and task
Mice were trained in the 5-choice serial reaction time task (5-CSRT) and in the pairwise
visual discrimination in automated Bussey–Saksida Mouse Touchscreen Systems
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model 81426 (Campden Instruments). Schedules were designed and data were
collected using the ABET II Touch software v.2.15 (Lafayette Instruments).

3.3.7.2 Pretraining
Before being trained on the pairwise visual discrimination or the 5-CSRT task, mice
were first put through a pretraining program. This consisted of first habituating the mice
to the testing chamber with the lights off for 15 min. The next day, mice were left in the
chamber with the lights off for 20 min, this time with the reward tray primed with a 150 μl
reward (strawberry milkshake; Saputo Dairy Products), and a tone was played
whenever the mouse entered the reward tray. Whenever the mouse returned to the
reward tray, it received a reward (7 μl) paired with the tone. This training was repeated
the next 2 d for 40 min sessions (phase 1).
The next training phase (phase 2) involved pairing the reward with the presentation of
the stimulus on the touchscreen. The stimulus appeared randomly in one of the
windows and after 30 s, it was removed and a reward (7 μl) was given paired with a
tone. If the mouse touched the screen while the image was displayed, it immediately
received a reward (7 μl). Once the mouse collected the reward a new trial was initiated.
This phase was repeated until the mouse completed 30 trials within 60 min (phase 2).
Phase 3 was used to further shape behavior. It involved displaying the stimulus
randomly in one of the windows. The mouse was required to touch the stimulus on the
screen to receive a reward (7 μl) paired with a tone. There was no response to the
mouse touching anything but the stimulus. Once again, this was repeated until the
mouse completed 30 trials within 60 min. Phase 4 was identical to phase 3 except that
the mouse was required to initiate each trial by nose poking the reward tray. Criterion
was 30 correct trials within 60 min.
Finally, in the last pretraining phase (phase 5), the previous procedure was repeated but
if the mouse touched an incorrect screen, it received a 5 s time-out, during which the
light was turned on. The final phase had a stricter criterion, requiring the mouse to
perform 30 trials in 60 min with at least 23 correct responses in 2 consecutive days.
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3.3.7.3 Pairwise visual discrimination and reversal
Pairwise visual discrimination and reversal task were performed as previously described
(Romberg et al., 2013). Mice used in this experiment were 6–8 months old. At the
beginning of each session, the reward tray was primed with 7 μl of milkshake. Briefly,
the mice were first trained to discriminate between two visual stimuli, which were
presented simultaneously, with their spatial location randomized over a 30 trial session.
If mouse nose poked the correct stimulus (S+), a tone was played and mouse received
a reward (7 μl), whereas if the incorrect stimulus (S−) was nose poked, light in the
chamber was turned on for 5 s (time-out) followed by a correction trial. During the
correction trial, the trial was repeated until the mouse poked the correct stimulus.
Criterion was reached when the mouse selected the correct image (S+) on 80% of the
trials, excluding correction trials, for 2 consecutive days. Once mice reached criteria,
they were given two sessions to assess baseline performance on the task. For reversal
learning the rule associated to each stimulus was switched, that is, the rewarded image
(S+) during acquisition became the (S−) image in reversal and was punished, while the
(S−) image from acquisition became the correct stimulus and was rewarded. Reversal
learning was assessed over the course of 10 sessions.

3.3.7.4 Training in 5-CSRT
The 5-CSRT task was performed as previously described (Romberg et al., 2011). A
distinct cohort of mice (8–10 months old) was trained in the 5-CSRT task. At the
beginning of each session, the reward tray was primed with 7 μl of milkshake. Each trial
was initiated after the mouse nose poked the magazine. In this phase, the stimulus was
delivered after a variable 5–10 s delay (delay period), during which the animal was
required to attend to the screen. In case the mouse prematurely touched the screen
during this delay, the response was recorded as premature and the mouse was
punished with a 10 s time-out. The stimulus duration was initially set to 4 s, followed by
a limited holding period of 5 s, during which the stimulus was absent, but the mouse
could still respond to the location (holding period). Responses to the stimulus window
during stimulus presence or the holding period were recorded as correct and a 7 μl
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reward was administered, while responses to any other window were recorded as
incorrect. A correct choice was rewarded with a tone and food delivery. An incorrect
response was punished with a 10 s time-out. A failure to respond to any window both
during stimulus display, or during the holding period, was recorded as an omission and
punished with a 10 s time-out. Perseverative responses to the screen after premature,
correct, and incorrect choices were also recorded. Once the performance of a mouse
reached criterion at 4 s stimulus duration (80% accuracy, 20% omissions for 3
consecutive days), the stimulus duration was reduced to 2 s. After reaching criterion
with the 2 s stimulus, mice were tested for two more days. The mean measurement of
those 2 d was used to assess baseline performance. If the mouse completed <30 trials,
it was considered not to have reached criteria, even if it met accuracy and omissions
thresholds.

3.3.7.5 Probe trial
To probe attention in mice we used a previously described probe trial schedule with
reduced stimulus durations (Romberg et al., 2011). Briefly, each mouse was tested for 2
consecutive days at a given stimulus duration (1.5, 1, 0.8, and 0.6 s). After each test,
the animal was retested onto the 2 s stimulus duration for 2 d or until criteria were
reached (80% accuracy, 20% omission), to assess baseline performance. The order of
the probe trial sessions were semi-randomized using a Latin square method.

3.3.7.6 Distraction task
To further test attentional demand, and assess susceptibility to distraction, we
developed a distraction version of the 5-CSRT task. During this task, a 1000 ms
distractor tone, different from the reward tone, was played semi-randomly at five
different time points during the delay period: 0 (corresponding to when the mouse
initiates the task), 0.5, 2.5, 4.5, and 5 s (corresponding to when the stimulus is
displayed on the touchscreens). Stimulus duration was set to 2 s. For each distractor
tone time point mice were tested for five sessions. At the end of the five sessions one
baseline task (50 trial, 2 s stimulus duration, no distractor sounds) was performed
before moving to the next distractor time point.
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3.3.7.7 5-CSRT task measures
On all 5-CSRT task sessions, accuracy was defined as the total number of correct
responses, divided by the number of correct and incorrect (touches to a wrong window
while the correct stimulus was still displayed) responses. The rate of omissions was the
proportion of omitted responses to total trials. Response latency was the time for the
mouse to touch the correct stimulus after its onset. Reward collection latency was the
time for the mouse to return to the reward tray once it had touched the correct stimulus.
A premature response was counted when the mouse touched one of the windows
before stimulus onset. Finally, a perseverative response was any identical response that
occurred following a correct, incorrect, or premature response.

3.3.7.8 Drug treatments
Galantamine hydrobromide, a cholinesterase inhibitor, (Sigma-Aldrich) was dissolved in
physiological saline (0.9% NaCl) before administration. Sixty minutes before being
tested on the 5-CSRT mice received an intraperitoneal injection of drug (100 μl, 1
mg/kg) or saline. The dose for galantamine was selected based on previous studies
(Prado et al., 2006; de Castro et al., 2009b; De Jaeger et al., 2013). Previously, we
have tested 3 mg/kg galantamine in other tasks, but this dose was no more effective
than 1 mg/kg and it produced hypersalivation in mice (de Castro et al., 2009b).
Moreover, at 1 mg/kg wild-type mice were able to increase their performance in the 5CSRT (see below). Mice were tested at the 0.6 s stimulus duration, which represents a
high attention demanding task (Romberg et al., 2011). The order of the injections was
counterbalanced. Between injections mice had three washout days wherein their
performance on the 5CSRT was re-baselined at the 2 s stimulus duration.

3.3.8 Statistical analysis
For the pairwise visual discrimination task response accuracy was calculated as the
number of correct trials divided by the total number of trials, excluding correction trials.
Data are expressed as mean ± SEM. SigmaStat 3.5 software was used for statistical
analysis. Comparison between two experimental groups was made by Student's t test or
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Mann–Whitney rank sum test, when the data did not follow a normal distribution. When
several experimental groups or treatments were analyzed, two-way ANOVA or two-way
ANOVA with repeated measures was used as required. When appropriate, a Tukey's
HSD post hoc comparison test was used. In all comparisons, p < 0.05 was considered
statistically significant.

3.4 Results

3.4.1VAChTSix3-Cre-flox/flox mice have reduced VAChT and
ACh release in the PFC
We have previously reported that VAChTSix3-Cre-flox/flox mice have the VAChT gene
deleted from >90% of their basal forebrain cholinergic neurons (Martyn et al., 2012). To
confirm that this deletion affected prefrontal cortical cholinergic signaling, we performed
Western blot analysis to assess VAChT expression. VAChTSix3-Cre-flox/flox mice have
a significant reduction in PFC VAChT protein expression (t(6) = 2.706, p = 0.0353; Fig.
5.1A). Moreover, this reduction in VAChT protein levels results in a significant decrease
in newly synthesized [3H] ACh release in slices of PFC from VAChTSix3-Cre-flox/flox
mice when compared with control mice (t(4) = 2.899, p = 0.0442; Fig. 5.1B). We used
qPCR to assess the expression of nicotinic receptors (nAChRs), which have been
shown previously to be critical for attentional performance. The PFC of VAChTSix3-Creflox/flox mice shows no significant change in the expression of α7nAChR mRNA (t(10) =
0.9300, p = 0.3743) nor β2nAChR mRNA (t(10) = 0.8359, p = 0.4227). Interestingly,
α4nAChR mRNA is slightly upregulated (t(10) = 2.550, p = 0.0289; Fig. 5.1 C).
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Figure 3.1 Expression of VAChT in the PFC of VAChTSix3-Cre-flox/flox mice. A, VAChT
protein expression in the PFC with representative immunoblots inset (n = 4). B, Release
of newly synthesized [3H]ACh in PFC slices (n = 3). C, qPCR analysis of nAChR
expression (n = 6, data are mean ± SEM, *p < 0.05).
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Figure 3.1 Expression of VAChT in the PFC of VAChTSix3-Cre-flox/flox mice.
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3.4.2 Decreased forebrain cholinergic tone specifically disturbs
reversal learning in the pairwise visual discrimination task
We have previously demonstrated that VAChTSix3-Cre-flox/flox mice have impairments
in reversal learning in the MWM (Martyn et al., 2012), suggesting the possibility that
these mice have behavior flexibility deficits. To determine whether VAChTSix3-Creflox/flox mice present alterations in cognitive flexibility we used a “nonhippocampal”
pairwise visual discrimination task (Romberg et al., 2013). This task has been
previously shown to depend on the PFC and also on striatal-cortical loops (Graybeal et
al., 2011). The performance of VAChTSix3-Cre-flox/flox mice did not differ from that of
controls (VAChTflox/flox) when they were trained to operate the touchscreen
(pretraining phase). The number of sessions the mice took to acquire each training
phase did not differ from control (RM-ANOVA, no effect of genotype F(1,54) = 0.3950, p
= 0.5398; main effect of training phase F(4,54) = 5.227, p = 0.0012; and no interaction
effect F(4,54) = 1.389, p = 0.2495; Figure 3.2A). Acquisition of the pairwise visual
discrimination task (Fig. 5.2B; for stimuli used) did not differ between genotypes, in
terms of sessions to criteria (Fig. 5.2C; t(14) = 0.2446, p = 0.8117), correction errors
made (Fig. 5.2D; t(14) = 0.2942, p = 0.7746), response latency (Fig. 5.2E; t(14) = 1.019,
p = 0.3256), or reward collection latency (Fig. 5.2F; t(14) = 0.2606, p = 0.7988). We
have previously reported that these mice are hyperactive in novel environments, but
they are able to habituate to the environment (Martyn et al., 2012). Hence, due to the
extensive training for the performance in the touchscreen tasks the lack of differences in
response and reward collection latencies is not surprising. However, VAChTSix3-Creflox/flox mice showed severe reversal learning impairment (Fig. 5.3A; for the stimuli
used), measured by the percentage of correct responses (Fig. 5.3B; RM-ANOVA, main
effect of genotype F(1,132) = 19.78, p = 0.0008; main effect of session F(11,132) =
23.28, p = 0.0001; and significant interaction effect F(1,12) = 5.035, p = 0.0001) and by
its increased correction errors (Fig. 5.3C; RM-ANOVA, main effect of genotype F(1,132)
= 14.72, p = 0.0024; main effect of session F(11,132) = 14.37, p = 0.0001; and
significant interaction effect F(1,12) = 2.817, p = 0.0025). Post hoc analysis showed that
VAChTSix3-Cre-flox/flox mice never improved significantly from the first reversal
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session and in 10 sessions they performed only at chance level. Importantly, during the
reversal trials, the VAChTSix3-Cre-flox/flox mice did not differ from controls in terms of
response latency (Fig. 5.3D; RM-ANOVA, no effect of genotype F(1,154) = 0.4233, p =
0.5258; main effect of session F(11,154) = 4.705, p = 0.0001; and no interaction effect
F(11,154) = 0.9997, p = 0.4493) or reward collection latency (Fig. 5.3E; RM-ANOVA, no
effect of genotype F(1,154) = 1.107, p = 0.3105; main effect of session F(11,132) =
3.965, p = 0.0001; and no interaction effect F(11,154) = 1.141, p = 0.3333). These
results suggest that forebrain cholinergic tone is important for cognitive flexibility.
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Figure 3.2. VAChTSix3-Cre-flox/flox mice show normal visual discrimination
learning. A, Mean number of trials required to reach criteria during the operant
conditioning, pretraining phases. B, Image of a mouse performing the task, with the fan
shown as the S+ and the marbles as the S−. C, Number of sessions to criteria in the
pairwise visual discrimination learning task. D, Correction errors made to achieve
discrimination criteria. E, Mean response latency. F, Mean reward collection latency. n =
8, data are mean ± SEM.
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Figure 3.2. VAChTSix3-Cre-flox/flox mice show normal visual discrimination learning.
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Figure 3.3. VAChTSix3-Cre-flox/flox mice have impaired reversal learning. A, Image of a
mouse performing the task, this time with the fan shown as the S− and the marbles as
the S+. B, Choice accuracy before (B1 and B2) and during reversal trials (R2–R10),
dashed line denotes chance (50%). C, Number of correction errors made across
reversal trials. D, Response latency across reversal trials. E, Reward collection latency
across reversal trials (n = 8, data are mean ± SEM, *p < 0.05, **p < 0.01, and ***p <
0.001).
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Figure 3.3. VAChTSix3-Cre-flox/flox mice have impaired reversal learning.
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3.4.3 VAChTSix3-Cre-flox/flox mice have impaired acquisition of
the 5-CSRT task
Similar to the results for visual discrimination experiments, the performance of the
second cohort of VAChTSix3-Cre-flox/flox mice did not differ from that of control mice
for touchscreen operation training (pretraining phase). The number of sessions
necessary to reach criteria across all pretraining phases did not differ between
genotypes (RM-ANOVA, no effect of genotype F(1,32) = 1.528, p = 0.2515; no effect of
training phase F(4,32) = 1.492, p = 0.2280; Figure 3.4A). However, when mice were
trained to respond to flashes of light displayed in one of the five spatial locations on the
touchscreen (training phase), VAChTSix3-Cre-flox/flox showed a significantly worse
performance, needing more sessions to reach criteria (RM-ANOVA, main effect of
genotype, F(1,8) = 10.06, p = 0.0132; main effect of stimulus duration, F(1,8) = 5.731, p
= 0.0436, no interaction effect, F(1,8) = 4.252, p = 0.0731; Fig. 5.4B).
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Figure 3.4. Training in the 5-CSRT task. A, Mean number of trials required to reach
criteria during the operant conditioning, pretraining phases.B, Mean number of trials
required to reach criteria at 4 and 2 s stimulus duration (n = 6, data are mean ± SEM,
*p < 0.05).
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Figure 3.4. Training in the 5-CSRT task
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3.4.4 Deletion of forebrain VAChT results in inattentive but not
impulsive or compulsive behavior
Once mice reached criteria they were tested for attentional performance by decreasing
stimulus duration to 1.5, 1, 0.8, and 0.6 s as previously described (Romberg et al.,
2011). At 1.5 s, VAChTSix3-Cre-flox/flox mice were able to perform identically to control
mice in both accuracy and omissions (Fig. 5.5A,B). In contrast, increasing attentional
demand by diminishing the stimuli period revealed an attentional deficit in VAChTSix3Cre-flox/flox mice. Response accuracy did not differ between genotypes (RM-ANOVA,
no effect of genotype F(1,24) = 0.0007548, p = 0.9788; main effect of stimulus duration
F(3,24) = 10.28, p < 0.001; Figure 3.5A). However, VAChTSix3-Cre-flox/flox mice
presented an increased rate of omission (RM-ANOVA, main effect of genotype F(1,24)
= 57.99, p < 0.0001; main effect of stimulus duration F(3,24) = 36.44, p < 0.0001; no
interaction effect F(3,24) = 2.176, p = 0.1171; Figure 3.5B). Post hoc analysis revealed
that VAChTSix3-Cre-flox/flox mice omitted more at 0.6–1 s stimulus durations.
Interestingly, VAChT-deficient mice had no alterations in premature responses (RMANOVA, no effect of genotype F(1,24) = 0.07440, p = 0.7874; no effect of stimulus
duration F(3,24) = 0.9891, p = 0.4146; Figure 3.5C) or perseverative responses (RMANOVA, no effect of genotype F(1,24) = 0.04610, p = 0.9695; no effect of stimulus
duration F(3,24) = 1.244, p = 0.3232; Figure 3.5D). Additionally, mutant mice did not
differ from littermate controls in response latency (RM-ANOVA, no effect of genotype
F(1,24) = 2.279, p = 0.1818; no effect of stimulus duration F(3,24) = 0.09686, p =
0.7662; Figure 3.5E) and reward collection latency (RM-ANOVA, no effect of genotype
F(1,24) = 2.279, p = 0.1818; no effect of stimulus duration F(3,24) = 1.189, p = 0.3420;
Figure 3.5F).
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Figure 3.5. VAChTSix3-Cre-flox/flox mice have attentional deficits. Performance and
response measures during 5-CSRT task probe trials. Mice were subjected to a series of
probe trials and the average values of 50 trial sessions are plotted. A, Mean
accuracy. B, Mean rate of omissions. C, Mean premature responses. D, Mean
perseverative responses. E, Mean response latency. F, Mean reward collection latency
(n = 6, data are mean ± SEM, *p < 0.05 and **p < 0.01).
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Figure 3.5. VAChTSix3-Cre-flox/flox mice have attentional deficits
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3.4.5 Deletion of forebrain VAChT impairs sustained attention
To assess sustained attention (vigilance), we analyzed both response accuracy and
rate of omissions over blocks of 10 trials (Romberg et al., 2011). Response accuracy of
control mice did not significantly vary across blocks, but did reduce significantly with
decreases in stimuli duration (RM-ANOVA, main effect of stimulus duration F(3,48) =
5.893, p = 0.0104; no effect of block F(4,48) = 1.214, p = 0.317; Figure 3.6A). In
contrast, response accuracy of VAChTSix3-Cre-flox/flox mice reduced significantly
across blocks and stimuli duration (RM-ANOVA, main effect of stimulus duration F(3,48)
= 4.257, p = 0.0077; main effect of block F(4,48) = 3.933, p = 0.0289; Figure 3.6B). As
with response accuracy, rate of omissions of control mice did not vary across blocks,
only with stimuli duration (RM-ANOVA, main effect of stimulus duration F(3,48) = 5.803,
p = 0.0228; no effect of block F(4,48) = 0.5352, p = 0.7105; Figure 3.6C), whereas rate
of omissions of VAChTSix3-Cre-flox/flox mice increased significantly across stimuli
duration and blocks (RM-ANOVA, main effect of stimulus duration F(3,48) = 9.387, p =
0.0018; main effect of block F(4,48) = 2.803, p = 0.0360; Figure 3.6D). Together the
data suggest that VAChTSix3-Cre-flox/flox mice have impaired ability to sustain
attention.
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Figure 3.6. VAChTSix3-Cre-flox/flox mice have impaired sustained attention. Mean
response accuracy for blocks of 10 trials for (A) VAChTflox/flox and (B) VAChTSix3-Creflox/flox

mice. Mean rate of omission for blocks of 10 trials for (C) VAChTflox/flox and (D)

VAChTSix3-Cre-flox/flox mice (n = 6, data are mean ± SEM, *p < 0.05).
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Figure 3.6. VAChTSix3-Cre-flox/flox mice have impaired sustained attention.
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3.4.6 Deletion of forebrain VAChT increases susceptibility to
distractions
To assess distractibility of VAChTSix3-Cre-flox/flox mice, we increased attentional
demand by testing them on a distraction variation of the 5-CSRT. Stimulus duration was
set to 2 s, where performance of both genotypes was identical, and distractor sounds
were played at set time points during trials. Response accuracy of VAChTSix3-Creflox/flox mice tended to be reduced by distractions compared with controls (RMANOVA, near significant effect of genotype F(1,32) = 4.825, p = 0.0589; main effect of
distractor onset F(4,32) = 3.583, p = 0.0159; Figure 3.7A). Rate of omission was
significantly higher in VAChTSix3-Cre-flox/flox mice than controls (RM-ANOVA,
significant effect of genotype F(1,32) = 6.809, p = 0.0312; no effect of distractor onset
F(4,32) = 2.564, p = 0.0572; Figure 3.7B). Importantly, neither response latency (RMANOVA, no effect of genotype F(1,32) = 1.045, p = 0.3367; main effect of distractor
onset F(4,32) = 7.069, p = 0.0003; Figure 3.7C) nor reward collection latency varied
between genotypes (RM-ANOVA, no effect of genotype F(1,32) = 0.7467, p = 0.4127;
main effect of distractor onset F(4,32) = 3.226, p = 0.0248; Figure 3.7D).
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Figure 3.7 VAChTSix3-Cre-flox/flox mice are more susceptible to distraction. Mice were
subjected to a series of distraction trials and the average values of 50 trial sessions per
distractor onset are plotted.A, Mean response accuracy. B, Mean rate of omission. C,
Mean response latency. D, Mean reward collection latency (n = 6, data are mean ±
SEM, * represents significant differences between genotypes, # represents significant
differences within genotypes; *p < 0.05).
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Figure 3.7 VAChTSix3-Cre-flox/flox mice are more susceptible to distraction.
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3.4.7 Galantamine improves attention in wild-type mice on a
demanding task
Detection of pro-attentive effects of pharmacological manipulations on the 5-CSRT is
hampered by possible ceiling effects (Robbins, 2002). To detect differences in mice it is
important to test the drug on challenging conditions, which can be achieved by
shortening the duration of the stimulus presentation (Romberg et al., 2011). To find a
suitably challenging task in which we could observe increased attention, we trained a
group (n = 8) of wild-type mice on the 5-CSRT, and ran them through the probe trial
series, serially reducing stimulus duration (1.5, 1, 0.8, and 0.6 s). Choice accuracy
(F(4,31) = 13.77, p < 0.0001; Fig. 3.8A) and rate of omissions (F(4,31) = 6.716, p =
0.0024; Fig. 3.8B) were significantly affected by reducing stimulus duration. Post hoc
analysis revealed that at 0.6 s stimulus duration the rate of accuracy was significantly
reduced, and omissions significantly increased from the 1.5 s stimulus duration. We
therefore chose both, 0.8 s stimulus duration and the more challenging 0.6 s stimulus
duration, for pharmacological testing. Administration of galantamine (1 mg/kg, i.p.) 1 h
before 5-CSRT testing at 0.8 s did not improve accuracy (paired t test, t(7) = 1.287, p =
0.2544; Fig. 3.8C) or omissions (paired t test, t(7) = 0.4581, p = 0.6661; Fig. 3.8D).
However, when administered before a 0.6 s stimulus duration session, galantamine (1
mg/kg) significantly improved accuracy compared with saline (paired t test, t(7) = 2.405,
p = 0.0471; Fig. 3.8E) and significantly reduced the rate of omission (paired t test, t(7) =
2.379, p = 0.0489;Fig. 3.8F). Response latency (paired t test, t(7) = 1.296, p = 0.2360),
and reward collection latency (paired t test, t(7) = 0.390, p = 0.7080) were not changed
by galantamine injections (data not shown). These results suggest that increased
cholinergic tone can increase attentional performance when the probe trial is sufficiently
demanding to avoid a potential ceiling effect.

3.4.8 Galantamine does not improve attention deficits in
VAChTSix3-Cre-flox/flox mice
To investigate if the deficits observed in VAChTSix3-Cre-flox/flox are exclusively related
to decreased levels of synaptic ACh, we injected mice with galantamine (1 mg/Kg IP), a
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dose that effectively improved performance of wild-type mice (Fig. 3.8), and tested both
VAChTSix3-Cre-flox/flox and VAChTflox/flox mice at 0.6 s (50 trials). Galantamine
tended to improve choice accuracy, albeit this effect did not reach statistical significance
(paired t test, t(5) = 1.954, p = 0.1224; Fig. 3.8G). However, the drug was able to
significantly reduce rate of omissions (paired t test, t(5) = 3.383, p = 0.0277; Fig. 3.8H)
in VAChTflox/flox mice. Interestingly, galantamine had no effect on the performance of
VAChTSix3-Cre-flox/flox mice, neither improving accuracy (paired t test, t(5) = 0.162, p
= 0.880; Fig. 8G) nor rate of omission (paired t test, t(5) = 0.868, p = 0.434; Fig. 3.8H).
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Figure 3.8 Galantamine improves attention in wild-type, but not in VAChTSix3-Creflox/flox

mice. Wild-type mice (n = 8) were subjected to a series of probe trials and the

average values of 50 trial sessions are plotted. A, Mean accuracy. B, Mean rate of
omissions. Effect of galantamine (1 mg/kg i.p.) on (C) response accuracy and (D) rate of
omission in wild-type mice at a 0.8 s stimulus duration (n = 8). Effect of galantamine on
(E) response accuracy and (F) rate of omission in wild-type mice at a 0.6 s stimulus
duration (n = 8). Effect of galantamine (1 mg/Kg I.P.) on (G) choice accuracy and (H)
rate of omission in VAChTflox/flox and VAChTSix3-Cre-flox/floxmice (n = 6, data are mean ±
SEM, *p < 0.05).
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Figure 3.8 Galantamine improves attention in wild-type, but not in VAChTSix3-Creflox/flox

mice.
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3.4.9 Deletion of forebrain VAChT results in metabolic
abnormalities in the PFC
The lack of effect of galantamine in VAChTSix3-Cre-flox/flox suggests that diminished
ACh release in mutant mice may not be sufficiently increased by galantamine to reverse
the attentional deficits in these mice. In addition to that, a chronic decrease in
cholinergic tone may cause circuitry or metabolic changes that could affect how
neuronal circuitries are recruited for specific cognitive tasks. We used in vivo magnetic
resonance spectroscopy to assess if metabolic parameters were affected in the
prefrontal region of VAChT-deficient mice (Fig. 3.9A; representative spectra). This
analysis revealed that VAChTSix3-Cre-flox/flox mice had significantly less Lac (t(6) =
2.600, p = 0.0428; Fig. 3.9B) and Tau (t(6) = 2.522, p = 0.0452; Fig. 3.9C) than controls.
Levels of NAA (t(6) = 0.0907, p = 0.9307; Fig. 3.9D), Myo (t(6) = 0.9598, p = 0.3742;
Fig. 3.9E), and Cho (t(6) = 0.1461, p = 0.8886; Fig. 3.9F) remained unchanged.
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Figure 3.9. VAChTSix3-Cre-flox/flox mice have metabolic abnormalities in the PFC. In
vivo magnetic resonance spectroscopy of neuronal metabolites. A, 9.4 tesla 1H
magnetic resonance spectroscopy data from VAChT flox/flox (top) and VAhTsix3creflox/flox

(bottom) mice. The VAChTflox/flox data are shown in gray with fit superimposed

(black line) and residual shown above. Individual component spectra for Tau and Lac
are also provided. B, Levels of Lac. C, Levels of Tau. D, Levels of NAA. E, Levels of
Myo. F, Levels of Cho (n = 4, data shown are the median and individual values per
mouse, *p < 0.05).
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Figure 3.9. VAChTSix3-Cre-flox/flox mice have metabolic abnormalities in the PFC.
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3.4.10 Deletion of forebrain VAChT results in altered RNA
metabolism in the PFC
Cholinergic deficits in AD have been proposed to cause major transcriptome changes
via aberrant hnRNPA2/B1 expression (Berson et al., 2012). hnRNPA2/B1 refers to a
family of proteins that functions as splicing factors and mRNA chaperones (Hoek et al.,
1998; Kamma et al., 1999). This gene family is critical for regulating alternative splicing
in numerous genes involved with synaptic plasticity and cognition (Berson et al., 2012).
Its expression is severely reduced in Alzheimer brain and appears enhanced in primary
mouse neurons under carbachol induction (Berson et al., 2012), suggesting cholinergic
regulation of hnRNPA2/B1 proteins. To determine whether the PFC of VAChTSix3-Creflox/flox shows parallel suppression of the hnRNPA2/B1 proteins, their levels were
assessed. Compared with controls, the PFC of VAChTSix3-Cre-flox/flox mice showed a
significant reduction in hnRNPA2/B1 expression (75% decrease, t(6) = 4.941, p =
0.0026; Fig. 3.10A). We then used qPCR to assess whether the decrease in
hnRNPA2/B1 could have a functional impact on RNA processing in the PFC. We
evaluated the alternative splicing of the key genes, SIPA1L1(SIPA), REELIN(RELN),
DRAM2, CD55, DYSTONIN (DST), and ENAH, as manifested by increased exon
inclusion tested both in Alzheimer's brain and in mouse brain depleted of its cholinergic
neurons by saporin-mediated treatment (Berson et al., 2012). This analysis revealed
that VAChTSix3-Cre-flox/flox mice had significant changes in the splicing of these
genes in the PFC, with significantly increased inclusion of exon 8 of CD55 (t(10) =
2.550, p = 0.0289), exon 41 of DST (t(10) = 7.436, p = 0.0001), exon 18 of RELN (t(10)
= 3.230, p = 0.0090), and exon 2 of DRAM2 (t(10) = 3.990, p = 0.0260). In addition the
inv isoform of the ENAH gene was also significantly increased (t(10) = 2.522, p =
0.0303). In contrast, intron 5 of SIPA (t(10) = 0.5449, p = 0.5978) and exon 3 of RELN
(t(10) = 2.215, p = 0.0511), which have also been shown to be affected in AD, were
unchanged, although we detected a trend for the latter (Fig. 3.10B).
hnRNPA2/B1 has been shown to regulate the splicing of pyruvate kinase M (PKM)
enzyme, which in turn dictates lactate metabolism (David et al., 2010). Knockdown of
hnRNPA2/B1 expression in vitro favors the PKM1 isoform, which leads to reduced
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levels of Lac, whereas upregulation hnRNPA2/B1 favors the PKM2 isoform and
increased Lac levels (Clower et al., 2010; for review, see Chen et al., 2010). To test
whether alternative splicing of PKM occurs in VAChTSix3-Cre-flox/flox mice, we
performed qPCR to determine the expression of the PKM1 and PKM2 splice variants.
Interestingly the VAChTSix3-Cre-flox/flox mice showed a significant upregulation of the
PKM1 variant (t(10) = 4.277, p = 0.0016), and a significant reduction in the PKM2
variant (t(10) = 3.073, p = 0.0110; Fig. 3.10C), effectively changing the ratio between
these two enzymes.
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Figure 3.10. VAChTSix3-Cre-flox/flox mice have abnormal RNA processing in the
PFC. A, hnRNPA2/B1 protein expression in the PFC with representative immunoblots
(inset, n = 4). B, qPCR analysis of alternative splicing events for CD55, ENAH, SIPA,
Dystonin (DST), Reelin (RELN), and DRAM2. C, Expression of the PKM1 and PKM2
isoforms. Alternative exon levels are normalized to a constitutive exon from the same
gene (n = 6, data are mean ± SEM, *p < 0.05, **p < 0.01, and ***p < 0.001).
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Figure 3.10. VAChTSix3-Cre-flox/flox mice have abnormal RNA processing in the
PFC.
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3.5 Discussion
In this report we show that forebrain VAChT knock-out mice present deficits in two
domains of executive function, cognitive flexibility and attention. Additionally, VAChTdeficient mice exhibit metabolic deficits in the PFC suggestive of changes in PFC
circuitry. Furthermore, these mice have reduced expression of a key splicing factor,
hnRNPA2/B1, which has been previously implicated in synaptic plasticity deficits in AD
(Berson et al., 2012) and in mutations that were recently discovered in rare
proteinopathies (Kim et al., 2013). These changes have a functional impact on RNA
metabolism in the PFC of VAChT-deficient mice. These results suggest that
VAChTSix3-Cre-flox/flox mice may represent a powerful tool to dissect the molecular
and neurochemical basis of executive dysfunction.

3.5.1 Cognitive flexibility in VAChTSix3-Cre-flox/flox mice
VAChTSix3-Cre-flox/flox mice were able to associate an image with a reward, and
another with a punishment, in the pairwise visual discrimination task. Acquisition of this
task has been shown to be dependent on glutamatergic signaling, with mice lacking the
GLAST glutamate transporter being unable to acquire the task (Karlsson et al., 2009).
Evidence suggests that the NMDA receptor is an important molecular switch for the
acquisition of the task (Brigman et al., 2008; Barkus et al., 2012). Our results indicate
that cholinergic signaling is not required for such learning. In contrast, when
contingencies of the pairwise task were reversed, forebrain VAChT knock-out mice
were unable to adapt and learn the new rule. Reversal learning in a visual discrimination
task has been proposed to serve as a measure of cognitive flexibility in rodents
(Izquierdo et al., 2006; Brigman et al., 2008). Neurochemical modulation of reversal
learning is complex, as it can be enhanced by targeting multiple neurotransmitter
signaling systems including serotonergic (Brigman et al., 2010), dopaminergic
(Izquierdo et al., 2006), and glutamatergic (Balschun et al., 2010). The role of
cholinergic signaling has been focused predominantly on muscarinic receptors (Ridley
et al., 1984, 1985). Determining the exact mechanism has been difficult, as M1 receptor
agonists facilitate cognitive flexibility (McCool et al., 2008; Shirey et al., 2009), but no
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effects on cognitive flexibility were observed in M1-null mice (Bartko et al., 2011). There
is evidence suggesting that M2 and M4 receptors may be involved in cognitive flexibility
(Nieves-Martinez et al., 2012). Our results indicate that cholinergic signaling is essential
for modulation of cognitive flexibility.

3.5.2 Attention deficits in VAChT-deficient mice
To further understand the role of forebrain ACh in executive function we evaluated
attention on forebrain VAChT knock-out mice using the 5-CSRT task, a test suggested
to be dependent on PFC cholinergic signaling (Guillem et al., 2011; for review, see
Robbins, 2000; Dalley et al., 2004a). In line with our previous finding with the
VAChTSix3-Cre-flox/flox mouse line having learning and memory deficits (Martyn et al.,
2012), these mice showed impairments in acquisition of the 5-CSRT, taking nearly twice
as long as controls to reach criteria at the 4 and 2 s phase of the training process.
Interestingly, they were not impaired during the pretraining phase, wherein mice are
taught to respond to the touchscreen. These results suggest that simple operant
conditioning is not dependent on forebrain cholinergic signaling, but rather that forebrain
ACh is responsible for the use of such information to perform higher order cognitive
tasks. Attentional demand deficits were probed by reducing stimulus duration. Choice
accuracy, perseverative, and premature responses of VAChTSix3-Cre-flox/flox mice
were unaffected. However, the rate of omission for VAChTSix3-Cre-flox/flox was
significantly increased. Additionally, in the presence of a noise distractor VAChTSix3Cre-flox/flox mice were significantly less attentive than controls, showing a much higher
rate of omissions. This test was performed under a condition in which the performance
of VAChT-deficient mice was on par with controls without the auditory distraction. The
auditory distraction task gives a clear indication that the attention deficits observed in
VAChTSix3-Cre-flox/flox mice were not due to visual abnormalities. These findings are
aligned with previous work, given that cue detection has been shown to involve
transient rises in ACh release (Himmelheber et al., 2000; Parikh et al., 2007). Our
experiments agree with previous work indicating a key role for cholinergic activity in
improving response to distractors in attentional tasks (Gill et al., 2000; Terry et al., 2002;
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Newman and McGaughy, 2008; Broussard et al., 2009; Howe et al., 2010; St Peters et
al., 2011).
Regulation of attentional performance by endogenous ACh has been investigated in
rats using immunolesion with IgG-192 saporin (Walsh et al., 1996; Risbrough et al.,
2002; Lehmann et al., 2003; Chudasama et al., 2004; Dalley et al., 2004b). Specifically,
deficits in choice accuracy and increases in perseverative responses were observed in
rats following 192 IgG-saporin-induced lesions (McGaughy et al., 2002; Dalley et al.,
2004b). In these studies no effects were observed on rates of omissions. Our
experiments show a somewhat distinct feature, demonstrating increased rates of
omission, without changes in perseverative response. Interestingly, selective elimination
of the β2 nAChR in mice also revealed an increase in rate of omissions (Guillem et al.,
2011). The differences between genetically modified and lesioned animals could
therefore be species related. Alternatively, this difference may reflect the capacity of
cholinergic neurons to secrete more than one neurotransmitter (El Mestikawy et al.,
2011; Prado et al., 2013). Basal forebrain cholinergic neurons can release glutamate in
vitro (Allen et al., 2006). There is also evidence that these neurons possess the
machinery to release GABA (Henny and Jones, 2008). Recent experiments targeting
striatum cholinergic neurons revealed striking behavioral differences between mice that
had cholinergic elimination, using immunolesion, or mice that were genetically targeted
to eliminate striatal ACh release (Kitabatake et al., 2003; Guzman et al., 2011; for
review, see Prado et al., 2013). Immunolesion of cholinergic neurons can therefore
have effects beyond impairing ACh release and could affect cotransmission. Whether
cotransmission has a role in the small phenotypic differences between our experiments
and previous work using rats injected with IgG-192-saporin remains to be determined.
Galantamine was unable to rescue the attention deficits in VAChTSix3-Cre-flox/flox
mice. We have previously shown, using a mouse line with decreased VAChT
expression, that galantamine could reverse social memory deficits (Prado et al., 2006)
and object recognition memory deficits (de Castro et al., 2009b; De Jaeger et al., 2013).
Hence, the fact that galantamine can improve performance of control mice, but not of
VAChTSix3-Cre-flox/flox mice, suggests that the latter may not release sufficient
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synaptic ACh to be enhanced by galantamine. Alternatively, these sophisticated tasks
may be more affected by changes in neuronal circuitry. The in vivo 1H spectroscopy
data suggest that critical metabolic changes occur in VAChT-deficient mice; namely,
reduced levels of both Tau and Lac in the prefrontal region. Lac has been proposed as
the preferred metabolic substrate for neurons (for review, see Pellerin et al., 2007),
suggesting that decreased cholinergic tone may lead to a general decrease in neuronal
activity.

3.5.3 Alterations in PFC function in VAChT-deficient mice
The reduction in PFC hnRNPA2/B1 observed in VAChTSix3-Cre-flox/flox mice is in line
with previous work indicating cholinergic-mediated regulation of its expression in AD
(Berson et al., 2012). Furthermore, we found that alternative splicing alteration pattern
in the PFC of these mice is similar to the pattern found in both AD patient samples and
hypocholinergic animal models (Berson et al., 2012). Overall, these changes suggest
alterations in the PFC circuitry. Furthermore, the splicing change found in the PKM gene
indicates a potential mechanism for cholinergic regulation of Lac metabolism. Of note,
nearly significant differential expression of the PKM variants was observed in exon array
datasets from the entorhinal cortices of three AD patients and three matched controls
studied previously, despite the small number of samples (Berson et al., 2012; p < 0.051;
raw data deposited in the GenBank).
Decreased Lac levels have been observed in mouse models of AD (Du Yan et al., 2000;
Marjanska et al., 2005). Moreover, in the CRND8 transgenic mouse model of AD, lower
levels of Tau were observed in vivo by H1-NMR (Salek et al., 2010). Interestingly, high
levels of Lac in cultured neurons decrease susceptibility to Aβ-derived peptides and
oxidative stress in vitro (Newington et al., 2012). Together, these data suggest that
VAChTSix3-Cre-flox/flox mice may be useful for understanding metabolic abnormalities
that occur in dementia.
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3.6 Conclusion
In summary, by eliminating VAChT from the forebrain we determined that cholinergic
signaling regulates executive function, affects metabolism, and also RNA processing in
the PFC. The PFC has been shown to mediate salient cue detection (Himmelheber et
al., 2000; Parikh et al., 2007), and it serves as a hub that regulates numerous
neurotransmitter interactions (Dalley et al., 2004a; Carr et al., 2007; Tait and Brown,
2008). Our work helps to define the specific role played by ACh in behaviors related to
cortical functioning, and its potential underlying mechanisms. Decreased levels of
VAChT in the brain have been reported in AD (Efange et al., 1997; Chen et al., 2011),
therefore the executive dysfunction and mRNA processing abnormalities we observed
in VAChT-deficient mice may be of relevance to model this specific deficiency in
humans. Therefore, this work provides novel insights into the basic neurochemical
contributors governing executive function.
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Chapter 4

α7 nicotinic ACh receptor‐deficient mice exhibit sustained
attention impairments that are reversed by β2 nicotinic ACh
receptor activation
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4.2 Chapter Summary
Disruptions of executive function, including attentional deficits, are a hallmark of a
number of diseases. ACh in the prefrontal cortex regulates attentive behaviour;
however, the role of α7 nicotinic ACh receptor (α7nAChR) in attention is contentious. In
order to probe attention, we trained both wild-type and α7nAChR knockout mice on a
touch screen-based five-choice serial reaction time task (5-CSRT). Following training
procedures, we then tested sustained attention using a probe trial experiment. To
further differentiate the role of specific nicotinic receptors in attention, we then tested the
effects of both α7nAChR and β2nAChR agonists on the performance of both wild-type
and knockout mice on the 5-CSRT task. At low doses, α7nAChR agonists improved
attentional performance of wild-type mice, while high doses had deleterious effects on
attention. α7nAChR knockout mice displayed deficits in sustained attention that were
not ameliorated by α7nAChR agonists. However, these deficits were completely
reversed by the administration of a β2nAChR agonist. Furthermore, administration of a
β2nAChR agonist in α7nAChR knockout mice elicited similar biochemical response in
the prefrontal cortex as the administration of α7nAChR agonists in wild-type mice. Our
experiments reveal an intricate relationship between distinct nicotinic receptors to
regulate attentional performance and provide the basis for targeting β2nAChRs
pharmacologically to decrease attentional deficits due to a dysfunction in α7nAChRs.

4.3 Introduction
Attentional performance can be severely compromised in different neuropsychiatric and
neurodegenerative diseases, including schizophrenia and Alzheimer's disease (Mega
and Cummings, 1994; Buckner, 2004). ACh release in the prefrontal cortex (PFC), a
brain area known to play a central role in attention (Kastner and Ungerleider, 2000;
Corbetta and Shulman, 2002; Buschman and Miller, 2007), is important for the
regulation of attentive behaviour (Elliott, 2003). Schizophrenic patients present severe
physiological and molecular dysfunctions in the PFC (Weinberger et al., 1986; Mirnics et
al., 2000; Guillozet-Bongaarts et al., 2014). One of the more profound molecular
changes is the loss of the α7 nicotinic ACh receptor (α7nAChR), encoded by the
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CHRNA7 gene. Although the genetic linkage between the CHRNA7 gene and
schizophrenia is complex, with studies pointing towards and against CHRNA7 as a risk
gene for the disease (Xu et al., 2001; Zammit et al., 2007), robust decreases in protein
and mRNA expression of the α7nAChR have been shown in the PFC of patients with
schizophrenia (Guan et al., 1999; Guillozet-Bongaarts et al., 2014). Moreover, in
Alzheimer's disease, Aβ peptides can bind to α7nAChRs (Wang et al., 2000) and
disrupt their function (Chen et al., 2006).
There is accumulating evidence demonstrating that cue detection during attentional
efforts is mediated by nicotinic receptor signalling (McGaughy et al., 1999a; Grottick and
Higgins, 2000; Parikh et al., 2007, 2010). β2nAChRs are both necessary and sufficient
to regulate attention in mice using a non-demanding five-choice serial reaction time task
(5-CSRT) paradigm (Guillem et al., 2011). On the other hand, the role of α7nAChRs in
attention is still not completely understood. Initial studies suggest that CHRΝΑ7−/− mice
present deficits in sustained attention (Hoyle et al., 2006; Young et al., 2007). However,
it has been reported that for less demanding tasks no deficits were observed in
α7nAChR-null mice (Guillem et al., 2011). Taken together, these results suggest that
attentional deficits in CHRΝΑ7−/− mice may depend on the attentional load.
Pharmacological manipulations of α7nAChRs have also produced conflicting results,
most likely because of the poor selectivity of the drugs used (Grottick and Higgins,
2000; Pichat et al., 2007; Rezvani et al., 2009; Wallace et al., 2011a). Interestingly,
studies in humans have shown that agonists for the α7nAChR can improve the
performance of patients suffering from schizophrenia on neurocognitive tests (Olincy et
al., 2006; Olincy and Stevens, 2007).
Here, we report that α7nAChR-null mice present deficits in their ability to sustain
attention in a demanding paradigm. Moreover, we found that activation of α7nAChRs
increased biochemical signalling and attention in wild-type (WT) mice, but not in
CHRΝΑ7−/− mice. Interestingly, activation of β2nAChRs triggered similar biochemical
pathways as α7nAChR agonists and reversed attentional deficits in α7nAChR-null mice.
These results suggest that α7nAChRs may contribute to attention performance, but
activation of β2nAChRs can bypass the deficits triggered by deficient α7nAChR
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signalling. Our results suggest that the α7nAChR plays a role in sustained attention
during demanding tasks and that β2nAChR drugs may be of potential use for correcting
cognitive and molecular signalling deficits seen in psychiatric or neurological disorders
in which α7nAChRs are affected.

4.4 Material and Methods
4.4.1 Animals
CHRΝΑ7−/− mice (B6.129S7 nAChR Chrna7tm1Bay/J) were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). Mice were housed in groups of three or four per
cage in a temperature-controlled room with 12/12 h light/dark cycle (07:00–19:00 h), and
water was provided ad libitum. Only male mice were used in these studies. For the 5CSRT studies, mice were housed in pairs and restricted to 85% of their free-feed weight
and maintained on 85% of their weight for the duration of the studies as described
(Kolisnyk et al., 2013a,b). All behavioural experiments were conducted between 12:00
and 17:00 h. We followed the ARRIVE guidelines (Kilkenny et al., 2010); hence, mice
were randomized for behavioural tests, and the experimenter was blind to the genotype.
All procedures were conducted in accordance with guidelines from the Canadian
Council of Animal Care at the University of Western Ontario with an approved
institutional animal protocol (2008-127).

4.4.2 Five-choice serial reaction time task training
A cohort of WT and CHRΝΑ7−/− mice (n = 7 per genotype, 5–6 months old) was trained
in the 5-CSRT task using the automated Bussey–Saksida Mouse Touch Screen System
model 81426 (Campden Instruments, Lafayette, IN, USA). Schedules were designed,
and data were collected using the abet ii touch software v.2.15 (Lafayette Instruments,
Lafayette, IN, USA). Mice were trained to respond to the touch screen chambers using
a previously described operant training procedure (Kolisnyk et al., 2013a, 2013b).
Training on the 5-CSRT task was performed as previously described (Romberg et al.,
2011). Once the performance of a mouse reached criterion (80% accuracy, 20%
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omissions for three consecutive days) at 4 s stimulus duration, stimulus duration was
reduced to 2 s. After reaching criterion at a 2 s stimulus duration, the mouse was tested
on probe trials.

4.4.3 Probe trial
To probe attention in mice, we used a previously described probe trial schedule with
reduced stimulus durations (Romberg et al., 2011; Kolisnyk et al., 2013a). Mice were
tested for 2 days at a given stimulus duration (1.5, 1, 0.8 or 0.6 s). Each day, sessions
lasted 50 trials or 1 h. After each test, the animal was retested at the 2 s stimulus
duration for 2 days, until the mice had been tested at all stimulus durations. The order of
the probe trial sessions was semi-randomized using a Latin square method.
Behavioural data were averaged over the 2 days of each stimulus duration.

4.4.4 Drug injections
For all drug experiments, mice were tested at the 0.6 s stimulus duration. The same
mice used for the initial 5-CSRT experiments were used for the drug studies. Animals
were injected 30 min before testing for the PHA-543,613 (Sigma-Aldrich, St Louis, MO,
USA) and PNU-228,927 (Tocris Bioscience, Bristol, UK) experiments and 15 min before
testing for the ABT-418 (Sigma-Aldrich) experiment (McGaughy et al., 1999b). Doses of
PHA-543,613 [0.33, 1 and 3 mg∙kg−1, i.p. (Acker et al., 2008)], PNU-282,927 [1, 3 and
5 mg∙kg−1, i.p. (Hajos et al., 2005; Vicens et al., 2013)] and ABT-418 [0.04, 0.13 and
0.39 mg∙kg−1, i.p. (McGaughy et al., 1999a)] were chosen based on previous studies. In
control experiments, vehicle (saline) was injected. The order of drug injections was
semi-randomized using a Latin square method. Between different doses in the drug
injection experiments, mice were given two washout days during which they were
baselined with a 2 s stimulus duration.

4.4.5 Analysis of 5-CSRT task
On all 5-CSRT task sessions, accuracy was calculated as the number of correct
responses divided by the number of correct and incorrect responses (touches to a
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wrong window while the correct stimulus was still displayed). Omissions were calculated
as the total number of omitted trials divided by the number of total trials. Response
latency was the time the mouse took to touch the correct stimulus after the onset of its
display. Reward collection latency was defined as the time it took the mouse to enter
the reward magazine following a correct response. A premature response was counted
when the mouse touched one of the windows prior to the stimulus being displayed.
Finally, a perseverative response was any identical response that occurred following a
correct, incorrect or premature response.

4.4.6 Food intake in food-deprived mice
Feeding behaviour was analysed as previously described (Semenova and Markou,
2007). Naive groups of WT and CHRΝΑ7−/− mice (n = 8 per genotype) were housed
individually and were deprived of food overnight before the test. During the test, mice
were placed in a clean cage and given 20 g of standard chow. Food intake was
measured 20, 40, 60 and 80 min after the start of the test. Food intake was normalized
to the body weight of the animals.

4.4.7 qPCR
Total RNA was extracted from freshly dissected PFC tissue, using the Aurum Total RNA
for fatty and fibrous tissue kit (Bio-Rad Laboratories, Hercules, CA, USA); cDNA
synthesis and quantitative PCR (qPCR) analysis of nicotinic receptor expression were
performed as previously described (Guzman et al., 2011; Kolisnyk et al., 2013a).

4.4.8 Western Blotting
Western blotting was performed as previously described (Martins-Silva et al., 2011). For
analysis of phospho-proteins in the PFC, mice were given i.p. drug injections and were
killed 30 min later. Tissue was then homogenized in lysis buffer supplemented with
protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific, Waltham, MA,
USA). The antibodies used were anti-vesicular ACh transporter (VAChT) (catalogue
#139103; Synaptic Systems, Göttingen, Germany), anti-ChAT (catalogue #1DB-001-
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0000849693; Millipore, Billerica, MA, USA), anti-synaptophysin (catalogue #S5768;
Sigma-Aldrich), anti-ERK1/2 (catalogue #4695; Cell Signaling Technology, Danvers,
MA, USA), anti-phospho-ERK1/2 (catalogue #4372; Cell Signaling Technology), anticFos (catalogue #4384; Cell Signaling Technology) and anti-β-actin (catalogue
#ab49900; Abcam, Cambridge, UK). Band intensity was quantified using fluorochemq
software (Thermo Fisher Scientific).

4.4.9 Statistical analyses
All data are expressed as mean ± SEM. sigmastat 3.5 (Systat Software, San Jose, CA,
USA) was used for all statistical analysis. Comparisons between two experimental
groups were made by Student's t-test. When several experimental groups or treatments
were analysed, one-way ANOVA or two-way ANOVA with repeated-measures tests
were used as required. Statistically significant effects were further analysed using
Tukey's honestly significant difference post hoc tests. In all analyses, P < 0.05 was
considered statistically significant.

4.5 Results
4.5.1 α7nAChR-null mice present normal acquisition on the 5CSRT task
No difference between CHRΝΑ7−/− mice and WT controls was observed in the number
of sessions required to reach criterion at any of the pre-training phases for the 5-CSRT
task [Fig. 4.1.1; RM-ANOVA: no effect of genotype, F(1,14) = 2.814, P = 0.1156; main
effect of training phase, F(4,14) = 104.3, P < 0.0001; no interaction effect,
F(4,14) = 1.126, P = 0.3535]. During training on the 5-CSRT task as well, CHRΝΑ7−/−
mice took as many sessions as WT controls to achieve criterion at both the 4 and 2 s
stimulus durations [RM-ANOVA: no effect of genotype, F(1,14) = 2.552, P = 0.1325;
main effect of stimulus duration, F(1,14) = 57.78, P < 0.0001; no interaction,
F(1,14) = 4.472, P = 0.0529; Fig. 4.1.1B]. It should be noted that there was a strong
tendency for the CHRΝΑ7−/− mice to take longer to learn the task at the 4 s stimulus
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duration, which may reflect previously documented impairments in procedural learning
in these mice (Young et al., 2011).

4.5.2 α7nAChR-null mice have impaired sustained attention
Once mice reached criterion at 2 s stimulus duration, we assessed attention
performance by using a probe trial, with reduced stimulus durations (1.5, 1, 0.8 and
0.6 s stimulus durations) as previously described (Romberg et al., 2011). Across all four
stimulus durations, CHRΝΑ7−/− mice performed similarly to controls in both total
measures of omissions [RM-ANOVA: no effect of genotype, F(1,36) = 3.235, P = 0.0972;
main effect of stimulus duration, F(3,36) = 14.50, P < 0.001; no interaction,
F(3,36) = 0.5136, P = 0.6755; Figure 4.1.2A] and accuracy [RM-ANOVA: no effect of
genotype, F(1,36) = 0.06134, P = 0.8086; main effect of stimulus duration,
F(3,36) = 9.208, P < 0.001; no interaction, F(3,36) = 0.6347, P = 0.5975; Figure 4.1.2B].
To assess sustained attention, we analysed rate of omissions and response accuracy
over blocks of 25 trials across the various stimulus durations of the probe trial
experiment. As each probe trial session ends after 50 trials or 1 h, analysing blocks of
25 trials divided the performance between two halves: block A and block B. This
procedure allowed us to determine if mice can sustain attention during the full period of
the probe trial and maintain performance between the first and second periods of
testing. Performance of control WT mice did not differ across the probe trial in terms of
omissions [RM-ANOVA: no difference between blocks A and B, F(1,6) = 1.904,
P = 0.2168; main effect of stimulus duration, F(3,18) = 8.661, P < 0.001; and no
interaction, F(3,18) = 0.4736, P = 0.7045; Figure 4.1.2C) or accuracy [RM-ANOVA: no
effect of blocks, F(1,6) = 4.319, P = 0.0829; main effect of stimulus duration,
F(3,18) = 4.897, P = 0.0166; and no interaction, F(3,18) = 0.4947, P = 0.6905; Figure
4.1.2D]. In contrast, CHRΝΑ7−/− mice displayed increased omission errors in the
second half of the probe trial experiment compared with the first half [RM-ANOVA: main
effect of block, F(1,6) = 20.59, P < 0.001; main effect of stimulus duration,
F(3,18) = 9.471, P < 0.001; and main interaction effect, F(3,18) = 12.13, P < 0.001;
Figure 4.1.2E). Post hoc analysis confirmed that CHRΝΑ7−/− mice had significantly
more omission errors during the second half of the task at both the 0.8 and 0.6 s
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stimulus durations, suggesting that these mice display impaired ability to sustain
attention. Interestingly, CHRΝΑ7−/− mice did not present accuracy impairments across
the two blocks [RM-ANOVA: no effect of block, F(1,6) = 1.348, P = 0.2897; main effect of
stimulus duration, F(3,18) = 5.877, P = 0.0056; and no interaction effect,
F(3,18) = 0.6404, P = 0.5989; Figure 4.1.2F].
Increases in omission on the 5-CSRT task have been proposed to be due to lack of
attention, lack of motivation or motor impairments (Robbins, 2002). Given that
CHRΝΑ7−/− mice were no different from controls in terms of latency to respond to
stimulus or latency to collect the reward, it is unlikely that motivation or motor
impairments are causing the deficits in sustained attention (Robbins, 2002; Spinelli et
al., 2004). To address this, we measured several other parameters to test for
motivational or aberrant behaviour in CHRΝΑ7−/− mice. α7nAChR-null mice showed no
difference in latency to respond to the stimulus [RM-ANOVA: no effect of genotype,
F(1,36) = 0.01533, P = 0.9035; no effect of stimulus duration, F(3,36) = 2.003,
P = 0.1310; no interaction, F(3,36) = 1.223, P = 0.3154; Figure 4.1.3A]. We then
assessed response latency across blocks of trials to determine if the sustained attention
deficits in CHRΝΑ7−/− mice may be due to delayed responsiveness. Response latency
did not differ across blocks for either the WT [RM-ANOVA: no effect of block,
F(1,6) = 0.07218, P = 0.7972; no effect of stimulus duration, F(3,18) = 2.749, P = 0.0792;
and no interaction effect, F(3,18) = 0.7886, P = 0.5159; Figure 4.1.3B] or CHRΝΑ7−/−
mice [RM-ANOVA: no effect of block, F(1,6) = 0.2481, P = 0.6362; no effect of stimulus
duration, F(3,18) = 2.2557, P = 0.1166; and no interaction effect, F(3,18) = 1.490,
P = 0.2501; Figure 4.1.3C]. We also assessed the time to retrieve their reward following
a correct response [RM-ANOVA, no effect of genotype, F(1,36) = 0.2025, P = 0.6607; no
effect of stimulus duration, F(3,36) = 1.153, P = 0.3410; no interaction, F(3,36) = 0.2954,
P = 0.8284; Figure 4.1.3D] when compared with WT controls. Furthermore, we
assessed reward latency across blocks of trials, and neither the WT [RM-ANOVA: no
effect of block, F(1,6) = 2.345, P = 0.1766; no effect of stimulus duration,
F(3,18) = 2.176, P = 0.1262; and no interaction effect, F(3,18) = 0.5404, P = 0.6677;
Figure 4.1.3E) nor CHRΝΑ7−/− mice [RM-ANOVA, no effect of block, F(1,6) = 0.02162,
P = 0.8879; no effect of stimulus duration, F(3,18) = 0.6190, P = 0.6617; and no
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interaction effect, F(3,18) = 0.3581, P = 0.7839; Figure 4.1.3F) showed alteration in
reward collection latency. To test whether CHRΝΑ7−/− mice differ from WT controls in
satiety, we measured food intake following food restriction in a group of naive mice.
Compared with controls, CHRΝΑ7−/− mice did not differ in food consumption over the
course of the test [RM-ANOVA: no effect of genotype, F(1,48) = 1.280, P = 0.2800; main
effect of time, F(4,48) = 73.88, P < 0.001; and no interaction effect, F(4,48) = 1.296,
P = 0.2849; Figure 4.1.3G]. This is in line with previous work showing that these mice
have normal motivation (Hoyle et al., 2011) and suggests that CHRΝΑ7−/− mice have
specific deficits in sustained attention.
Impulsivity and compulsivity were also assessed in CHRΝΑ7−/− mice during the probe
trial experiment. Compared with controls, CHRΝΑ7−/− mice were no different in terms
of premature responses, a measure of impulsivity [RM-ANOVA: no effect of genotype,
F(1,36) = 0.9222, P = 0.3575; no effect of stimulus duration, F(3,36) = 0.4541,
P = 0.7161; no interaction effect, F(3,36) = 0.09521, P = 0.9621; Fig. 4.1.4A, B], or
perseverative responses, a measure of compulsive behaviour [RM-ANOVA: no effect of
genotype, F(1,36) = 0.04477, P = 0.8363, main effect of stimulus duration,
F(3,36) = 4.105, P = 0.0140; no interaction effect, F(3,36) = 0.8660, P = 0.4685, Fig.
4.1.4C, D].
The ability to release normal levels of ACh is critical to attention (Kolisnyk et al.,
2013a,b); therefore, we investigated expression levels of the cholinergic machinery in
the PFC of CHRΝΑ7−/− mice. Compared with WT controls, CHRΝΑ7−/− mice showed
no significant change in expression of the VAChT [t(4) = 0.375, P = 0.7291] or ChAT.
The sustained attention deficits in CHRΝΑ7−/− mice are therefore not a result of an
inherent dysfunction in the machinery required for ACh release (Figure 4.1.5A).
α7 nicotinic ACh receptor deletion has been suggested to cause compensatory changes
in other nicotinic receptors during development (Yu et al., 2007). To determine if the
PFC of adult CHRΝΑ7−/− mice displayed altered expression of nicotinic receptors, we
examined their expression by qPCR analysis. The PFC of CHRΝΑ7−/− mice showed no
significant change in the expression of CHRNA4 [t(8) = 1.104, P = 0.3016] or of
CHRNB2 expression [t(8) = 0.4893, P = 0.6378]. In addition, we evaluated the
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expression of the enzyme AChE and observed no significant difference between
genotypes [t(8) = 0.0409, P = 0.9684]. As expected, we did not detect CHRNA7
expression in CHRΝΑ7−/− animals (Figure 4.1.5B).
To evaluate the biochemical correlates of neuronal activity in the PFC of CHRΝΑ7−/−
mice, we determined protein levels of the immediate-early gene cFos, a known marker
of activated neurons. Compared with the WT control, CHRΝΑ7−/− mice showed no
significant change in cFos protein levels [t(4) = 0.779, P = 0.4792, Figure 4.1.5C].
Moreover, to test if the CHRΝΑ7−/− had impaired activation of relevant second
messenger signalling cascades involved with nicotinic response in attention (Wallace
and Porter, 2011b), we evaluated the phosphorylation status of ERK1/2 and observed
no significant difference between genotypes [t(4) = 0.331, P = 0.7575, Figure 4.1.5D].
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Figure 4.1.1. Pre-training on the 5-CSRT task. (a) Sessions to criteria during
pretraining for the 5-CSRT task. Numbers designate phases of the pre-training (1 –
‘habituation’, 2 – ‘initial touch’, 3 – ‘must touch’, 4 – ‘must initiate’, 5 – ‘punish incorrect’).
(b) Sessions to criteria during training on the 5-CSRT task. (Data are presented as
mean ± SEM.).
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Figure 4.1.1. Pre-training on the 5-CSRT task.
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Figure 4.1.2. CHRNA7−/− mice have impaired sustained attention. Comparison
between genotypes of (A) omissions and (B) accuracy during the probe trial experiment
using the 5-CSRT task. (C) Omissions and (D) accuracy across bins of 25 trials in WT
mice. (E) Omissions and (F) accuracy across bins of 25 trials in CHRNA7−/− mice (data
are presented as mean ± SEM; *P < 0.05,**P < 0.01, ***P < 0.001).
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Figure 4.1.2. CHRNA7−/− mice have impaired sustained attention.
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Figure 4.1.3. CHRNA7−/− mice have normal motivation and motor function during
the 5-CSRT task. Comparison between genotypes of response latencies (A). Response
latencies across bins of 25 trials in wild-type (B) and CHRNA7−/− mice (C). Comparison
between genotypes of reward collection latencies (D). Reward collection latencies
across bins of 25 trials in wild-type (E) and CHRNA7−/− mice (F). (G) Food
consumption following food deprivation as a measure of motivation (data are presented
as mean ± SEM).
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Figure 4.1.3. CHRNA7−/− mice have normal motivation and motor function during
the 5-CSRT task.
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Figure 4.1.4. Response patterns did not differ in α7nAChR null mice on the 5CSRT task probe trial. Premature (a) and perseverative (b) responses between WT
(clear bars) and CHRNA7−/− mice (dark bars). (Data are presented as mean ± SEM.)
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Figure 4.1.4. Response patterns did not differ in α7nAChR null mice on the 5CSRT task probe trial.
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Figure 4.1.5. Evaluation of the expression of cholinergic markers and relevant
signalling pathways in the PFC of CHRNA7−/− mice. (A) Immunoblot of VAChT and
ChAT expression in the PFC. (B) qPCR expression of nicotinic receptors and AChE in
the PFC. (C) cFos protein levels and (D) ERK1/2 phosphorylation in the PFC (data are
presented as mean ± SEM).
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Figure 4.1.5. Evaluation of the expression of cholinergic markers and relevant
signalling pathways in the PFC of CHRNA7−/− mice.
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4.5.3 Effect of α7nAChR agonists on attention
To evaluate acute roles of α7nAChR in regulating sustained attention behaviour, we
investigated two selective α7nAChR agonists, PHA-543,613 (Acker et al., 2008) and
PNU-282,987 (Hajos et al., 2005), in WT mice using the 5-CSRT task. Mice were tested
at a 0.6 s stimulus duration, which represents a cognitively demanding version of the
task (Romberg et al., 2011; Kolisnyk et al., 2013a). PHA-543,613 significantly improved
rate of omissions [RM-ANOVA: main effect of dose, F(3,18) = 12.52, P < 0.001; Figure
4.2.1A], with post hoc analysis confirming that the 1 mg∙kg−1 dose significantly
improved performance over saline. Conversely, PHA-543,613 significantly altered
response accuracy in higher doses [RM-ANOVA: main effect of dose, F(3,18) = 12.55,
P < 0.001; Figure 4.2.1B]. Post hoc analysis revealed that at the highest dose tested
(3 mg∙kg−1), PHA-543,613-injected mice performed significantly worse than mice
injected with saline. PHA-543,613 did not significantly alter response latency [RMANOVA: no effect of dose, F(3,18) = 1.568, P = 0.2318, Fig. 4.2.2A] or reward collection
latency [RM-ANOVA: no effect of dose, F(3,18) = 0.7517, P = 0.5382; Fig. 4.2.2B]. In
addition, PHA-543,613 did not alter premature [RM-ANOVA: no effect of dose,
F(3,18) = 0.7599, P = 0.4930) nor perseverative responses [RM-ANOVA: no effect of
dose, F(3,18) = 0.1404, P = 0.8821, Fig. 4.2.2C, D]. To address the effects of PHA543,613 on sustained attention, we analysed performance of mice over blocks of 25
trials and observed that PHA-543,613 did not significantly alter sustained omissions
between the two blocks of testing [RM-ANOVA: main effect of dose, F(3,36) = 13.20,
P < 0.0001; no effect of block, F(1,12) = 0.7069, P = 0.4327; and no interaction,
F(3,36) = 1.288, P = 0.3088; Figure 4.2.1C], nor did it alter accuracy in WT mice [RMANOVA: main effect of dose, F(3,36) = 14.63, P < 0.0001; no effect of block,
F(1,12) = 1.729, P = 0.101; and no interaction effect, F(3,18) = 0.0713, P = 0.9749;
Figure 4.2.1D). At 1 mg∙kg−1, the percentage of omissions seemed to be slightly
reduced in the second block, suggesting modest improvement in the performance.
The second α7nAChR agonist tested, PNU-282,987, also significantly improved rate of
omissions [RM-ANOVA: main effect of dose, F(3,18) = 2.767, P = 0.0437, Figure
4.2.1E], with post hoc analysis confirming that both the 1 and 3 mg∙kg−1 doses
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significantly improved performance over saline. Conversely, PNU-282,978 significantly
altered response accuracy [RM-ANOVA: main effect of dose, F(3,18) = 5.637,
P = 0.0066; Figure 4.2.1F). Post hoc analysis revealed that at the highest dose tested
(5 mg∙kg−1) mice injected with PNU-282,978 performed significantly worse than mice
injected with saline. PNU-282,978 did not significantly alter response latency [RMANOVA: no effect of dose, F(3,18) = 0.9985, P = 0.4018; Fig. 4.2.2E] nor reward
collection latency [RM-ANOVA: no effect of dose, F(3,18) = 1.131, P = 0.3375; Figure
4.3.2.2.1F]. PNU-282,978 did not alter the number of premature [RM-ANOVA: no effect
of dose, F(3,18) = 3.015, P = 0.1157] or perseverative responses [RM-ANOVA: no effect
of dose, F(3, 18) = 0.4522, P = 0.6707, Fig. 4.2.2G, H]. In terms of the effects of PNU282,978 on sustained attention, analysis of injected mice over two blocks of 25 trials
showed that PNU-282,978 did alter the rate of omissions, with 3 mg∙kg−1 improving
omission rates over the two blocks [RM-ANOVA: main effect of dose, F(3,36) = 6.095,
P = 0.0031; no effect of block, F(1,12) = 0.5240, P = 0.4761; and main interaction effect,
F(3,36) = 3.218, P = 0.0407; Figure 4.2.1G], but did not alter sustained accuracy [RMANOVA: main effect of dose, F(3,36) = 6.044, P = 0.0019; no effect of block,
F(1,12) = 0.222, P = 0.6458; and no interaction effect, F(3,18) = 0.0701, P = 0.9755;
Figure 4.2.1H].
To evaluate the biochemical correlates of acute α7nAChR agonist activation in the PFC,
we injected PHA-543,613 on WT mice and determined protein levels of cFos and the
phosphorylation status of ERK1/2. These experiments used a separate cohort of mice,
which were injected with drug or saline and then killed 30 min later and had their PFC
dissected to obtain protein extracts. Compared with saline, PHA-543,613 injected in
mice led to a significant increase in the levels of cFos protein in their PFC [one-way
ANOVA: main effect of dose, F(2,6) = 7.404, P = 0.0240; Figure 4.2.1I], with post hoc
analysis showing that cFos levels were increased at both doses of PHA-543,613.
Similarly, injections of PHA-543,613 significantly increased ERK1/2 phosphorylation
levels in a dose-dependent way [one-way ANOVA: main effect of dose, F(2,6) = 28.80,
P < 0.001; Figure 4.2.1J].
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Figure 4.2.1 α7nAChR agonists improve attention in wild-type mice. (A) Omission
and (B) accuracy following injections of PHA-543,613 in WT mice. (C) Omissions
and (D) accuracy over bins of 25 trials following administration of PHA-543,613. (E)
Omission and (F) accuracy following injections of PNU-282,987 in WT mice. (G)
Omissions and (H) accuracy over bins of 25 trials following administration of PNU282,987. (I) cFos protein levels and (J) ERK1/2 phosphorylation following injection of
PHA-543,613 (data are presented as mean ± SEM; *P < 0.05,**P < 0.01, ***P < 0.001).
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Figure 4.2.1 α7nAChR agonists improve attention in wild-type mice.
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Figure 4.2.2 α7nAChR agonists did not alter response patterns in wild-type mice.
Premature responses (a), perseverative responses (b), response (c) and reward
collection (d) latencies following PHA-543,613 injections in WT mice. Premature
responses (e), perseverative responses (f), response (g) and reward collection (h)
latencies following PNU-282,927 injections in WT mice. (Data are presented as
mean ± SEM.)
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Figure 4.2.2 α7nAChR agonists did not alter response patterns in wild-type mice.
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4.5.4 Positive and negative effects of α7nAChR agonists are
abolished in CHRΝΑ7−/− mice
To confirm the specificity of both PHA-543,613 and PNU-282,987 for α7nAChRs, we
administered both compounds to CHRΝΑ7−/− mice prior to testing them on the 5-CSRT
task with a 0.6 s stimulus duration. Compared with saline, PHA-543,613 had no effect
on the performance of the mice at any dose tested. PHA-543,613 did not alter rate of
omissions [RM-ANOVA: no effect of dose, F(3,18) = 1.528, P = 0.2515; Figure 4.3.1A] or
response accuracy [RM-ANOVA: no effect of dose, F(3,18) = 0.1121, P = 0.8733; Figure
4.3.1B], response latency [RM-ANOVA: no effect of dose, F(3,18) = 0.2490, P = 0.7348;
Figure 4.3.2A] or reward collection latency [RM-ANOVA: no effect of dose,
F(3,18) = 0.3018, P = 0.6621; Figure 4.3.2B]. PHA-543,613 did not alter the number of
premature [RM-ANOVA: no effect of dose, F(3,18) = 1.104, P = 0.3579] or perseverative
responses [RM-ANOVA: no effect of dose, F(3,18) = 2.101, P = 0.1738, Figure 4.3.2C,
D]. Furthermore, when we analysed performance over blocks of 25 trials, we observed
that PHA-543,613 did not alter impaired omission deficit of CHRΝΑ7−/− mice at 0.6 s,
which remained significantly higher in block B across all doses [RM-ANOVA: no effect
of dose, F(3,36) = 1.528, P = 0.2414; main effect of block, F(1,12) = 14.89, P = 0.0084;
and no interaction F(3,12) = 0.2209, P = 0.8806; Figure 4.3.1C]. PHA-543,613 did not
alter sustained accuracy in CHRΝΑ7−/− mice either [RM-ANOVA: no effect of dose,
F(3,36) = 0.2017, P = 0.8945; no effect of block, F(1,12) = 0.00701, P = 0.9343; and no
interaction, F(3,36) = 0.02177, P = 0.9956; Figure 4.3.1D].
As with the PHA-543,613, PNU-282,987 had no effect on the performance of
CHRΝΑ7−/− mice at any of the tested doses. The drug did not alter rate of omissions
[RM-ANOVA: no effect of dose, F(3,18) = 0.1515, P = 0.9277; Figure 4.3.1E], response
accuracy [RM-ANOVA: no effect of dose, F(3,18) = 0.1458, P = 0.9310; Figure 4.3.1F],
response latency [RM-ANOVA: no effect of dose, F(3,18) = 0.0586, P = 2.808, Figure
4.3.2E] or reward collection latency [RM-ANOVA: no effect of dose, F(3,18) = 0.8089,
P = 0.4603, Figure 4.3.2F]. PNU-282,978 did not alter the number of premature [RMANOVA: no effect of dose, F(3,18) = 0.2767, P = 0.8316] or perseverative responses
[RM-ANOVA: no effect of dose, F(3,18) = 0.2218, P = 0.8036, Figure 4.3.2G, H]. Also,
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analysis of performance of injected mice over blocks of 25 trials showed that the
α7nAChR agonist had no effect on the impaired omission deficit that we consistently
observed on CHRΝΑ7−/− mice [RM-ANOVA: main effect of block, F(1,6) = 9.112,
P = 0.0234; no effect of dose, F(3,18) = 0.2542, P = 0.8573; and no interaction,
F(3,18) = 0.2546, P = 0.8570; Figure 4.3.1G] nor on sustained accuracy [RM-ANOVA:
no effect of blocks, F(1,6) = 0.0258, P = 0.9945; no effect of dose, F(3,18) = 1.123,
P = 0.3729; and no interaction, F(3,18) = 0.2665, P = 0.8491; Figure 4.3.1H]. Taken
together, these results demonstrate that modulation of attention performance on the 5CSRT task by both PHA-543,613 and PNU-282,987 depends on their activity on
α7nAChR.
Additionally, to confirm the selectivity of the molecular changes observed following
PHA-543,613 administration in WT mice, we injected CHRΝΑ7−/− mice with the highest
dose of the drug (3 mg∙kg−1) and then, 30 min later, measured the effects on cFos
protein levels and ERK1/2 phosphorylation in the PFC. Unlike PHA-543,613-injected
WT mice, CHRΝΑ7−/− mice exhibited no change in cFos levels [t(4) = 0.387,
P = 0.7186; Figure 4.3.1I] or ERK1/2 phosphorylation [t(4) = 0.1029, P = 0.9230; Figure
4.3.1J], suggesting that both the behaviour and molecular effects of the drug are
specific to activation of α7nAChR.
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Figure 4.3.1. α7nAChR agonists do not alter attention in mice lacking α7nAChR.
(A) Omission and (B) accuracy following injections of PHA-543,613 in CHRNA7−/−
mice. (C) Omissions and (D) accuracy over bins of 25 trials following administration of
PHA-543,613 in CHRNA7−/− mice. (E) Omission and (F) accuracy following injections
of PNU-282,987 in CHRNA7−/− mice. (G) Omissions and (H) accuracy over bins of 25
trials following administration of PNU-282,987. (I) cFos protein levels and (J) ERK1/2
phosphorylation following injection of PHA-543,613 (data are presented as
mean ± SEM; *P < 0.05,**P < 0.01, ***P < 0.001).
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Figure 4.3.1. α7nAChR agonists do not alter attention in mice lacking α7nAChR.
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Figure 4.3.2. α7nAChR agonists did not alter response patterns in CHRNA7-null
mice. Premature responses (a), perseverative responses (b), response (c) and reward
collection (d) latencies following PHA-543,613 injections in CHRNA7−/− mice.
Premature responses (e), perseverative responses (f), response (g) and reward
collection (h) latencies following PNU-282,927 injections in CHRNA7−/− mice. (Data are
presented as mean ± SEM.).
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Figure 4.3.2. α7nAChR agonists did not alter response patterns in CHRNA7-null
mice.
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4.5.5 The β2nAChR agonist ABT-418 improves attention
In order to explore the relationship between distinct types of nicotinic receptors on
attentional performance, we used ABT-418, a β2nAChR agonist, and treated WT mice
that were tested with the 0.6 s stimulus duration paradigm. Injections of ABT-418 were
able to significantly improve both rate of omissions [RM-ANOVA: main effect of dose,
F(3,18) = 4.544, P = 0.0132; Figure 4.4.1A] and response accuracy [RM-ANOVA: main
effect of dose, F(3,18) = 6.950, P = 0.0020; Figure 4.4.1B] without altering response
latency [RM-ANOVA: no effect of dose, F(3,18) = 0.06377, P = 0.9014; Figure 4.4.2A] or
reward collection latency [RM-ANOVA: no effect of dose, F(3,18) = 0.2936, P = 0.8797;
Figure 4.4.2B]. ABT-418 did not alter the number of premature [RM-ANOVA: no effect
of dose, F(3,18) = 1.228, P = 0.3103] or perseverative responses [RM-ANOVA: no effect
of dose, F(3,18) = 0.3062, P = 0.6764, Figure 4.4.2C, D]. To evaluate the effects of ABT418 on sustained attention, we analysed accuracy and omissions across blocks of 25
trials. ABT-418 did not significantly alter sustained omissions across blocks for WT mice
[RM-ANOVA: no effect of block, F(1,6) = 0.6582, P = 0.6013; main effect of dose,
F(3,18) = 0.2542, P = 0.8573; and no interaction, F(3,18) = 0.6582, P = 0.5847; Figure
4.4.1C]. ABT-418 had no effect on sustained accuracy in WT mice, with the
improvements brought on by the drug spanning across both blocks of trials [RMANOVA: no effect of block, F(1,6) = 0.7267, P = 0.4083; main effect of dose,
F(3,18) = 7.744, P = 0.0003; and no interaction F(3,18) = 1.084, P = 0.3662; Figure
4.4.1D).
Given that nicotinic receptors may be expressed in similar populations of neurons and
could crosstalk (Azam et al., 2003), we evaluated whether β2nAChR receptor activation
could impact attention in mice lacking α7nAChR. As with the WT mice, ABT-418 was
able to significantly improve both omissions [RM-ANOVA: main effect of dose,
F(3,18) = 5.466, P = 0.0066; Figure 4.4.3A] and accuracy [RM-ANOVA: main effect of
dose, F(3,18) = 3.383, P = 0.0373; Figure 4.4.3B] in CHRΝΑ7−/− mice, without altering
response latency [RM-ANOVA: no effect of dose, F(3,18) = 1.622, P = 0.2495; Figure
4.4.4A] or reward collection latency [RM-ANOVA: no effect of dose, F(3,18) = 0.8793,
P = 0.4359; Figure 4.4.4B]. ABT-418 did not alter the number of premature [RM-
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ANOVA: no effect of dose, F(3,18) = 0.1450, P = 0.81133] or perseverative responses
[RM-ANOVA: no effect of dose, F(3,18) = 0.1254, P = 0.8336; Figure 4.4.4C, D].
Importantly, ABT-418 was able to reverse the sustained attention deficits observed in
CHRΝΑ7−/− mice (Figure 4.4.3C) and improved the sustained omission deficits in these
mice [RM-ANOVA: main effect of block, F(1,6) = 11.82, P = 0.0138; main effect of dose,
F(3,18) = 7.640, P = 0.0017; and no interaction effect, F(3,18) = 1.707, P = 0.2013;
Figure 4.4.3C]. Post hoc analysis revealed that this occurred even at the lowest dose
administered. Sustained accuracy was not altered [RM-ANOVA: no effect of block,
F(1,6) = 0.1284, P = 0.7324; main effect of dose, F(3,18) = 5.017, P = 0.0106; and no
interaction, F(3,18) = 1.054, P = 0.3929; Figure 4.4.3D].
To determine the biochemical correlates of treatment with ABT-418 on CHRΝΑ7−/−
mice, we injected a new cohort of CHRNA7−/− mice with 0.39 mg∙kg−1 of ABT-418 and
30 min later evaluated cFos and ERK1/2 phosphorylation levels in the PFC of the mice.
Compared with saline-injected mice, CHRΝΑ7−/− mice injected with ABT-418 showed a
significant increase in cFos protein levels 30 min after injection [t(4) = 5.610, P = 0.0050;
Figure 4.4.3E]. ABT-418 was also able to significantly increase ERK1/2 phosphorylation
levels in the PFC of mice lacking α7nAChR [t(4) = 5.300, P = 0.0061; Figure 4.4.3F].
Importantly, given that the mice had been exposed to the task numerous times, we
evaluated the performance of the mice over the course of the various injections in order
to ensure that the improvements brought on by the ABT-418 were not due to the mice
becoming better at the task. We compared the performance (both rates of omission and
accuracy) of the mice from the vehicle injections of each drug experiment with their
naive performance (the performance at a 0.6 s stimulus duration during the probe trial
experiments). Both the WT {omission [one-way ANOVA: no effect of treatment,
F(6,18) = 0.7467, P = 0.4692; Figure 4.4.57A] and accuracy [one-way ANOVA: no effect
of treatment, F(6,18) = 0.6749, P = 0.6716; Figure 4.4.57B]} and CHRΝΑ7−/− mice
{omission [one-way ANOVA: no effect of treatment, F(6,18) = 2.565, P = 0.1154; Figure
4.4.57C] and accuracy [one-way ANOVA: no effect of treatment, F(6,18) = 1.005,
P = 0.3876; Figure 4.4.57D]} demonstrated no significant change in performance in both
omissions and accuracy from their naive performance across all injections.
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Figure 4.4.1. β2nAChR agonists improve attention in wild-type mice. (A) Omission
and (B) accuracy following injections of ABT-418 in WT mice. (C) Omissions and (D)
accuracy over bins of 25 trials following administration of ABT-418 in WT mice (data are
presented as mean ± SEM; *P < 0.05,**P < 0.01.
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Figure 4.4.1. β2nAChR agonists improve attention in wild-type mice.
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Figure 4.4.2. ABT-418 did not alter response patterns in wild-type mice. Premature
responses (a), perseverative responses (b), response (c) and reward collection (d)
latencies following ABT-418 injections in WT mice. (Data are presented as
mean ± SEM.).
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Figure 4.4.2. ABT-418 did not alter response patterns in wild-type mice.
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Figure 4.4.3. Sustained attention deficits of CHRNA7 null mice are reversed by
β2nAChR agonists. (A) Omission and (B) accuracy following injections of ABT-418 in
CHRNA7−/− mice. (C) Omissions and (D) accuracy over bins of 25 trials following
administration of ABT-418. (E) cFos protein levels and (F) ERK1/2 phosphorylation
following injection of ABT-418 (data are presented as mean ± SEM; *P < 0.05,**P < 0.01.
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Figure 4.4.3. Sustained attention deficits of CHRNA7 null mice are reversed by
β2nAChR agonists.
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Figure 4.4.4. ABT-418 did not alter response patterns in CHRNA7 null mice.
Premature responses (a), perseverative responses (b), response (c) and reward
collection (d) latencies following ABT-418 injections in CHRNA7−/− mice. (Data are
presented as mean ± SEM.).
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Figure 4.4.4. ABT-418 did not alter response patterns in CHRNA7 null mice.
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Figure 4.4.5. Performance of mice did not differ across all drug treatments.
Evaluation of accuracy (a) and omissions (b) from vehicle treatments from all drug trials
in wild-type mice. Evaluation of accuracy (c) and omissions (d) from vehicle treatments
from all drug trials in wild-type mice CHRNA7−/− mice. (Data are presented as
mean ± SEM.).
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Figure 4.4.5. Performance of mice did not differ across all drug treatments.
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4.6 Discussion
In this study, we demonstrated that the genetic elimination of the CHRNA7 gene
disturbs sustained attentional performance, as measured by the 5-CSRT task, and that
this deficit is reversed by administration of ABT-418, a β2nAChR agonist. CHRΝΑ7−/−
mice exhibited impaired performance (increased omission errors) during the second half
of testing sessions of the 5-CSRT, suggestive of deficits in sustained attention, or
vigilance. Increases in omission errors on the 5-CSRT task may reflect either decreased
attentional processing or a lack of motivation (Robbins, 2002; Spinelli et al., 2004).
However, given the normal performance of CHRΝΑ7−/− mice on the food intake test,
this phenotype is unlikely to represent a motivational issue, suggesting that the lack of
α7nAChRs impairs the ability to maintain performance levels during the task.
Pharmacological activation of α7nAChRs in WT mice by two distinct α7nAChR agonists,
PHA-543,613 and PNU-282,987, in lower doses improved attentional performance but
did not change sustained attention. These effects were specific to their actions on
α7nAChRs, as these compounds were ineffective on CHRΝΑ7−/− mice.
Pharmacological activation of the β2nAChR by ABT-418 was able to reverse the
sustained attention deficit in CHRΝΑ7−/− mice, suggesting that the deficits observed in
these mice can be rescued by β2nAChR signalling.
Post-mortem analysis of human patient samples has shown that ERK1/2 MAP kinase
signalling is reduced in brains of schizophrenic patients (Yuan et al., 2010). Moreover,
an inability to induce phosphorylation of ERK1/2 MAP kinases in the PFC is thought to
underlie certain cognitive deficits in animal models of schizophrenia (Kamei et al.,
2006). α7nAChR activation has been shown to induce phosphorylation of ERK1/2 MAP
kinases both in vitro and in vivo (Bitner et al., 2007). Similar effects have been observed
in second-generation antipsychotics (Lu et al., 2004). We showed that pharmacological
activation of the α7nAChR by PHA-543,613 induced a dose response increase in both
ERK1/2 phosphorylation levels and cFos in WT mice. These effects were not detected
in CHRΝΑ7−/− mice. Whether this biochemical correlation of α7nAChR activation
relates to the biochemical and attentional deficits observed in schizophrenia is
unknown. Interestingly, when CHRΝΑ7−/− mice were treated with the β2nAChR agonist
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ABT-418, both ERK1/2 phosphorylation and cFos protein levels were increased and
were correlated with the reversal of the sustained attention deficits. Although it is
currently unclear if the neurons that respond to ABT-418 and the α7nAChR drugs PHA543,613 and PNU-282,987 are the same, one potential important implication of the
behavioural data is that ABT-418 can reverse the sustained attention deficits due to
abnormal CHRNA7 expression.
Interestingly, in WT mice, all α7nAChR targeting drugs used presented an inverted ‘U’shaped behavioural response. This is not uncommon with nicotinic signalling with
similar responses observed across cognitive domains and even species (Picciotto,
2003; Olincy et al., 2006; Wallace et al., 2011a; Braida et al., 2013). Desensitization of
the receptor is often suggested as a potential mechanism underlying this U-shaped
behavioural response. Our data suggest that this may not be the case for α7nAChR
activation, given that we see increases in the levels of phospho-ERK1/2 following
administration of a high dose of α7nAChR agonist in WT mice, which results in poor
performance on the 5-CSRT task. Interestingly, it has been proposed that overactivity of
this second messenger signalling pathway can actually impair executive function and
lead to distractibility (Birnbaum et al., 2004). We have also recently shown that
increased cholinergic tone by overexpression of VAChT and increased cholinergic
signalling in BAC ChAT-Chr2-EYFP mice disturbs attentional processing (Kolisnyk et
al., 2013b).
The ability of nicotine to improve attention has been well documented in rodents (Young
et al., 2004), non-human primates (Prendergast et al., 1998) and humans (Lawrence et
al., 2002). A common technique to evaluate the role of α7nAChR signalling in attention
has been to co-treat rodents with both nicotine and the α7nAChR antagonist MLA.
These studies have, however, provided mixed results. Some investigators obtained
evidence for α7nAChR signalling in the pro-attentive effects of nicotine (Hahn et al.,
2011), and others failed to implicate α7nAChR signalling in nicotine-induced
improvements in attention (Grottick and Higgins, 2000). Studies using AR-R17779, a full
agonist of the α7nAChR, have failed to demonstrate pro-attentive effects of α7nAChR
stimulation (Grottick and Higgins, 2000; Grottick et al., 2003; Hahn et al., 2003). This
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compound, however, has also been shown to poorly penetrate the blood brain barrier
(Mullen et al., 2000). On the other hand, R3487/MEM 3454, an α7nAChR agonist and 5HT3 receptor antagonist, has been shown to improve measures of sustained attention
in both rats (Rezvani et al., 2009) and macaque monkeys (Wallace et al., 2009). Our
experiments utilized both PHA-543,613 and PNU-282,987, α7nAChR agonists, which
have been previously reported to easily cross the blood brain barrier (Acker et al.,
2008). Indeed, the biochemical activation reflected by increased cFos levels or
phospho-ERK supports the contention that these drugs were able to activate the PFC in
mice. Importantly, our data further support results from previous studies, suggesting that
α7nAChR signalling has a role in sustained attention (Young et al., 2007), specifically
characterized by increased omission errors on the 5-CSRT task in α7nAChR-null mice
(Young et al., 2004).
Cholinergic transients in the PFC have been shown to be important for cue detection
and attentional processing (Parikh et al., 2007). α7nAChR activation increases the
duration of these transients 10–15-fold, and interestingly, this effect is lost when
dopaminergic afferents to the PFC are eliminated, suggesting a complex interplay
between neurotransmitter systems (Parikh et al., 2010).
An important role of nicotinic receptors in the CNS is to influence the release of other
neurotransmitters. Nicotinic receptors have been shown to influence the release of
glutamate (Gioanni et al., 1999), dopamine (Zhou et al., 2001), GABA (Alkondon et al.,
1999), noradrenaline (Fu et al., 1998), 5-HT (Kenny et al., 2000) and ACh itself (Rowell
and Winkler, 1984). Efflux of all of these neurotransmitters in PFC has been associated
with performance on the 5-CSRT task (reviewed in Robbins, 2002). Electron
microscopy studies point to ACh release potentially being auto-regulated by presynaptic
α7nAChRs in the PFC (Duffy et al., 2009). On the other hand, post-synaptic β2nAChRs
have been shown to be necessary and sufficient to regulate performance on the 5CSRT task (Guillem et al., 2011; Poorthuis and Mansvelder, 2013). In addition to the
possibility that α7 and β2 receptors can form functional heteromeric receptors (Liu et al.,
2009; Moretti et al., 2014), our data reveal a complex interplay between these two
receptors in regulating sustained attention. Given that our results suggest that activation
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of β2nAChRs can bypass α7nAChRs, it is possible that activation of α7nAChRs could
induce ACh release in the PFC, which would then activate post-synaptic β2nAChRs to
regulate sustained attention. If this model is correct, it may explain the inconsistency
amongst studies using non-selective nicotinic agonists and antagonists. Co-treatment
with nicotine and methyllycaconitine, a α7nAChR antagonist, would still activate
β2nAChRs and thus improve attentive processing. Therefore, these previous
experiments would not exclude a role of α7nAChRs in attentional performance.
In conclusion, our data support a role for α7nAChRs in sustained attention and reveal
an intricate relationship between distinct nicotinic receptors to regulate attentional
performance. Our results indicate that activation of β2nAChRs can bypass attentional
deficits due to α7nAChR deficiency, suggesting that β2nAChRs may be an important
pharmacological target in cognitive dysfunctions in which impaired α7nAChRs have
been implicated, such as schizophrenia and Alzheimer's disease (Parri et al., 2011).
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Chapter 5
Cholinergic surveillance over hippocampal RNA metabolism and
Alzheimer’s-like pathology
This is a pre-copyedited, author-produced version of an article accepted for publication
in Cerebral Cortex following peer review.

5.1 Chapter Summary
The relationship between long-term cholinergic dysfunction and risk of developing
dementia is poorly understood. Here we used mice with deletion of the vesicular
acetylcholine transporter (VAChT) in the forebrain to model cholinergic abnormalities
observed in dementia. Whole genome RNA-sequencing of hippocampal samples
revealed that cholinergic failure causes changes in RNA metabolism. Remarkably, key
transcripts related to Alzheimer’s disease are affected. BACE1 for instance, shows
abnormal splicing caused by decreased expression of the splicing regulator
hnRNPA2/B1. Resulting BACE1 overexpression leads to increased APP processing
and accumulation of soluble Aβ1-42. This is accompanied by age-related increases in
GSK3 activation, tau hyper-phosphorylation, caspase-3 activation, decreased synaptic
markers, increased neuronal death and deteriorating cognition. Pharmacological
inhibition of GSK3 hyperactivation reversed deficits in synaptic markers and tau
hyperphosphorylation induced by cholinergic dysfunction, indicating a key role for GSK3
in some of these pathological changes. Interestingly, in human brains there was a high
correlation between decreased levels of VAChT and hnRNPA2/B1 levels with increased
tau hyperphosphorylation. These results suggest that changes in RNA processing
caused by cholinergic loss can facilitate Alzheimer’s-like pathology in mice, providing a
mechanism by which decreased cholinergic tone may increase risk of dementia.
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5.2

Introduction

Alzheimer’s disease (AD), the predominant form of dementia, is pathologically
characterized by accumulation of amyloid plaques and neurofibrillary tangles that
ultimately lead to neuronal death. One of the early alterations identified in AD-affected
individuals with cognitive decline is a profound decrease in basal forebrain cholinergic
neurons (Whitehouse et al., 1982), which gave rise to the cholinergic hypothesis of AD
(Bartus et al., 1982). Accordingly, Alzheimer’s Disease Neuroimaging Initiative data
reveal atrophy of the basal forebrain in individuals with mild cognitive impairment
(Grothe et al., 2014), and increased forebrain cholinergic atrophy in Alzheimer’saffected individuals (Grothe et al., 2013). Cholinergic dysfunction correlates with
decreased hippocampal volume and pathology (Teipel et al., 2014). Furthermore, recent
epidemiological data suggest that long-term use of drugs with anti-cholinergic activity by
elderly individuals increases the future risk of dementia (Gray et al., 2015). These
observations reveal an intimate, but poorly understood relationship, between cholinergic
dysfunction and the pathological and cognitive deficits in AD. However, whether
cholinergic malfunction has a causal role in increasing the risk of dementia or regulating
pathology is unknown. Moreover, the causal and temporal relationships between
cholinergic malfunctioning and long-term changes in hippocampal neurons in AD are
still unclear.
To test the capacity of cholinergic tone to regulate long-term functions in target cells we
examined the hippocampal transcriptome in genetically-modified mice with
compromised hippocampal cholinergic tone. Using forebrain-specific deletion of the
vesicular acetylcholine transporter (VAChT), a protein required for acetylcholine (ACh)
release (de Castro et al., 2009; Prado et al., 2013), we unveil that long-term cholinergic
deficiency causes global changes in gene expression and alternative splicing in the
hippocampus. This leads to abnormal alternative splicing of BACE1 with consequent
age-dependent changes in amyloid precursor protein (APP) processing, tau hyperphosphorylation, hippocampal neuronal loss and cognitive decline. Comparative
analyses in the AD brain enabled us to identify links between cholinergic deficiency and
AD pathology, together supporting the notion that early cholinergic dysfunction may be
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a pivotal step in AD pathology initiation and progression. Our data provide potential
mechanisms to explain how cholinergic deficiency may facilitate pathology in AD.

5.3

Materials and Methods

5.3.1 Mouse lines
Generation of VAChTflox/flox mice was previously described (de Castro et al., 2009).
VAChTNkx2.1-Cre-flox/flox mice were generated by crossing VAChTflox/flox (crossed
for 5 generations with C57BL/6J) with the Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx21- cre)2Sand/J), purchased from The Jackson Laboratory (JAX stock no. 008661).
Unless otherwise stated, all control mice used were VAChTflox/flox littermates. All
procedures were conducted in accordance with guidelines of the Canadian Council of
Animal Care (CCAC) and in accordance with ARRIVE guidelines, at the University of
Western Ontario with an approved institutional animal protocol (2008-127). Only male
mice were used for all experiments.

5.3.2 RNA Sequencing
Mouse hippocampal tissue was rapidly dissected and total RNA was extracted from
individual samples using the PureLink RNA Mini Kit (Ambion). 2 µg of total RNA were
then sent to the Centre for Applied Genomics, The Hospital for Sick Children, where the
cDNA library was prepared using the TruSeq Stranded Total Sample Preparation kit
(Illumina) and run in a HiSeq 2500 platform with coverage of 200-250 million pair reads
per lane. 5 animals were run per lane to obtain enough coverage for alternative splicing
analysis (50 million pair reads per sample). The sequenced reads were aligned to the
mouse genome using the TopHat program against the mouse genome in Ensembl
(version EnsMart72) to enable quantification of splice junctions in addition to gene level
measurements. Differential gene expression analysis was conducted using the
Bioconductor DESeq package which accounts for the counts binomial distribution
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(Anders and Huber, 2010). Datasets are available on ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-3897.
For human brains, we used the SQUARETM RNA library construction approach which
utilizes different sets of 5’- and 3’-site specific primers to segregate all full-length
transcripts into sub-pools defined by the selective nucleotides in the respective primers.
Unlike traditional sequencing, which is based on the use of universal primers that
produce a pool of fragmented RNA products for a given gene, we used 12 different sets
of 3’-primers that complement all distinct di-nucleotides at transcript 3’-polyadenylation
sites and enable separate sequencing of the corresponding intact RNA molecules for
each of the primer sets through barcoding. This unprecedented depth of segregated
brain RNA-Seq data was made publicly accessible by establishing a user-friendly
website where the sequenced variants for any given brain-expressed transcript can be
found (http://apainad.weebly.com/). Sequencing files were processed and analyzed for
differential expression and functional enrichment.
RNA sequencing libraries made from the temporal gyrus samples yielded an average
of 6.0*106 (STD=2.0*106) uniquely aligned 75 base pair (bp) single end reads, or
approximately 7.0*107 (STD=1.8*107) total read counts when combining all 12
SQUARE fields for each sample. These reads were mapped against the
GRGCh37/hg19 version of the Homo sapiens genome (http://genome.ucsc.edu/).
Transcripts with more than 1 read per kilobase per million (RPKM) per SQUARE field
were defined as being detected (Hebenstreit and Teichmann, 2011). An average of
6610±1367 genes per field were detected across the 12 fields (details in Supplementary
Table 5.6.2). Expression criteria were set to RPKM>1 in at least one of the SQUARE
fields, in at least 80% of the tested donor cohorts.

5.3.3 Immunofluorescence
Immunofluorescence experiments were performed as previously described (de Castro
et al. 2009). Primary antibodies used were anti-Choline Transporter (CHT1; 1:200),
which was kindly donated by Dr. R. Jane Rylett, University of Western Ontario, London,
Ontario, anti-hnRNPA2/B1 (1:200 Santa Cruz Biotechnology Catalog no. sc-10035),
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anti-Cleaved caspase-3 (1:500 Thermo Fisher Scientific, Catalog no. PA5-16335), antiAT180 (1:1000 Thermo Fisher Scientific, Catalog no. EN-MN1040), anti-NeuN (1:200
PhoshphoSolutions, Catalog no. 583-FOX3), anti-GFAP, anti-PSD95. Sections were
visualized by Zeiss LSM 510 Meta (Carl Zeiss, Oberkochen, Germany) confocal system
(40x, 63x objectives, with an N.A. of 1.3 and 1.4, respectively) and by Leica TCS SP8
(Leica Microsystems Inc, Ontario, Canada) confocal system (63x objective, with an N.A.
of 1.4), a 488-nm Ar laser and 633-nm HeNe laser were used for excitation of
fluorophores.

5.3.4 Western Blotting
Mouse hippocampi were collected, protein was isolated, and immunoblotting was
performed as previously described using RIPA lysis buffer supplemented with protease
and phosphatase inhibitors (Guzman et al., 2011). Band intensities were quantified
using FluoroChemQ software (Thermo Fisher Scientific).

5.3.5 Gene Ontology Analysis
Gene ontology functional analysis was performed using the GOrilla software through the
web application. Using the two-un-ranked lists method as described (Eden et al., 2009).
KEGG pathway analysis was performed using the ClueGO plug-in of Cytoscape
(Bindea et al., 2009).

5.3.6 RNA Binding Protein Analysis
To predict potential RNA-binding proteins that may be implicated in the observed
changes in alternative splicing, alternatively spliced sequences were run through the
RBPmap software (Paz et al., 2014) to detect potentially altered RNA binding proteins.
The list of RNA binding proteins that were suggested by the software were then run
through the Allen Brain Atlas (http://mouse.brain-map.org/) in order to ensure that they
were expressed in the murine hippocampus. All RNA binding proteins not expressed in
the hippocampus were excluded.
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5.3.7 qPCR
To measure mRNA expression, total RNA was extracted from freshly dissected
hippocampal tissue, using the Aurum Total RNA for fatty and fibrous tissue kit (Bio-Rad)
according to the manufacturer's instructions. cDNA synthesis and qPCR analysis were
performed as previously described (Guzman et al., 2011). For alternative splicing
experiments, the alternative exon levels were normalized to a constitutively expressed
exon from the same gene.

5.3.8 Primary Neuronal Cultures
Primary mouse hippocampal neurons were produced from E16 embryos as previously
described (Ostapchenko et al., 2013). Neurons were cultured for 15 days. Knockdown
of hnRNPA2/B1 from the cultured neurons was achieved by treatment with a shRNA, as
previously described (Berson et al., 2012). A separate set of cultured neurons was
treated with 10M of carbachol, 10M of carbachol and 100M Atropine, or 100M
Atropine alone for 48 hours.

5.3.9 APP Processing
Biochemical analysis of the processing of APP was performed as previously described
(Dewachter et al., 2002). Forebrains from VAChT deficient and control mice were
homogenized in 50mM Tris-HCl (pH 8.5), samples were then ultracentrifuge at
135,000g for 1 hour at 4oC, and the supernatant was collected and analyzed by
Western blotting and ELISA. The pellet was re-suspended and ultracentrifuged again
and diluted in 8M guanidine HCl to obtain the insoluble fraction for ELISA analysis.

5.3.10 ELISA
Murine β-amyloid was measured from the hippocampal homogenate using the Wako
Human/Rat (Mouse) β-Amyloid (42) ELISA High-Sensitive Kit (Catalog Number: 29264501). The ELISA assay was performed according to the manufacturer's protocol.
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5.3.11 Congo Red Staining
Congo red staining was performed as previously described (Thompson and Walker,
2015), using a Congo-Red solution (Sigma C-6277) in 100% ethanol.

5.3.12 Silver staining
Assessment of argyrophilic cells in the hippocampus was done by using NeuroSilverTM
staining kit II (FD NeuroTechnologies, Inc., Baltimore, MD), which provides detection of
degenerating neurons, including neuronal somata, axons, and terminals.

5.3.13 Estimation of Hippocampal Volume
NeuN immunohistochemistry was performed in order to estimate the volume of and
number of neurons of hippocampal regions CA1, CA3, and the dentate gyrus (DG) as
described (Beauquis et al., 2014). Briefly, tissue sections were stained with mouse
monoclonal anti-NeuN (1:500 PhosphoSolutions, Catalog no. 583-FOX3), using the
ABC kit (Vector Laboratories) and developed with 2 mM diaminobenzidine (Sigma,
USA) and 0.5 mMH2O2 in 0.1 M Tris buffer. The total number of NeuN (T) cells in the
various hippocampal regions was estimated using the following formula: T=(N*V)/t ,
where N is the cell density, V is the volume of the structure, and t is the thickness of the
section.

5.3.14 GSK3 Inhibition
To inhibit GSK3 in VAChTNkx2.1-Cre-flox/flox mice, a cohort of aged animals (12
months old, n=5 AR-A014418 treated, n=4 saline treated) were implanted with Alzet
micro-osmotic pumps (Model 1004; DURECT Corp, Cupertino, Calif). The pumps were
implanted subcutaneously in the intra-scapular region of each mouse. The reservoir of
each pump was preloaded with 96 μL of either sterile saline solution or the GSK3
inhibitor AR-A014418. The pumps administered 5 mg/kg/d of AR-A014418, a dose
shown to produce a significant inhibition of GSK3 in vivo (Ly et al., 2013). During the
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implantation procedure, mice were anesthetized with ketamine (100 mg/kg) and
xylazine (15 mg/kg). Drug treatment lasted for 28 days.

5.3.15 Morris Water Maze
The spatial version of the Morris water maze (MWM) was conducted as described
previously to investigate spatial memory (Kolisnyk et al., 2013b; Martyn et al., 2012;
Vorhees and Williams, 2006). Briefly, animals were given four training trials a day (90 s
each) for 4 d, with a 15 minute inter-trial interval. If the mice did not find the platform
after 90 s during the learning phase, they were gently directed to the platform. On the
fifth day, memory was assessed via a probe trial (60 s), during which the platform is
removed and time spent in the target quadrant is measured. The task was performed in
a 1.5-m-diameter pool with 25°C water. The platform was submerged 1 cm below the
surface of the water, and spatial cues (posters, streamers, and plastic props) were
distributed around the pool. Sessions were recorded and analyzed using the ANY-Maze
Software.
The classification of search strategies mice employed during training was defined as
previously described (Garthe et al., 2009). An experimenter blind to genotypes scored
search strategies as follows: (1) thigmotaxis, characterized by maintaining close
proximity to the wall (>70% trial within 10-cm of wall); (2) random search, illustrated by
global swimming with no classified strategy; (3) scanning, characterized by a preference
for the central pool area (>50% trial within 35-cm of pool center); (4) chaining,
characterized by searching near the correct radial distance of the platform to the wall
(>75% trial 20–50-cm from the pool center, <15% within 10-cm of wall, and <10% within
20-cm of pool center); (5) directed search, characterized by a preference for a
passageway toward the platform or platform quadrant (>80% trial within a 50-cm-wide
region from the start point to the platform); (6) focal search, characterized by a highly
localized search near the platform (≥50% trial in a circular target zone with a 15-cm
radius); (7) direct swim, characterized by a maintained heading toward the platform
(Little to no deviation in path to reach platform from start point). Total block lengths were
the sum of all blocks for one strategy and one mouse.
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5.3.16 Protein Isolation from Human post-mortem brain tissue
Samples from parietal cortical tissues from age/ sex-matched controls (n = 6, 3 females
and 3 males) and AD-affected individuals (n = 6, 3 females and 3 males) and
information related to age and demographics have been previously published
(Ostapchenko et al., 2013). The samples were homogenized in RIPA buffer
supplemented with protease inhibitor cocktail (Calbiochem), and Western blotting was
performed as described above.

5.3.17 Statistical analysis
Sigmastat 3.5 software was used for statistical analysis. Student’s t-test was used for
comparison between two experimental groups. Two-way ANOVA or two-way ANOVA
with repeated measures (RM) were used when more than two groups were compared.

5.4 Results

5.4.1 Forebrain Cholinergic dysfunction modifies expression
levels of hippocampal transcripts and alternative splicing
To determine the contribution of cholinergic tone to the regulation of hippocampal
transcript levels, we used VAChTNkx2.1-Cre-flox/flox mice, a mouse line with selective
deletion of the VAChT gene from forebrain regions, including the medial septum, which
contains cholinergic neurons that project to the hippocampus. VAChT has been shown
to be essential for ACh packaging and release (de Castro et al., 2009; Lima Rde et al.,
2010; Prado et al., 2006). Non-biased whole genome transcriptome RNA-sequencing of
hippocampal samples from three VAChT-deficient and four control mice yielded a total
of 14,200 expressed genes. Comparative analysis revealed that 1,098 genes were
differentially expressed in VAChTNkx2.1-Cre-flox/flox hippocampi compared to control
mice (Figure 5.1.1A-B, FDR corrected p < 0.05). Of those, 763 genes were upregulated
and 362 down-regulated in the transgenic mice. In addition, a linear regression analysis
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on reciprocal junction pairs detected roughly 4% of hippocampal transcripts in
VAChTNkx2.1-Cre-flox/flox mice as alternatively spliced in high confidence as
compared with control mice. Equal proportion of exon inclusion and exclusion events
was observed; mainly events of cassette exons were detected (Figure 5.1.1C),
suggesting widespread changes in several splicing regulation related pathways and/or
cellular mechanisms (Soreq et al., 2014).
We interrogated these differentially expressed/spliced genes for involvement in
neuronal function and AD-like pathology. A number of genes involved in critical
pathways including PI3K-Akt signalling pathway [a regulator of neuronal vulnerability
(Endo et al., 2006; Gary and Mattson, 2001)], spliceosome regulation and regulation of
microtubule-based processes were identified using Gene Ontology (GO) KEGG
pathway analysis (Figure 5.1.1D, Table 5.1). qPCR validation and correlation between
changes observed in RNA-Seq and in an independent mouse cohort are shown in Fig.
5.1.2 for the different gene pathways and alternative splicing events. These results
suggest that abnormal cholinergic signalling can effectively modulate several major
gene pathways with potential to influence the function of target cells in the
hippocampus.
We also performed small molecule RNA-Seq and additional miRNA microarray
hybridization experiments, and observed limited changes in miRNA expression in the
hippocampus of VAChT-deficient mice (Fig. 5.1.3). VAChTNkx2.1-Cre-flox/flox
hippocampus showed a mature miRNA expression profile with only marginal differences
from controls. Only 7 of 700 detectable miRNAs were differentially expressed, and of
the 20 miRNAs most highly expressed in the hippocampus, comprising 82% of total
counts, none were differentially expressed (Fig. 5.1.3). These findings point to
alternative splicing and transcription, or changes in mRNA turnover, rather than miRNA,
as potential main contributors to phenotypes in VAChT-deficient mice.

288
Figure 5.1.1. Forebrain deletion of VAChT induces alterations in hippocampal
transcriptome. (A) Principal component analysis of transcripts from the hippocampi of
control (VAChTflox/flox; gray circles) and VAChTNKx2.1-Cre-flox/flox (red circles) mice. (B) Cluster
analysis of differentially regulated transcripts in the hippocampus of VAChT NKx2.1-Cre-flox/flox
(n=3) mice compared to controls (n=4). (C) Number of genes at indicated significance
cut-off that were found to have an exon inclusion or exclusion event and summary of
alternative splicing events. (D) List of genes from the PI3K-AKT pathway (grey shading),
Spliceosome pathway (blue shading), Microtubule polymerization pathway (green
shading) and other AD genes of interest (yellow shading), identified from KEGG pathway
analysis of altered transcripts in VAChTNKx2.1-Cre-flox/flox mice. For each gene corresponding
fold change, corrected statistical significance levels, and RNA expression change is also
shown. Altered mRNA expression of these genes has been confirmed by qPCR (see Fig.
5.1.2).
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Figure 5.1.1. Forebrain deletion of VAChT induces alterations in hippocampal
transcriptome.
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Figure 5.1.2. qPCR validation of RNA-Seq data. (A) qPCR validation and Pearson’s
correlation analysis on transcripts annotated to the spliceosome KEGG pathway
quantified by RNA-Seq data from the hippocampus of VAChT NKx2.1-Cre-flox/flox mice and
controls [(r=0.8528, p=0.001), n=6 data are mean ± SEM.]. (B) qPCR validation and
Pearson’s correlation analysis with RNA-Seq data of transcripts annotated to the PI3kAKT KEGG pathway [(r=0.8528, p=0.001). (C) qPCR validation and Pearson’s
correlation analysis of transcripts annotated to the microtubule polymerization pathway
[(r=0.8528, p=0.001).
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Figure 5.1.2. qPCR validation of RNA-Seq data.
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Figure 5.1.3. Global hippocampal expression of miRNA is not altered in VAChT
deficient mice. (A) Small RNA sequencing from six VAChTNkx2.1-Cre-flox/flox mice and five
controls demonstrated miR-592-5p, miR-219-2-3 and 148a-3p as differentially
expressed (DE) after FDR correction (P<0.05). (B) Principal Component Analysis (PCA)
showed marginal separation of the two groups, suggesting that VAChT transcript
removal does not induce a global change in small RNA expression. (C) Extent of
absolute change was limited, as none of the top 20 miRNAs expressed in the
hippocampus were modified, leaving 82% of hippocampal miRNAs unchanged. (D)
Similar fractions of small RNA reads mapped to parts of the pre-miRNA molecules other
than the mature-miRNA in VAChTNkx2.1-Cre-flox/flox mice and controls (E) Processing rate
and/or efficacy might be affected, as a set of 7 seemingly unmodified miRNAs
presented drastically reduced pre-miRNA levels when quantified by long RNA
sequencing in VAChTNkx2.1-Cre-flox/flox mice.
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Figure 5.1.3. Global hippocampal expression of miRNA is not altered in VAChT
deficient mice.
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Table 5.1 AD Related Genes Identified in RNA-Seq Data. Genes in either the AKT
pathway (grey shading), Spliceosome pathway (blue shading), or Regulation of
Microtubule Polymerization (green shading) and role(s) in AD-like pathology.
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Table 5.1 AD Related Genes Identified in RNA-Seq Data.
Gene
Bcar1

Link to AD
Linked to APP transcription (Seenundun and Robaire,
2007).

Col5a3

SNP linked to AD (Silver et al., 2012).

Fgfr1

Altered expression in aging (Walker et al., 1998).

Gng7

Associated with depression in the elderly (Schol-Gelok et
al., 2010).
Protein alterations in animal model of neurodegeneration
(Karlsson et al., 2012).
Upregulated in astrocytes in AD brain (Orre et al., 2014).
Potential to bind Ab (Sabo et al., 1995).
Potential to bind Ab (Sabo et al., 1995).
Mediates cell survival and apoptosis via AKT (BlumeJensen et al., 1998)
SNP linked to AD (Taguchi et al., 2005)
Regulates neuronal apoptosis (Liu et al., 2004)
Up-regulated in AD brain (Scott et al., 1995)
SNP linked to AD (Cozza et al., 2008)
SNP linked to AD (Taguchi et al., 2005)
Altered transcription in AD brain (Brooks et al., 2007)
SNP linked to AD (Clarimon et al., 2009)
Up-regulated in rat model of AD (Bakalash et al., 2011)
Up-regulated in AD brain (Liang et al., 2012)
Altered transcription in AD brain (Kalback et al., 2004)
SNP linked to AD (Meda et al., 2012; Sherva et al., 2011)
Increased levels in CSF of AD patients (Tarkowski et al.,
2002)
Linked to alternative splicing in neurodegeneration
(Tollervey et al., 2011)

Itga4
Itga7
Kit
Lamb1
Myb
Ngfr
Pck2
Prkaa1
Prlr
Pxn
Thbs3
Tnxb
Vegfc
Cdc40

Ddx39b

SNP linked to Late-Onset-AD (Mohsen et al., 2015)

Hspa2

SNP linked to Late-Onset-AD (Broer et al., 2011; Clarimon
et al., 2003)

Prpf40b
Sf3a2

Implicated in human neurodegeneration (Passani et al.,
2000)
Altered in aging mouse brain(Meshorer and Soreq, 2002)

Snrnp70

Up-regulated and aggregated in AD brain (Bai et al., 2013)

Srsf2

Regulates splicing events in AD (Raj et al., 2014)
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Srsf9

Regulates splicing events in AD (Qian and Liu, 2014)

Wbp11

Upregulated in accelerated aging murine model (Carter et
al., 2005)

APC
CAMSAP2

Increased expression in AD brain (Leroy et al., 2001)
Altered protein levels in animal model of
neurodegeneration (McGorum et al., 2015)
No known link to AD
Interacts with APP protein in vivo (Bai et al., 2008)
Epigenetic modifications in AD mouse model (Cong et al.,
2014)
Upregulated in tau deficient mice (Ma et al., 2014)
Binds soluble A in vitro (Clemmensen et al., 2012)
No known link to AD
Protein expression altered by A and tau (Hoerndli et al.,
2007)
Altered activity in AD brain (Moore et al., 1998)
Transcription altered in AD brain (Zhang et al., 2015)
Decreased expression in neurodegeneration (Desplats et al.,
2006)

CLASP1
EBP4.1
LSP1
MAP1A
MON2
NCOR1
PKCZ
RALBP1
STRIP2
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5.4.2Cholinergic deficit triggers abnormal BACE1 alternative
splicing and APP Processing
One of the detected abnormally alternatively spliced genes in our database was the
protease BACE1 (Figure 5.2.1D), which is responsible for the cleavage of APP (Luo et
al., 2001). The predicted alternative splicing event in VAChT-deficient mice is expected
to increase expression of BACE1-501, the active protein isoform (Mowrer and Wolfe,
2008). qPCR analysis validated the predicted splicing event and demonstrated
increased exon 3/4 inclusion for BACE1 (Figure 5.2.1A).
Bioinformatics analysis using the RBP-Map tool revealed an enrichment of binding sites
for hnRNPA2/B1 in BACE1 mRNA. hnRNPA2/B1 is part of a family of RNA binding
proteins that regulate pre-mRNA splicing, trafficking and maturation (Bekenstein and
Soreq, 2013). Notably, AD-associated impairments in cholinergic signalling are
accompanied by decreased expression of hnRNPA2/B1 protein in the AD cerebral
cortex and in cholinergic impaired mice (Berson et al., 2012; Kolisnyk et al., 2013a).
Correspondingly, the hippocampus of VAChTNkx2.1-Cre-flox/flox mice showed reduced
hnRNPA2/B1 protein levels (Figure 5.2.1 B). We then investigated whether
hnRNPA2/B1 regulates BACE1 splicing by exposing primary hippocampal cultured
neurons to lentivirus carrying shRNA against hnRNPA2B1. Our results showed changes
in BACE1 splicing similar to cholinergic deficiency (Figure 5.2.1C), directly implicating
hnRNPA2/B1 in the regulation of BACE1 splicing. To test for the role of cholinergic
signalling and the different cholinergic receptors in mediating this splicing event, we
treated cultured hippocampal neurons with the cholinergic mimetic carbachol. This
treatment was able to decrease the proportion of BACE1-501. This decrease was
blocked by co-treatment with the muscarinic antagonist atropine (Figure 5.2.1D). These
data implicate muscarinic receptors in the regulation of BACE1 splicing. This splicing
event in BACE1 predicts an increase in the levels of the mature BACE1 protein and
indeed, immunoblot analysis revealed a 2-fold increase of BACE1 levels in the
hippocampus of VAChT-deficient mice (Figure 5.2.1E).
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In late onset AD BACE1 expression is upregulated (Hebert et al., 2008) and it is thought
to contribute to age-dependent progression in AD pathology (Ly et al., 2013). We
therefore tested for changes in APP processing in VAChTNkx2.1-Cre-flox/flox mice.
Aged VAChT-deficient mice (11-14 month old) displayed a modified pattern of Trissoluble APP fragments (Figure 5.2.1 F), similar to that of mouse models with APP/PS1
mutations (Jankowsky et al., 2004; Oddo et al., 2003). In contrast, membrane-bound Cterminal fragments of APP (α and β CTFs), alterations of which can suggest impaired
proteolytic processing of the protein [Reviewed in (Selkoe, 2000)], were similar in
VAChT-deficient mice and controls (Figure 5.2.1 G). APP processing was not modified
in aged Nkx2.1-Cre mice (Figure 5.2.2 A), suggesting that this effect is due to
cholinergic dysfunction rather than to Cre expression.
We then assessed the levels of mouse amyloid peptides using an ELISA kit validated
for both mouse and human A peptides (Teich et al., 2013). The hippocampus of aged
VAChTNkx2.1-Crecompared to controls (Figure 5.2.1 H), reaching about one third of the levels of those
found in aged 5XFAD mouse model of AD, which is one of the most aggressive models
of AD amyloidosis. In comparison, insoluble amyloid peptide was undetectable in the
brains of VAChT-deficient mice, whereas it was highly abundant in the 5XFAD mice
(Figure 5.2.1 H). In addition, neither control nor VAChT-deficient mice displayed positive
Congo red staining, unlike brain sections from 5XFAD mice, which exhibited numerous
Congo red plaques (Figure 5.2.1 I). These data indicate that although VAChT-deficient
mice show increased levels of soluble A peptides, they do not seem to accumulate in
extracellular amyloid plaques. Indeed, the murine amyloid peptide is much less prone to
aggregation than human A due to two amino acid changes (Jankowsky et al., 2007).

299
Figure 5.2.1 Disrupted APP processing and alternative splicing of BACE1 in
cholinergic deficient mice. (A) qPCR analysis of alternative splicing events for BACE1
in the hippocampus of controls and (VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox
(red bars). Alternative exon levels are normalized to a constitutive exon from the same
gene (n=6, data are mean ± SEM. **P<0.01). (B) Representative Western blot and
quantification of hnRNPA2/B1 protein expression in the hippocampus of controls
(VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars) mice. hnRNPA2/B1
expression was normalized to actin (n=4, data are mean ± SEM. **P<0.01). (C)
Quantification of the BACE1 alternative splicing in primary neuron cultures treated with
hnRNPA2B1-shRNA (*P<0.05). (D) Quantification of the BACE1 alternative splicing in
primary neuron cultures treated with 10mM Carbachol and Atropine (n=4, data are
mean ± SEM. **P<0.05). (E) Representative Western blot and quantification of BACE1
protein levels in the hippocampus of controls (VAChTflox/flox; gray bars) and VAChTNKx2.1Cre-flox/flox

(red bars) mice. BACE1 expression was normalized to actin (n=3, data are

mean ± SEM. *P<0.05). (F) Biochemical analysis and quantification of murine APP
fragments in brain homogenates of aged expressed as a % [(Signal intensity of the
fragment/signal intensity of full-length protein) x100]. 11-14 month old controls
(VAChTflox/flox; gray bars), VAChTNKx2.1-Cre-flox/flox (red bars) and APPswe/PS1dE9 (green
bars) hippocampal tissue extracts were resolved by Western blotting (data are mean ±
SEM n=3). (G) Analysis of membrane-bound APP fragments in aged controls
(VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars) and APPswe/PS1dE9
(green bars) (data are mean ± SEM n=3). (H) Murine soluble and insoluble levels of
Aβ42 in aged (11-14 months old) controls (VAChTflox/flox; gray bars), VAChTNKx2.1-Creflox/flox

(red bars) and 5xFAD (black bars) measured by ELISA (n=4) (I) Congo red

staining in the CA1 region of the hippocampus in aged (11-14 months old) controls,
VAChTNKx2.1-Cre-flox/flox, and 5xFAD mice. Arrowheads indicate positive-Congo red
staining suggestive of amyloid plaques. (n=3, Scale bar, 100µm).
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Figure 5.2.1 Disrupted APP processing and alternative splicing of BACE1 in
cholinergic deficient mice.
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Figure 5.2.2 Absence of altered APP processing in aged (11-14 month old)
C57/BJ6-Nkx2.1-Cre mice. (A) Western blot of APP processing from Tris-soluble
fraction and quantification of APP fragments detected in aged C57BL/6J-Nkx2.1-Cre
mice (11-14 month old) showing no significant differences compared to controls
(n=4).(Data are mean +/- S.E.M.).
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Figure 5.2.2 Absence of altered APP processing in aged (11-14 month old)
C57/BJ6-Nkx2.1-Cre mice.
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5.4.3 Cholinergic deficit leads to age-dependent hippocampal
tauopathy
In AD, increased levels of soluble A peptides are thought to precede abnormal
phosphorylation of the microtubule associated protein tau (Iqbal et al., 2010). Previous
reports suggested that cholinergic activity and tau phosphorylation might be interrelated (Hellstrom-Lindahl, 2000). Therefore, we used immunofluorescence to assess
levels of the AT180 tau epitope (T231/S235) in the hippocampus of VAChT-deficient
mice. This phosphorylation-dependent antibody specific to pT231 has been shown to
label approximately 70% of paired helical filaments (PHF) in AD brains (Goedert et al.,
1994). Phosphorylation at this epitope reduces the binding of tau to microtubules
potentially increasing its toxicity (Lim et al., 2008). Immunofluorescence imaging
revealed a robust increase of AT180 immunoreactivity in the hippocampus of
VAChTNkx2.1-Cre-flox/flox mice compared to aged-matched controls (Figure 5.3A- 1114 month-old mice). To test if the positive immunoreactivity of pTau in VAChT-deficient
mice is associated with an induction of pathological tau, immunofluorescence with MC1
antibody was performed. Positive reactivity of conformation-dependent MC1 antibody
depends on the proximity of N terminal (a.a. 7-9) and C-terminal (313-333) amino acid
sequences of tau, which is one of the earliest alterations of tau in AD (Weaver et al.,
2000; Wolozin et al., 1986). Immunostaining with MC1 revealed positive
immunoreactivity in the hippocampus of aged cholinergic-deficient mice, but not in agematched controls (Figure 5.3B).
In agreement with the immunofluorescence data, hippocampal extracts of
VAChTNkx2.1-Cre-flox/flox mice showed approximately four-fold increases in pTau
immunoreactive bands, including higher order oligomers detected with AT180, when
compared to controls (Figure 5.3C and D). On the other hand, total tau and pTauS262
levels were unmodified in VAChT-deficient mice (Figure 5.3C and D). Taken together,
our data indicate that deletion of hippocampal VAChT induces hyper-phosphorylation of
tau and leads to tau pathological conformation as detected by MC1, both of which are
consistently observed in AD. These data suggest the potential for neuronal toxicity due
to cholinergic dysfunction.
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Figure 5.3. Hippocampal cholinergic failure triggers tauopathy in an agedependent manner. (A) Phosphorylated Tau levels monitored by immunolabeling with
phosphorylation-dependent antibodies specific to pT231. Representative images of
pT231 and Hoeschst labeling in the hippocampus of aged (11-14 month old) controls
(left) and VAChTNKx2.1-Cre-flox/flox (right) mice. (n=3, Scale bar, 100µm). (B) Representative
images of MC1 and Hoeschst labeling in the CA1 region of the hippocampus of controls
(left) and VAChTNKx2.1-Cre-flox/flox (right) mice. (n=3, Scale bar, 100µm). (C) Western blot
analysis of controls (VAChTflox/flox) and VAChTNKx2.1-Cre-flox/flox aged (11-14 month old)
hippocampal samples for tau using phosphorylation-dependent anti-tau antibodies
pT231, Ser 262 and for total Tau protein expression. (D) Quantification of Western
blots. pT231, Ser 262, and total tau expression were normalized to actin (n= 4, data are
mean ± SEM. **P<0.01).
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Figure 5.3. Hippocampal cholinergic failure triggers tauopathy in an agedependent manner.
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5.4.4 Cholinergic deficiency exacerbates age-dependent neuronal
vulnerability and impaired learning
Synaptic health is compromised in mouse models of AD and synaptic loss is a
consistent finding in AD-affected individuals (Klein, 2006). To examine synaptic integrity
we stained hippocampal sections with the synaptic marker PSD95. Aged
VAChTNkx2.1-Cre-flox/flox mice displayed hippocampal decreases in PSD95immunoreactivity, increased microglial activation and up-regulation of inflammatory
markers, in comparison to age-matched controls, suggesting large-scale synaptic
dysfunction in these mutants (Figure 5.4.1A-C). These observations predict neuronal
vulnerability; therefore, we stained brain sections with silver, which accumulates in
neurons that are more vulnerable to neurodegeneration (DeOlmos and Ingram, 1971).
Aged VAChT-deficient mice presented intensified silver staining compared to controls;
this increased silver staining was not observed in young VAChT-deficient mice (Figure
5.4.1D-E), suggesting that long-lasting decrease in cholinergic signalling may increase
the vulnerability of hippocampal neurons. Parallel staining of hippocampal sections from
aged 5XFAD mice compared to control mice performed as a positive control revealed
similar increases in silver staining as that for VAChT-deficient mice (Figure 5.4.2).
Activated caspase-3, a marker of apoptosis, was augmented in young VAChTNkx2.1Cre-flox/flox mice compared to controls (Figure 5.4.1F). However, aging significantly
increased the number of activated caspase-positive cells in VAChT-deficient mice when
compared to controls (Figure 5.4.1F). Also, young VAChT-deficient mice showed no
alteration in the number of NeuN positive cells across all regions of the hippocampus
(Figure 5.4.1G, Figure 5.4.2); while NeuN positive cells in CA1 and CA3 region, but not
dentate gyrus were decreased in aged VAChT-deficient mice (Figure 5.4.1G, Figure
5.4.2), predicting functional implications for this aging-related hippocampal neuronal
vulnerability. Thus, impaired cholinergic signalling induces global changes in transcript
levels, followed by age-related exacerbation of synaptic and neuronal vulnerability.
To test whether long-lasting cholinergic failure may have age-dependent consequences
in cognitive function, we subjected aged (11-14 months old) VAChT-deficient mice to
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the MWM task. Young VAChT-deficient mice (3-6 months old) show little difference from
controls in acquisition performance on the Morris Water Maze (MWM) task (Al-Onaizi et
al., 2016). In contrast, aged VAChT-deficient mice took significantly longer and swam a
greater distance than age-matched controls to find the platform across the four days of
acquisition (Figure 5.4.1E-F). Furthermore, aged VAChT-deficient mice used distinct
strategy preferences to find the platform, indicating that their deteriorated performance
was due to modified learning capacities. Briefly, the analysis of search strategies used
by each animal was based on a fixed set of criteria (Figure 5.4.1H). At a young age,
both controls and VAChTNkx2.1-Cre-flox/flox mice predominantly used a more direct
strategy to reach the platform (strategies 5/6/7, Figure 5.4.1I). In contrast, aged VAChTdeficient mice used random swimming predominantly as their strategy to acquire the
task (strategy 2, Figure 5.4.1I), while aged control mice maintained the use of more
direct strategies. Aged VAChT-deficient mice also exhibited deficits in the probe trial
(Figure 5.4.1G). Taken together, these results suggest that long-term cholinergic
deficiency in VAChTNkx2.1-Cre-flox/flox mice led to progressive loss of neurons in the
hippocampus that worsened spatial information acquisition and cognitive functioning.
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Figure 5.4.1. Hippocampal cholinergic failure leads to increased neuronal
vulnerability and worsens cognitive functioning. (A) Immunofluorescence imaging
showing PSD-95 protein levels in the hippocampus of aged controls or VAChT Nkx2.1-Creflox/flox

mice and corresponding (B) Western blot analysis for PSD-95 protein levels in the

hippocampus of VAChTNkx2.1-Cre-flox/flox mice compared to controls (t(6)=4.286, p=0.0052,
n=4). (C) Immunofluorescence imaging and quantification showing CD-68
immunoreactivity in the hippocampus of aged VAChTNkx2.1-Cre-flox/flox mice as well as
levels of IL-1 transcripts as measured by qRT-PCR (t(10)=2.312, p=0.0434, n=6) and IL6 transcripts as measured by qRT-PCR (t(10)=2.882, p=0.0204) (Data are mean +/S.E.M., *P<0.05, n=6). (D) Representative images of silver staining in the CA1 region of
young (3-6 months) and aged (11-14 months) mice. Scale bar, 100µm. (E)
Quantification of silver stain-positive cells between young and aged hippocampi of
controls (VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars). (n=5, data are
mean ± SEM. **P<0.01). (F) Representative immunofluorescence images for activatedcaspase 3 labelling in the hippocampi of young (Top) and aged (Bottom) mice.
Quantification of activated caspase-3 immunolabelling in young and aged hippocampi of
controls (VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars). (n= 3, data are
mean ± SEM. *P<0.05, **P<0.01, Scale bar, 100µm). (G) Distribution of neuron-specific
nuclear antigen (NeuN)-positive neurons in the CA1 region of the hippocampus in
young (top) and aged (bottom) mice (Scale bar, 100µm). Quantitative comparison of the
number of neurons labelled by NeuN in the CA1 region of the hippocampus in young
(top) and aged (bottom) mice (n= 6, data are mean ± SEM. *P<0.05). (H)
Representative examples of the 7 classified criteria to score the strategies mice used to
perform in the MWM. Strategies are color coded. (I) Strategy plot reflecting the mean
strategy-recruitment values for the first and fourth trials of each day for young (left) and
aged (right) mice. Quantification comparison of total block length values of individual
mice and their employed strategies over the course of 4-day training period. Grey bars
represent control mice and red bars represent VAChT-deficient mice. (n= 8, data are
mean ± SEM. *P<0.05 **P<0.01).
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Figure 5.4.1. Hippocampal cholinergic failure leads to increased neuronal
vulnerability and worsens cognitive functioning.
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Figure 5.4.2 Estimation of neuronal volume in the CA3 and DG region of the
hippocampus of young (3-6) and aged (11-14) month old cholinergic deficient
mice as well as cognitive deficits in aged cholinergic deficient mice. (A) Young
VAChTNkx2.1-Cre-flox/flox mice show no change in number of NeuN positive cells in the CA3
(t(18)=0.1894, p=0.8519), However in (B) there is a significant reduction in number of
NeuN positive cells in the CA3 of aged VAChTNkx2.1-Cre-flox/flox mice (t(18)=2.454,
p=0.0246). No change in the number of NeuN positive cells in the DG region was
observed in either young (C) (t(18)=0.7814, p=0.4447) or old (D) (t(18)=0.01758,
p=0.9862) VAChTNkx2.1-Cre-flox/flox mice (Data are mean +/- S.E.M., **p<0.01, n=9).
Significantly impaired latency (E) (RM-ANOVA, main effect of genotype F(1,7)=6.359,
p=0.0397), and distance to reach the platform (F) (RM-ANOVA, main effect of genotype
F(1,7)=7.845, p=0.0265) in aged (11-14 month old) VAChTNkx2.1-Cre-flox/flox mice. (G) Aged
(11-14 month old) VAChTNkx2.1-Cre-flox/flox mice do not show a preference for the target
platform during the probe trial portion of the MWM task (RM-ANOVA, main effect of
interaction F(3,21)=6.068, p<0.0038). (Data are mean +/- S.E.M., *p<0.05, **p<0.01,
***p<0.001, n=8). (H) Representative images of silver staining procedure from 11-14
month old wild-type and 5xFAD mice. (I) Quantification of percent silver stain area from
11-14 month old wild-type and 5xFAD mice (Data are mean +/- S.E.M., ***p<0.001,
n=3). Scale bar 100 µm.
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Figure 5.4.2 Estimation of neuronal volume in the CA3 and DG region of the
hippocampus of young (3-6) and aged (11-14) month old cholinergic deficient
mice as well as cognitive deficits in aged cholinergic deficient mice.
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5.4.5 Cholinergic mediated age dependent pathology is partially
mediated by GSK3 activation
In addition to APP processing and tau hyperphosphorylation, we observed other critical
biochemical pathways altered in response to cholinergic deficiency, including aberrant
GSK3 signalling, which has also been shown to play multiple roles in AD (Endo et al.,
2006; Gary and Mattson, 2001). As several genes that regulate the PI3-AKT pathway
were upregulated in VAChT-deficient mice (Fig. 5.1.1D, 5.1.2), we tested for
dysregulation of PI3-AKT signalling pathway in these mice by evaluating the
phosphorylation status of the AKT protein and its downstream target GSK3. AKT
presented decreased phosphorylation at residue Ser473, with unmodified Thr308
phosphorylation, in VAChTNkx2.1-Cre-flox/flox hippocampus compared to controls
(Figure 5.5.1A). Additionally, GSK3 tyrosine phosphorylation, which reflects
activation of GSK3, was increased in these mutants (Figure 5.5.1B). Hence in addition
to increased levels of proteins involved in AD pathology, these results suggest potential
contributions of GSK3 activation in cholinergic-induced deficits.
To test the role of GSK3 in the abnormal hippocampal changes in cholinergic-deficient
mice, we chronically treated a cohort of aged (11 months old) VAChTNKx2.1-Creflox/flox mice with the GSK3 inhibitor AR-A014418 (Figure 5.5.1C). After 28 days of
treatment, we found that VAChT-deficient mice treated with AR-A014418 showed a
significant decrease in GSK3 α and  tyrosine phosphorylation when compared to
VAChTNKx2.1-Cre-flox/flox mice treated with saline (Figure 5.5.1D). Increased
phosphorylation at Tyr residues 216 or 279 augments GSK3 activity (Hur and Zhou,
2010) and examining GSK3 phosphorylation at these residues has been used to
determine the effectiveness of AR-A014418 (Carter et al., 2014; Yadav et al., 2014). We
then assessed some of the key alterations detected in the hippocampus of aged
VAChTNKx2.1-Cre-flox/flox mice. AR-A014418 treatment was able to significantly
decrease tau T231 hyperphosphorylation and MC1-immunopositive tau in Western blots
(Chai et al., 2011; Petry et al., 2014), by approximately 50% in VAChTNKx2.1-Creflox/flox mice when compared to saline VAChTNKx2.1-Cre-flox/flox mice. Total levels of
tau where unchanged (Figure 5.5.1E). Immunofluorescence staining (Figure 5.5.1F)
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also demonstrated reduced levels of T231 hyperphosphorylated tau in AR-A014418
treated mice. Compared to saline treated animals, AR-A014418 treatment was able to
significantly increase levels of PSD-95 protein (Figure 5.5.1G).
Interestingly, we observed no changes in protein levels of BACE1 following ARA014418 treatment in aged VAChTNKx2.1-Cre-flox/flox mice (Fig. 5.5.2A). Furthermore
AR-A014418 treatment did not alter the alternative splicing event in the BACE1 gene
(Figure 5.5.2A). Together, these data suggest that the hnRNPA2/B1-mediated
alternative splicing and subsequent increase in BACE1 protein level are not mediated
by GSK3 activation. Surprisingly, despite reduced levels of hyperphosphorylated tau, 1month AR-A014418 treatment was unable to decrease the elevated levels of activated
caspase-3, (Figure 5.5.2B).
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Figure 5.5.1 Cholinergic mediated tau hyperphosphorylation is regulated by GSK3
activation. (A) Representative Western-blot and quantification analysis of pAKT(S473)
and pAKT(Thr308) levels in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice. (n=4, data
are mean ± SEM. *P<0.05 (B) Representative Western blot and quantification analysis
of phospho-GSK3α and  in the hippocampus of aged (11-14 month old) controls (left)
and VAChTNKx2.1-Cre-flox/flox (right) mice. Levels of pGSK3α and β to the respective GSK3
(n= 5 and 3, data are mean ± SEM. **P<0.01, ***P<0.001). (C) Implantation of osmotic
pumps and delivery of AR-A014418 to aged VAChTNKx2.1-Cre-flox/flox mice. (D)
Representative Western blot and quantification analysis of phospho-GSK3α and  in the
hippocampus of aged VAChTNKx2.1-Cre-flox/flox mice treated with AR-A014418 or saline. (E)
Western blot analysis aged VAChTNKx2.1-Cre-flox/flox treated with AR-A014418 or saline for
Tau hyper-phosphorylation at T231, MCI immunopositive tau and total Tau protein
expression. (F) Representative immunolabelling of reduced T231 Tau in the
hippocampus of aged VAChTNKx2.1-Cre-flox/flox mice (Scale bar, 100µm). (G) Western blot
analysis for PSD-95 protein levels in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice
treated with AR-A014418 or saline. (n= 4 saline treated, n=5 AR-A014418 treated, data
are mean ± SEM. *P<0.05 ***P<0.001).
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Figure 5.5.1 Cholinergic mediated tau hyperphosphorylation is regulated by GSK3
activation.

316
Figure 5.5.2 Cholinergic mediated age dependent pathology is partially mediated
by GSK3 hyper-phosphorylation. (A) Representative Western blot and quantification
analysis of BACE1 protein levels, along with qPCR analysis of alternative splicing of
exon 3/4 of the BACE1 gene in hippocampus of VAChTNKx2.1-Cre-flox/flox treated with ARA014418 or saline. (B) Quantification of activated caspase-3 immunolabelling in the
hippocampus of VAChTNkx2.1-Cre-flox/flox mice treated with AR-A014418 or saline (Scale
bar, 100µm) (n= 4 saline treated, n=5 AR-A014418 treated, data are mean ± SEM.
*P<0.05 **P<0.01).
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Figure 5.5.2 Cholinergic mediated age dependent pathology is partially mediated
by GSK3 hyper-phosphorylation.
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5.4.6 Cholinergic dysfunction in human AD brains
Whether cholinergic genes are expressed in lower levels in human AD brain compared
to cognitively alert controls and may contribute to phenotypes detected herein is not
fully understood. To examine that, we extracted total RNA from a cohort of 24 adult
human temporal gyrus samples collected at the Netherland Brain Bank (sample
information in Table 5.61), including 8 sporadic AD patients and 16 from age-matched
controls. We then profiled AD-related transcript differences by adopting the particularly
deep SQUARETM RNA library construction approach (Hebenstreit and Teichmann,
2011). Of those, 10,885 genes that were expressed showed a significant change. Next,
we quantified the levels of those transcripts composing the expanded family of
cholinergic regulator genes (Soreq, 2015). Detected cholinergic transcripts showed
significantly lower expression levels than other protein-coding genes in the temporal
gyrus of AD patients compared to aged-matched controls (Figure 5.6A).
Brain samples from a distinct cohort of AD patients (Ostapchenko et al., 2013)
supported the RNA-Seq analysis results by showing a significant VAChT loss in AD
brains compared to age and sex-matched controls (Figure 5.6B), in agreement with
previous observations (Chen et al., 2011; Efange et al., 1997). Furthermore, the cohort
of AD brains exhibited 50% decrease in hnRNPA2/B1 protein levels compared to
age/gender-matched controls (Figure 5.6C), confirming previous results obtained with a
distinct AD cohort (Berson et al., 2012). Additionally, we found a significant positive
correlation between VAChT and hnRNPA2/B1 protein levels (Figure 5.6D). AD brain
samples also showed drastic increases in tau-Thr231 phosphorylation (Figure 5.6E),
which was inversely proportional to the levels of VAChT (Figure 5.6F). Our findings
using cholinergic-deficient mice support an intricate timeline whereby cholinergic
dysfunction per se precedes and may have strong influence in pathological changes
observed in AD.
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Figure 5.6 Cholinergic Failure in the human AD Brain associates with loss of
hnRNPA2/B1 and hyperphosporylation of tau. (A) Cholinergic Genes are downregulated in the AD temporal gyrus. Shown are cumulative distribution functions (CDFs)
for the global change in the expanded family of cholinergic genes (as listed in Soreq,
2015) compared to global expression patterns between AD and control brain tissues (n=
8, Kolmogorov Smirnov p=0.03, red and blue lines, correspondingly). (B) Western blot
analysis of VAChT protein levels in AD brains. (C) Western blot analysis of
hnRNPA2/B1 protein levels in AD brains. (D) Correlation between hnRNPA2/B1 protein
levels and VAChT protein levels in AD brains. (E) Western blot analysis of Tau-Thr231
phosphorylation levels and (F) correlation between VAChT protein levels and Tau Thr231 phosphorylation levels. (n= 6, data are mean ± SEM. *P<0.05 **P<0.01).
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Figure 5.6 Cholinergic Failure in the human AD Brain associates with loss of
hnRNPA2/B1 and hyperphosporylation of tau.
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Table 5.6.1 Data for cohort of human brain samples. Samples collected from the
Netherland Brain Bank, from which total RNA was extracted and sequenced, n=24.
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Table 5.6.1 Data for cohort of human brain samples.
NBB id

sex

age

Post
mortem
delay

ph

weight

region

2008-047

M

77

06:35

6.10

1250

superior temporalis gyrus

2000-066

M

80

04:20

7.08

1160

inferior temporalis gyrus

2007-025

M

82

05:15

6.34

1182

superior temporalis gyrus

2007-052

M

82

04:15

6.41

1205

medial temporalis gyrus

2009-040

M

83

06:10

5.91

1102

superior temporalis gyrus

2008-029

M

84

08:05

5.95

1195

superior temporalis gyrus

2001-044

M

85

04:25

6.20

1383

superior temporalis gyrus

2001-063

M

85

04:45

6.38

1215

superior temporalis gyrus

2010-016

M

86

06:15

?

1211

superior temporalis gyrus

2009-107

M

88

04:40

6.22

1054

superior temporalis gyrus

2005-010

M

93

04:30

6.46

1040

superior temporalis gyrus

2002-087

M

71

07:40

6.20

1150

superior temporalis gyrus

2001-016

M

77

08:25

7.19

1118

superior temporalis gyrus

2000-015

M

78

05:35

6.63

1417

inferior temporalis gyrus

2005-044

M

80

07:15

5.80

1331

superior temporalis gyrus

2001-021

M

82

07:40

6.07

1318

inferior temporalis gyrus

2009-005

M

82

05:10

6.75

1087

superior temporalis gyrus

2001-086

M

88

07:00

6.84

1368

superior temporalis gyrus

2003-035

M

96

06:30

6.65

1300

superior temporalis gyrus

2005-019

M

74

05:00

6.70

1115

superior temporalis gyrus

2003-084

M

82

10:00

6.53

1488

superior temporalis gyrus

2009-039

M

82

12:55

6.21

1406

superior temporalis gyrus

2005-073

M

87

06:05

6.96

1468

superior temporalis gyrus

2009-075

M

88

07:00

6.76

1230

superior temporalis gyrus
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Table 5.6.2 Number of detected genes per patient. Number of detected genes
(RPKM>1) per patient, per SQUARE field. Rows are patients and columns are
SQUARE fields.
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Table 5.6.2 Number of detected genes per patient.

AD

Con

1

2

3

4

5

6

7

8

9

10

11

12

1

6152

6729

6154

7224

9942

6284

4273

5176

6504

7879

5815

7500

2

6961

6995

6251

7516

9611

6478

4549

5294

6698

7778

6204

7747

3

6945

7107

6627

7388

9746

6221

4529

5037

6789

7983

6145

6059

4

6811

6704

6530

7555

9664

6193

2877

4868

6250

7976

6246

8079

5

6123

6417

5848

7628

9529

5953

4637

4639

6140

7481

5814

7654

6

6956

7093

6308

7469

9927

6730

4542

4951

6091

7465

5699

6550

7

6310

6217

5749

7176

9410

5910

4393

4695

6247

7203

5531

7122

8

6770

6999

6436

7352

9675

6730

4451

5233

6761

7500

6114

7589

9

6374

6456

5957

6785

9250

6039

3889

4726

6506

7182

5307

6633

10

6820

6919

6083

6883

9270

5950

4367

4861

6763

7729

5266

6545

11

5771

6029

5191

6705

9445

5654

4197

4565

6188

6804

5649

6986

12

5660

7181

6486

7208

10160

7867

5148

5422

6939

8082

6243

6555

13

6332

6962

6220

6468

9430

6576

3876

5126

6959

7805

5361

6657

14

6103

6486

5507

7139

9583

5781

4467

4604

6150

7328

5632

7412

15

6380

6414

5592

6486

9377

5557

3940

4277

6225

7869

5571

7090

16

6511

6673

6217

7495

9710

6147

4238

4947

6788

8011

5732

7296

17

6265

6450

5903

7247

9142

5907

4403

4718

6022

7212

5424

7478

18

7153

7552

6945

7596

9822

6549

4382

5424

7282

8388

5926

7285

19

6294

5943

5668

7300

9259

5648

4255

4416

6108

7468

5690

7321

20

6268

6583

5753

7391

9732

6125

4635

4815

5896

7847

5733

7395

21

7674

7822

6969

8201

10588

7826

5027

5787

7348

8095

6059

7434

22

7274

7185

6793

7824

9945

6982

4755

5377

7258

8310

6185

7737

23

7149

7073

6654

7206

9895

6774

4890

5274

6915

8485

5796

8190

24

5676

6113

5303

6938

9863

6393

4630

4835

6651

7721

5964

6474
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5.5 Discussion
We employed transcriptome and biochemical assays on cholinergic-deficient mouse
brain samples to explore the impact of long-lasting forebrain cholinergic dysfunction.
Whole-genome RNA sequencing demonstrated that cholinergic deficiency modifies
expression levels and isoform abundance of several key transcripts related to
Alzheimer’s disease in the hippocampus of VAChT-deficient mice. Cholinergic-mediated
abnormal BACE1 mRNA splicing in VAChT-mutant mice increased BACE1 protein
levels and APP processing. Accordingly, cholinergic deficiency caused a 10-fold
increase in soluble mouse Aβ peptides, age-dependent hippocampal tauopathy,
synaptic abnormalities, neuronal inflammation, neuronal vulnerability and cognitive
decline. We also showed that GSK3 activation is critical for cholinergic modulation of
tau hyperphosphorylation and synaptic vulnerability. Furthermore, we confirmed that
human AD brains present cholinergic dysfunction and showed that it correlates to
changes in the levels of hnRNP A2/B1 and hyperphosphorylated tau. Our findings
indicate that cholinergic impairments confer widespread hippocampal damage and
malfunction. Furthermore, our data support a causal role for cholinergic signalling as a
surveillance mechanism controlling hippocampal transcript levels, maintenance of
cognitive function and neuronal viability in mice.
Our RNA sequencing analysis revealed a group of differentially expressed transcripts
related to spliceosome regulation in the hippocampus of VAChTNkx2.1-Cre-flox/flox
mice, suggesting that the splicing machinery in these mutants could be altered. In fact,
a significant number of alternative splicing event abnormalities were observed in the
hippocampus of VAChT-deficient mice. These results are consistent with previously
reported global changes of alternative splicing in the AD brain (Bai et al., 2013; Berson
et al., 2012; Tollervey et al., 2011). Importantly, spliceosome signalling pathway
changes can have broad implications for gene regulation [reviewed in (Shin and
Manley, 2004)].
Alternative splicing in the nervous system is particularly widespread and is essential for
multiple aspects of neuronal function (Raj and Blencowe, 2015). However, the signal-
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transduction pathways that regulate splicing are not well known (Shin and Manley,
2004). Our study adds a role for cholinergic signalling in the maintenance of balanced
alternative splicing. At least part of the cholinergic-control of alternative splicing seems
to involve hnRNPA2/B1. We have shown that cholinergic deficiency in the cortex
(Berson et al., 2012; Kolisnyk et al., 2013a) and hippocampus (Figure 2B) leads to
decreased expression of the hnRNPA2/B1 protein. Related work demonstrated that
hnRNPA2/B1 is a cholinergic regulated splicing factor (Kolisnyk et al submitted).
Importantly, knockdown of hnRNPA2/B1 in cultured hippocampal neurons shifted
splicing of BACE1 mRNA towards increased expression of mRNA species coding for
the BACE1-501 protein isoform as observed in the hippocampus of VAChT-deficient
mice. This splicing change led to increased expression of the BACE1 protein that was
accompanied by a pattern of APP processing similar to that observed in commonly used
mouse models of AD. The alternative splicing event in BACE1 observed in VAChTmutant mice is regulated my M1 muscarinic receptors (Kolisnyk et al., submitted).
Cholinergic tone has been thought to regulate APP processing through muscarinic
receptors (Davis et al., 2010; Nitsch et al., 1992). Specifically, M1 signalling has been
shown to regulate the stability of the BACE1 protein (Davis et al., 2010). BACE1-501 is
a more stable and active form of the protein (Mowrer and Wolfe, 2008). Remarkably,
BACE1 expression is increased in late-onset AD (Hebert et al., 2008). Our data suggest
potential mechanisms by which cholinergic regulation can affect BACE1 expression and
AD pathology. Interestingly, our data suggest changes in alternative splicing occurs
post-transcriptionally and independent of GSK3 signalling. Thus, cholinergic deficiency
may affect BACE1 expression differently than previously described in AD, in which
GSK3 can regulate BACE1 transcription by increasing promoter activity (Ly et al.,
2013). Our findings promote upstream cholinergic mechanisms as a target for
diminishing aberrant APP processing in AD.
In addition to increased levels of soluble A, VAChTNkx2.1-Cre-flox/flox mice also show
tau hyper-phosphorylation, which destabilizes microtubules and significantly disrupts
axonal transport. Tau hyper-phosphorylation may also contribute to increased
vulnerability leading to neuronal death (Billingsley and Kincaid, 1997). In fact, VAChT-
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deficient mice show age-dependent increases in hippocampal argyrophilic staining and
neuronal death.
Oligomeric protein aggregation has been linked to toxicity and to neurodegenerative
disorders, including AD (Maeda et al., 2006). The formation of NFTs alone is insufficient
for neurodegeneration, yet oligomeric tau may contribute to neurodegeneration and
synaptic loss in AD (Berger et al., 2007; de Calignon et al., 2012). These observed
changes in tau in VAChT-deficient mice (i.e. increased oligomer formation), the
associated age-dependent increase in immunoreactivity of activated caspase-3, and
ultimately neuronal loss all support a relationship between cholinergic failure and ADlike pathology in mice.
Tau hyper-phosphorylation can occur due to the increased activity of GSK3, which
subsequently leads to an array of impairments, including disruption of LTP (Hooper et
al., 2007) and cell death in vitro (Zheng et al., 2002). GSK3 over-activation is an
important hallmark in AD (Hooper et al., 2008). Thus, the GSK3 overactivation observed
in VAChT-mutant mice represents a potential mechanism by which reduced cholinergic
activity may have multiple influences in AD pathology in target cells. We tested this
hypothesis by pharmacological inhibition of GSK3 in aged VAChT-deficient mice. GSK3
inhibition was able to decrease tau hyperphosphorylation. Also, GSK3 inhibition partially
restored PSD95 protein levels, but did not decrease caspase-3 activation. These
findings demonstrate that cholinergic-induced changes in tau and in amyloid processing
are potentially independent of each other and suggest that cholinergic dysfunction is
contributing to the pathological outcomes in these animals by altering multiple
pathways. The pharmacological inhibition of GSK3 was tested in mice in which certain
pathology was already present (11-12 month-old mice). Hence, further experiments
should test longer treatments with the compound or genetic ablation of GSK3 genes in
VAChT-deficient mice to comprehensively dissect the contribution of overactive GSK3
in other phenotypes.
Aged VAChT-deficient mice showed a decrease in the number of hippocampal neurons,
a deficiency that was not observed in young mutants, suggesting that cholinergic tone
may play a role in guarding hippocampal neuronal health. Additionally, aged VAChT-
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deficient mice showed increased neuroinflammation and reduced number of synapses;
which are pathologies observed in AD brains (DeKosky and Scheff, 1990; Rogers and
Shen, 2000; Smale et al., 1995). Mice with excess acetylcholinesterase, which present
decreased cholinergic function, also show neuroinflammation (Shaked et al., 2009).
Furthermore, similar to our observation, mice lacking the 2 nicotinic receptor subunit
show age-dependent loss of hippocampal neurons (Zoli et al., 1999). Of note,
hippocampal neuronal loss is a critical feature in AD, which is not observed in mouse
models overexpressing APP and or presenilin 1 with human AD mutations (Stein and
Johnson, 2002). Hence, long-term cholinergic deficiency may model this aspect of AD in
a better way. Potential mechanisms involved in cholinergic dysfunction induced
pathology are shown on Figure 5.7.
In line with an age-dependent loss of hippocampal neurons, we found that aged
VAChT-deficient mice showed significant impairments in their learning strategy in the
MWM task. Poor performance and acquisition on the MWM task has been associated
with loss of neurons in the hippocampus (Olsen et al., 1994). This suggests that
neuronal loss in the hippocampus has functional consequences in mice as well.
In AD brains, we found evidence of cholinergic decline and showed a striking
relationship between VAChT levels and tau hyper-phosphorylation. Together with the
mouse data, these observations support the notion that deficient cholinergic signalling in
AD may correlate to key pathological events, including Tau hyper-phosphorylation.
Our data reveal that cholinergic deficiency can affect a number of transcriptional
processes, disturb splicing of key genes and interfere with protein networks that
normally protect neurons. Interestingly, recent work revealed that basal forebrain
cholinergic neurons present intraneuronal Aβ accumulation even in young adults, which
may contribute to their selective vulnerability in AD (Baker-Nigh et al., 2015).
Cholinergic neurons are thought to be highly dependent on the presence of trophic
factors for their optimal function and survival (Boskovic et al., 2014; Naumann et al.,
2002), which may also contribute to their demise. Regardless of the mechanisms for
increased cholinergic vulnerability in AD, it seems that cholinergic dysfunction persisting
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for a long period is highly related to hippocampal pathology and amyloid accumulation
(Teipel et al., 2014).
In short, our results suggest that long-term cholinergic failure per se, which we model by
disrupting synaptic cholinergic function, can trigger AD-like pathology in mice. More
importantly, we find that long-term cholinergic deficiency leads to age-dependent
cognitive decline that is related to neuronal death, a key feature of late-onset AD that is
not modeled in mice overexpressing human genes with AD-related mutations. Our
experiments provide a mechanism to explain how decreased cholinergic tone, for
example due to long-term use of anti-cholinergic drugs, could lead to increased risk of
dementia (Gray et al., 2015), which may depend on global changes of RNA metabolism,
including alternative splicing and gene expression. It remains to be determined if
rescuing cholinergic function prior to development of AD could have an impact in the
risk of dementia or AD-related pathology. However, it is noteworthy that recent
observations in potential prodromal AD-affected individuals indicate that cholinesterase
inhibition decreases the rate of hippocampal atrophy by 45% during one-year treatment
(Dubois et al., 2015). Our data points towards cholinergic signalling being a global
mediator of several distinct processes that when dysfunctional lead to pathology.
Developing effective strategies to reverse the cholinergic deficits in the AD brain may
therefore prove to be more fruitful then specific therapies based on reversing the
individual processes it regulates.
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Figure 5.7. Summary of findings. (A) In control animals, cholinergic input from the
medial septum regulates target neurons in the hippocampus, through nicotinic and
muscarinic acetylcholine receptors. Long-term cholinergic signaling maintains
transcriptome integrity likely by a combination of muscarinic and nicotinic activation.
These maintain balance of signaling pathways that regulate AD-like pathology. (B)
Conversely, in cholinergic deficient mice, which models long-term cholinergic
dysfunction, lack of signaling by muscarinic and nicotinic receptors affects differential
expression of spliceosome-related genes and reductions in hnRNPA2/B1. BACE1
mRNA is abnormally spliced leading to an increase of BACE1 expression. As a
consequence, APP processing is altered, yielding accumulation of soluble Aβ peptides.
Furthermore, abnormal gene expression influences AKT-GSK3 modulatory genes with
consequences for AKT and GSK3 phosphorylation. These changes contribute to
increases in pathological tau phosphorylation and misfolding, neuroinflammation,
synaptic loss, hippocampal neuronal death and ultimately leading to cognitive decline in
these animals.
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Figure 5.7. Summary of findings.
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Chapter 6
Cholinergic Regulation of hnRNPA2/B1 Translation by M1
Muscarinic Receptors
6.1 Chapter Summary
Cholinergic vulnerability, characterized by loss of acetylcholine (ACh), is one of the
hallmarks of Alzheimer's disease (AD). Recent work has suggested that decreased ACh
activity in AD may contribute to pathological changes through global alterations in
alternative splicing. This occurs, at least partially, via the regulation of the expression of
a critical protein family in RNA processing, hnRNP A/B proteins. These proteins
regulate several steps of RNA metabolism, including alternative splicing, RNA
trafficking, miRNA export and gene expression, providing multilevel surveillance in RNA
functions. To investigate the mechanism by which cholinergic tone regulates
hnRNPA2/B1 expression, we employed a combination of genetic mouse models and in
vivo and in vitro techniques. Decreasing cholinergic tone reduced levels of
hnRNPA2/B1, while increasing cholinergic signalling in vivo increased expression of
hnRNPA2/B1. This effect is not due to decreased hnRNPA2/B1 mRNA expression,
increased aggregation or degradation of the protein, but rather to decreased mRNA
translation by nonsense mediated decay regulation of translation. Cell culture and
knockout mice experiments demonstrated that M1 muscarinic signalling is critical for
cholinergic control of hnRNPA2/B1 protein levels. Our experiments suggest an intricate
regulation of hnRNPA2/B1 levels by cholinergic activity that interferes with alternative
splicing in targeted neurons mimicking deficits found in AD.
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6.2

Introduction

Dementia affects roughly 44 million individuals worldwide and represents a large
economic burden (Wimo et al., 2013). Individuals affected with Alzheimer’s disease
(AD) present a profound decrease in basal forebrain cholinergic neurons (Whitehouse
et al., 1982). These findings led to the cholinergic hypothesis of AD and the use of
cholinesterase inhibitors to mitigate cholinergic failure (Bartus et al., 1982). Recent work
suggests that the use of cholinesterase inhibitors for one year in possible prodromal
AD-affected individuals halved rates of hippocampal atrophy, suggesting an intricate
relationship between cholinergic tone and neurodegeneration (Dubois et al., 2015).
Cholinergic tone can modulate signal processing by changing electrical properties of
cells and by modulating intracellular signalling (Dajas-Bailador and Wonnacott, 2004;
Soreq, 2015). In addition, it has become clear that cholinergic signalling can also
regulate long-term gene expression, miRNAs (Shaked et al., 2009; Soreq, 2015) and
alternative splicing (Berson et al., 2012; Kolisnyk et al., 2013a), all of which can
modulate functional properties of cells (Blencowe, 2006; Novarino et al., 2014). A key
protein that regulates splicing events in AD is the heterogeneous nuclear
ribonucleoprotein (hnRNP) A2/B1, which is reduced in brains of AD patients due to
cholinergic deficiency (Berson et al., 2012) and is reduced in mice with a conditional
deletion of the Vesicular Acetylcholine Transporter in the forebrain (VAChT) (Kolisnyk et
al., 2013a).
hnRNPs are a large family of proteins which package pre-mRNA into larger hnRNP
particles (Dreyfuss et al., 1993). Each of the hnRNPs contain distinct RNA binding
motifs, which allows them to exert their roles in pre-mRNA processing (Black, 2003;
Weighardt et al., 1996). hnRNPA2/B1 is one of the major hnRNP isoforms in the brain
regulating alternative splicing and the transport of mRNA to distal cellular processes
(Han et al., 2010). Importantly, knockdown of hnRNPA2/B1 in vivo caused impairments
in learning and memory (Berson et al., 2012). Taken together, these findings suggest a
critical role for this RNA binding protein in neuronal function and cognition.
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Previous work suggests that cholinergic tone can regulate levels of hnRNPA2/B1,
however the mechanisms involved are unclear. Here we show that hnRNPA2/B1 is a
cholinergic controlled splicing factor. M1 muscarinic receptor activity is critical for
cholinergic regulation of hnRNPA2B1 translation. This work provides a new mechanism
by which acetylcholine (ACh) can influence targeted neurons, leading to potential
widespread changes in neuronal function.

6.3

Materials and Methods

6.3.1 Mouse lines
All animals with targeted elimination of VAChT were generated using the VAChTflox/flox
mouse described in (Martins-Silva et al., 2011). To eliminate VAChT from the forebrain,
VAChTflox/flox mice were crossed with C57BL/6J-Tg(Nkx2-1-cre)2Sand/J mice (Xu et
al., 2008) to generate VAChTNkx2.1-Cre-flox/flox (Al-Onaizi et al., 2016). To eliminate
VAChT from the striatum the VAChTflox/flox mice were crossed with D2-Cre mice
(Drd2, Line ER44) to generate VAChTD2-Cre-flox/flox (Guzman et al., 2011). VAChT
overexpressing, ChAT-ChR2-EYFP mice were from the Jackson Laboratory, B6.CgTg(Chat-Cop4*H134R/EYFP)6Gfng/J (Zhao et al., 2011). Generation of TgR (Shaked et
al., 2009), M1-KO (Hamilton et al., 1997) and M4-KO mice (Gomeza et al., 1999) were
previously described. All procedures were conducted in accordance with guidelines of
the Canadian Council of Animal Care (CCAC) at the University of Western Ontario with
an approved institutional animal protocol (2008-127). Only male mice were used for all
experiments.

6.3.2 Immunofluorescence
Immunofluorescence experiments were performed as previously described (Guzman et
al., 2011). Primary antibodies used were anti-hnRNPA2/B1 (1:200 Santa Cruz
Biotechnology Catalog no. sc-10035), anti-NeuN (1:200 PhosphoSolutions, Catalog no.
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583-FOX3), and anti-GFAP (1:500 AbCam, Catalogue no. ab7260). Sections were
visualized by Zeiss LSM 510 Meta (Carl Zeiss, Oberkochen, Germany) confocal system
(10x, 40x, 63x objectives), a 488-nm Ar laser and 633-nm HeNe laser were used for
excitation of fluorophores.

6.3.3 Western Blotting
Mouse hippocampi were collected, proteins were isolated, and immunoblotting was
performed as previously described using RIPA lysis buffer supplemented with protease
and phosphatase inhibitors (Guzman et al., 2011). Band intensities were quantified
using FluoroChemQ software (Thermo Fisher Scientific).

6.3.4Subcellular Fractionation
To isolate nuclear and cytoplasmic proteins from hippocampal tissue, the NE-PER
Nuclear Protein Extraction Kit (Thermo Scientific, USA) was used following the
manufacturer’s instructions.

6.3.5 Sarkosyl Insolubility
Isolation of Sarkosyl insoluble protein was performed as described (Bai et al., 2013).
Hippocampal tissue was homogenized in a low salt buffer (10 mM Tris, pH 7.5, 5 mM
EDTA, 1 mM DTT, 10% (wt/vol) sucrose, Sigma protease inhibitor cocktail, ∼10 ml
buffer per gram tissue) to detect total protein, a detergent buffer (the low salt buffer with
the addition of 1% (wt/vol) sarkosyl, N-Lauroylsarcosine) for the sarkosyl soluble
fraction, and finally 8 M urea with 2% (wt/vol) SDS for the sorkosyl insoluble fraction.

6.3.6 Ubiquitination Assay
The ubiquitination status of the hnRNPA2/B1 protein was determined using previously
described protocols (Choo and Zhang, 2009). Briefly, the hnRNPA2/B1 protein was
immunoprecipitated using the Santa Cruz sc-10035 antibody and run on an SDS-Page
gel. The gel was then blotted with an anti-ubiquitin antibody (Abcam ab7780).
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6.3.7 Stereotaxic injections of adeno-associated virus
Injection of AAV virus has been described (Al-Onaizi et al., 2016). Briefly, mice were
anesthetized with ketamine (100 mg/kg) and xylazine (25 mg/kg, and 1 μl (titer of
~1013 GC/ml) of AAV8-GFP-Cre-GFP or control virus (AAV8-GFP, Vector BioLabs,
Eagleville, PA, USA) was injected into the medial septum (0.98 AP, 0.1 LL and 4.1 DV)
of VAChTflox/flox mice. A recovery period of 4 weeks was given to allow transgene
expression, prior to subsequent analyses.

6.3.8 RNA Sequencing
Total RNA was extracted from hippocampal tissues. cDNA library was prepared using
TruSeq Stranded Total Sample Preparation kit (Illumina) and ran in a HiSeq 2500
platform. Datasets are available on ArrayExpress (http://www.ebi.ac.uk/arrayexpress/)
under accession number E-MTAB-3897. Full description and analysis of the results of
the RNA-Sequencing dataset are found in chapter 5.

6.3.9 qPCR and RT-PCR
To measure mRNA expression, total RNA was extracted from freshly dissected
hippocampal tissue, using the Aurum Total RNA for fatty and fibrous tissue kit (Bio-Rad)
according to the manufacturer's instructions. cDNA synthesis and qPCR analysis were
performed as previously described (Guzman et al., 2011). For alternative splicing
experiments, the alternative exon levels were normalized to a constitutively expressed
exon from the same gene. RT-PCR was performed as previously described (Ribeiro et
al., 2007).

6.3.10 Isolation of Polysomal RNA
Isolation of polysomal RNA was performed as described (Wagnon et al., 2012).
Samples were homogenized in 1.5 ml of ice-cold lysis buffer (20 mM Tris-HCl, pH 7.4, 3
mM MgCl2, 10 mM NaCl, 2% sucrose, 0.3% Triton X-100, 2 mM vanadyl ribonucleoside
complexes [VRC] supplemented with protease inhibitors (complete mini, EDTA-free,
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Roche, Indianapolis, IN). The homogenate was then centrifuged at 10,000 g for 10
minutes at 4°C, and the supernatant was transferred to a fresh tube. The lysate was
treated with either 30 mM EDTA or 0.1 mg/ml RNase A for 30 minutes on ice or if they
were to be treated with EDTA, VRC was not included in the lysis buffer. Lysates were
then carefully layered onto 15–55% of sucrose in 25 mM Tris-HCl, pH 7.4, 25 mM NaCl,
5 mM MgCl2 (and 30 mM EDTA for the EDTA Samples). Gradients were
ultracentrifuged in a Beckman Instruments SW40Ti rotor at 150,000g for 2 hours and 25
minutes at 4°C.
To isolate RNA from the fractions, RNA was collected into 1.5 ml of 7.7 M guanidineHCl, 2 ml of 100% ethanol was added, and samples were stored at −20°C. Samples
were then centrifuged at 4000 for 50 minutes at 4°C. The supernatant was removed and
200 µL DEPC-treated H2O was added to the pellet. To precipitate the RNA, 500 µL of
100% ethanol, 20 µL of 3 M sodium acetate, pH 5.2, and 10 µg glycogen were added,
and the samples were stored overnight at −20°C. The samples were then centrifuged at
14,000g for 30 minutes at 4°C. Pellets were washed with ice-cold 75% ethanol and air
dried for 15 minutes at room temperature. RNA was re-suspended in 30 µL DEPCtreated H2O and quantified by nanodrop, before being converted into cDNA using the
Applied biosystems cDNA conversion kit. RT-PCR was then performed using primers
designed to amplify hnRNPA2/B1 or -Actin.

6.3.11Primary Neuronal Cultures
Primary cultures of hippocampal neurons from E17 mouse embryos were obtained as
described previously (Beraldo et al., 2013). Cultures were maintained in Neurobasal
medium with 2% B-27 supplement (Invitrogen). On day 4, cytosine arabinoside (2 μM;
Sigma) was added to prevent astrocyte growth. Half of the culture medium was
changed every 2–3 days. Neurons were cultured for 15 days
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6.3.12 Pharmacological manipulations in Primary Neuronal
Cultures
On the 15th day of culture, the neurons were treated with different doses of carbachol
(0, 5, 10, or 50M) dissolved in saline and, 48 hours later, total protein was isolated and
levels of hnRNPA2/B1 were determined by Western blotting and immunofluorescence.
To evaluate the contribution of nicotinic and muscarinic receptors in regulating
hnRNPA2/B1 protein levels, neurons were pre-treated with either mechamylamine (100
M), atropine (100 M), or both. Then, 1 hour later, neurons were treated with
carbachol (10 M). Finally, to assess the effect of M1 muscarinic activation, neurons
were treated with different doses of AF102B (0, 10, 100, 500 M) dissolved in saline.

6.3.13 Statistical Analysis
Data are presented as mean ± SEM, unless otherwise stated. GraphPad Prism 6
software was used for statistical analysis. Comparison between two experimental
groups was done by Student's t test. When several experimental groups or treatments
were analyzed, one-way ANOVA and, when appropriate, a Tukey's HSD post hoc
comparison test was used.

6.4 Results

6.4.1Cholinergic Modulation of hnRNPA2/B1 Protein Levels
Previous experiments indicated that hnRNPA2/B1 is decreased in the AD brains, but
this is not modeled in genetic mouse models of AD (Berson et al., 2012). In contrast,
either genetic or immunotoxin disruption of cholinergic tone led to decreased expression
of hnRNP A2/B1 (Berson et al., 2012; Kolisnyk et al., 2013a). As expected
VAChTNkx2.1-Cre-flox/flox animals presented a robust decrease in hnRNPA2/B1 levels
in the hippocampus (Fig. 6.1 A).
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The Nk2.1 promoter turns on Cre expression early during development (Xu et al., 2008)
and therefore the resulting decrease in hnRNPA2/B1 levels could potentially be a result
of developmental suppression of cholinergic tone, rather than being cholinergic
regulated in adult mice. To test this possibility, we deleted the VAChT gene specifically
in medial septum neurons and parts of the diagonal band (Al-Onaizi et al., 2016), which
provides most of the hippocampal cholinergic innervation, of adult VAChTflox/flox mice
using AAV8-Cre virus. AAV8-Cre-injected mice showed inter-related decline of both
VAChT and hnRNPA2/B1 proteins, whereas AAV8-GFP-injected mice did not (Fig.
6.1B). There was a significant relationship between VAChT and hnRNP A2/B1 levels
(r2=0.755, p<0.001) (Fig. 6.1B). In addition, we tested whether, in the striatum,
elimination of cholinergic tone would affect hnRNPA2/B1 expression by using
VAChTD2-Cre-flox/flox mice, with selective striatal VAChT deficiency (Guzman et al.,
2011). These mice showed no changes in hnRNPA2/B1 in their striatum (Fig. 6.1C),
indicating hippocampal specificity of these effects.
If expression of hnRNPA2/B1 is a cholinergic-regulated process, one would expect that
increased cholinergic tone should have opposite effects than those observed by
decreased VAChT expression. ChAT-ChR2-EGFP mice overexpress VAChT in the
hippocampus and consequently present increased cholinergic tone and ACh release
(Kolisnyk et al., 2013b). These mice present increased hnRNPA2/B1 protein levels (Fig.
6.1D), suggesting that VAChT levels critically regulate hnRNPA2/B1 expression.
Decline of hnRNPA2/B1 could be solely related to VAChT depletion, or alternatively, it
could reflect the functional loss of ACh signalling in the CNS. To distinguish between
these possibilities, we tested the hippocampus of TgR mice over-expressing soluble
AChE (Shaked et al., 2009), which causes cholinergic insufficiency. TgR mice showed
decrease in hnRNPA2/B1 levels similar to mice with decreased VAChT (Fig. 6.1E),
suggesting that ACh synaptic levels are causally involved in the regulation of
hnRNPA2/B1 expression. Cre expression by itself had no effect on hnRNPA2/B1 levels
as can be seen when we compared expression of hnRNPA2/B1 in the hippocampus of
Nkx2.1-Cre and WT mice (Fig. 6.1F). Taken together these data give strong support for
the hypothesis that hnRNPA2/B1 is a cholinergic regulated splicing factor.
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RNA binding proteins such as hnRNPA2/B1 are predominantly expressed in the
nucleus, but they can accumulate in the cytoplasm and cause neuronal toxicity (Kim et
al., 2013; Wolozin, 2012). We therefore determined by immunofluorescence staining if
the localization of hnRNP A2/B1 is changed in response to decreased cholinergic tone.
Compared to controls VAChTNkx2.1-Cre-flox/flox had a decrease in hnRNPA2/B1
immunostaining in the CA1, CA3, and Dentate Gyrus regions of the hippocampus (Fig
6.2A-D). hnRNPA2/B1 was present mainly in the nucleus of both neurons (labeled by
NeuN, Fig. 2-A-D) as well as in astrocytes (Fig. 6.2E) in control mice. We did not
observe any shift in the localization of hnRNPA2/B1 in VAChT-deficient mice, only an
overall decrease in the levels of staining. To confirm these observations we used
subcellular fractionation to assess if VAChTNkx2.1-Cre-flox/flox mice show changes in
hnRNPA2/B1 distribution between the nuclear and cytoplasmic fractions (Fig. 6.2F). In
both control and VAChT-deficient mice, hnRNPA2/B1 was predominantly nuclear,
following the distribution of the nuclear enzyme PIAS1 (Soares et al., 2013). However,
VAChTNkx2.1-Cre-flox/flox mice showed consistently reduced nuclear hnRNPA2/B1
levels (Fig. 6.2F).
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Figure 6.1. Analysis of hnRNPA2/B1 protein levels in genetically modified mice
with differential expression of VAChT. (A) Representative Western blot and
quantification of hnRNPA2/B1 protein expression in the hippocampus of VAChTflox/flox
and VAChTNKx2.1-Cre-flox/flox mice. hnRNPA2/B1 expression was normalized to actin (n=
6). (B) hnRNPA2/B1 protein levels positively correlate with AAV induced reduction of
VAChT. The graph shows values for each individual mice injected either with GFP or
CRE. The image is from the medial septum of a virus-injected mice (C) Striatal
elimination of VAChT does not alter hnRNPA2/B1 protein levels in the striatum of
VAChTD2-Cre-flox/flox mice (n=4). (D) Transgenic mice over-expressing VAChT have
increased hnRNPA2/B1 protein levels compared to controls (n=4). (E) hnRNPA2/B1
protein levels from the hippocampus of TgR transgenic mice (n=3). (F) No change in
hnRNPA2/B1 protein levels compared to controls in the hippocampus of c567BL/6JNkx2.1-Cre mice (n=3) (Data are mean +/- S.E.M., *p<0.05, **p<0.01).
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Figure 6.1. Analysis of hnRNPA2/B1 protein levels in genetically modified mice
with differential expression of VAChT.
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Figure 6.2. Characterization of decreased hnRNPA2/B1 protein levels in the
hippocampus of VAChT-deficient mice. (A) Representative images of
staining for NeuN, hnRNPA2/B1 and Hoeschst in the CA1 region of the hippocampus in
controls (A) and VAChTNKx2.1-Cre-flox/flox mice (B) (Scale bar, 50 um). Expression of
hnRNPA2/B1 in the CA3 (C) and dentate gyrus (D) by immunofluorescence reveals
general decrease of the protein and nuclear localization in VAChT-deficient mice. (E)
Localization of hnRNPA2/B1 with GFAP glial marker in the hippocampus of VAChTNkx2.1Cre-flox/flox mice.

(F) Subcellular fractionation assay of hnRNPA2/B1 protein shows

hnRNPA2/B1 expression is mainly nuclear (data are mean +/- SEM, *P<0.05).
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Figure 6.2. Characterization of decreased hnRNPA2/B1 protein levels in the
hippocampus of VAChT-deficient mice.
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6.4.2 Mechanisms of cholinergic modulation of hnRNPA2/B1
To investigate mechanisms by which cholinergic tone may regulate the levels of
hnRNPA2/B1 protein, we evaluated ubiquitination, a modification that can facilitate
protein degradation by the proteasome (Hochstrasser, 1996). Immunoprecipitated
hnRNPA2/B1 from the hippocampus of controls and VAChTNkx2.1-Cre-flox/flox mice
was resolved by SDS-PAGE and probed with ubiquitin antibodies. VAChT-deficient
mice showed no change in ubiquitination status of hnRNPA2/B1 protein, when
normalized to total hnRNPA2/B1 protein levels (Fig. 6.3A).
We also examined whether cholinergic tone affects aggregation of hnRNPA2/B1.
Notably, hnRNPA2/B1 has a prion-like domain that favours increased aggregation when
mutated (Kim et al., 2013). Protein aggregation was investigated by fractionating
hippocampal extracts into sarkosyl soluble and insoluble fractions (Fig. 6.3B). In both
controls and VAChT-deficient mice, hnRNPA2/B1 was mainly present in soluble
fractions, unlike the U1-70k snRNP which has been shown to be present in insoluble
fractions (Bai et al., 2013) (Fig. 6.3B). This result excluded the option that cholinergic
tone increases aggregation of hnRNPA2/B1. Interestingly, despite different levels of
hnRNPA2/B1 protein expression, both control and VAChT-deficient mice exhibited
similar hnRNPA2/B1 mRNA levels as determined by RNA-Sequencing (Fig. 6.3C), as
observed in AD brains (Berson et al., 2012).
It has been previously reported that protein levels of hnRNPA2/B1 are directly
proportional to changes in the RNA editing of the 3’ UTR of its mRNA, with a shift away
from a nonsense mediated decay (NMD) sensitive transcript increasing protein levels
(Bonomi et al., 2013) (Fig. 6.3D). We evaluated by qPCR the ratio of NMD sensitive to
NMD insensitive versions of the hnRNPA2/B1 transcript in the hippocampus of
VAChTNkx2.1-Cre-flox/flox mice. Compared to controls, we observed a significant shift
towards the NMD+ product in VAChT-deficient mice (Fig. 6.3E).
We then tested whether cholinergic tone modulation of NMD+ transcript could regulate
hnRNPA2/B1 protein expression levels by limiting protein translation. For this, we
studied the recruitment of hnRNPA2/B1 mRNA to ribosomes. Ribonucleotide-protein
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complexes (RNPs) were isolated from hippocampal lysates, and sucrose density
gradient fractionation was used to separate polyribosomes from large neuronal RNA
granules (Fig. 6.4A) (Wagnon et al., 2012). Distribution of hnRNPA2/B1 transcripts in
individual fractions was determined by RT–PCR in three individual mice of each
genotype (Fig. 6.4B-C). In control mice, hnRNPA2/B1 mRNAs associated with
polysomes and RNA granules, and treatment with EDTA, which dissociates mRNA from
polysomes, equally distributed hnRNPA2/B1 mRNAs across fractions (Fig. 6.4D-E).
However, in VAChTNkx2.1-Cre-flox/flox mice, distribution of hnRNPA2/B1 mRNAs was
widespread throughout the fractions, resembling the distribution observed after EDTA
treatment (Fig. 6.4D-E). The abundant β-actin mRNA remained unaltered between
genotypes, demonstrating specificity towards hnRNPA2/B1 (Fig. 6.3F-G). These results
indicate that decreased cholinergic tone leads to diminished translational capacity of
hnRNPA2/B1 mRNA transcripts to modulate the efficiency of hnRNPA2/B1 protein
translation.
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Figure 6.3. Mechanisms of cholinergic regulation of hnRNPA2/B1 protein levels.
(A) No change in ubiquitination status of hnRNPA2/B1 was observed when
hnRNPA2/B1 from the hippocampus of VAChT deficient mice (p= 0.3067, n=7 Control
and n=6 VAChTNkx2.1-Cre-flox/flox mice) was immunoprecipitated using anti-hnRNPA2/B1
antibody and probed with anti-ubiquitin antibody. (B) Sarkosyl insolubility assay shows
no aggregation of hnRNPA2/B1 in VAChTNkx2.1-Cre-flox/flox mice (n=4). (C) Transcript level
of hnRNPA2/B1 in the RNA-Seq dataset (p=0.9124, FDR=1). (D) Cartoon of the
alternative splicing in the 3’UTR of hnRNPA2/B1 transcripts (Figure adapted from
(Bonomi et al., 2013), the FL transcript is predicted to be stable and undergo translation
whereas the NMD sensitive transcript is not; primers used to assay this event are show
in the schematic. (E) Increased in the proportion of NMD+ hnRNPA2/B1 transcripts in
the hippocampus of VAChTNkx2.1-Cre-flox/flox mice (n=4, p<0.01).
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Figure 6.3. Mechanisms of cholinergic regulation of hnRNPA2/B1 protein levels.
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Figure 6.4. Forebrain cholinergic tone regulates translation of hNRNPA2/B1 in the
hippocampus. (A) Hippocampal brain tissue was fractionated on a linear sucrose
gradient. Fractions were collected and analyzed by spectrophotometry to determine
position of monosome (80s), polysomes and RNA granules. (B) RT-PCR of
hnRNPA2/B1 transcripts in VAChTflox/flox and VAChTNkx2.1-Cre-flox/flox mice in the absence
or presence of EDTA. (C) RT-PCR of Actin transcripts in VAChTflox/flox and
VAChTNkx2.1-Cre-flox/flox mice in the absence or presence of EDTA. (D-E) show
quantification of data for the hnRNPA2/B1 transcripts from the three different VAChTdeficient and three control mice in the absence or presence of EDTA. (F-G) show
quantification results for Actin transcripts from the three different VAChT-deficient and
three control mice in the absence or presence of EDTA. 1-12 are the fraction numbers.
The values plotted are averaged from gels in (C) (Data are mean).

366
Figure 6.4. Forebrain cholinergic tone regulates translation of hNRNPA2/B1 in the
hippocampus.
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6.4.3 Muscarinic Signalling Regulates hnRNPA2/B1 Translation
by an NMD Mechanism
To further understand how cholinergic signalling regulates hnRNPA2/B1 levels, we
treated neuronal hippocampal cultures from wild-type mice with the cholinergic mimetic
carbachol (10µM) (Fig 6.5 A-B). This treatment effectively increased hnRNPA2/B1
protein levels in immunofluorescence and immunoblot experiments, and this effect
could be blocked by muscarinic, but not by nicotinic antagonist treatment (Fig. 6.5C).
To study the contribution of muscarinic receptor subtypes, we evaluated hnRNPA2/B1
levels in the hippocampus of muscarinic receptor knockout mice. Compared to wild-type
mice, M1, but not M4 receptor knockout mice, showed a decrease in hnRNPA2/B1
protein levels, resembling VAChTNkx2.1-Cre-flox/flox mice (Fig. 6.5D). Taken together,
these experiments suggest that decreased cholinergic tone, likely due to insufficient M1
receptor activation, changes hnRNPA2/B1 protein levels by regulating mRNA
translation.
To further investigate the importance of M1 muscarinic receptors in the regulation of
hnRNPA2/B1 protein levels in hippocampal neurons we treated neuronal hippocampal
cultures from wild-type mice with the M1 muscarinic agonist AF102B (Fisher et al.,
1989). Compared to saline treated neurons, those treated with 100 µM of AF102B
showed a significant increase in protein levels of hnRNPA2/B1 (Fig. 6.5E). Interestingly,
neurons treated with 500 µM of the compound did not show this effect, suggesting a “Ushaped” dose-effect function for this effect, a reported effect for M1 muscarinic
receptors (Thomsen et al., 2012).
We then evaluated whether in vitro cholinergic regulation also changes the NMD+
product. Compared to saline treatment, carbachol shifted the expression of
hnRNPA2/B1 RNA towards the NMD insensitive full-length mRNA product (Fig 6.5F).
Furthermore co-treatment with atropine blocked this effect and returned the ratio to
control levels, similar to what we observed for hnRNPA2/B1 protein levels (Fig. 6.5C).
These data suggest that the ratio of NMD+ hnRNPA2/B1 gene products predict change
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in protein levels, and that the regulation of NMD sensitivity is dependent on muscarinic
signalling.
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Figure 6.5. Muscarinic Regulation of hnRNPA2/B1 Translation. (A) Representative
immunofluorescence images and (B) Western blots with quantification of hnRNPA2/B1
protein levels in primary hippocampal neurons after treatment with carbachol for 48
hours. hnRNPA2/B1 expression was normalized to actin (n=3, Data are mean ± SEM.
*p<0.05). (C) Representative Western blot and quantification of hnRNPA2/B1
expression in primary hippocampal neurons after treatment with carbachol,
mecamylamine, and atropine. hnRNPA2/B1 expression was normalized to actin (n=4,
*p<0.05). The values plotted are averaged from the gels of each individual experiment.
(D) Representative Western blot and quantification of hnRNPA2/B1 expression in
hippocampal tissue of M4 muscarinic knockout mice (n=7), and M1 receptor knockout
mice (n=7 Control and n= 8 M1 KO mice *p<0.05). (E) M1 muscarinic receptor agonist
AF102B significantly increased hnRNPA2/B1 protein levels in primary hippocampal
cultures (n=5 *p<0.05). (F) Increased expression of the full-length hnRNPA2/B1
transcripts of cells treated with carbachol is blocked by the administration of atropine
(n=5, *p<0.05). (G) Proposed model wherein muscarinic M1 receptors signaling would
shift the ratio of hnRNPA2/B transcripts, favouring the full length transcripts, and
therefore increase translation of the protein.
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Figure 6.5. Muscarinic Regulation of hnRNPA2/B1 Translation.
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6.5 Discussion
In this study we combined a variety of in vivo and in vitro techniques to evaluate the
contribution of cholinergic signalling to expression levels of hippocampal hnRNPA2/B1
protein. Using a number of mouse lines, we demonstrated that hnRNPA2/B1 protein
levels in the hippocampus are exquisitely sensitive to changes in cholinergic tone.
Interestingly, we observed no change in hnRNPA2/B1 protein levels in striatum- specific
VAChT mutants, whereas there is a body of evidence that cholinergic signalling can
affect the levels of this protein in both cortical and hippocampal regions in vivo (Berson
et al., 2012; Kolisnyk et al., 2013a). Given these findings it is likely that it is an intrinsic
property of the target cells themselves that dictate their change in hnRNPA2/B1
translation in response to cholinergic activity. Our results highlight the critical role of the
Gq coupled M1 muscarinic receptor in governing hnRNPA2/B1 protein levels.
Unlike the rare hnRNPA2/B1 mutation that increases aggregation and nuclear exclusion
(Kim et al., 2013), we did not find aggregation of hnRNPA2/B1 in mice with forebrain
cholinergic deficiency, suggesting that in these mice, and likely in AD brains,
hnRNPA2/B1 dysfunction occurs by a separate and distinct mechanism. Furthermore,
we did not see an increase in ubiquitination, suggesting that changes in hnRNPA2/B1
protein levels do not occur at the post-translational level. In line with this, we found that
it may in fact be abnormal translation that drives regulation of hnRNPA2/B1.
A common mechanism for the regulation of the translation of RNA binding proteins is
regulation by unproductive splicing and translation (RUST), where the alternative
spicing of a transcript affects its translation efficiency (Lareau et al., 2007; McGlincy and
Smith, 2008). This may serve as a potential mechanism for cholinergic control of the
translation of this RBP. Accordingly, we found that the levels of hnRNPA2/B1 transcripts
were maintained in cholinergic-deficient mice or AD brains (Berson et al., 2012), but
hnRNPA2/B1 translation was selectively decreased. Notably, hnRNPA2/B1 has been
shown to be auto-regulated by a RUST mechanism involving alternative splicing in its
3′-untranslated region that leads to NMD driven by mTOR1C (Dempsey, 2012;
McGlincy et al., 2010), which is a key effector of muscarinic receptor signalling (Slack
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and Blusztajn, 2008). Correspondingly, we found that cholinergic control of
hnRNPA2/B1 translation is mediated by M1 muscarinic receptors (Figure 6.5G).
Targeting the interactions between RBPs and RNA may serve as a new potential
therapeutic avenue to restore the RNA-editing deficits observed in neurodegenerative
diseases (Bai et al., 2013; Berson et al., 2012; Qian and Liu, 2014; Tollervey et al.,
2011). A number of substances, including regularly prescribed antibiotics, have been
shown to non-selectively alter alternative splicing in the brain (Graveley, 2005; Kole et
al., 2012; Tollervey et al., 2011), however this approach lacks the ability to specifically
target “impaired” RBP-RNA interactions.
Cholinergic failure is one of the hallmarks of AD, with the basal forebrain cholinergic
system being heavily affected by the disease (Whitehouse et al., 1982). Data from the
ADNI (Alzheimer’s Disease Neuroimaging Initiative) consortium, has linked cholinergic
failure in AD to both pathological outcomes (Teipel et al., 2014) as well as cognitive
impairments in AD (Grothe et al., 2014). Further evidence for the importance of
cholinergic signalling to the etiology of AD comes from clinical evidence that the longterm use of anticholinergic medication, specifically anti-muscarinic drugs, significantly
increases the risk of developing dementia (Gray et al., 2015). Interestingly,
administration of anti-muscarinic agents to AD patients exacerbates their symptoms
(Lim et al., 2015). Together these results suggest a crucial role for cholinergic tone in
AD, with specific importance of muscarinic signalling.
The main pathological hallmarks of AD are the accumulation of Aplaques and of
hyperphosphorylated tau (Huang and Jiang, 2009). M1 muscarinic signalling has been
linked to both of these processes. Activation of the receptor has been shown to alter tau
phosphorylation both in vitro (Sadot et al., 1996) and in vivo (Genis et al., 1999).
Moreover, deletion of M1 muscarinic receptors increases Arelated pathology in a
transgenic mouse model overexpressing mutated APP (Davis et al., 2010).
Furthermore, M1 agonists have been shown to reverse Arelated pathology in mouse
models of AD (Caccamo et al., 2006). These findings suggest that M1 receptors are key
mediators of AD pathology. How hnRNPA2/B1 protein expression may contribute to
pathology remains to be determined.
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Cholinergic failure also plays an important role in one of the most important and
apparent cognitive deficits of AD, memory loss (Bartus et al., 1982). There is a strong
correlation between loss of basal forebrain cholinergic neurons and cognitive
functioning in AD patients. Furthermore, mice with a forebrain specific deletion of
VAChT have severe deficits in performance on the Paired-associates learning (PAL)
touchscreen task (Al-Onaizi et al., 2016), a rodent version of the Cambridge
Neuropsychological Test Automated Battery (CANTAB) tests used in humans, which
has been shown to be selective for the memory impairments in AD patients (Egerhazi et
al., 2007). Importantly, lentiviral mediated knockdown of hnRNPA2/B1 also produced
cognition impairments in mice (Berson et al., 2012).
Taken together, our findings indicate an intricate relationship between M1 muscarinic
signalling and hnRNPA2/B1 translation. These findings lay the ground work for new
therapeutic avenues for the treatment of AD. Specifically, it points to the potential of M1
muscarinic positive allosteric modulators to improve long-term changes in RNA
metabolism and cognitive deficits due to cholinergic malfunction in AD. Noteworthy M1
muscarinic positive allosteric modulators have shown promising results to improve
cognition in non-human primates (Lange et al., 2015). Our results show novel
mechanisms by which log-term cholinergic dysfunction can regulate target cells.
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7

Chapter 7

Summary and Conclusion

7.1 Summary of Major Findings
Cholinergic dysfunction is a hallmark of Alzheimer’s disease. This dysfunction is
hypothesized to underlie cognitive symptoms of the disease. However, the exact
contribution of cholinergic dysfunction to the etiology of the disease is unclear. In this
thesis, we sought out to determine whether alterations in cholinergic signalling in the
brain (either increased or decreased) leads to changes in cognitive functioning.
Furthermore our goal was to determine the molecular mechanisms of cholinergic
dysfunction, and how changes in these mechanisms can contribute to the pathological
outcomes in Alzheimer’s disease.

In chapter 2 of this thesis, we characterized a mouse line which carries several copies
of the vesicular acetylcholine transporter (VAChT) gene. We showed that increase in
VAChT gene copy number leads to overexpression of functional VAChT with
consequent increase in cholinergic tone. We then carried out a series of behavioural
assays to determine the implications on cognition of increased cholinergic tone. We
demonstrated that these mice have marked improvement in motor endurance. However,
they also have severe cognitive deficits, including attention deficits and dysfunction in
working memory and spatial memory. These data, taken together, showed that
increased VAChT expression increases acetylcholine release in the brain and that this
is severely detrimental to the cognitive processing of the animals. Although cholinergic
tone is reduced in the Alzheimer’s brain, the data presented highlight the importance of
striking a balance in cholinergic signalling in the brain.

In chapter 3, we endeavoured to evaluate the effect of long-term cholinergic dysfunction
in the forebrain. We evaluated the involvement of acetylcholine to forebrain function by
genetically eliminating VAChT from this population of neurons. Included in the

382
acetylcholine innervated forebrain regions is the PFC, a key brain region in the
regulation of executive functioning. We therefore tested mice on measures of executive
function. This was assessed using both a pairwise visual discrimination test and a 5choice serial reaction time task (5-CSRT). Results of the pairwise test showed that
VAChT-mutant mice were able to learn the initial stimulus pairing, however when the
stimulus pairings were switched the mice failed to learn the new stimulus-reward rule.
Similarly, on the 5-CSRT the VAChT mutant animals were able to learn the task, but
once the stimulus presentation length was reduced (increasing attentional demand), the
mice showed prominent impairments on the task compared to controls.

Given the impaired cognition of the animals, we performed in vivo magnetic resonance
spectroscopy, to assess potential changes in PFC circuitry and neuronal function. This
analysis showed changed levels of the metabolites taurine and lactate. The results
suggested changes in neuronal metabolism in the PFC of the VAChT-deficient mice.
The PFC of the mice showed a severe decrease in the protein levels of the RNA binding
protein heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1). Accordingly, a
number of genes in the PFC of VAChT-deficient mice were found to be alternatively
spliced. Amongst these genes was pyruvate kinase M, a key enzyme involved in lactate
metabolism. In chapter 3, we were able to determine the impact of cholinergic
dysfunction in the forebrain and furthermore were able to determine some of the
molecular mechanisms that result from cholinergic dysfunction. We therefore sought to
expand upon these two key findings in the following chapters.

Chapter 4 was specifically designed to dissect the mechanism underlying cholinergic
control of attention, based on our findings in chapter 3 that mice lacking release of
acetylcholine into the PFC were impaired on a task of attention. Chapter 4 was
dedicated to determining the roles of nicotinic cholinergic receptors in this task.
Significant literature exists examining the role of 2 nicotinic receptors (b2nAChR) on
the 5-CSRT, however, the role of the α7 nicotinic ACh receptor (α7nAChR) in attention
is ambiguous. To clarify the role of the receptor on the task, we trained α7nAChR
knockout mice on the 5-CSRT task. α7nAChR knockout mice showed impairments in
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measures of sustained attention. This was assessed by comparing the performance on
the first half of the task to the second half. We were able to completely reverse these
impairments by treating mutant mice with an agonist of the β2nAChR. In addition,
treating α7nAChR knockout mice with β2nAChR agonist activated the same
biochemical response in the PFC as did the administration of a α7nAChR agonists in
control, non-transgenic mice. The work presented in chapter 4 of this thesis details a
complex interplay between the α7nAChR and β2nAChR receptors. This complex
relationship regulates attentional performance on the 5CSRT task in mice. These data
provide detailed mechanistic insight into cholinergic regulation of attention.

In chapter 5, we pursued the specific molecular mechanisms that underlie long-term
cholinergic dysfunction in the brain. To achieve this, we used mice with a deletion of
VAChT in the forebrain in order to model cholinergic aberrations. We then employed
RNA-sequencing of hippocampal samples from these mice to study genome-wide
transcriptome changes. Using this approach we were able to show that cholinergic
dysfunction produces alterations in RNA metabolism. We then determined the impact of
these changes in RNA metabolism by focusing our studies on changes in key
transcripts. We showed that VAChT-mutant mice had abnormal splicing of
the BACE1 gene, and that this was regulated by hnRNPA2/B1. This change in BACE1
splicing lead to an overall increase in protein levels of BACE1, altered APP processing
and accumulation of soluble Aβ1-42 in the brain of these animals. These pathological
changes also involved age-related increased tau hyper-phosphorylation, and other
neuronal abnormalities, ultimately leading to neuronal death in the
hippocampus. These results indicate that alterations in RNA metabolism are a key
mechanism by which cholinergic signalling in the brain can trigger Alzheimer’s-like
pathology in mice.

In chapter 6, we identified specific cellular mechanisms underpinning cholinergic
regulation of hnRNPA2/B1. In both chapters 3 and 5 we provided evidence of the
importance of this relationship to neuronal function. To study this relationship, we
employed a series of genetically modified mouse models, pharmacology, and a
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combination of in vivo and in vitro techniques. In VAChTNkx2.1-Cre-flox/flox transgenic mice,
we showed that reducing cholinergic signalling decreased protein levels of
hnRNPA2/B1. Genetic manipulations that increased cholinergic signalling, by increasing
gene copy number of VAChT, had the opposite effect, increasing hnRNPA2/B1 protein
levels. We then provided biochemical evidence that regulation of hnRNPA2/B1 protein
levels is not mediated by transcription, protein aggregation, or protein degradation. We
found however that cholinergic signalling regulates the translation of hnRNPA2/B1.
Furthermore, by combining in vitro and in vivo experiments, we demonstrated that M1
muscarinic receptors control hnRNPA2/B1 protein levels. In this chapter we outlined a
sophisticated regulatory mechanism of hnRNPA2/B1 by cholinergic activity,
complimenting findings of previous chapters.

7.2 Limitations and Future Studies.

The mouse line used for studies presented in Chapter 2, the ChAT-ChR2-EYFP mice
were originally designed for optogenetic experiments. In these mice, the BAC construct
was engineered to express an excitatory rhodopsin specifically in cholinergic neurons.
However given the unique organization of the cholinergic gene locus (See Chapter
1.2.1), the VAChT gene is present in the BAC. Given our findings that these mice
present several additional functional gene copies of VAChT, the utility of these mice for
optogenetic experiments is questionable. Therefore future endeavours should focus on
this question. A second mouse line was also generated using this same approach (Zhao
et al., 2011), the B6.Cg-Tg(Chat-COP4*H134R/EYFP,Slc18a3)5Gfng/J mouse line.
Evaluating whether or not this second mouse line also has additional copy numbers of
VAChT would be critical. If these mice do not have a functional increase in VAChT it
would be of importance to compare findings from optogenetic stimulation in the ChATChR2-EYFP mice to evaluate the contribution of VAChT overexpression to these
studies.
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In chapter 3 of this thesis we used a genetic method to target the elimination of VAChT
from the basal forebrain. This method is not without limitations and differential
approaches should be used to confirm our findings. We have validated the use of
stereotaxic injection of Cre viruses into specific populations of neurons to delete VAChT
(Al-Onaizi et al., 2016). Delivering a Cre virus to the nucleus basalis magnocellularis
(NBM) would provide a means to evaluate the specific contribution of cholinergic tone in
the PFC, without manipulating acetylcholine release in other brain regions. Viral
mediated elimination of VAChT to the NBM would also rule out potential developmental
changes contributing to the phenotype of forebrain VAChT-deficient mice.
The major phenotype we identified for α7nAChR knockout mice in chapter 4 was
impaired sustained attention. We were able to reverse this phenotype by activating
2nAChRs. A critical step would be to provide electrophysiological evidence that the
drug effects occur in the PFC, as we only provided correlative evidence that the
interaction between these receptors occurs in the PFC. One possibility is that the
interplay between these receptors occurs at the same synapses in the PFC.
Conversely, it is possible that the α7nAChR signalling and the 2nAChR signalling are
separate and distinct. In agreement with the former possibility, α7nAChR (Duffy et al.,
2009) and 2nAChR (Poorthuis et al., 2013) are found both pre and post-synaptically in
the PFC. Genetically eliminating these receptors from specific synaptic locations would
provide valuable insight into the exact interaction between these receptors and their
relative contributions to attention.

In Chapter 5 of the thesis we used an in silico analysis of the data from our RNASequencing experiment, to identify hnRNPA2/B1 as one of the RNA binding protein
which mediates the alternative splicing in the hippocampus of forebrain VAChT-mutant
mice. However hnRNPA2/B1 was not the sole RNA-binding protein identified by this
analysis. Other candidates for potential splicing factors, identified in chapter 5 are RNA
binding proteins that have also been implicated in neurodegenerative disorders such as
CLEF4 (Gallo and Spickett, 2010), SRSF2 (Raj et al., 2014) and SART3 (Stamper et
al., 2008). Similar in vivo and in vitro approaches used to study hnRNPA2/B1 in
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chapters 5 and 6 could elucidate how cholinergic tone could regulate these proteins.
Furthermore, the RNA binding protein analysis was limited to exon inclusion events,
leaving an entire half of the data (the exon exclusion events) to be subjected to the
same analysis. Analysing the exon exclusion event data will allow us to expand upon
our findings and determine novel mechanisms by which cholinergic signalling can
regulate RNA-metabolism.
The basis of the argument in chapter 5 is that VAChT deficiency leads to increased
BACE1 activity, by mediating hnRNPA2/B1 protein levels. We proposed that this
increase in BACE1 alters APP processing and increases soluble A. It will therefore be
critical to evaluate this hypothesis in vivo. To determine a causal role for BACE1 in the
observed altered APP processing in the forebrain VAChT mutant mice, it would be
important to inhibit BACE1 in vivo. This could be done either genetically or
pharmacologically, and APP processing and soluble Alevels should then be assessed.
In chapter 6 we provided evidence that M1 muscarinic receptors regulate the translation
of hnRNPA2/B1in hippocampal neurons. The M1 muscarinic receptor is a G q coupled
receptor and can signal through Gq and Gs (Thomas et al., 2008). This receptor can
signal through various second messenger pathways including PKC signalling, PIP2 and
modulation of intracellular calcium levels (Delmas and Brown, 2005). Given the potential
signalling diversity of this receptor, determining the specificity of how M1 muscarinic
receptors increases translation of hnRNPA2/B1 is critical to target this interaction for
potential therapeutic benefits.
It would also be an important line of study to determine the time course of cholinergic
regulation of hnRNPA2/B1. All in vitro studies presented in chapter 6 involved treating
cultured neurons for 48 hours. Determining the shortest amount of time needed to
change hnRNPA2/B1 protein levels would be critical for understanding the mechanism
of regulation. These findings could then be validated in vivo. This could be achieved by
pharmacological or chemogenetic based approaches, to stimulate M1 muscarinic
pathway in mice.
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7.3 Significance of Research and Conclusion.
Although the specific mechanisms by which cholinergic signalling in the brain can
regulate cognition and neuronal function remain elusive, the data put forward in this
thesis demonstrate the importance of cholinergic tone to both cognition and AD
molecular pathology. A long line of literature has examined the role of cholinergic
signalling in cognitive functioning. The data presented in this thesis advance this body
of knowledge and expands upon how the different receptors for acetylcholine regulate
different cognitive functions. In addition, we categorized for the first time the molecular
hallmarks of long-term cholinergic dysfunction, using a wide range of approaches. In
this thesis, I demonstrated a clear link between cholinergic dysfunction and the
development of age-dependant molecular pathology in mice. Notably, I showed that
some of these molecular changes brought on by long term cholinergic dysfunction are
mediated by M1 muscarinic receptors. The data provided evidence that targeting this
receptor may be beneficial to correct molecular alteration in patients with
neurodegenerative disorders.
The current primary treatment for Alzheimer’s disease in the clinic are
acetylcholinesterase inhibitors. This line of treatment has shown improvements in
cognition have been observed in patients, and are viewed as being moderately
beneficial for patients (Courtney et al., 2004; Dubois et al., 2015; Kaduszkiewicz et al.,
2005; Raina et al., 2008; Winblad et al., 2006). The data put forward in the thesis
highlights key mechanisms by which cholinergic signalling in the brain can regulate
cognition and molecular pathology. These mechanisms may serve as novel targets for
the development of novel therapeutic interventions in humans affected by dementia.
The discovery and development of positive allosteric modulators of cholinergic
receptors (especially M1 muscarinic receptors) present an exciting new approach to the
development of therapeutics for dementia, which could serve to target many of the
mechanisms studied in this thesis.
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Acetylcholine, the first chemical to be identified as a
neurotransmitter, is packed in synaptic vesicles by the activity
of VAChT (vesicular acetylcholine transporter). A decrease in
VAChT expression has been reported in a number of diseases,
and this has consequences for the amount of acetylcholine loaded
in synaptic vesicles as well as for neurotransmitter release. Several
genetically modified mice targeting the VAChT gene have been
generated, providing novel models to understand how changes in
VAChT affect transmitter release. A surprising finding is that most
cholinergic neurons in the brain also can express a second type of
vesicular neurotransmitter transporter that allows these neurons
to secrete two distinct neurotransmitters. Thus a given neuron

can use two neurotransmitters to regulate different physiological
functions. In addition, recent data indicate that non-neuronal cells
can also express the machinery used to synthesize and release
acetylcholine. Some of these cells rely on VAChT to secrete
acetylcholine with potential physiological consequences in the
periphery. Hence novel functions for the oldest neurotransmitter
known are emerging with the potential to provide new targets for
the treatment of several pathological conditions.

INTRODUCTION

homology with VAChT in their transmembrane segments. These
transporters use the electrochemical gradient generated by a Vtype proton ATPase to transport and accumulate neurotransmitters
in vesicles [8].
Synaptic vesicles accumulate thousands of ACh molecules
to form a quantum. Interestingly, in vitro analysis suggests
that VAChT is a very slow transporter [10], thus serving as a
limiting factor in the recycling of functional cholinergic synaptic
vesicles (loaded with ACh) to maintain neurotransmitter release.
Indeed, recent experiments in neurons using glutamate uncaging
indicate that the VGLUT (vesicular glutamate transporter) is also
a very slow transporter [11]. Therefore expression of vesicular
transporters and their activity may have major influences on the
release of ACh. In the present review we will evaluate novel
genetic insights regarding the role of VAChT for transmitter
release in neuronal and non-neuronal cells as well as the functional
consequences of alterations in VAChT expression. Excellent
reviews on the use of genetically modified mice to probe for the
specific roles of subtypes of muscarinic and nicotinic receptors
have been published previously [12–18], so we will not discuss
these results.

Cholinergic neurons in the CNS (central nervous system) and in
the periphery secrete the neurotransmitter ACh (acetylcholine)
to regulate a plethora of physiological functions. In addition to
ACh, many cholinergic neurons in the brain can also secrete
the neurotransmitter glutamate [1], whereas cholinergic neurons
in the periphery can also secrete a number of peptides and
ATP, suggesting the potential for sophisticated modulation of
physiological functions by these neurons. Moreover, ACh is also
present in a number of non-neuronal cells, where it may have
paracrine or autocrine functions [2,3]. Given its cationic nature,
ACh does not diffuse effectively through membranes; therefore,
a transport mechanism is required for this neurotransmitter to be
secreted. Although certain organic cation transporters can carry
ACh [2], both in neurons, as well as certain non-neuronal tissues,
this chemical messenger is first stored in vesicles prior to being
released by exocytosis [4–6].
ACh synthesis (Figure 1) depends on the uptake of
the ACh precursor choline by CHT1 [high-affinity choline
transporter/SLC5A7 (solute carrier family 5 member 7)] that is
mainly expressed in cholinergic neurons [7], although it can also
be found in certain non-neuronal cells [2,5]. In the cytoplasm
of nerve endings, ACh is synthesized by the enzyme ChAT
(choline acetyltransferase) (EC 2.3.1.6) and is then loaded into
synaptic vesicles by VAChT [vesicular ACh transporter/SLC18A3
(solute carrier family 18 member 3)] [4,8]. VAChT is a 12
transmembrane domain protein that is part of a Major Facilitator
Superfamily of transporters [9]. This superfamily also includes
the neurotransmitter transporters VMAT (vesicular monoamine
transporter) 1 and VMAT2, which share a high degree of

Key words: Alzheimer’s disease, heart failure, Parkinson’s
disease, sepsis, synaptic vesicle, vascular dementia.

VAChT BIOCHEMISTRY AND CELL BIOLOGY

The structure of VAChT has not been resolved experimentally,
but a three-dimensional model for this transporter has been
proposed based on structural information from two members
of the Major Facilitator Superfamily (lactose permease and
glycerol 3-phosphate) [9]. The 12 transmembrane domains of
VAChT are proposed to fold into two main bundles comprising

Abbreviations used: ACh, acetylcholine; ChAT, choline acetyltransferase; CHT1, high-affinity choline transporter 1; CNS, central nervous system;
DA, dopamine; GABA, γ-aminobutyric acid; GI, gastrointestinal; hnRNP, heterogeneous nuclear ribonucleoprotein; IL, interleukin; KD, knockdown; KDHET ,
heterozygous KD; KDHOM , homozygous KD; KO, knockout; LDCV, large-dense core vesicle; LTP, long-term potentiation; MEPP, miniature-endplate potential;
MSN, medium spiny neuron; MWM, Morris water maze; NMJ, neuromuscular junction; OCT, organic cation transporter; PKC, protein kinase C; VAChT,
vesicular ACh transporter; VGLUT, vesicular glutamate transporter; VMAT, vesicular monoamine transporter.
1
Correspondence may be addressed to either of these authors (email
or
).

c The Authors Journal compilation 
c 2013 Biochemical Society

266

Figure 1
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Schematic drawing of ACh storage and release

(1) Uptake of the ACh precursor choline by CHT1 that is mainly expressed in cholinergic neurons. (2) In the cytoplasm of nerve endings, ACh is synthesized by the enzyme ChAT, and then it is
loaded into synaptic vesicles (3) by VAChT. (4) Upon arrival of the nerve impulse, vesicles fuse to the plasma membrane and release the neurotransmitter that can then signal through nicotinic (N)
and muscarinic (M) receptors (5). ACh is rapidly degraded into acetate and choline (6) by the enzyme AChE (acetylcholinesterase). The number of transmembrane domains for CHT1 is 13 [160] and
for VAChT is 12. These are not shown faithfully in the Figure due to space limitations. Ch, choline.

transmembrane helices I–VI and VII–XII respectively [19], with
N- and C-terminal regions directed to the cytoplasm. According
to this model, a central transport path is formed by these two
bundles and a rocker motion of the bundles allows for exposure
of the substrate-binding site to the cytoplasm or to the interior of
the synaptic vesicle. VAChT exchanges two luminal protons for
each cytoplasmic ACh molecule [20]. Site-directed mutagenesis
studies suggest that the ACh-binding site is located close to Trp331
at the beginning of transmembrane helix VIII, in the luminal part
of the transport channel [21]. Asp398 is suggested to be involved
in translocation of one of the protons [22,23].
Studies in PC12 cells overexpressing human VAChT [10]
indicate that transport of [3 H]ACh by VAChT is saturable, with an
apparent K m value of 1 mM and a V max value of 580 pmol/min/mg.
In vivo, VAChT concentrates ACh inside synaptic vesicles by
100-fold. This gradient is around 30-fold smaller than that
predicted from the available free energy from the exchange
of two protons [8], suggesting that ACh storage is regulated
[4,24]. Although the mechanisms for regulation are unknown,
it has been demonstrated that the amount of ACh stored per
vesicle depends on the amount of VAChT that is expressed
[25–27]. Thus VAChT is likely to be rate limiting for ACh
release. Indeed, early pharmacological experiments using the drug
vesamicol [( − )-trans-2-(4-phenylpiperidino) cyclohexanol], the
prototype VAChT inhibitor, provided evidence that ACh storage
in synaptic vesicles is critical for release; although considerations
of pharmacological specificity in vivo need to be considered
(for a review see [24]). For example, early work used high
concentrations of vesamicol and binding to other unrelated
targets was observed in the peripheral nervous system [28].
Also, interaction with sigma receptors in the brain has been
described. However, novel vesamicol analogues have been produced showing higher specificity for VAChT [29,30].
In the striatum, cholinergic neurons were shown to express
VGLUT3, and this transporter activity influences ACh loading in
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synaptic vesicles by a process named vesicular synergy [31]. The
exact mechanism is not yet clear, but it is likely that negatively
charged glutamate may affect the pH value to increase transport
activity [1,32]. Hence, in addition to accumulating glutamate
inside cholinergic vesicles, VGLUT3 may also influence ACh
storage. Dopaminergic neurons, on the other hand, express
VGLUT2, and DA (dopamine)/glutamate co-transmission has
been suggested to play important roles during development and
to regulate DA-dependent functions [33,34]. Interestingly, recent
experiments suggest that the closely related transporter, VMAT2,
mediates release of GABA (γ -aminobutyric acid) in the striatum
[35]. This adds to the remarkable lack of specificity for these
transporters. Indeed, choline can also be taken up by VAChT,
although the affinity for ACh is 7-fold higher than that of choline
[36,37].
Vesamicol, a tertiary amine that spontaneously passes through
membranes, binds to VAChT and inhibits the transport of ACh
[8,22,23,38]. Vesamicol is a non-competitive inhibitor of
ACh transport, exhibiting a dissociation constant of 20 nM.
Phosphorylation of VAChT at a PKC (protein kinase C) site in
the C-terminal domain of VAChT blocks inhibition of transport
by vesamicol and a high-affinity analogue of vesamicol [39–
41]. However, it has not been determined whether VAChT
phosphorylation is important for the modulation of ACh storage
in vivo. Vesamicol and related compounds bind to VAChT with
high affinity and readily cross the blood–brain barrier, therefore
intensive efforts have been dedicated to develop analogues of
vesamicol that emit either a positron or a gamma photon, suitable
for imaging by PET (positron emission tomography) or SPECT
(single-photon emission computed tomography) respectively
[29,30,42–44]. These compounds have potential applications in
the diagnosis of a number of diseases characterized by cholinergic
dysfunction including Alzheimer’s disease, Down’s syndrome,
Parkinson’s disease, autonomic dysfunction in cardiovascular
diseases and schizophrenia.

VAChT expression and ACh storage
VAChT LOCALIZATION AND TRAFFICKING

The molecular basis for localization of vesicular transporters in
synaptic vesicles has been reviewed elsewhere [45,46]. VAChT
is found predominantly in synaptic vesicles in nerve terminals
[47]. Early work on the trafficking of VMATs and VAChT
indicated that, in cultured cells, these transporters differ in
their localization; VAChT was predominantly present in synaptic
vesicles, whereas VMATs were found mostly in LDCVs (largedense core vesicles) [48-50]. Synaptic vesicles and LDCVs are
present in most neurons and may regulate the secretion of
classical neurotransmitters and peptides or other neuromodulators
respectively. Additional studies demonstrated that the C-terminal
region of VAChT contains a di-leucine motif required for clathrinmediated endocytosis [51–54]. Interestingly, this di-leucine motif
is regulated by a phosphorylation site that can alter the proportion
of VAChT present in small synaptic vesicles or LDCVs [49],
suggesting that ACh storage in distinct types of vesicles might
occur and be subject to regulation. The C-terminal region of
VAChT is also important for its localization in small synaptic
vesicles [50,53,55]. Extensive mutational analysis failed to
uncover other motifs in the C-terminal tail, other than the dileucine motif, that can influence VAChT trafficking [53,55].
Interestingly, endocytosis of CHT1, which is also located in
synaptic vesicles, is dependent on clathrin and on a di-leucine-like
motif present in its C-terminal tail [7,56–58].
A small number of proteins have been described to interact
with VAChT. Notably, clathrin adaptor proteins interact with the
C-terminal tail of VAChT [52]. In addition, a functional interaction
between VAChT and synaptobrevin has also been described in
Caenorhabditis elegans [59]. These interactions are believed to
participate in VAChT trafficking. SEC14, a phosphatidylinositol
transfer protein, has also been shown to interact with VAChT
[60]; however, the functional consequences of this interaction are
unknown.
VAChT expression levels have been shown to change in
response to drug treatments [61], as well as in diseases including
Alzheimer’s disease [62,63], sepsis [64], hypertension [65] and
Huntington’s disease [66]. Small changes in the expression of
VAChT in vesicles may have the potential to change synaptic
transmission, as the amount of transmitter released by a single
vesicle does not seem to be enough to saturate post-synaptic
receptors [67]. This appears to be the case at the neuromuscular
junction, as suggested by the extensive variability of quantum
size [24]. In central cholinergic terminals, especially where
cholinergic terminals do not have opposed post-synaptic cells
forming classical synapses, volume transmission may not be
enough to saturate ACh receptors [68]. However, classical forms
of neurotransmission may also be relevant for ACh in the brain.
For example, VAChT-expressing terminals are found close to α7
nicotinic ACh receptors thus suggesting that classical synapses
are involved in fast transmission of information by ACh in the
brain, in addition to volume transmission [69].
REGULATION OF ACh RELEASE BY VAChT

The relationship between ACh storage and release is complex
[24]. Experiments using vesamicol and vesamicol analogues
have demonstrated that inhibition of ACh transport into synaptic
vesicles decreases ACh release from nerve terminals [8,24].
Overexpression of VAChT in immature neurons [25] has also
been used to investigate the in vitro relationship between ACh
storage and release. These elegant experiments demonstrated that
increased VAChT expression augmented the amplitude (quantal
size) and frequency of miniature excitatory currents, presumably
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by increasing the number of vesicles capable of storing ACh
[25]. In addition, mice with increased VAChT expression show
increased ACh release [70]. Other experiments demonstrated that
VAChT activity is required for physiological storage of ACh,
as VAChT-KO (knockout) mice do not survive following birth
owing to compromised respiratory activity [71]. Decreased levels
of VAChT affect both the peripheral nervous system and the CNS
[26,27,71–76], suggesting that, in contrast with the VMAT family
which has two members [77], VAChT is the unique transporter
for ACh. Neuromuscular phenotypes in VAChT-KO mice were
similar, if not identical, to phenotypes described for ChAT-KO
mice [78,79]. The normal apoptotic process that prunes the
number of motoneurons during development is compromised
by lack of VAChT and motoneuron numbers are increased.
At the NMJ (neuromuscular junction), nerve endings show
increased size and number. Moreover, skeletal muscle presents
degeneration and atrophy indicating that, during development,
secretion of ACh required for neuromuscular development
depends mainly on VAChT activity. Remarkably, the levels of
ACh in terminals lacking VAChT were increased, suggesting
that feedback inhibition of ACh synthesis is not operational in
cholinergic nerve terminals [71].
Surprisingly, electrophysiological analysis of VAChT-KO mice
detected small-amplitude MEPPs (miniature-endplate potentials)
of very low frequency in the NMJ preparations of null embryos,
suggesting that some diffusion and accumulation of ACh in
synaptic vesicles occurs in the absence of VAChT. However,
this process is insufficient to sustain minimal levels of ACh
release at the NMJ. In agreement with these data, release of
newly synthesized ACh from brain synaptosomes is completely
abolished in VAChT-KO mice [71].
Interestingly, a 50 % decrease in VAChT expression in
heterozygous VAChT-KO mice did not affect muscular function
[72]. Conversely, these mutant mice present behavioural deficits
in object recognition memory [72,80]. These results suggest that
central cholinergic synapses are much more dependent on VAChT
than NMJ terminals to sustain neurotransmitter release. This is
probably because of reduced numbers of synaptic vesicles, or
their frequent reuse, in central nerve terminals compared with
the NMJ. Further insight into the mechanisms through which
altered VAChT expression regulates ACh release came from
studies using VAChT-KD (knockdown) mice [26,27]. VAChTKDHET (heterozygous KD) mice show a 40 % decrease in VAChT
expression. Similar to heterozygous VAChT-KO mice, VAChTKDHET mice do not present muscular dysfunction. Microdialysis
analysis in freely moving mice showed that VAChT-KDHET mice
have decreased levels of ACh release in the brain. These mutants
show deficits in object recognition memory and social recognition
memory [26]. These results suggest that the NMJ has a much
higher safety factor than central synapses to maintain ACh release.
VAChT-KDHOM (homozygous KD) mice have a 70 % decrease
in VAChT expression and provide a model for understanding
the consequences of profound decrease in VAChT expression for
ACh release. Quantal analysis demonstrated that VAChT-KDHET
mice have normal MEPP frequency and slightly reduced MEPP
amplitude, indicative of the amount of ACh within vesicles.
In contrast, VAChT-KDHOM mice show reduced amplitude of
MEPPs, consistent with decreased ACh storage, but also a 50 %
decrease in the frequency of MEPPs [26,27]. As a consequence
of these molecular changes, VAChT-KDHOM mice are myasthenic.
Moreover, endplate potentials were also reduced in these mutants
[27]. Independent analysis of exocytosis and endocytosis using the
fluorescent dye FM1-43 indicated that synaptic vesicle fusion and
recycling were not affected in these mutant mice. Furthermore,
post-tetanic potentiation is compromised in the NMJ of these
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Figure 2
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Cholinergic nerve terminal in mice with decreased VAChT expression

The left-hand side shows a nerve terminal in wild-type (WT) mice. The right-hand side shows a nerve terminal in VAChT-KDHOM mice. Some synaptic vesicles will have no transporter and will be
unable to store significant levels of ACh. These vesicles will compete for release sites and decrease fusion of vesicles fully loaded with ACh. An animated version of this Figure can be found at
http://www.biochemj.org/bj/450/0265/bj4500265add.htm. Ch, choline; M, muscarinic receptor; N, nicotinic receptor.

VAChT mutant mice, suggesting that ACh storage can regulate
synaptic plasticity [27]. Together, these experiments suggest that
reduced levels of VAChT affect ACh storage in synaptic vesicles
(Figure 2).
The number of copies of VAChT in a synaptic vesicle
is unknown. Studies considering other vesicular transporters
estimated that one to three transporters are present in one synaptic
vesicle [24]. However, central synapses may contain up to ten
copies of neurotransmitter transporters [81]. It is tempting to
hypothesize that, in conditions of reduced VAChT expression,
some synaptic vesicles will have no transporter and will be unable
to store significant levels of ACh (Figure 2). These vesicles
would not be able to sustain ACh release; however, because
exocytosis and endocytosis in these ACh-empty vesicles is
normal, they would compete for releasing sites at the NMJ. The net
effect would be a reduction in the frequency of fusion of vesicles
containing ACh, which can be detected using electrophysiology
(MEPP frequency). These results suggest that even small changes
in the levels of VAChT found in Alzheimer’s disease and other
pathological conditions would have drastic effects on ACh release
in the brain, with a reduction in the amount of transmitter released
by vesicles, but also a decrease in the number of synaptic vesicles
capable of sustaining ACh release.

VAChT AND CHOLINERGIC TONE IN THE CNS

Cholinergic tone has been proposed to modulate a number of
brain functions including learning, memory, attention, arousal,
sleep, food intake and drug abuse [82–88]. Owing to space
limitations we will not discuss these effects in the present review;
rather, we will focus on novel aspects of cholinergic neurotransmission uncovered in recent years.
It has been shown that a large number of cholinergic neurons
in the CNS co-express a member of the vesicular glutamatetransport protein family and therefore have the potential to corelease glutamate. To note, cholinergic neurons in the habenula
co-express VGLUT1 [89], whereas basal forebrain cholinergic
neurons projecting to the amygdala [90] as well as tonically active
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cholinergic interneurons in the striatum co-express VGLUT3 [91].
In the retina, GABA has been shown to be co-released with ACh
[92]. In cultured cholinergic neurons from the basal forebrain,
glutamate release has been shown to occur [90]. More recently,
evidence from optogenetic studies indicates that cholinergic
neurons can co-release glutamate in brain slices [89,93]. Brief
photostimulation of cholinergic axonal terminals was shown
to induce fast excitatory post-synaptic currents mediated by
glutamate receptors [89,93], whereas tetanic photostimulation
generated slow post-synaptic currents mediated by nicotinic
receptors in the habenula [89].
Genetic approaches have been used to investigate the
physiological significance of ACh/glutamate co-transmission in
the striatum (Figure 3). Studies using mice with null expression
of VGLUT3 (VGLUT3-KO) show evidence that VGLUT3 is coexpressed with VAChT in synaptic vesicles and facilitates ACh
filling of these vesicles [31]. VGLUT3-KO mice are hyperactive,
more responsive to cocaine and less prone to haloperidolinduced catalepsy than their wild-type littermates [31]. Given
that mice with ablated cholinergic neurons in the striatum show
a similar phenotype [94,95], it was initially suggested that these
behavioural changes resulted from the decreased striatal ACh
release observed in VGLUT3-KO mice [31]. Recently it was
demonstrated that mice with selective elimination of VAChT
from striatal cholinergic interneurons (VAChTD2 − Cre − flox/flox mice)
are not hyperactive and show minimal alteration in behavioural
responses to cocaine. These results strongly suggest that glutamate
released from cholinergic neurons, rather than ACh, is critical
for cocaine-induced behavioural manifestations [76]. Conversely,
it was shown that elimination of striatal ACh release affects
DA metabolism. It also appeared to affect the response of
MSNs (medium spiny neurons) to DA where up-regulation
of DA receptors and a change in behavioural responses to
dopaminergic agonists was observed [76]. These data indicate
that cholinergic interneurons use two distinct neurotransmitters
to differentially regulate behaviour. Moreover, synchronized
activity of cholinergic interneurons was shown to depolarize DA
nerve terminals directly and evoke DA release, independently
of the action potentials in DA soma [96,97], indicating that the
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ACh/glutamate co-transmission in the mammalian striatum, and the effects of molecular manipulations

(A) Schematic representation of the normal ACh/glutamate co-transmission and vesicular synergy in the striatum. (B) Loss of VGLUT3 results in elimination of glutamate release. (C) Targeted KO of
VAChT in the striatum results in loss of ACh release.

ACh-driven DA signal has crucial outcomes for DA nerve
function. Striatal cholinergic neurons can also regulate MSNs by
activating GABA release from interneurons and silencing MSNs
[98]. Importantly, these findings demonstrate that co-transmission
has the potential to significantly affect the functioning of
striatal neurons and hence of basal ganglia. Additionally, these
results suggest that other roles previously attributed to ACh in
striatal function might either result from glutamate released from
cholinergic interneurons or depend on the combined action of
both transmitters.
Basal forebrain cholinergic neurons, which provide the
major input to the cortex and hippocampus, undergo moderate
degenerative changes during normal aging, and the resulting
cholinergic hypofunction has been associated with age-related
memory deficits [99]. A more profound alteration in basal
forebrain cholinergic cells is thought to underlie some of
the cognitive and behavioural symptoms observed in both
Alzheimer’s disease and vascular dementia as well as in
Parkinson’s disease [100–102]. Importantly, VAChT levels are
decreased in the brains of Alzheimer’s disease patients [62,63].
Studies using animal models of cholinergic dysfunction
generated by ablation of basal forebrain cholinergic neurons using
electrolytic or excitotoxic methods, as well by the more selective
strategy of cholinergic immunolesion, have given inconsistent
results concerning the cognitive and behavioural processes that
are affected by altering cholinergic transmission [103]. These
studies have been hampered by the fact that both non-cholinergic
and cholinergic projection neurons are destroyed in many cases, or
that the lesions produced do not fully deplete cholinergic neurons.
Moreover, these studies cannot separate potential roles of ACh
and glutamate that have the potential to be secreted together
by these neurons. Genetically modified mice with selective
elimination of VAChT expression in forebrain cholinergic neurons
provide a model to isolate the consequences of cholinergic
deficiency in dementia [75]. Behavioural analysis of mice with
selective forebrain VAChT deficiency (VAChTSix3 − Cre − flox/flox mice)
indicates that these mice are hyperactive [75]. Other mouse
lines with decreased cholinergic tone also show augmented
locomotion [74]. Hyperactivity in mice is related to a number
of possible psychiatric-like behaviours, including a potential
increase in anxiety-like behaviour, but this is not the case
in these mutant mice. Importantly, the hyperactivity observed

in VAChTSix3 − Cre − flox/flox mice is not due to elimination of
VAChT in the striatum [76]. Thus these data highlight the
importance of basal forebrain cholinergic neurotransmission for
the modulation of locomotor activity. Additionally, forebrain
VAChT deficiency compromised the ability of mice to use spatial
cues to find the platform in the MWM (Morris water maze)
[75]. Although these mice show deficits on MWM acquisition,
they develop alternative strategies to recall the correct location
of the platform in probe trials. Interestingly, forebrain VAChT
deficiency impaired the capacity of mice to extinguish a previous
location and learn a new platform location, suggesting that
ACh is important for behavioural flexibility. Accompanying
this spatial memory impairment, we found an impairment
in LTP (long-term potentiation) in VAChTSix3 − Cre − flox/flox mice.
This effect on LTP did not involve changes in glutamatergic
synaptic transmission, as input/output relationship and pairedpulse facilitation were not affected [75]. Together, these
results suggest that VAChTSix3 − Cre − flox/flox mice have cellular and
behavioural deficits that prevent proper encoding of spatial
memory information, which is one of the first behavioural
deficits observed in Alzheimer’s disease patients. Hence, these
mice may provide a more reliable model of neurochemical
changes in Alzheimer’s disease and other types of dementia.
Potential long-term functions affected by cholinergic deficiency
are still largely unknown. Exciting new data suggest that loss
of the nuclear ribonucleoproteins hnRNP (heterogeneous nuclear
ribonucleoprotein) A/B family, which is observed in the entorhinal
cortex of Alzheimer’s disease patients, is induced by cholinergic
deficiency [104]. Furthermore, loss of the hnRNP splicing factors
was shown to cause alternative splicing impairments, dendrite
loss in primary neurons and cognitive impairments [104].

REGULATION OF CHOLINERGIC TONE IN THE AUTONOMIC
NERVOUS SYSTEM BY VAChT

ACh is the primary chemical neurotransmitter at parasympathetic
nerve endings and modulates the function of many peripheral
organs in the body. VAChT-positive neurons have been
identified in several different organs including the retina, GI
(gastrointestinal) tract and respiratory tract, as well as the heart
[105].
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In the heart, co-ordinated interplay between the two branches
of the ANS (autonomic nervous system) is important in
maintaining proper function. Activation of the sympathetic branch
increases heart rate and contractile force, whereas activation of
the parasympathetic branch reduces heart rate by altering the
conduction velocity of both the sinoatrial and atrioventricular
nodes [106]. It has long been recognized that overactivation
of the sympathetic tone contributes to cardiac dysfunction
[107–109]; in contrast, much less is known about the role
of failing cholinergic neurotransmission in cardiac disease.
Vagal stimulation has been shown to improve the outcomes
in experimental heart failure [110–118] and it is an approach
currently being explored to ameliorate a number of diseases
in humans. Recent studies using VAChT-KDHOM mice, which
show a systemic reduction in VAChT, provided direct evidence
that decreased cholinergic neurotransmission also causes plastic
alterations that contribute to heart dysfunction [73,119]. The
hearts of VAChT-KDHOM mice have altered calcium handling,
show changes in myocyte contractility and express several
markers of cardiac stress, which are activated during cardiac
remodelling and heart failure [73]. Importantly, all of these
changes can be reversed through treatment with pyridostigmine,
a peripheral cholinesterase inhibitor, suggesting that cardiac
dysfunction in these mice results from a deficiency in cholinergic
tone [73]. Mice lacking M2 muscarinic receptors show increased
cardiac stress [120], and experiments using mice lacking one
of the high-affinity choline transporter alleles confirmed that
decreased cholinergic tone affects heart function [121].
The cholinergic system is important in regulating the innate
immune response. In fact, several studies have provided novel
insight into the specific mechanisms through which neuronal
ACh can act peripherally to control the immune response. This
inflammatory reflex, termed the cholinergic anti-inflammatory
pathway, is dependent on the peripheral actions of ACh released
from the vagus nerve [110,122,123]. ACh binds to α7 nAChRs
(nicotinic acetylcholine receptors) on macrophages and thereby
inhibits the release of pro-inflammatory cytokines including
TNFα (tumour necrosis factor α), IL (interleukin)-1β and IL6 [122,123]. Inhibition of cytokine release has been shown to
be beneficial in several disease states, including endotoxaemia,
sepsis and heart failure [124–127]. Consistent with these results,
VAChT-KDHOM mice have been shown to develop an increased
inflammatory immune response when infected with parasites
[128], indicating disturbance of the cholinergic anti-inflammatory
reflex in this mutant.
In the retina, ACh is released in response to light stimulation
and leads to direct and rapid excitation of the retinal ganglion
cells [129]. Release of ACh in the enteric nervous system
induces smooth muscle contractions in the GI tract [130,131].
Cholinergic signalling also leads to smooth muscle contraction
in the respiratory tract [132]. Whether decreased cholinergic tone
has pathological implications related to eye function, the enteric
system or the respiratory tract has not yet been systematically
investigated.

NON-NEURONAL CHOLINERGIC MACHINERY

ACh is also produced in many different cell types, leading
to the idea that a non-neuronal cholinergic system plays a
significant role in regulating various physiological functions
[133]. Indeed, the machinery necessary to produce ACh as well
as the neurotransmitter itself has been identified in a range of
cells including lymphocytes [134,135], epithelial cells [136–
138], vascular endothelial cells [139] and the α-cells of the
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pancreas [6]. Furthermore, this machinery has been identified
in cardiomyocytes [5,140,141].
Immune cells, including lymphocytes, possess the machinery
necessary to synthesize ACh [134,135,142,143]. It has been
recently demonstrated that a small population of T-lymphocytes
can synthesize and release ACh in response to autonomic nervous
system activity in the spleen as part of the cholinergic antiinflammatory pathway [144]. It is important to note that T-cells
as well as macrophages express both muscarinic and nicotinic
ACh receptors and are also able to produce ACh [145]. The exact
mechanism by which ACh is released from these cells to regulate
the immune system has not yet been uncovered.
The ability of epithelial cells to synthesize ACh is well
characterized; in fact, it has previously been reported that this
molecule can be secreted from cultured bronchial epithelial cells
[137]. However, ACh release from epithelial cells does not
appear to be dependent on VAChT, but rather on the organic
cation transporters OCT (organic cation transporter) 1 and OCT2
[146,147]. ACh released by epithelial cells acts through both
nicotinic as well as M1 muscarinic receptors and increases their
proliferation rate [148]. Moreover, in a number of cancer cells,
particularly in lung cancer, ACh has been shown to play an
autocrine role [149–151].
ACh is important in regulating insulin release from β-cells
of the pancreas. It has long been suggested that the source of
this ACh is the parasympathetic nerve endings in the endocrine
pancreas, which can trigger insulin release following binding
to the M3 muscarinic receptor [152,153]. Interestingly, recent
work has revealed that, although insulin secretion from β-cells
is regulated by neuronal parasympathetic signalling in mice,
humans possess the machinery to synthesize and release ACh
from α-cells. VAChT plays an important role in the release of
ACh from α-cells as positive immunostaining was observed for
the transporter in these cells and pharmacological manipulation
blocked ACh release. This suggests that ACh is maintained in
exocytotic vesicles within α-cells and is released quantally in a
manner similar to that observed in neurons [6]. Owing to the fact
that β-cells are mostly localized close to α-cells in the pancreatic
islets, the non-neuronal ACh released by α-cells can act as a
paracrine molecule on neighbouring β-cells and initiate the insulin
secretion cascade [6].
Vascular endothelial cells play a critical role in the regulation
of blood pressure by inducing the relaxation of vascular smooth
muscle cells. This pathway is well characterized and ACh is
known to mediate vasodilation through binding to muscarinic
ACh receptors on endothelial cells. This interaction leads to the
production of the EDRF (endothelium-derived relaxing factor),
now known to be nitric oxide, which leads to vasodilation [154].
Although ACh appears to have a profound effect on vascular
function, it is important to note that parasympathetic innervation
of endothelial cells is virtually non-existent and there are high
levels of acetylcholinesterases in circulation. It is now evident
that endothelial cells have the ability to synthesize and secrete
ACh via a PKC-independent mechanism [139,155]. Importantly,
previous work has confirmed the presence of VAChT in two
different endothelial cell culture models, suggesting that ACh may
be released from these cells via a VAChT-dependent mechanism
[156,157].
It has previously been proposed that cardiomyocytes are
able to synthesize and release ACh at the cellular level as
they possess the machinery for production of ACh [140,141].
Owing to limited innervation of ventricular cardiomyocytes
by parasympathetic neurons [158,159], it has been suggested
that ventricular cardiomyocytes may synthesize ACh. VAChT
was shown to be present in vesicles in cardiomyocytes [141]
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suggesting a quantal release of ACh from these cells [5]. In
cell culture models, isoproterenol and other adrenergic activators
can induce cellular hypertrophy and remodelling. ACh released
by cardiomyocytes plays an important role in protecting these
cells against isoproterenol-induced cardiomyocyte remodelling
[5]. Furthermore, expression of both VAChT and ChAT was
increased in cultured cardiomyocytes treated with adrenergic
drugs [5], suggesting a potential mechanism for regulation
of this machinery. This non-neuronal ACh may then act in
an autocrine/paracrine fashion to enhance neuronal cholinergic
signalling. Although demonstrated only in vitro, these results
suggest a novel mechanism to protect the heart under stressful
conditions. These data provide for an unanticipated mechanism by
which non-neuronal ACh, secreted from VAChT-positive vesicles,
may play an important role in cardiac function.
CONCLUSION

The potential to uncover novel physiological functions of ACh
using genetically modified mice, in which the cholinergic
machinery can be spatially and temporally targeted, has already
changed our understanding of functions by this neurotransmitter.
Otto Loewi’s [161] findings of ACh as a neurotransmitter can
now be expanded to a role in paracrine/autocrine communication
in a number of non-neuronal cells. By using the Cre/lox system,
BAC (bacterial artificial chromosomes) transgenic mice and
optogenetics, we now have the ability to activate or inactivate
the cholinergic machinery or cholinergic neurons at will. These
novel approaches will lead to increased knowledge of how
ACh contributes to different bodily functions. Additionally,
these approaches will be fundamental to unravelling how
different populations of cholinergic neurons in the brain can
regulate distinct biochemical and physiological processes. It
is tempting to speculate that optogenetics, used to activate
or inactivate cholinergic neurons in the peripheral nervous
system, may be effectively used in the future as treatment for
a number of pathologies involving dysregulated sympathetic
or parasympathetic activity. Finally, inactivation of cholinergic
machinery in non-neuronal tissues using genetically modified
mice will provide the ultimate proof for the physiological
significance of non-neuronal release of ACh.
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Hyperactivity and attention deficits in mice with decreased levels of
stress-inducible phosphoprotein 1 (STIP1)

ABSTRACT
Stress-inducible phosphoprotein I (STIP1, STI1 or HOP) is a cochaperone intermediating Hsp70/Hsp90 exchange of client proteins,
but it can also be secreted to trigger prion protein-mediated neuronal
signaling. Some mothers of children with autism spectrum disorders
(ASD) present antibodies against certain brain proteins, including
antibodies against STIP1. Maternal antibodies can cross the fetus
blood-brain barrier during pregnancy, suggesting the possibility that
they can interfere with STIP1 levels and, presumably, functions.
However, it is currently unknown whether abnormal levels of STIP1
have any impact in ASD-related behavior. Here, we used mice with
reduced (50%) or increased STIP1 levels (fivefold) to test for potential
ASD-like phenotypes. We found that increased STIP1 regulates the
abundance of Hsp70 and Hsp90, whereas reduced STIP1 does not
affect Hsp70, Hsp90 or the prion protein. Interestingly, BAC
transgenic mice presenting fivefold more STIP1 show no major
phenotype when examined in a series of behavioral tasks, including
locomotor activity, elevated plus maze, Morris water maze and fivechoice serial reaction time task (5-CSRTT). In contrast, mice with
reduced STIP1 levels are hyperactive and have attentional deficits on
the 5-CSRTT, but exhibit normal performance for the other tasks. We
conclude that reduced STIP1 levels can contribute to phenotypes
related to ASD. However, future experiments are needed to define
whether it is decreased chaperone capacity or impaired prion protein
signaling that contributes to these phenotypes.
KEY WORDS: Touchscreen, Autism, ASD, Stress-inducible
phosphoprotein 1, Attention deficits, Mouse model, BAC

INTRODUCTION

In autism spectrum disorders (ASD), alterations in genetic variance
and neurodevelopmental are both thought to contribute to
phenotype heterogeneity. Womb environment and autoimmune
responses have been proposed to contribute to the complex
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behavioral alterations observed in ASD, which include, but are
not limited to, abnormal socialization and communication and
stereotyped behavior (Brimberg et al., 2013; Goldani et al., 2014).
Several distinct groups have investigated the existence of antibodies
against fetal brain tissue in mothers of ASD children (Bauman et al.,
2013; Braunschweig et al., 2012b, 2013; Dalton et al., 2003;
Nordahl et al., 2013). Passive transfer of maternal anti-brain
antibodies to pregnant experimental animal models (including mice,
rats and non-human primates) has shown that their offspring
develop a number of endophenotypes that resemble phenotypes in
ASD (Bauman et al., 2013; Braunschweig et al., 2012b; Dalton
et al., 2003). Indeed, a recent study indicated that the prevalence of
antibodies against fetal brain proteins is increased fourfold in
mothers of an ASD child compared with control groups (Brimberg
et al., 2013). Proteomics analysis has identified six brain proteins as
targets for ASD antibodies, including lactate dehydrogenase A and
B (LDH), cypin, stress-inducible phosphoprotein protein1 (STIP1),
collapsine response mediator proteins 1 and 2 (CRMP1, CRMP2)
and Y-box-binding protein (YBX1) (Braunschweig et al., 2013).
Interestingly, injection of maternal antibodies that recognize LDH,
STIP1 and CRMP1 in developing mouse embryos causes an
increase in cortical neural precursor proliferation and cortical
neuron volume, with consequent increase in brain size and weight
(Martinez-Cerdeno et al., 2014). These phenotypes are consistent
with the notion that the presence of maternal autoantibodies can
affect neuronal development.
STIP1, also known as heat-shock organizing protein (Hop) or
STI1, is a co-chaperone that interacts concomitantly with heatshock proteins 70 and 90 (Hsp70 and HsP90) (Abbas-Terki et al.,
2002; Chen et al., 1996; Nicolet and Craig, 1989; Picard, 2002;
Smith et al., 1993). The chaperone machinery is thought to provide a
buffer for cells to respond to environmental challenges; disturbance
of Hsp70/90 chaperone activity decreases cellular resilience to
stress (Chen et al., 2015; Hashimoto-Torii et al., 2014; Taipale et al.,
2010, 2014). The absence of STIP1 in mice has important
consequences for development, including increased apoptosis,
DNA damage and death (Beraldo et al., 2013). These phenotypes
are rescued by transgenic BAC expression of STIP1 (Beraldo et al.,
2013).
In addition to its intracellular role as a co-chaperone, STIP1 is also
secreted by a variety of cells (Erlich et al., 2007; Eustace and Jay,
2004; Hajj et al., 2013; Lima et al., 2007; Wang et al., 2010) via
extracellular vesicles (Hajj et al., 2013). Extracellular STIP1 can
signal via the prion protein (PrPC) to produce a myriad of effects
related to brain development (Beraldo et al., 2010, 2013; Caetano
et al., 2008; Lopes et al., 2005; Soares et al., 2013). Here, we used
Stip1 heterozygous mice (STI1 −/+ mice), as well as mice
overexpresssing four- to fivefold more STIP1 (STI1 TGA mice), to
investigate the consequences of alteration of STIP1 levels in vivo.
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TRANSLATIONAL IMPACT
Clinical issue
Autism spectrum disorders (ASD) represent a range of
neurodevelopmental disorders with no cure. ASD is characterized by
difficulties in communication and socialization, repetitive movements,
hyperactivity, impulsivity, and an impaired ability to concentrate and
attend to simple tasks. Genetic variance and neurodevelopmental
alterations are both thought to contribute to the heterogeneity of the ASD
phenotype. Recent studies have demonstrated that some mothers of
children with ASD produce antibodies against six specific proteins
present in the fetal brain; presumably, these antibodies can interfere with
protein function in the developing brain. One of these antibodies targets a
protein known as stress inducible phosphoprotein 1 (STIP1). Moreover, a
polymorphism for STIP1 was recently identified as a potential risk factor
in attention deficit hyperactivity disorder, which shares some phenotypes
with ASD. STIP1 is a co-chaperone that mediates the Hsp70/Hsp90
exchange of client proteins. It also triggers prion protein-mediated
neuronal signaling.
Results
Here, to investigate the potential involvement of STIP1 in ASD, the
authors examine mice that express reduced (50%) or increased (fivefold)
levels of STIP1. They show that increased STIP1 levels regulate the
abundance of Hsp70 and Hsp90. By contrast, reduced STIP1 levels
have no effect on Hsp70, Hsp90 or prion protein levels. Notably,
however, mice expressing increased levels of STIP1 show no major
phenotype when examined using a range of behavioral tasks, whereas
mice expressing reduced levels of STIP1 exhibit attention deficits and
are hyperactive.
Implications and future directions
Because attention deficits and hyperactivity are present in ASD, these
findings suggest that interference with STIP1 functions (but not
increased STIP1 levels) can contribute to ASD-like phenotypes.
Changes in STIP1 levels, possibly triggered by the presence of
maternal anti-STIP1 antibodies during brain development, might
interfere with the development of brain circuits that affect ASD-like
behavior. Additional experiments are required to determine whether
decreased STIP1 contributes to ASD-like phenotypes by decreasing
chaperone capacity in the developing brain, by impairing prion protein
signaling, or through some other mechanism, and to define fully the
consequences of disturbed STIP1 activity in ASD.

We report that decreased, but not increased, STIP1 levels affect
attention and cause hyperactivity in mice, two phenotypes that are
related to ASD-like phenotypes. Our results suggest that interference
with STIP1 functions, which presumably occur in the presence of
STIP1 antibodies, has the potential to contribute to ASD-like
phenotypes.
RESULTS

We initially confirmed previous data to show that STI1−/+ mice
present 50% of STIP1 mRNA levels in their brain, whereas STI1TGA
mice express almost sixfold more mRNA (Fig. 1A; one-way
ANOVA; revealed main effect of genotype F(2.15)=8.521,
P<0.0001). In contrast, mRNA levels of known STIP1 interaction
partners PrPC (Fig. 1B; one-way ANOVA F(2.16)=1.475, P=0.2580),
Hsp70 (Fig. 1C; one-way ANOVA F(2.16)=0.301, P=0.744)
and Hsp90 (Fig. 1D; one-way ANOVA F(2.8)=1.249, P=0.337)
were not altered in the brain of the two lines, compared with
control mice.
Protein levels for STIP1 followed mRNA levels for both STI1 TGA
(Fig. 2A; t (15)=4.721, P=0.003) and STI1 −/+ (Fig. 2B; t (14)=6.433,
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P<0.0001). PrPC protein levels were not different from controls in
both lines (Fig. 2C,D; t (10)=1.049, P=0.391 and t (13)=1.128,
P=0.279, respectively). Interestingly, levels of Hsp70 were
decreased by 50% in STI1 TGA brains (Fig. 2E; t (7)=5.846,
P=0.0006), whereas no change in Hsp70 levels was detected in
STI1 −/+ mice (Fig. 2F; t (7)=0.123, P=0.9051), compared with
controls. Additionally, Hsp90 levels detected with a pan Hsp90
antibody were doubled in STI1 TGA brains (Fig. 2G; t (22)=4.618,
P=0.0001) but not changed in STI1 −/+ brains (Fig. 2H; t (10)=0.308,
P=0.7639), compared with controls. We then evaluated expression
levels of Hsp90α (inducible form) and Hsp90β (constitutive form)
in the brains of STI1 TGA mice and observed that both forms were
significantly increased (Fig. 2I,J; t (22)=4.618, P=0.0016 and
t (16)=5.954, P<0.0001, respectively).
Spontaneous locomotor activity in a new environment can
provide information on neuropsychiatric phenotypes in mice
associated with genetic mutations. The increased number of Stip1
copies, with concomitant overexpression of Hsp90 and decreased
expression of Hsp70 in STI1 TGA mice did not seem to have any
major impact on spontaneous locomotion (Fig. 3A,B; t (29)=1.140,
P=0.942) or time spent in the center of the box, which provides
insight on anxiety-like behavior (Fig. 3C; t (29)=1.236, P=0.8669).
In contrast, locomotor activity and total locomotion in a new
environment were increased in STI1 −/+ mice (Fig. 3D,E;
t (44)=1.879, P=0.0078). However, STI1 −/+ mice did not show
increased anxiety-like behavior, as determined by the time spent in
the center of the box (Fig. 3F; t (40)=1.221, P=0.341). We also
examined another cohort of STI1 −/+ mice using automated
metabolic cages. In this experiment, which mimics the home cage
environment, STI1 −/+ mice again showed hyperactivity during the
day and night periods, considering both total activity (Fig. 3G;
t (14)=2.558, P=0.0228 and t (14)=2.230, P=0.0426) and ambulatory
activity (Fig. 3H; t (14)=2.420, P=0.00297 and t (14)=2.230,
P=0.0426). Given this increased motor activity, STI1 −/+ mice also
demonstrated less sleep time ( periods of inactivity) (Fig. 3I;
t (14)=3949, P=0.0015 and t (14)=2.724, P=0.0165). Also, STI1 −/+
mice showed increased consumption of O2 during the light and dark
cycle (Fig. 3J; t (14)=2.464, P=0.027 and t (14)=2.169, P=0.047) and
CO2 production during the dark cycle, but not in the light cycle
(Fig. 3K; t (14)=2.307, P=0.036 and t (14)=1.360, P=0.195). No
differences were observed in other parameters such as respiratory
ratio (Fig. 3L; t (14)=0.4455, P=0.6627 and t (14)=0.459, P=0.653),
food consumption (Fig. 3M; t (14)=0.5216, P=0.6101 and
t (14)=0.6134, P=0.5494), water consumption (Fig. 3N;
t (14)=1.801, P=0.0933 and t (14)=0.2752, P=0.7872), and heat
production (Fig. 3O; t (14)=1.014, P=0.3276 and t (14)=0.1935,
P=0.8494) comparing STI1 −/+ to STI1 +/+ mice for both cycles
(light and dark).
In order to test for other neuropsychiatric-like behaviors as a result
of altered STIP1 levels we tested both STI TGA and STI1 −/+ mice for
anxiety-like behavior (Fig. 4A-D) and depression-like behavior
(Fig. 4E,F). Given the hyperactivity of STI1 −/+ mice, we also
decided to investigate whether they had alterations in compulsivelike behavior, assessed by measurement of self-grooming and
marble burying (Fig. 4G-I). There was no difference in the behavior
of either STI TGA (Fig. 4A,B,E) or STI1 −/+ (Fig. 4C,D,F-I) mice
compared with control mice in all these behavioral tasks: time spent
in the open arm (Fig. 4C; t19=0.310, P=0.7590), time spent in the
closed arm (Fig. 4D; t (19)=0.3730, P=0.7133), forced swim test
(Fig. 4F; t (12)=1.184, P=0.2594), grooming bouts (Fig. 4H;
t (20)=0.7848, P=0.4418), time grooming (Fig. 4G; t (20)=0.6072,
P=0.5505) and marble burying (Fig. 4I; t (21)=0.4956, P=0.6253).
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Next, we investigated spatial navigation memory in both Stip1
mutant mice using the Morris water maze (MWM). Neither
STI1 TGA nor STI1 −/+ mice presented deficits in acquisition
or retrieval of spatial memory in the MWM. For both STI1 TGA
and STI1 −/+, performance during the 4-day acquisition phase was
indistinguishable from their wild-type controls in terms of latency to
find the target (Fig. 5A; RM-ANOVA F(1,13)=0.062, P=0.806) or
speed (Fig. 5C; F(1,10)=0.215, P=0.652). When spatial memory
retrieval was performed on the day-5 probe trial, again no
differences were observed between STI1 TGA and STI1 −/+ mice,
compared with their wild-type controls, for time spent investigating
the target quadrant (Fig. 5D; F(1,13)=1.046, P=0.3251) or latency
(Fig. 5E; F(1,10)=0.215, P=0.294).
Given the hyperactivity phenotype and genetic data suggesting
the potential of STIP1 to be linked to ADHD (Mick et al., 2011), a
trait commonly found in ASD (Gadow et al., 2006; Goldstein and
Schwebach, 2004; Lee and Ousley, 2006; Mulligan et al., 2009), we
also determined whether changes in STIP1 levels affected
attentional processing. For this, we used the 5-CSRTT. After mice
were trained to perform to a criterion (>80% accuracy, <20%
omissions) at a 2 s stimulus duration, we assessed attentional
performance by using reduced stimulus durations in probe trials
(1.5, 1, 0.8 and 0.6 s stimulus durations) as previously described
(Romberg et al., 2011). We observed no differences in attentional
performance in STI1 TGA mice compared with their littermate
controls. There was no difference in accuracy (Fig. 6A; RMANOVA showed no effect of genotype F(1,20)=0.0057, P=0.9403,
main effect of stimulus duration F(3,60)=12.14, P<0.0001 and no
significant interaction F(3,60)=0.1328, P=0.9402) or omission rates
(Fig. 6B; RM-ANOVA showed no effect of genotype
F(1,18)=0.2429, P=0.6281, main effect of stimulus duration
F(3,54)=17.62, P<0.0001 and significant interaction F(3,54)=3.854,
P=0.0143). Post-hoc analysis showed that there was no significant
difference between STI1 TGA mice and controls. There was also no
difference in premature responses, a measure of impulsivity
(Fig. 6C; RM-ANOVA showed no effect of genotype
F(1,9)=0.00056, P=0.9419, no effect of stimulus duration
F(3.27)=0.8254, P=0.4914 and no significant interaction

F(3,27)=1.109, P=0.3625). Moreover, we did not find any
difference in motivation, measured as latency to touch the screen
(Fig. 6D; RM-ANOVA showed no effect of genotype F(1,9)=3.399,
P=0.0983, main effect of stimulus duration F(3.30)=4.281, P=0.0125
and no significant interaction F(3,30)=2.332, P=0.0941).
Compulsivity and motivation were not altered either, as assessed
by perseverative responses (Fig. 6F; RM-ANOVA, showed no
effect of genotype F(1,9)=3.974, P=0.0774, main effect of stimulus
duration F(3,27)=4.808, P=0.0083 and no significant interaction
F(3,27)=0.1773, P=0.9108) and reward collection latency (Fig. 6E;
RM-ANOVA showed no effect of genotype F(1,10)=1.291,
P=0.2824, no effect of stimulus duration F(3,30)=2.162, P=0.1132
and no significant interaction F(3.30)=0.7372, P=0.5381).
In contrast, when attentional demand was increased, STI1 −/+
mice presented decreased accuracy (Fig. 6G; RM-ANOVA, main
effect of genotype F(1,25)=6.872, P=0.0147, main effect of stimulus
duration F(3,75)=41.95, P<0.0001, significant interaction effect
F(3,75)=4.170, P=0.0087) and increased omission rates (Fig. 6H;
RM-ANOVA, main effect of genotype F(1,25)=6.584, P=0.0167,
main effect of stimulus duration F(3,75)=24.62, P<0.0001,
significant interaction effect F(3,75)=3.401, P=0.0220). Post-hoc
analysis revealed that the STI1 −/+ mice were significantly impaired
in both accuracy and omissions at the 0.6 s stimulus duration. The
worse performance of STI1 −/+ mice was not related to changes in
motivation (latency to respond to the stimulus, RM-ANOVA, no
effect of genotype F(1,25)=0.01856, P=0.8925, no effect of stimulus
duration F(3,75)=1.720, P=0.1702, no interaction F(3,75)=1.070,
P=0.3669). There was also no difference in latency to retrieve the
reward following a correct response (RM-ANOVA, no effect of
genotype F(1,25)=0.03176, P=0.8600, no effect of stimulus duration
F(3,75)=0.3997, P=0.7536, no interaction F(3,75)=1.785, P=0.8284).
Moreover, we detected no increase in premature responses (RMANOVA, no effect of genotype F(1,25)=0.0958, P=0.7595, main
effect of stimulus duration F(3,75)=2.907, P=0.0401, no interaction
effect F(3,75)=2.017, P=0.1187) or perseverative responses (RMANOVA, no effect of genotype F(1,25)=0.04188, P=0.8395, main
effect of stimulus duration F(3,75)=6.975, P=0.0003, no interaction
effect F(3,75)=1.139, P=0.3389).
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Fig. 1. Analyses of mRNA for STIP1
partners in STI1 +/+, STI1 −/+ and STI1 TGA
mouse brains. (A) STIP1 mRNA
expression (n=9 STI1 +/+, n=5 STI1 TGA and
n=4 STI1 −/+). (B) PrPC mRNA expression
(n=8 STI1 +/+, n=4 STI1 TGA and n=7 STI1 −/+).
(C) Hsp70 mRNA expression (n=8 STI1 +/+,
n=4 STI1TGA and n=7 STI1−/+). (D) Hsp90
mRNA expression (n=3 STI1 +/+, n=4
STI1 TGA and n=4 STI1 −/+). Results are
presented as means±s.e.m.; data were
analyzed and compared by one-way ANOVA
and Bonferroni multiple comparisons
post-hoc test; **P<0.001 and ***P<0.0001
compared with control.
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DISCUSSION

The present experiments tested whether alterations in STIP1 levels
have consequences for psychiatric-like behaviors in mice. Our
results suggest that decreased, but not increased, STIP1 levels cause
significant behavioral alterations in mice. Spatial learning and
memory, as well as anxiety and depression-like behavior do not
seem to be affected by reduced STIP1 levels. However, mutant mice
deficient for STIP1 are hyperactive and present attention deficits.
STIP1 has recently emerged as a protein of potential interest in
ASD and endophenotypes related to ASD. Maternal autoantibodies
against STIP1 have been identified in mothers of children with ASD
(Braunschweig et al., 2013). Moreover, recent global-wide
association study (GWAS) analysis identified a polymorphism in
STIP1 (the human gene coding for STIP1/HOP) as a potential risk
factor in a population of individuals diagnosed with attention-deficit
disorder (Mick et al., 2011), a co-morbidity often associated with
ASD (Brimberg et al., 2013; Goldani et al., 2014). The consequences
of this polymorphism for STIP1 expression is unknown, but the
presence of autoantibodies against STIP1 might affect expression
levels of the protein, given that antibodies can penetrate the blood
brain barrier of the fetus during pregnancy (Braunschweig et al.,
2012a; Diamond et al., 2009; Fox et al., 2012; Zhang et al., 2012).
Indeed, maternal antibodies that recognize STIP1 and other targets
when injected in pregnant rodents or developing pups can lead to
offspring with abnormal neurons and behaviors that relate to ASD
1460

(Braunschweig et al., 2012b; Camacho et al., 2014). To a degree,
STI1 −/+ mice model this early developmental deficit in STIP1 levels.
However, in STI1 −/+ mice STIP1 expression is persistently decreased
through life, which could also have important consequences for the
phenotypes described.
STIP1 is a modular protein containing several tetratricopeptide
(TRP) repeat domains and aspartate-proline (DP) reach domains
(Taipale et al., 2010). TRP1 and TRP2B can interact with Hsp70
(Flom et al., 2007; Scheufler et al., 2000), whereas TPR2A is required
for interaction with Hsp90 (Flom et al., 2007, 2006). Hsp90 activity is
regulated by STIP1 and previous work has shown that in mice no
other co-chaperone can replace STIP1 (Beraldo et al., 2013). Recent
experiments have indicated that the chaperone machinery, activated
by the transcription factor heat shock factor 1 (HSF1), is responsible
for preventing damaging effects from environmental factors in the
developing brain (Hashimoto-Torii et al., 2014). Indeed, the
chaperone machinery can buffer many stresses at the cellular level
and, therefore, it is not surprising that functional changes in its
components have physiological consequences.
In addition to its intracellular chaperone function, STIP1 is also
secreted by a myriad of cells, including astrocytes via an
extracellular vesicle population, which includes exosomes (Hajj
et al., 2013). Extracellular STIP1 also mediates important
physiological responses in the brain. Acting as a trophic factor to
engage PrPC to signal in neurons, it regulates neuritogenesis and
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Fig. 2. Analyses of protein levels for STIP1 partners in STI1 +/+, STI −/+ and STI1 TGA mouse brains. (A,B) STIP1 expression in STI1 TGA (n=9 STI1 +/+ and n=8
STI1 TGA) and STI1 −/+ mice (n=8 STI1 +/+ and n=8 STI1 −/+). (C,D) PrPC expression in STI1 TGA (n=6 STI1 +/+ and n=6 STI1 TGA) and STI1 −/+ mice (n=6 STI1 +/+
and n=9 STI1 −/+). (E,F) Hsp70 expression in STI1 TGA (n=5 STI1 +/+ and n=4 STI1 TGA) and STI1 −/+ mice (n=5 STI1 +/+ and n=4 STI1 −/+). (G,H) HSP90 expression
in STI1 TGA (n=10 STI1 +/+ and n=14 STI1 TGA) and STI1 −/+ mice (n=6 STI1 +/+ and n=6 STI1 −/+). (I,J) Hsp90β (n=10 STI1 +/+ and n=8 STI1 TGA) and Hsp90α (n=5
STI1 +/+ and n=4 STI1 TGA) in STI1 TGA mice. Results are presented as means±s.e.m.; data were analyzed and compared by Student’s t-test; *P<0.05 and
***P<0.0001 compared with control.
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Fig. 3. Locomotor activity in STI1 TGA and STI1 −/+mice and metabolic analyses in STI1 −/+mice. (A) Horizontal locomotor activity in an open-field for STI1 TGA
(n=14) and STI +/+ control mice (n=14). (B) Cumulative 1 h locomotion for STI1 TGA (n=14) and STI +/+ control mice (n=14). (C) Time spent in the center of the
locomotion boxes for STI1 TGA (n=14) and STI +/+ control mice (n=14). (D) Horizontal locomotor activity in an open-field for STI1 −/+ (n=8) and STI +/+ control mice
(n=8). (E) Cumulative 1 h locomotion for STI1 −/+ (n=22) and STI +/+ control mice (n=24). (F) Time spent in the center of the locomotion boxes for STI1 −/+ (n=22)
and STI +/+ control mice (n=24). (G) Total activity in metabolic cages for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (H) Ambulatory activity in metabolic cages
for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (I) Sleep time for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (J) VO2 for STI1 −/+ (n=8) and STI +/+ control mice
(n=8). (K) VCO2 for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (L) Respiratory exchange ratio for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (M) Food
consumption for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (N) Water consumption for STI1 −/+ (n=8) and STI +/+ control mice (n=8). (O) Energy expenditure for
STI1 −/+ (n=8) and STI +/+ control mice (n=8). Results are presented as means±s.e.m.; data were analyzed and compared by Student’s t-test; *P<0.05 compared
with control.

neuronal survival (Beraldo et al., 2010; Lopes et al., 2005; Roffe
et al., 2010). STIP1 has a role in functional recovery in stroke
(Beraldo et al., 2013; Lee et al., 2013). Moreover, STIP1 also
modulates toxicity of Aβ peptides in models of Alzheimer’s disease
(Brehme et al., 2014; Ostapchenko et al., 2013).
It is remarkable that mice with increased levels of STIP1 (up to
almost fivefold) do not present any major behavioral alteration. In

the extensive evaluation of cognitive phenotypes in this study,
which included anxiety and depression-like behaviors, spatial
memory and attention, we showed that STI1 TGA mice perform as
well as littermate controls. These results suggest that strategies to
increase STIP1 levels should not cause toxicity with consequences
for brain functions. This is important, given that increased STIP1
levels might be protective against insults such as stroke-mediated
1461
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Fig. 4. Anxiety-like behavior, depression-like behavior, social
behavior and compulsivity in STI1 TGA and STI1 −/+ mice.
(A) Percentage of time spent in the closed arm for STI1 TGA (n=17)
and control mice (n=14). (B) Percentage of time spent in the open
arm for STI1 TGA (n=17) and control mice (n=14). (C) Percentage
of time spent in the closed arm for STI1 −/+ (n=13) and control
mice (n=10). (D) Percentage of time spent in the open arm for
STI1 −/+ (n=13) and control mice (n=10). (E) Immobility time in the
forced-swimming test for STI1 TGA (n=17) and control mice
(n=14). (F) Immobility time in the forced-swimming test for STI1 −/+
(n=6) and control mice (n=8). (G,H) Time spent grooming and
number of grooming bouts for STI1 −/+ (n=11) and control mice
(n=11). (I) Marbles buried by STI1 −/+ (n=12) and control mice
(n=12).

MATERIALS AND METHODS
Animals

STI1 −/+ and STI1 TGA mice were generated as described (Beraldo et al.,
2013). Both mouse lines were in the C57BL/6J background. All
experimental procedures were conducted in compliance with the
Canadian Council of Animal Care guidelines for use and care of animals
and in accordance with approved animal use protocols at the University of
Western Ontario (2008/127). Animals were housed in groups of two or four
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per cage. Mice were kept in a temperature-controlled room with a 12/12
light/dark cycle (7 am/7 pm) with food and water provided ad libitum unless
stated otherwise. For behavioral studies, only male mice were used. Mice
were randomized and the experimenter was blind to genotypes. For most of
the behavioral tasks, software-based analyses were used to score mice
performance with minimum human interference.
qPCR and Western blot

For real-time quantitative PCR (qPCR), brain tissues were homogenized in
Trizol and total RNA was extracted using the Aurum Total RNA kit for fatty
and fibrous tissue (Bio-Rad, Hercules, CA, USA). qPCR were performed as
previously described (Martins-Silva et al., 2011). Primer sequences:
STIP1-F, 5′-GCCAAGAAAGGAGACTACCAG-3′; STIP1-R, 5′-TCATAGGTTCGTTTGGCTTCC-3′; HsP90-F, 5′-CCACCCTGCTCTGTACTACT-3′; HsP90-R, 5′-CCAGGGCATCTGAAGCATTA-3′; HsP70-R,
5′-ACCTTGACAGTAATCGGTGC-3′; HsP70-F, 5′-CTCCCGGTGTGGTCTAGAAA-3′; PRP-F, 5′-GAACCATTTCAACCGAGCTG-3′; PRP-R,
5′-CATAGTCACAAAGAGGGCCAG-3′; Actin-F, 5′-TGGAATCCTGTGGCATCCATGA-3′; and Actin-R, 5′-AATGCCTGGGTACATGGTGGTA-3′. Immunoblot analysis was carried out as described previously
(Beraldo et al., 2013). The antibodies used were anti-STIP1 (1:5000, inhouse antibody generated by Bethyl Laboratories Montgomery, USA using
recombinant STIP1) (Beraldo et al., 2013), anti-Hsp90 (1:1000), anti-Hsp70
(1:1000), anti-Hsp90α (1:1000), anti Hsp90β (1:1000) (Cell Signaling,
Danvers, USA) and anti-PrP 8H4 (1:2000) (Abcam, Cambrige, UK).
Locomotor activity

Mice were acclimated to the testing room for 30 min prior to beginning the
test; locomotor activity was automatically recorded (Omnitech Electronics
Inc., Columbus, USA). Mice were placed in the center of the apparatus and
locomotor activity was measured at 5 min intervals for 1 h as described
previously (Martyn et al., 2012).
Elevated plus maze

To access anxiety-like behavior, mice were acclimated to the testing room
for 30 min prior to beginning the test and then placed in the center of the
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cell death and in Alzheimer’s disease (Beraldo et al., 2013;
Ostapchenko et al., 2013). Interestingly, whereas increased levels of
STIP1 seem to affect the chaperone machinery, prion protein
expression is not affected by decreasing the level of Hsp70 and
increasing Hsp90. These consequences of increased STIP1 seem to
occur at the post-translational level, given that mRNAs for Hsp70
and 90 were not affected. It is unknown at the moment whether
increased STIP1 levels stabilize a complex containing Hsp90,
preferentially leading to increased turnover of Hsp70.
At present, the exact mechanism by which decreased STIP1 levels
affect psychiatric-like behavior is still unknown. Although it is
possible that decreased levels of STIP1 during early development
have persistent effects in brain circuits, culminating with hyperactivity
and attentional deficits, we cannot discard the possibility that
STIP1 plays a role in regulating circuitry function in the adult brain.
Our experiments at the moment do not discriminate whether the
phenotypes observed in mutant mice result from decreased STIP1cochaperone function, diminished STIP1 extracellular signaling or both.
Our results suggest that reduced levels of STIP1 have important
consequences for behavior and seem to affect brain circuits that
regulate attention. It is possible that exposure to STIP1 antibodies
during pregnancy could reduce STIP1 levels, which, based on the
present results, would have important consequences. Future
experiments are required to define potential mechanisms as well as
the consequences of disturbed STIP1 activity in ASD.
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elevated plus maze (Med Associates Inc., St Albans, USA). The activity was
recorded and videos were analyzed using ANY-maze software (Stoelting
Co., USA) to determine the amount of time spent in the closed and open
sections of the maze.
Forced swimming test

Depressive-like behavior was assessed by a forced swim test (FST) as
described previously (Martyn et al., 2012). Briefly, mice were placed in a 2 l
beaker containing 1.7 l of water at 25-27°C for 6 min. Experimental sessions
were recorded and immobility time was evaluated using ANY-Maze
Software (Stoelting Co., USA). Data obtained from the last 4 min of testing
were used for the analysis.
Morris water maze

The spatial version of Morris water maze (MWM) was conducted as
described previously (Kolisnyk et al., 2013; Martyn et al., 2012; Vorhees and
Williams, 2006). Briefly, the task was performed in a 1.5-m diameter/1-m
deep pool filled with water at 25°C. Spatial cues, 40×40 cm boards containing

black symbols (vertical and horizontal stripes, triangles, squares and circles),
were placed on the walls distributed around the pool and the platform was
submerged 1 cm below the surface of the water. Mice were submitted to four
training trials a day (90 s each) for four consecutive days with a 15 min
intertrial interval. On day 5, memory was assessed by a single 60 s trial on
which the platform was removed and the time spent in the target quadrant was
evaluated. All the experimental sessions were recorded and analyzed using the
ANY-Maze Software.
Five-choice serial reaction time task

The five-choice serial reaction time task (5-CSRTT) was used to
evaluate attention in mice as described previously (Kolisnyk et al., 2013;
Romberg et al., 2011). Mice were trained in the 5-CSRTT in automated
Bussey–SaksidaTouch screen systems (Campden Instruments Limited,
Loughborough, EN) and the data collected using ABET II Touch software
V.2.18 (Lafayette Instruments, Lafayette, USA). Mice were submitted to a
pre-training program, which consisted of first habituating the mouse to the
testing chamber with the lights off for 10 min. The next day, the mouse was

1463

Disease Models & Mechanisms

Fig. 5. Spatial memory in STI1 TGA and STI1 −/+ mice. For
the tests, n=14 STI1 +/+ and 14 STI1 TGA mice were used to
test spatial memory in STI1 TGA mice and n=11 STI1 +/+ and
11 STI1 −/+ for STI1 −/+ mice. (A) Latency to find the platform.
(B) Distance traveled. (C) Speed for STI1 TGA mice.
(D) Percentage time spent by STI1 TGA mice and controls in
target quadrant (T) and in opposite (O), right (R) and left (L)
quadrants was measured on day 5 in a 60 s probe trial with
the platform removed. (E) Latency to find the platform.
(F) Distance traveled. (G) Speed for STI1 −/+ mice.
(H) Percentage time spent by STI1 −/+ mice and controls in
each quadrant was measured on day 5 in a 60 s probe
trial with the platform removed. Results are presented as
means±s.e.m.; data were analyzed and compared by
two-way ANOVA; ***P<0.001 and ****P<0.0001 compared
with time spent in target quadrant.
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put in the chamber with the lights off for 20 min. After two days of
habituation with no reward been offered, the reward tray was primed with
11% fat strawberry milkshake (Nielson - Saputo Dairy Products) and a tone
was played when the mouse entered the reward tray. This was repeated for the
next 2 days for 40 min sessions. Whenever the mouse returned to the reward
tray, the reward was offered and paired with a tone (phase I). The following
training phase consisted in pairing the reward with the presentation of a
random stimulus (flash of light in one of the five windows), which is
removed after 30 s. At this phase, if the mouse touched the screen when the
stimulus was displayed, it received a reward. This cycle was repeated until the
mouse completed 30 trials or 60 min timeout (phase II). At phase III of the
training, the stimulus was displayed randomly in one of the five windows.
The mouse had to touch the window where the stimulus was displayed to
receive the reward paired with a tone. Similar to phase II, this cycle was
repeated until the mouse completed 30 trials or 60 min timeout. The next step
(phase IV) was identical to phase III except by the fact that the mouse had to
poke its nose into the reward trail to initiate the task. This process was
repeated in the last phase of the pre-training ( phase V); however, if the mouse
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touched an incorrect screen, it received a 5 s timeout and the light in the
chamber was turned on. After the mouse had finished pre-training and
reached criterion at 4 s and 2 s stimulus duration (80% accuracy, 20%
omission for three consecutive days), mice were probed for attention deficits
following probe trial schedules: each mouse was tested over two sessions at
1.5, 1.0, 0.8 and 0.6 s stimulus duration (the order of the probe trial sessions
was randomized and the groups counterbalanced). Between each different
stimulus duration, each mouse was returned to a 2 s stimulus for two
consecutive sessions. Number of trials to criterion, accuracy, omission,
reward collection latency and perseverative response were analyzed.
Metabolic assessments

Oxygen consumption, carbon dioxide production, respiratory exchange
ratio (RER), carbon dioxide production, water and food intake and physical
activity were simultaneously measured for adult STI1 +/+ and STI1 +/− mice
by using the Comprehensive Lab Animal Monitoring System (CLAMS)
interfaced with Oxymax Software (Columbus Instruments, Columbus, OH,
USA) as previously described in detail (Guzman et al., 2013; Kolisnyk et al.,
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Fig. 6. Five-choice serial reaction time task used to measure attention in STI1 TGA and STI1 −/+. For the tests, n=10 STI1 +/+ and 10 STI1 TGA mice were used to
test attention in STI1 TGA mice and n=13 STI1 +/+ and 13 STI1 −/+ for STI1 −/+ mice. (A) Accuracy during probe trial sessions. (B) Rate of omission. (C) Premature
responses. (D) Response latency. (E) Reward collection latency. (F) Perseverative responses for STI1 TGA mice. (G) Accuracy during probe trial sessions.
(H) Rate of omission. (I) Premature responses. (J) Response latency. (K) Reward collection latency. (L) Perseverative response for STI1 −/+ mice. Results are
presented as means±s.e.m.; data were analyzed and compared by RM-ANOVA; *P<0.05, **P<0.001 compared with control.

2013). Briefly, mice were individually housed in the metabolic chambers
with ad libitum access to water and food. Following a 16-h habituation
period, all measurements were obtained every 10 min for 24 h (12 h light/
12 h dark).
Marble burying task

A marble burying task was used to assess repetitive and anxiety-like
behavior as previously described (Deacon, 2006).
Assessment of self-grooming

Self-grooming was assessed to evaluate repetitive behavior, as previously
described (McFarlane et al., 2008). Briefly, each mouse was placed
individually in a clean, empty, cage and given a 10 min habituation period,
after which the mice were filmed for another 10 min. Cumulative time spent
grooming and number of grooming bouts were counted by an experimenter
blinded to the genotypes of the mice.
Statistical analyses

Data are presented as mean±s.e.m. Statistical analyses were performed using
SigmaStat 3.5 software. Student’s t-test was used to compare two
experimental groups and for comparison of several experimental groups,
two-way ANOVA or two-way repeated-measures ANOVA were used as
required. Tukey’s post hoc comparison was used when required.
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Abstract
Cholinergic dysfunction has been associated with cognitive abnormalities in a variety of neurodegenerative and
neuropsychiatric diseases. Here we tested how information processing is regulated by cholinergic tone in genetically modiﬁed
mice targeting the vesicular acetylcholine transporter (VAChT), a protein required for acetylcholine release. We measured longterm potentiation of Schaffer collateral-CA1 synapses in vivo and assessed information processing by using a mouse
touchscreen version of paired associates learning task (PAL). Acquisition of information in the mouse PAL task correlated to
levels of hippocampal VAChT, suggesting a critical role for cholinergic tone. Accordingly, synaptic plasticity in the hippocampus
in vivo was disturbed, but not completely abolished, by decreased hippocampal cholinergic signaling. Disrupted forebrain
cholinergic signaling also affected working memory, a result reproduced by selectively decreasing VAChT in the hippocampus.
In contrast, spatial memory was relatively preserved, whereas reversal spatial memory was sensitive to decreased hippocampal
cholinergic signaling. This work provides a reﬁned roadmap of how synaptically secreted acetylcholine inﬂuences distinct
behaviors and suggests that distinct forms of cognitive processing may be regulated in different ways by cholinergic activity.
Key words: Alzheimer’s disease, long-term potentiation, Morris water maze, paired associates learning, vesicular acetylcholine
transporter, working memory

Introduction
Basal forebrain cholinergic neurons provide input to the entire cortex and hippocampus. In particular, the hippocampus receives
most of its cholinergic innervation from neurons in the medial
septal nucleus (MS) and vertical limb of the diagonal band of
Broca (vdB), whereas the cerebral cortex and the amygdala receive
cholinergic inputs from neurons located in the nucleus basalis of
Meynert (NBM) (Mesulam et al. 1992; Kitt et al. 1994). Abnormalities
in forebrain cholinergic nuclei have been implicated in several

cognitive disorders (Bartus 2000; Mesulam 2004), including Alzheimer’s disease (AD ; Grothe, Schuster, et al. 2014; Teipel et al. 2014).
Moreover, cumulative use of drugs with anticholinergic activity is
associated with increased risk for dementia and AD (Gray et al.
2015). However, the relationship between cholinergic dysfunction
and maintenance of cognitive abilities in these diseases is not
fully understood, due to concomitant pathologies that may contribute to cognitive abnormalities (Mesulam 2013).
Cholinergic signaling is involved in the regulation of hippocampal synaptic transmission and plasticity (Ji et al. 2001;
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facilitating translational studies between species (Morton et al.
2006; Talpos et al. 2009, 2010; Romberg et al. 2011; Mar et al.
2013). The paired associates learning (PAL) test has been shown
to efﬁciently detect cognitive alterations that are consistently observed in AD (Swainson et al. 2001; Blackwell et al. 2004; de Rover
et al. 2011) and schizophrenia (Wood et al. 2002; Barnett et al.
2005). In dementia, PAL has been shown to differentiate between
mild cognitive impairment and AD (Blackwell et al. 2004). Here we
investigated cognitive performance in mice with deletion of
VAChT, a protein required for synaptic release of ACh, in either
forebrain cholinergic neurons or selectively in septohippocampal
cholinergic neurons. Our experiments reveal that dysfunction in
hippocampal cholinergic activity inﬂuences synaptic plasticity in
vivo and disturbs performance in PAL and working memory,
whereas spatial navigation seems relatively preserved.

Material and Methods
Animals
Generation of VAChTﬂox/ﬂox mice was previously described (Martins-Silva et al. 2011). VAChTﬂox/ﬂox mice (mixed C57BL/6J × 129/
SvEv background, backcrossed to C57BL/6J for 5 generations) were
crossed to VAChTNkx2.1-Cre-ﬂox/ﬂox mice so that offspring from this
mating provided control and test littermates. VAChTNkx2.1-Cre-ﬂox/
ﬂox
mice were generated by crossing VAChTﬂox/ﬂox with the
Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx2-1-cre)2Sand/J), purchased from The Jackson Laboratory (JAX stock no. 008661).
This line has been previously used to eliminate ChAT from forebrain neurons (Patel et al. 2012). Unless otherwise stated, all control mice used for behavioral studies were VAChTﬂox/ﬂox
littermates. The reporter mouse line Nkx2.1(td-Tomato) was generated by crossing B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J mice,
purchased from The Jackson Laboratory (JAX stock no. 007909)
with the Nkx2.1-Cre mouse line (JAX stock no. 008661).
Animals were housed in groups of 3 per cage without environmental enrichment in a temperature controlled room (12:12 light
to dark cycles), and food and water were provided ad libitum for
most experiments. Animals that underwent touchscreen testing
were housed in pairs; food restricted to no more than 85% of their
original weight, and they were maintained at the target weight
for the duration of behavioral testing. Male mice 3 months old
were used for behavioral studies. We followed the ARRIVE guidelines (Kilkenny et al. 2010); hence, mice were randomized for behavioral tests and the experimenter was blind to the genotype.
All procedures were performed in accordance with the Canadian
Council of Animal Care guidelines at the University of Western
Ontario with an approved animal protocol (2008–127).

Immunoﬂourescence Microscopy
Mice were anesthetized with ketamine (100 mg/kg) and xylazine
(25 mg/kg) in 0.9% sodium chloride, and then sacriﬁced by transcardial perfusion: phosphate-buffered saline (PBS, pH = 7.4) for
3 min and 4% paraformaldehyde for 5 min. Brains were harvested
and placed in 4% paraformaldehyde in 1× PBS at 4 °C for 4 h; they
were kept at 4 °C until sliced using a vibratome. Brain sections
(40 µm) were prepared and free-ﬂoating sections in 1× PBS
(1 per well in a 24-well plate) were permeabilized with 0.4% Triton
X-100 in 1× PBS for 1 h. Non-speciﬁc epitopes were blocked using
a solution of 1× PBS/0.4% Triton X-100 containing 0.1% glycine
(wt/vol), 0.1% lysine (wt/vol), 1% BSA (wt/vol), and 1% normal
donkey serum (wt/vol). The primary antibodies used were
anti-VAChT (catalog no. 139103; Synaptic Systems), anti-ChAT
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Leung et al. 2003; Seeger et al. 2004; Ge and Dani 2005; Gu and
Yakel 2011). Septal cholinergic activation, either by electrical
stimulation or by optogenetics, allows the expression of distinct
time-dependent forms of hippocampal plasticity (Gu and Yakel
2011). Pharmacological (Decker and Majchrzak 1992; Anagnostaras et al. 1999; Gale et al. 2001; Wallenstein and Vago 2001; Chudasama et al. 2004; Pichat et al. 2007; Timmermann et al. 2007;
Ragozzino et al. 2012) and genetic studies (Anagnostaras et al.
2003; Seeger et al. 2004; Poulin et al. 2010) have shown that
modulation of cholinergic receptors inﬂuence learning and
memory processes. Indeed, both nicotinic receptors (nAChRs)
and muscarinic receptors (mAChRs) have been linked with various forms of plasticity (Vidal and Changeux 1993; Gray et al. 1996;
Ji and Dani 2000; Seeger et al. 2004; Gautam et al. 2006; Giessel and
Sabatini 2010; Zheng et al. 2012). For example, M1 knockout mice
exhibit selective cognitive impairments in tasks requiring interactions between the hippocampus and cortex (Anagnostaras
et al. 2003), while M2 knockout mice display impairments in
working memory, cognitive ﬂexibility, and hippocampal plasticity (Seeger et al. 2004). Moreover, recent evidence shows that
activation of M1 mAChRs induces long-term potentiation (LTP),
suggesting that M1 mAChRs could play a role in regulating hippocampal plasticity (Dennis et al. 2015). Furthermore, the nAChR
β2-subunit knockout mice are impaired in learning the MWM,
suggesting that the β2-subunit may mediate effects of ACh on
learning and memory (Zoli et al. 1999). However, long-term
changes in cholinergic activity, as observed in a number of
neurodegenerative diseases, are more complex to model using
speciﬁc receptor knockouts, given the plethora of subtypes of
muscarinic and nicotinic receptors.
One widespread alternative to mimic cholinergic dysfunction
is the selective elimination of these neurons using toxins in rodents (Baxter and Bucci 2013; Prado et al. 2013). It is somewhat
controversial whether selective 192 IgG-saporin lesion of septohippocampal cholinergic neurons can lead to signiﬁcant impairments in hippocampal-dependent learning and memory tasks in
rodents, with some authors ﬁnding little effect (Berger-Sweeney
et al. 1994; Baxter and Gallagher 1996; Pizzo et al. 2002; Frick et al.
2004; Parent and Baxter 2004), whereas others ﬁnd a miriad of
deﬁcits (Walsh et al. 1996; Janis et al. 1998; Gil-Bea et al. 2011).
In addition, cholinergic neurons have been shown to contain
more than one class of neurotransmitter transporters and secrete 2 neurotransmitters (Gras et al. 2008; El Mestikawy et al.
2011; Guzman et al. 2011; Prado et al. 2013; Nelson et al. 2014;
Saunders et al. 2015). Therefore, it is difﬁcult to interpret results
with toxin lesions for speciﬁc contributions of neurotransmitters
in neurons that release 2 chemical messengers. Indeed, recent
work has shown that some basal forebrain cholinergic neurons
can also secrete GABA which acts as a neurotransmitter in the
cortex (Saunders et al. 2015).
Genetic targeting of either the vesicular acetylcholine transporter (VAChT; Guzman et al. 2011; Martyn et al. 2012) or choline
acetyltransferase (ChAT; Patel et al. 2012) using the Cre/lox system has provided a way for investigating speciﬁc contributions of
ACh when there is co-transmission (Prado et al. 2013). Decreased
VAChT levels severely compromise packaging of acetylcholine
(ACh) into synaptic vesicles and thus reduce ACh release by nerve
terminals (Prado et al. 2006; de Castro, De Jaeger, et al. 2009). Conversely, overexpression of VAChT enhances ACh secretion proportionally (Song et al. 1997; Kolisnyk, Guzman, et al. 2013) .
The recent development of automated touchscreen behavioral testing for rodents has greatly improved mouse behavioral assessment. Touchscreen tasks were designed using almost
identical paradigms and methodologies used in humans,
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(1:200) (catalog no. AB144P, Merck Millipore), and anti-Choline
Transporter (CHT1; 1:200), which was kindly donated by
Dr R. Jane Rylett, University of Western Ontario, London, Ontario.
The primary antibody was incubated in blocking buffer overnight
at 4 °C. Sections were then washed 5 times in 1× PBS/0.4% Triton
X-100 (10 min each). Hoechst 3342 (Life Technologies, Bibco, Carlsbad, CA, USA) (2–5 µg/mL) and secondary antibodies (1:500; anti488, catalog no. A-11034, ThermoFisher; 1:500 anti-633, catalog
no. A-21082, ThermoFisher) were diluted in blocking buffer and
slices were incubated for 1 h at RT. Sections were visualized by
Zeiss LSM 510Meta (Carl Zeiss, Oberkochen, Germany) confocal
system (63 × objective, 488-nm Ar laser and 633-nm HeNe laser
were used for excitation of ﬂuorophores).

Western Blotting

Training on the PAL Task
Prior to training, both groups of mice (3 months old) were food restricted until they reached approximately 85% of their original
weight. Training of the animals to the PAL task was previously described (Talpos et al. 2009). Brieﬂy, the training phase for the mice
in the touchscreen chambers involved a habituation session,
where they were placed in the chambers with the lights off for
20 min to habituate to the environment for 2 days. Next, mice
were put in the chamber with the same parameters as in the habituation phase, but this time a 150 µL reward (strawberry milkshake; Saputo Dairy Products, Canada) was introduced in the
reward receptacle. Every time the mouse attended to the reward
in the reward receptacle, a tone was played. This 40 min training
session was done for the next 2 days until mice completed 36 trials
in 60 min (Habituation; Phase 1)
The mice were then trained to associate the reward with a 30 s
presentation of training stimuli, which varied in brightness,
shape, and pattern, on one of the 3 screens (Initial touch training;
Phase 2). Mice were required to touch any of the screens whenever the stimulus was presented to receive the reward, which
was paired with a tone. A new trial was automatically initiated
once the mice collected the reward. This was done until the
mice completed 36 trials in 60 min for 1 day. Next, mice are required to touch the stimulus that is displayed randomly in one
of the 3 windows to receive the reward (must touch stimuli training; Phase 3). Mice are only moved to next training after completing 36 trials in 60 min for 1 day. In the next training phase, food is
delivered and tray light is turned on. The mouse must nose poke
and exit the reward tray before a stimulus is displayed randomly
on the screen (Must initiate; Phase 4). This was done until mice
completed 36 trials in 60 min for 1 day. Next, animals go to the
last phase of the training program required for the PAL task.
This training phase is referred to as “punish incorrect” (Phase
5). This phase is similar to the previous one, but if the mouse
touched the incorrect screen, that is, one of the blank screens,
it was presented with a 5-s time-out. This time-out was accompanied by the presentation of a bright light in the chamber.
Criterion to successfully proceed from this training phase
was 23 correct responses out of 30 trials in 60 min for 2 consecutive days. Next, both experimental groups were subjected to acquisition training, where 2 stimuli are displayed at the same
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time during a trial. One will be in the correct location (S+) and
the other will be in the incorrect location (S−). Mice were required
to touch the correct stimulus (S+) presented on one of the 3 screens
to complete a trial and receive the reward. In this acquisition phase,
mice were on an unpunished version in which touching the S− was
ignored. A completion of a trial was only considered when the
mouse touches the S+. Criterion for this training phase is completion of 36 trials in 1 session (1 day). All mice from both experimental
groups were able to reach criterion in acquisition training.

PAL Task
After successfully completing the training phase, the mice were
placed on a PAL task (dPAL), which involves a different stimulus
being presented in each trial. A trial starts in dPAL when the
mouse initiates it by touching the food receptacle, which triggers
the display of both S+ and S− on the screen. S+ refers to when the
stimulus is in the correct location, and S− refers to when the
stimulus is in the incorrect location. There were 6 possible trial
types and 3 different stimuli were presented (ﬂower, plane, and
spider). Within trials, an S+ is the ﬂower presented in the left window, the plane in the middle window, or the spider in the right
window. Thus, mice are required to learn to associate a stimulus
to its correct location. A response by touching the S− resulted in a
10 s time-out and the chamber light was activated for 10 s, acting
as an indication for an incorrect response for the mouse. After
10 s, the next initiation by the mouse was considered a correction
error trial, where the same S+ and S− were presented as for the
unsuccessful previous trial. The number of correction trials was
not counted toward the total number of trials performed per session. An S+ response, however, led to a tone, as well as the reward
being dispensed in the receptacle.

Electrophysiology
Animals were anesthetized with urethane (1 g/kg i.p.) and placed
in a stereotaxic apparatus. Atropine methyl nitrate was administered (5 mg/kg i.p.) to reduce airway secretions during stereotaxic
surgery. Animal body temperature was monitored between
36.5 °C and 37 °C using a feedback controlled rectal thermometer
and heating pad. Stimulating electrodes were placed into stratum
radiatum at P 1.8, L 2.3 or P 2.5, L2.4 (Franklin and Paxinos 2008) to
stimulate Schaeffer collaterals projecting from CA3 to CA1
(Hutchison et al. 2009). A silicon probe, with 16 electrodes separated by 50 µm on a vertical shank, was placed in area CA1 at
P 2.2, L 1.8. Laminar proﬁles of the average (4 sweeps) ﬁeld excitatory postsynaptic potentials evoked by single pulse stimulation
of the Schaffer collaterals at 1.5-2 × threshold stimulus intensity.
Current-source density analysis using 100 µm step size was used
to determine current sources and sinks. The maximal slope (of
1 ms duration) during the rising phase of the excitatory sink, at
its maximum in CA1 stratum radiatum, was used for LTP assessment. After a stable baseline of the excitatory sink slope was established for 30 min (coefﬁcient of variation [SEM/mean] of the
sink slopes <0.05), a high-frequency tetanus (100 Hz for 1 s) was
delivered at 2–3 times the threshold intensity, and the response
was measured for 120 min after the tetanus. For each mouse,
the slope of the excitatory sink was normalized by the average
value of the baseline, and LTP across mice was averaged and reported as a multiple of the baseline slope.

Rotarod and Neuromuscular Tests
The rotarod task was conducted as previously described (Prado
et al. 2006; de Castro, Pereira, et al. 2009). Forelimb and hind
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Immunoblotting was performed as previously described (MartinsSilva et al. 2011; Kolisnyk, Al-Onaizi, et al. 2013; Kolisnyk, Guzman,
et al. 2013). Antibodies used were anti-VAChT (catalog no. 139103;
Synaptic Systems) and anti-Synaptophysin (catalog no. S5768;
Sigma-Aldrich).
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limb grip strength was assessed using a previously described
protocol (Prado et al. 2006). The hang-wire experiments were performed as described (Sango et al. 1996).

Morris Water Maze

Two-Trial Morris Water Maze
A task used to assess working memory was the 2-trial variation of
the MWM. The task was carried out using previously described
protocols (Vorhees and Williams 2006; Kolisnyk, Guzman, et al.
2013). The mice were trained on the task over the course of
5 days. During the training period, the mouse was ﬁrst given a
90-s trial with a 15 s inter-trial interval. Next, the mouse was
given a second trial with the same platform location and starting
point; this was repeated 3 additional times. After completing the
training phase, the mouse was ﬁrst given a 90 s trial with a 15 s
inter-trial-interval. The mouse was then given a second trial
with identical platform location and starting point. This was repeated with 4 unique starting location/platform location combinations a day. Mean latency and distance savings ratios were
then calculated as previously described (Kolisnyk, Guzman,
et al. 2013). Sessions were recorded for both tests and were analyzed using the ANY-Maze video tracking software (Stoelting Co.)

Spontaneous Alterations Y-maze
To assess working memory in the mice, we used the spontaneous
alternations Y-maze as previously described (Kolisnyk, Guzman,
et al. 2013). Brieﬂy, mice were placed in a symmetrical plastic
Y-maze apparatus, and both the number and order of arm entries
were recorded. A spontaneous alternation was deﬁned as when
the mouse visited all 3 of the arms in a row, without having revisited a previous arm of the maze. Sessions were recorded and
analyzed using the ANY-Maze Software.

Stereotaxic Injections of Adeno-Associated Virus
To obtain selective deletion of VAChT in the medial septum, mice
were anesthetized with ketamine (100 mg/kg) and xylazine
(25 mg/kg) in 0.9% sodium chloride, and 1 µL (titer of ∼1013 GC/mL)
of adeno-associated virus (AAV)8-GFP-Cre- or control virus
(AAV8-GFP, Vector BioLabs, Eagleville, PA, USA) was injected
into the medial septum/vertical limb of the diagonal band (0.98
AP, 0.1 LL and 4.1 DV) of VAChTﬂox/ﬂox mice. The injecting

Statistical Analysis
All data are expressed as mean ± SEM. Sigmastat 3.5 software was
used for statistical analysis. Comparison between 2 experimental
groups was done with Student’s t-test. When several experimental groups or treatments were analyzed, 2-way analysis of variance (ANOVA) or 2-way ANOVA with repeated measures (RM)
were used as required. When appropriate, a Bonferonni post hoc
analysis test was used.

Results
Deletion of VAChT in Forebrain Projection Neurons
Nkx2.1-driven Cre is expressed in forebrain cholinergic neurons
as assessed using a reporter mouse line (see Supplementary
Fig. 1A and Table 1). Immunoblot analysis shows that VAChT
levels in the prefrontal cortex (t (4) = 6.162, P = 0.0035), hippocampus (t (4) = 4.461, P = 0.0097), and striatum (t (4) = 8.625, P = 0.0010)
were severely diminished in VAChTNkx2.1-Cre-ﬂox/ﬂox mice (see
Supplementary Fig. 1B–D). In contrast, VAChT levels remained
unchanged in the brainstem of VAChTNkx2.1-Cre-ﬂox/ﬂox compared
with controls (t (4) = 1.040, P = 0.3571, see Supplementary Fig. 1E).
Moreover, immunoﬂuorescence imaging indicated decreased
VAChT immunoreactivity in the hippocampus of VAChTNkx2.1Cre-ﬂox/ﬂox
mice compared with controls (Fig. 1A,B). Importantly,
these mice presented no neuromuscular deﬁcits (see Supplementary Fig. 2A–C). We have previously shown that reduced
VAChT levels proportionally decrease the release of ACh in vivo
and in vitro (Prado et al. 2006; Guzman et al. 2011; Kolisnyk,
Al-Onaizi, et al. 2013; Kolisnyk, Guzman, et al. 2013).
Forebrain VAChT is Required for Performance in the PAL Task
We tested VAChTNkx2.1-Cre-ﬂox/ﬂox mice on the PAL task, which requires sophisticated processing of information for proper association of images with speciﬁc locations. VAChTNkx2.1-Cre-ﬂox/ﬂox
mice and their matched controls were assessed on the dPAL
task using an automated touchscreen system (Fig. 1C and see
Supplementary Videos 3 and 4). Prior to being subjected to the
PAL task, both experimental groups are trained on a different
training sessions (initial touch, must touch stimuli, must initiate,
and punish incorrect) to learn how to operate the touchscreen,
which includes learning to touch the screen when a stimulus is
presented and initiating the task by inserting the head into the
reward chamber. In the “punish incorrect” training, when only
one stimulus is presented randomly in one of the 3 screens,
mice are taught to touch the screen that shows the stimulus.
Mice from both experimental groups were able to reach criterion
in this phase of the training and no differences were observed between the 2 genotypes (t (12) = 0.0749) (Fig. 1D), indicating that
VAChT-deﬁcient mice are able to learn that they need to touch
the screen when an image is shown. Additionally it argues that
VAChT-deﬁcient mice do not present any major visual impairment. During the course of the 9 weeks that mice were tested
on the dPAL task, we observed that control mice signiﬁcantly improved their accuracy performance, while VAChT deletion
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The spatial version of the MWM was performed as previously described (Vorhees and Williams 2006; Martyn et al. 2012; Kolisnyk,
Guzman, et al. 2013). Testing was performed in a 1.5-m diameter
pool with 25 °C water. A hidden platform was submerged in a
constant location 1 cm below the surface of the water in one of
the 4 arbitrarily deﬁned quadrants, and spatial cues were distributed around the pool. Brieﬂy, mice were given four 90-s trials for
the duration of 4 days to ﬁnd the hidden platform, with an ITI of
15 min. The animals were introduced to the pool from different
locations within the pool for each trial. Mice that did not ﬁnd
the platform within the 90 s were gently guided to the platform.
On the ﬁfth day, spatial memory recall was tested by a 60-s probe
trial, where the hidden platform is removed and the amount of
time the animal spends in the target quadrant is calculated. To
test reversal learning, the hidden platform was relocated to the
opposite quadrant, where the animals were given four 90-s trials
for 4 days. On the ﬁfth day, the animals were given a 60-s probe
trial. Data were analyzed using ANY-Maze video tracking software (Stoelting Co.).

micropipette was inserted and left for 2 min to stabilize. After
stabilization, a 0.2 µL/min infusion was performed using a micropump followed by a 30 min rest period to allow local diffusion of
the virus and avoid virus efﬂux. The micropipette was then
slowly removed and the scalp sutured. A recovery period of
4 weeks was given before behavioral testing to allow transgene
expression.
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experimental groups to reach criterion during the operant conditioning, pretraining, and training phases. (E–H) Data for the acquisition of the dPAL task for VAChTﬂox/ﬂox
(n = 7 clear squares) and VAChTNKx2.1-Cre-ﬂox/ﬂox (n = 7 dark circles) mice. Each week represents 5 testing sessions of 36 trials. (E) Mean accuracy; (F) Mean correction
errors; (G) Response latency; (H) Reward collection latency (Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.0001).

mutants did not (2-way RM ANOVA shows signiﬁcant effect
of weeks F8,48 = 21.11, P < 0.0001, an effect of genotype F1,6 = 56.94,
P = 0.0003, and an interaction effect F8,48 = 2.871, P = 0.0074,
Fig. 1E). VAChTﬂox/ﬂox mice (controls) were able to improve performance reaching 77 ± 1% accuracy by Week 9 (Fig. 1E). In contrast, peak accuracy performance of VAChTNkx2.1-Cre-ﬂox/ﬂox mice in
the dPAL task during the same period was 58 ± 2% (Fig. 1E). Although
VAChTNkx2.1-Cre-ﬂox/ﬂox mice were able to perform the 36 trials required in each 1-h session, they failed to associate the stimulus to
its correct location. Their poorer performance was also reﬂected in
the number of correction errors performed (Fig. 1F). VAChTNkx2.1-Creﬂox/ﬂox
mice failed to decrease the number of correction errors made
over the course of 9 weeks, while control mice improved the number
of correction errors performed during the course of the study (2-way
RM ANOVA shows signiﬁcant effect of weeks F8,48 = 12.05, P < 0.0001,
an effect of genotype F1,6 = 39.41, P = 0.0008, and an interaction effect
F8,48 = 1.224, P = 0.0306, Fig. 1F). Correct response latency was not different between the 2 groups over the course of 9 weeks (2-way RM
ANOVA shows signiﬁcant effect of weeks F8,48 = 7.508, P < 0.0001,
no effect of genotype F1,6 = 2.437, P = 0.1695, and no interaction
F8,48 = 1.195, P = 0.3220, Fig. 1G). Furthermore, VAChTNkx2.1-Cre-ﬂox/ﬂox

mice were no different from controls when the latency to collect
the reward was measured, which indicated that motivation
was not a factor in their poorer performance (2-way RM ANOVA
shows a signiﬁcant effect of weeks F8,48 = 7.596, P < 0.0001, no effect
of genotype F1,6 = 0.0001380, P = 0.7681, and no interaction F8,48 =
0.6061, P = 0.7681 Fig. 1H). In summary, VAChTNkx2.1-Cre-ﬂox/ﬂox mice
were able to learn that they had to touch the screen when the
images were shown; however, they failed in making associations,
that is, they were unable to assign each image to a speciﬁc position.
Hippocampal LTP is Disrupted in Forebrain-Speciﬁc VAChT
Knockout Mice In Vivo
Formation of associations might depend on lasting increases in
synaptic strength. To determine whether VAChTNkx2.1-Cre-ﬂox/ﬂox
mice have intact synaptic plasticity, we examined LTP of the synapse of the Schaffer collaterals on hippocampal CA1 neurons in
anaesthetized mice in vivo. VAChTNkx2.1-Cre-ﬂox/ﬂox mice showed
decreased LTP which lasted about 90 min post-tetanus delivery
while LTP in VAChTﬂox/ﬂox mice was maintained for 120 min
(Fig. 2A,B). This indicated that the lack of cholinergic signaling
disturbs synaptic plasticity in hippocampal CA1 area in vivo.
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Figure 1. VAChTNKx2.1-Cre-ﬂox/ﬂox mice display impairments in the acquisition of dPAL. (A) Representative 3-dimensional reconstructed Z stack immunoﬂuorescence
images of VAChT (green) and Hoechst (blue) in the CA1 and CA3 regions of the hippocampus in VAChTﬂox/ﬂox (n = 3) and (B) VAChTNkx2.1-Cre-ﬂox/ﬂox mice (n = 3) (Scale
bar = 100 µm). (C) Image depicting a mouse performing the task, where the ﬂower is shown as S+ and the airplane as S−. (D) Number of sessions required by both
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did not correlate to mean response latency across the task (Pearson’s r = 0.1349, CI = −0.3273 to 0.5450, P = 0.5708, Fig. 3E) or mean
reward collection latency across the task (Pearson’s r = −0.1799,
CI = −0.5676 to 0.2731, P = 0.4352, Fig. 3F), suggesting that response patterns and motivation are unaltered by reduced
VAChT levels. Taken together these results show that the less
VAChT protein in the hippocampus the worse is the mouse performance in the dPAL task, indicating that dPAL learning is
modulated by septohippocampal cholinergic signaling.

VAChT and Spatial Navigation

mice in vivo. (A) Normalized slopes of the excitatory sink recorded at CA1
stratum radiatum (apical dendrites) of VAChTﬂox/ﬂox (clear squares, n = 5) and
VAChTNkx2.1-Cre-ﬂox/ﬂox (dark circles, n = 6) mice. Baseline was monitored for
30 min prior to tetanus delivery (t = 0), and posttetanic response was monitored
for 120 min. A 1-s 100 Hz train, delivered at 2–3 times the threshold intensity
(arrow), induced higher and more prolonged potentiation in VAChTNkx2.1-Cre-ﬂox/ﬂox
mice than VAChTﬂox/ﬂox controls. Insets show representative current sink time
response taken at 80 min (red traces), overlaid on the pretetanus baseline
response (black traces), from each genotype. (B) Normalized excitatory sink
slope averaged across 30-min time intervals (mean ± SEM) in VAChTﬂox/ﬂox and
VAChTNkx2.1-Cre-ﬂox/ﬂox mice, with signiﬁcant difference between mouse groups
at 90–120 min (t (9) = 3.911, P = 0.0036).

To speciﬁcally evaluate the contribution of hippocampal cholinergic tone to PAL performance, we stereotaxically injected
AAV8-GFP-Cre or AAV8-GFP virus to the medial septum and vertical limb of the diagonal band (MS/VDB) of VAChTﬂox/ﬂox mice
(AAV8-GFP-Cre n = 13; AAV8-GFP n = 7). Mice were trained on the
dPAL task 1 month after viral injection. Following completion of
the task, mice were sacriﬁced to evaluate VAChT protein levels.
Given the length of the experiment (≈4 months), and the observation that viral injection was only partially effective to reduce
hippocampal VAChT levels (see Supplementary Fig. 6B), we did
not exclude any mouse from the analysis, even if viral mediated
recombination was not effective to eliminate the transporter.
Instead, we correlated VAChT levels in the hippocampus from
both AAV8-GFP-Cre and AAV8-GFP to their performance on the
PAL task.
Performance on the ﬁnal week of the experiment was positively correlated to VAChT protein levels in terms of response
accuracy (Pearson’s r = 0.5208, CI = 0.1015–0.7829, P = 0.0186,
Fig. 3A) and negatively correlated to number of correction errors
(Pearson’s r = −0.6518, CI = −0.8494 to −0.2940, P = 0.0018, Fig. 3B).
We also evaluated the relationship between hippocampal VAChT
protein levels to learning the PAL task. We calculated the rate of
learning as the slope of the learning curve of both response
accuracy and correction errors across all the weeks of the task.
VAChT protein level was positively correlated to the rate of
learning of response accuracy (Pearson’s r = 0.5053, CI = 0.08072–
0.7747, P = 0.0231, Fig. 3C) and negatively correlated to the correction error rate of learning (Pearson’s r = −0.1799, CI = −0.7982 to
−0.1418, P = 0.0120, Fig. 3D). Importantly, VAChT protein levels
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Figure 2. Hippocampal LTP is disrupted in forebrain-speciﬁc VAChT knockout

Given the strong deﬁcit of association of the image with its correct location in the PAL task, it seemed of importance also to
evaluate spatial memory in these mice. Spatial memory is widely
used to assess information acquisition and storage in the hippocampus, but cholinergic dysfunction has only mild effects in
the MWM in mice (Moreau et al. 2008; Martyn et al. 2012). Our
data showed that spatial learning on the MWM was relatively
normal in VAChTNkx2.1-Cre-ﬂox/ﬂox mice compared with controls
(see Supplementary Fig. 5A–C). On the probe trial of the MWM,
both groups of mice spent signiﬁcantly more time in the target quadrant compared with the opposite quadrant (2-way ANOVA shows a
signiﬁcant effect of quadrant, F3,80 = 39.58, P < 0.0001, and an interaction effect F3,80 = 2.914, P = 0.0394, see Supplementary Fig. 5D), post
hoc analysis revealed that both groups spent signiﬁcantly more time
in the target quadrant. However, VAChTNkx2.1-Cre-ﬂox/ﬂox mice had
signiﬁcantly fewer platform crosses compared with littermate
controls (t (20) = 2.795, P = 0.0112, see Supplementary Fig. 5E).
To speciﬁcally evaluate the contribution of hippocampal cholinergic tone to learning and memory performance in the spatial
version of the MWM, we stereotaxically injected AAV8-GFP-Cre
(n = 25) virus to the MS/VDB in another cohort of VAChTﬂox/ﬂox
mice (see Supplementary Fig. 6A,B). VAChTﬂox/ﬂox mice injected
with AAV8-GFP (n = 14) were used as controls. AAV8-GFP-Cre-injected mice that showed more than 50% of hippocampal VAChT
protein levels (n = 11) compared with controls were excluded
from the analysis (see Supplementary Fig. 6E). In AAV8-GFPCre-injected mice with reduced hippocampal VAChT levels,
VAChT protein in the prefrontal cortex was not changed (97% of
AAV8-GFP VAChT levels, t (4) = 0.453, P = 0.665, see Supplementary
Figure 6C,D). AAV8-GFP-Cre-mediated deletion of VAChT from
the medial septum did not signiﬁcantly alter acquisition of the
spatial version of the MWM (Latency, 2-way RM ANOVA shows
an effect of days F3,39 = 22.84, P < 0.0001, no effect of Cre virus injection F1,13 = 0.2228, P = 0.6447, and no interaction, F3,39 = 1.302,
P = 0.2876, Fig. 4A). Similar results were obtained for distance
travelled (2-way RM ANOVA shows an effect of days, F3,39 = 23.5,
P < 0.0001, no effect of Cre expression F1,13 = 0.3125, P = 0.5856,
and no interaction, F3,39 = 1.329, P = 0.2787, Fig. 4B). In the probe
trial, mice injected with the AAV8-GFP-Cre virus did not differ
from controls in terms of preference for the target quadrant
(2-way ANOVA shows a signiﬁcant effect of quadrant, F3,104 = 37.81,
P < 0.0001, no effect of Cre expression, F1,104 = 0.6452, P = 0.4237, and
no interaction F3,104 = 0.3988, P = 0.7541, Fig. 4D) or platform crosses
(t (26) = 0.9547, P = 0.3603, Figure 4E). Taken together, these results
suggest that decreased levels of hippocampal cholinergic activity
do not seem to affect MWM performance.
VAChTNkx2.1-Cre-ﬂox/ﬂox mice were also tested on the reversal
learning protocol of the MWM. During the course of 4 days, control mice signiﬁcantly improved in their latency to ﬁnd the hidden platform in contrast to VAChTNkx2.1-Cre-ﬂox/ﬂox mice (2-way
RM ANOVA shows a signiﬁcant effect of days F3,30 = 8.632,
P = 0.0003, main effect of genotype F1,10 = 11.17, P = 0.0075, and
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n = 13) injected mice. (C,D) Linear regression and correlation between response accuracy (r = 0.4460, P = 0.0487) and correction errors (r = -0.1799, P = 0.0120) across all the
weeks of the PAL task and hippocampal VAChT protein expression levels. (E,F) The relationship between response latency (r = 0.1349, P = 0.5708) and reward collection
latency (r = −0.1799, P = 0.4352) across all the weeks of the PAL task and VAChT expression levels.

Figure 4. Performance of medial septum AAV8-GFP-Cre-injected mice in the MWM. VAChTﬂox/ﬂox injected with AAV8-GFP virus (clear squares, n = 14) or AAV8-GFP-Cre
virus (dark circles, n = 14) were tested in the spatial paradigm of the MWM. Data average of four 90-s trials per day were plotted. (A) Latency to reach the platform, (B)
distance to reach the platform, (C) speed to reach the platform, (D) the percentage of time spent in each quadrant of the pool measured on Day 5 in a 60-s probe trial
with the platform removed. (E) Number of platform crosses during the probe trial. (F) Representative path traces of 2 AAV8-GFP and 2 AAV8-GFP-Cre-injected mice in
the probe trial. The target quadrant is in the upper right. Data are mean ± SEM. *P < 0.05. T, target; O, opposite; L, left; R, right.

no interaction F3,30 = 1.501, P = 0.2342, Fig. 5A–C). Notably, on the
probe trial, control mice spent considerably more time in the target quadrant compared with the other quadrants (2-way ANOVA

shows a signiﬁcant effect of quadrant, F3,80 = 7.226, P = 0.0002, and
an interaction effect F3,80 = 3.133, P = 0.0301, Fig. 5D), while
VAChTNkx2.1-Cre-ﬂox/ﬂox mice visited all quadrants almost equally.
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Figure 3. Medial septum AAV8-GFP-Cre-injected mice show deﬁcits in dPAL. (A,B) Linear regression and correlation between response accuracy (r = 0.5208, P = 0.0186) and
correction errors (r = −0.5154, P = 0.0168) on Week 9 and hippocampal VAChT protein expression levels for AAV8-GFP (clear squares, n = 7) and AAV8-GFP-Cre (dark circles,
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(dark circles, n = 11) were tested in the reversal paradigm of the MWM. Data average of four 90-s trials per day were plotted. (A) Latency to reach the platform, (B) distance to
reach the platform, (C) speed to reach the platform, (D) the percentage of time spent in each quadrant of the pool measured on Day 5 in a 60-s probe trial with the platform
removed. (E) Number of platform crosses during the probe trial. (F) Representative path traces for 2 VAChTﬂox/ﬂox and 2 VAChTNkx2.1-Cre-ﬂox/ﬂox in the probe trial. The target
quadrant is in the upper left. (G–L) AAV8-GFP (clear squares, n = 14) or AAV8-GFP-Cre (dark circles, n = 14)-injected mice were tested in the reversal paradigm of the
MWM. The data average of four 90-s trials per day were plotted. (G) Latency to ﬁnd the platform, (H) distance, (I) speed, (J) the percentage of time spent in each
quadrant of the pool was measured on Day 5 in a 60-s probe trial with the platform removed. (K) Number of platform crosses during the probe trial. (L) Two AAV8GFP- and 2 AAV8-GFP-Cre-injected mice in the probe trial. The target quadrant is indicated with a T. Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.0001. T, target; O,
opposite; L, left; R, right.

The number of platform crosses was also higher for control mice
compared with VAChT mutants (t (20) = 2.797, P = 0.0111, Fig. 5E).
These results indicate that, different from control mice,
VAChTNkx2.1-Cre-ﬂox/ﬂox mice were unable to extinguish the previously learned position and relearn the new position of the hidden
platform.
To account for compromised striatal cholinergic signaling in
VAChTNkx2.1-Cre-ﬂox/ﬂox mice for the performance in the MWM
(see Supplementary Fig. 1D), we also tested a mouse line with

selective deletion of VAChT in striatal neurons (VAChTD2-Cre-ﬂox/
), but spared hippocampal VAChT (Guzman et al. 2011; see
Supplementary Fig. 7). Interestingly, VAChTD2-Cre-ﬂox/ﬂox mice
did not differ from controls (VAChTﬂox/ﬂox) in both acquisition
and reversal versions on the MWM (see Supplementary Fig. 7D–
H). These results suggest that deﬁcits seen in reversal learning
in VAChTNkx2.1-Cre-ﬂox/ﬂox mice are not likely due to impaired striatal cholinergic transmission, but rather a result of hippocampal
or cortical deﬁcits or combined cortical hippocampal
ﬂox
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Figure 5. Reversal learning is affected in VAChTNkx2.1-Cre-ﬂox/ﬂox and medial septum AAV8-GFP-Cre-injected mice. VAChTﬂox/ﬂox (clear squares, n = 11) and VAChTNkx2.1-Cre-ﬂox/ﬂox
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Regulation of Working Memory by Septohippocampal
VAChT
To determine whether other cognitive domains of importance in
neuropsychiatric disorders that could contribute to the PAL deﬁcits may also be regulated by synaptically released ACh, we evaluated the performance of the VAChTNkx2.1-Cre-ﬂox/ﬂox mice on 2
measures of working memory: the working memory version of
the MWM and spontaneous alternations in the Y-maze. In the
working memory version of the MWM, VAChTNkx2.1-Cre-ﬂox/ﬂox
mice failed to improve their performance from the ﬁrst to the
second trial resulting in signiﬁcant impairments in measures of
latency savings (t (12) = 3.580, P = 0.0030, Fig. 6A) and distance
savings (t (12) = 2.852, P = 0.0127, Fig. 6B), suggesting that the
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VAChTNkx2.1-Cre-ﬂox/ﬂox mice have impaired working memory.
Similarly, VAChTNkx2.1-Cre-ﬂox/ﬂox mice revisited arms in the
maze more often than controls resulting in a signiﬁcant decrease
in spontaneous alternations in the Y-maze (t (12) = 2.674,
P = 0.0182, Fig. 6C), suggesting that forebrain VAChT is required
for normal working memory performance.
When tested on the working memory MWM test, mice with
selective elimination of septohippocampal VAChT by virus injection (same cohort used in the MWM) also showed impaired latency savings ratio (t (26) = 2.847, P = 0.0111, Fig. 6D) and distance
savings ratio (t (26) = 2.149, P = 0.0473, Fig. 6E). On the spontaneous
alternations Y-maze task, AAV8-GFP-Cre-injected mice showed
impairments on working memory, measured as a signiﬁcant decreased rate of spontaneous alternations (t (26) = 3.347, P = 0.0041,
Fig. 6F). It is interesting to note that working memory deﬁcits observed for AAV8-GFP-Cre-injected mice were similar to deﬁcits
observed for VAChTNkx2.1-Cre-ﬂox/ﬂox mice. Taken together these
results indicate that working memory is highly sensitive to hippocampal cholinergic tone.

Discussion
The present work shows that selective inhibition of cholinergic
signaling in the hippocampus in mice leads to disruption of synaptic plasticity and speciﬁc cognitive impairments. In particular,
we show that hippocampal cholinergic signaling is important for
the modulation of cognitive tasks shown to be impaired in
schizophrenia and dementia, including the PAL task. Interestingly, some hippocampal-dependent tasks appear to be more sensitive to decreased cholinergic signaling than others. Our results
provide a comprehensive map of cholinergic-regulated hippocampal cognitive processing that may be useful to understand
similar deﬁcits in humans with cholinergic deﬁciency.
Notably, we report novel data indicating the importance of
cholinergic signaling in regulating the PAL task. Clinically, the
PAL task has been suggested as a potential cognitive marker of
decline in psychosis (Wood et al. 2002). Signiﬁcant impairments

Figure 6. Working memory depends on hippocampal cholinergic tone. (A) Latency savings ratio and (B) distance savings ratio for VAChTﬂox/ﬂox (clear, n = 7) and
VAChTNkx2.1-Cre-ﬂox/ﬂox (dark, n = 7) mice in the working memory version of the MWM. (C) Spontaneous alternations in the Y-maze for VAChTNkx2.1-Cre-ﬂox/ﬂox. (D)
Latency savings ratio and (E) distance savings ratio for AAV8-GFP (clear, n = 14) and AAV8-GFP-Cre (dark, n = 14) mice in the working memory version of the MWM. (F)
Spontaneous alternations in the Y-maze for virus-injected mice. Data are mean ± SEM. *P < 0.05, **P < 0.01.
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dysfunction. To discern among these possibilities, we used virusinjected mice.
Selective reduction of hippocampal cholinergic tone in
virus-injected mice also increased latency to ﬁnd the platform
in reversal learning (2-way RM ANOVA shows an effect of
days, F3,39 = 21.96, P < 0.0001 and a signiﬁcant interaction effect,
F3,39 = 7.507, P = 0.0004), with post hoc analysis revealing that
AAV8-GFP-Cre-injected mice performed signiﬁcantly worse on
Day 4 compared with controls (Fig. 5G). During the probe trial,
mice injected with AAV8-GFP-Cre virus showed signiﬁcant impairments, failing to show a preference for the target quadrant
(2-way ANOVA shows a signiﬁcant effect of quadrant, F3,104 = 23.3,
P < 0.0001, and an interaction effect, F3,104 = 7.173, P = 0.002,
Fig. 5J). Post hoc analysis revealed that the AAV8-GFP-Cre mice
did not prefer the target quadrant compared with the other
quadrants, while the AAV8-GFP-injected controls had a strong
preference for the target quadrant. Furthermore, the AAV8-GFPCre-injected mice showed a decrease in the number of platform
crosses (t (26) = 0.9547, P = 0.0010, Fig. 5K). These results reveal
that disruption of hippocampal cholinergic tone, but not striatal
or cortical cholinergic activity, compromises information
processing in the MWM reversal learning.
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hippocampus decrease acquisition performance, suggest that
the hippocampal cholinergic tone may facilitate acquisition of
the PAL task. However, it is unlikely that only one brain region
is involved in such a complex task.
The mechanisms by which ACh tone facilitates PAL performance are not fully understood. It is possible that cholinergic tone
is required for speciﬁc types of synaptic plasticity. Indeed, hippocampal LTP in vitro is disturbed in a different mouse line lacking
forebrain VAChT (Martyn et al. 2012). We corroborated this ﬁnding
in vivo in VAChTNkx2.1-Cre-ﬂox/ﬂox mice and demonstrated that in
the absence of VAChT expression, hippocampal LTP is compromised, suggesting that disturbances of synaptic plasticity might
contribute to the deﬁcit. To note, previous studies have shown
that levels of VAChT are correlated to levels of ACh release
(Prado et al. 2006; de Castro, Pereira, et al. 2009, reviewed in
Prado et al. (2013)); an increase in VAChT levels increases ACh release whereas decreased levels have the opposite effect (Song
et al. 1997; Prado et al. 2006; Kolisnyk, Guzman, et al. 2013).
VAChT is decreased in AD (Parent et al. 2013). These results suggest that correlating levels of VAChT detected with PET ligands
(Efange 2000) to performance in the PAL test (Harel et al. 2013)
might provide a potential biomarker of remaining cholinergic
function and cognitive reserve.
We showed that acquisition of the spatial version of the MWM
and recall of platform location was mildly affected in
VAChTNkx2.1-Cre-ﬂox/ﬂox mice, while AAV8-GFP-Cre-injected mice
did not show any deﬁcit in this behavioral task. Similarly, impairments in the spatial version of the MWM have been observed
in rats with combined lesions of MS/VDB and nucleus basalis
magnocellularis (NBM) cholinergic neurons produced by immunotoxin 192 IgG-saporin (Pizzo et al. 2002), while rats with immunotoxin lesions restricted to MS/VDB did not show any
impairment (Berger-Sweeney et al. 1994; Baxter and Gallagher
1996; Pizzo et al. 2002; Frick et al. 2004). Interestingly, rats with
192 IgG-saporin lesions restricted to NBM also did not show behavioral impairments in the MWM (Pizzo et al. 2002). These
data suggest that forebrain cholinergic signaling is necessary
for reference spatial learning and memory assessed using the
MWM; however, it seems that both the cortical and hippocampal
cholinergic projections need to be compromised to produce a
severe spatial deﬁcit. Thus, providing that cortical cholinergic
projections are intact, hippocampal cholinergic activity is not
absolutely required for this behavioral task. It remains to be established whether GABA or glutamate, which could potentially
be co-released with ACh (Guzman et al. 2011; Saunders et al.
2015) in both the hippocampus and cortex, may contribute to
regulation of spatial memory by cholinergic neurons.
In contrast to the reference memory test, both VAChTNkx2.1-Cre-ﬂox/
ﬂox
and AAV8-GFP-Cre-GFP-injected mice when tested in the
MWM reversal learning task presented extensive deﬁcits,
suggesting a prominent role for hippocampal cholinergic signaling in reversal learning. The impairments seen in VAChTdeﬁcient mice in reversal learning could relate to the loss of
muscarinic presynaptic inhibition of excitatory feedback within
cortical circuits (Hasselmo and McGaughy 2004), which would
slow the extinction of a previously learned strategy (Hasselmo
et al. 2002; Hasselmo 2006). To note, the ﬁndings with
VAChTNkx2.1-Cre-ﬂox/ﬂox mice recapitulated the deﬁcits seen in reversal learning in a different mouse line with deﬁcient forebrain
cholinergic tone we generated previously (Martyn et al. 2012;
Kolisnyk, Al-Onaizi, et al. 2013). Interestingly, rats with 192 IgGsaporin lesions restricted to NBM also show behavioral ﬂexibility
impairments (Cabrera et al. 2006). Taken together, these results
suggest that both NBM-cortical and septohippocampal cholinergic
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in PAL have been observed in patients with schizophrenia with a
positive correlation between failure on the PAL task and negative
symptoms (Barnett et al. 2005). Additionally, hippocampal activation during PAL is changed in patients with mild cognitive impairment compared with aged-matched controls (de Rover et al.
2011). Hence, PAL has also been considered a sensitive task for
predicting cognitive decline in AD (Swainson et al. 2001; Blackwell et al. 2004).
Nonetheless, whether cholinergic signaling is required for acquisition of the task has not been clearly established. Systemic
administration of donepezil, a cholinesterase inhibitor, improved
post-acquisition PAL performance in mice, an effect that was attenuated with administration of muscarinic antagonists (Bartko,
Vendrell et al. 2011). Similar results have been observed in monkeys where both mecamylamine (nicotinic antagonist) and scopolamine (muscarinic antagonist) induced deﬁcits in PAL
performance (Taffe et al. 2002; Katner et al. 2004). These results
suggest that cholinergic signaling might be relevant for PAL.
Also, rats previously trained in PAL that received injections into
the dorsal hippocampus of either scopolamine or mecamylamine and that were re-tested did not show deﬁcits in performance, suggesting that hippocampal cholinergic signaling might
not modulate recall in this task (Talpos et al. 2009). Our results indicate that disruption in forebrain cholinergic tone disturbs PAL
learning. Additionally, our data suggest that dysfunctional hippocampal cholinergic signaling may decrease PAL performance,
as performance of mice in the PAL task correlates with hippocampal VAChT protein levels. Importantly, these deﬁcits occurred in
the absence of alterations in latency to touch the screen or to collect the reward, indicating that motivation was not a factor in the
poorer performance of mice with lower cholinergic tone. Interestingly, mice deﬁcient for the M1 receptor presented no differences
compared with controls in their acquisition of the PAL task (Bartko,
Romberg et al. 2011), suggesting that nicotinic and/or other muscarinic receptors might be involved in mediating learning in this
hippocampal-dependent task.
Performance in PAL, as well as in other paired-associated
tasks, may depend on intact hippocampal function in humans
and rats (Talpos et al. 2009; de Rover et al. 2011). For example,
short-lasting inactivation of the rat hippocampus using lidocaine
(non-selective Na+ channel blocker) signiﬁcantly impairs performance postacquisition of the PAL task, suggesting that the
hippocampus is required at least for performance in this task
(Talpos et al. 2009). In addition, human fMRI studies have
shown bilateral BOLD activation of the hippocampus during the
encoding phase of the PAL task (de Rover et al. 2011). Interestingly,
subjects with memory deﬁcits showed decreased hippocampal
activation with increased memory demand, whereas healthy
controls showed the opposite (de Rover et al. 2011). Moreover,
PAL performance correlates with hippocampal volume loss in
schizophrenia and mild cognitive impairment (MCI) (Keri et al.
2012). Intriguingly, recent reports indicate that mice with hippocampal lesions are still able to acquire the PAL task (Delotterie
et al. 2015; Kim et al. 2015). One possible explanation (Kim et al.
2015) regarding these ﬁndings is that with a functional hippocampus the task is acquired in a hippocampal-dependent manner, but with a dysfunctional hippocampus, the task can be
learnt using an alternative hippocampal-independent strategy.
For example, mice with hippocampal lesions could have used
the dorsal striatum to acquire the task (Delotterie et al. 2015). Indeed, the development of such behavioral plasticity has been
shown in rats with unilateral hippocampal lesions (Zou et al.
1999). Our ﬁndings that forebrain VAChT-deﬁcient mice seem unable to acquire the task, whereas decreased VAChT levels in the
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